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Lessons from Trypanosome TFIIH: 
Discovery of the Essential Roles of CRK9 in Gene Expression and  
of the Divergent Helicase Paralog XPB-R in Nucleotide Excision Repair 
Nitika Badjatia 
University of Connecticut, [2015] 
Eukaryotic TFIIH consists of a core of seven subunits, including the DNA helicase 
Xeroderma Pigmentosum B (XPB), and a cyclin-dependent kinase (CDK)-activating complex 
(CAK) that contains CDK7. XPB is crucial for DNA unwinding during transcription and nucleotide 
excision repair (NER) while the CAK complex phosphorylates RNA polymerase II (RNAPII) 
carboxy terminal domain (CTD), enabling the enzyme’s promoter clearance.  
Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are lethal human 
parasites, belonging to the early-diverged order Kinetoplastida. They transcribe genes 
polycistronically and require spliced leader (SL) trans splicing for the maturation of mRNAs from 
polycistronic precursors. SL RNA gene (SLRNA) transcription by RNAPII depends on 
trypanosome TFIIH complex which contains orthologs of all core subunits but lacks the CAK 
complex. Despite this, the trypanosome CTD is phosphorylated and essential for SLRNA 
transcription. Gene silencing of CDC2-related kinase 9 (CRK9) revealed its importance for 
parasite survival and CTD phosphorylation. Interestingly, this loss of phosphorylation did not 
cause a specific RNAPII transcription defect. Instead, CRK9 silencing blocked trans splicing and 
caused hypomethylation of SL RNA’s extensively modified cap. Sedimentation analysis of 
tandem affinity purified CRK9 revealed a putative tripartite complex including a novel L-type 
cyclin (CYC12), and a CRK9-associated protein (CRK9AP). Silencing CYC12 or CRK9AP 
recapitulated the defects observed upon CRK9 silencing, confirming that they functionally 
partner with CRK9 in vivo. CRK9AP depletion caused a rapid co-loss of CRK9 and CYC12, 
suggesting its role in complex assembly. This project identified CRK9 as crucial for parasite- 
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specific gene expression. As a CDK, CRK9 is a promising drug target against trypanosomes 
which was validated in a mouse model. 
 Another feature related to trypanosome TFIIH is the presence of two divergent paralogs 
of XPB in kinetoplastid genomes while only the larger XPB paralog consistently co-purified with 
TFIIH.  Gene knockout of the second paralog, termed XPB-R showed that XPB-R is specialized 
in NER but dispensable for transcription. While XPB-R does not assemble into a TFIIH complex, 
reciprocal co-immunoprecipitations revealed an interaction with the p52 ortholog, a TFIIH 
component and known regulator of XPB in other systems, indicating that trypanosomes possess 
a TFIIH whose function is restricted to transcription and a XPB-R/p52 repair complex.  
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Chapter I 
Introduction 
1. Trypanosomatids and human diseases
Trypanosomatids are eukaryotic unicellular flagellates that are obligate parasites of 
vertebrates, invertebrates and plants. They belong to the phylogenetic order Kinetoplastida and 
family Trypanosomatidae. Kinetoplastids are thought to have diverged early from the main 
eukaryotic lineage during evolution and they are characterized by the presence of the 
kinetoplast, a structure that refers to a network of catenated DNA in a single large 
mitochondrion located near the origin of flagellum. (Shlomai, 2004; Stechmann and Cavalier-
Smith, 2002). The Trypanosomatidae include several species of Trypanosoma and Leishmania 
that cause severe vector-borne diseases in humans and livestock. Trypanosoma brucei and 
Trypanosoma cruzi cause Human African Trypanosomiasis (HAT), also known as (a.k.a.) 
Sleeping sickness, and Chagas disease, respectively, while several species of Leishmania 
cause a group of diseases called Leishmaniasis. These diseases, often lethal if untreated, 
collectively affect millions of people in tropical and sub-tropical regions of the world. 
Infection with Trypanosoma brucei causes HAT in humans and Nagana in livestock. The 
parasite is transmitted to its vertebrate hosts by sanguivorous tsetse flies of the Glossina genus. 
Tsetse flies as well as the disease are prevalent in 36 countries in the sub-Saharan region of 
Africa. Currently just under 10,000 cases are reported each year although the exact number of 
infected individuals is not known as the disease is mainly prevalent in remote rural areas in 
Africa.  T. brucei is classified in three subspecies: human-pathogenic, T brucei gambiense and 
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  T. brucei rhodesiense; and human non-pathogenic, T. brucei brucei. T. brucei gambiense is 
found in west and central Africa, causes chronic infections and currently accounts for 97% of 
reported cases of sleeping sickness. On the other hand, T. brucei rhodesiense infection, 
prevalent in east and southern Africa, is usually acute, and accounts for fewer than 3% of 
reported cases. (Kennedy, 2013) T. brucei brucei typically doesn’t infect humans but causes 
animal trypanosomiasis in cattle and wild animals along with other Trypanosoma species such 
as T. vivax. Wild animals can also host human pathogenic species and while they do not 
develop the disease, they serve as important reservoirs from which tsetse flies can gain an 
infection (Franco et al., 2014). The species of Trypanosoma including T. brucei brucei that are 
non-pathogenic in humans are highly susceptible to trypanosome lytic factors (TLFs) which are 
present in human serum. The two types of TLFs are TLF-1, which is high-density lipoprotein 
particle consisting of apolipoprotein L1 (APOL1) and haptoglobin-related protein (HPR), and 
TLF-2 which contains IgMs as a major component along with several other proteins including 
HPR and APOL1. APOL1 is considered as the trypanolytic component of both complexes. 
Human infective T brucei gambiense and T. brucei rhodesiense use distinct proteins to 
neutralize APOL1 trypanolytic action, which makes them resistant to human serum (Pays et al., 
2014). 
 The disease progression in HAT can be divided into two major stages, the 
haemolymphatic stage and the meningoencephalitic or neurological stage. In the first stage, the 
parasites multiply in subcutaneous tissue, lymph and blood. The early stage symptoms that are 
typically observed 1-3 weeks after the insect bite are intermittent fever, headache, itching, 
malaise, fatigue etc. The recurrent intermittent fever in the first stage is associated with the 
waves of parasitemia caused due to antigenic variation which is a primary mechanism that 
enables parasites to evade the immune system in their hosts (Horn, 2014). As the disease 
develops, other clinical features such as lymphadenopathy; enlargement of the spleen and liver; 
2
	  cardiac malfunction, ophthalmological features can become evident.  The onset of the second 
stage of the disease correlates with the parasites crossing the blood-brain barrier to infect the 
central nervous system. The typical symptoms are mental disturbances, poor coordination, 
sensory and motor disturbances and abnormal reflexes. Sleep abnormalities that give the 
disease its name are also observed during late stage. This includes reversal of the sleep cycle 
and irrepressible episodes of sleep. Eventually the patient succumbs to coma and death if left 
untreated (Kennedy, 2013). 
 Trypanosoma cruzi infection causes Chagas disease in humans, also known as 
American trypanosomiasis. This disease is mainly endemic in Latin America but widespread 
emigration in last few decades of infected individuals from endemic areas to other nations, 
including the United States, Canada, and Western Europe, has caused the disease to spread 
elsewhere. According to the WHO, between 6-7 million people are estimated to be infected 
worldwide, mostly in Latin American nations. Transmission in humans is mainly through contact 
with the feces of an infected Triatomine bug also known as the kissing bug. Other ways of 
transmission are consumption of contaminated food, congenital transmission, blood transfusion, 
and organ transplants. Unlike T. brucei, T. cruzi is predominantly an intracellular parasite that 
can invade many different cell types and establish a chronic infection. Infection is manifested in 
two stages: acute and chronic stages. The acute Chagas phase, typically lasting for about two 
months after infection, can be mild or asymptomatic.  However, 10-30% of infected individuals 
will display symptoms such as swelling or lesion at the site of infection, fever, headache, 
enlarged lymph glands, abdominal pain, anorexia etc. Rarely, myocarditis or 
meningoencephalitis during acute phase can result in death. The majority of infected people 
enter a prolonged asymptomatic phase with low or undetectable parasitemia in blood. About 30-
40% of infected asymptomatic carriers develop chronic disease. Clinical manifestations of the 
chronic stage are dilated cardiomyopathy which can cause sudden death due to cardiac arrest 
3
	  and/or digestive disorders typically due to megacolon and megaesophagus (Bonney, 2014; 
Nunes et al., 2013).  
 Leishmaniasis is caused by infection from over 20 different species of Leishmania. It is 
transmitted through the bite of females of certain species of sandfly.  The disease affects over 
80 countries worldwide but it is primarily endemic in tropical and sub-tropical countries. 
According to a recent World Health Organization (WHO) report, about 1.3 million new cases and 
20,000-30,000 deaths are reported annually due to this disease.  There are two major forms of 
this disease, namely cutaneous leishmaniasis, which is caused by most Leishmania species 
and visceral leishmaniasis, which is primarily caused by Leishmania donovani and Leishmania 
infantum. Cutaneous Leishmaniasis, the less severe and more common form of the disease, 
causes skin lesions such as ulcers which can produce lifelong scars. Muco-cutaneous 
leishmaniasis is a more serious form of the cutaneous disease, affecting mucous membranes of 
nose, mouth and throat. Visceral leishmaniasis, fatal if untreated, is characterized by prolonged 
oscillating fever, weight loss, anemia, and the enlargement of lymphatic organs (Chappuis et al., 
2007; Murray et al., 2005).  
 Diseases caused by trypanosomatids are amongst the most important neglected tropical 
diseases, collectively affecting over 21 million people worldwide (McCall and McKerrow, 2014) 
and causing approximately 150,000 deaths annually (Nussbaum et al., 2010). Over 2 million 
new cases are reported each year (McCall and McKerrow, 2014). In the absence of vaccines, 
chemotherapeutic drugs are the only means of treatment.  However, some of the current 
medications are unsatisfactory due to high toxicity, poor efficacy and increasing drug resistance.  
 Pentamidine and Suramin are the main drugs for first stage HAT treatment while 
Melarsoprol and Eflornithine are typically administered in the second stage. In 2009, a 
combination therapy of Eflornithine and Nifurtimox was also introduced for second stage of the 
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  disease (Barrett and Croft, 2012).  Most of these compounds cannot be administered orally, and 
have undesirable, sometimes fatal, side-affects. Moreover, poor efficacy and increasing 
resistance further limits the treatment with these drugs. Benznidazole and nifurtimox are the two 
main drugs for treatment of Chagas disease (Barrett and Croft, 2012). Although both are 
effective in curing the disease during the acute phase, their efficacy is reduced the longer a 
person has been infected.  Additionally, both drugs are not suitable for individuals with kidney or 
liver malfunction and for pregnant women. This is significant since Chagas disease can be 
transmitted congenitally; an infected mother would invariably pass the disease to the infant 
unless treated. Pentavalent antimonials can be used for treatment of Leishmaniasis but 
resistance is on the rise in some areas (Barrett and Croft, 2012). Some other drugs are 
allopurinol and amphotericin B. Thus there is a pressing need for the development of new and 
more effective drugs for all three trypanosomatid diseases (Castillo et al., 2010; Nussbaum et 
al., 2010; Patterson and Wyllie, 2014).  Since trypanosome parasites share several unique 
biological features that are distinct from their hosts, it is possible to envision a potential drug 
target common in all three parasites. One such shared feature is the mechanism of protein 
coding gene expression in trypanosomes and factors crucial for this process can be potentially 
suitable therapeutic targets for the treatment of trypanosomatid diseases. 
2. Gene expression in trypanosomatids 
 Trypanosomatid genomes are organized into large gene clusters containing functionally 
unrelated, tandemly linked protein coding genes that are transcribed polycistronically by RNA 
polymerase (pol) II. This is highly unusual as transcription is typically monocistronic in 
eukaryotic organisms with specific initiation and termination sites. For each gene the binding of 
basal transcription factors to the core promoter recruits RNA pols to the transcription initiation 
site, and allows precise transcription initiation. On the other hand, polycistronic transcription is 
not initiated at a concrete transcription initiation site and, so far, no transcription factors or 
5
	  promoter elements have been identified for transcription initiation at these gene arrays (Siegel 
et al., 2011). Instead, open chromatin formation in divergent strand switch regions appears to be 
sufficient to allow bidirectional RNA polymerase II transcription initiation to occur at multiple 
sites in these regions (Kolev et al., 2010; Siegel et al., 2009). 
 The polycistronic primary transcripts in trypanosomes are resolved into individual 
mRNAs by the coupled processes of spliced leader (SL) trans splicing and polyadenylation 
(LeBowitz et al., 1993; Matthews et al., 1994). The process of SL trans splicing was first 
discovered in Trypanosoma brucei (Boothroyd and Cross, 1982; Campbell et al., 1984; Kooter 
et al., 1984; Milhausen et al., 1984; Van der Ploeg et al., 1982) but later on it was also identified 
in other members of Euglenozoa as well as in some multicellular organisms such as Nematoda, 
Platyhelminthes, Hydra etc. Some instances of trans splicing have been observed in Drosophila, 
C. elegans and mosquitoes where exons from two different pre-mRNA molecules are joined 
together through trans splicing (Lasda and Blumenthal, 2011). Similar to cis splicing, SL trans 
splicing requires two transesterification reactions with a Y-structure intermediate which is 
analogous to the cis splicing specific lariat structure (Murphy et al., 1986; Sutton and Boothroyd, 
1986).  
 During SL trans splicing, the 39-nucleotide long SL, also known as mini-exon, is fused to 
the 5' ends of all mRNAs in the cell.  The SL is derived from a small nuclear RNA called SL 
RNA, also known as SL donor. Since maturation of each and every mRNA crucially depends on 
SL trans splicing, this RNA processing step is an absolutely essential process for the survival of 
trypanosomatid parasites. Whereas in most eukaryotes the mRNA capping enzymes associate 
with RNA pol II and co-transcriptionally cap pre-mRNA, in trypanosomes, the 5' cap is obtained 
as part of the SL post-transcriptionally during trans splicing (Figure 1.1). Thus, SL trans splicing 
uncouples capping from RNA pol II in trypanosomatids (Gunzl, 2010; Michaeli, 2011; Preußer et 
al., 2012). The SL harbors an extensively modified cap structure called cap4, consisting of a 7-
6
	  methylguanosine followed by four methylated nucleotides (Bangs et al., 1992). Cap4 appears to 
be essential for SL trans splicing (McNally and Agabian, 1992; Ullu and Tschudi, 1991) and it 
was also shown to be important for efficient translation (Zamudio et al., 2009a).  
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Figure 1.1 Protein coding gene transcription and mRNA processing in trypanosomes. 
RNA pol II transcription of protein coding genes produces polycistronic transcripts that are processed 
spliced leader (SL) trans splicing and polyadenylation to generate mature individual mRNAs.  During 
trans splicing, the capped SL, derived from the small nuclear SL RNA, is added to the 5’ end of each 
mRNA. SL RNA genes (SLRNA) are transcribed monocistronically from a RNA pol II promoter. SL RNA 
acquires the complex cap4 structure m7G pppm6,6AmpAmpCmpm3Um that is implicated in trans splicing. 
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 In SL trans splicing, the conserved 5’ splice site (SS) dinucleotide GU is located on the 
SL RNA while the 3’ SS dinucleotide AG is present on the pre-mRNA. The region upstream of 
the 3’ SS on the pre mRNA also contains the branchpoint (BP) adenosine and a large 
polypyrimidine tract (Y~20), typically just downstream of the BP. During the first step of trans 
splicing, the 2’ hydroxyl (OH) group of the BP adenosine performs a nucleophilic attack at the 5’ 
SS or donor SS which results in the release of the SL with a free 3’ OH and the formation of a 
Y-structure intermediate. In the second step, the free 3’ OH end of the SL does a nucleophilic 
attack on the 3’ SS or acceptor SS which results in joining of the SL to the mRNA. Upon 
completion of the splicing process, the Y-structure intermediate is rapidly degraded (Figure 1.2). 
 Interestingly, while all mRNAs in trypanosomes are trans spliced, two trypanosomatid 
genes also harbor introns which are removed by cis splicing (Kolev et al., 2010; Mair et al., 
2000a).  Both cis and trans splicing are catalyzed by the spliceosome, consisting of five U-rich 
small nuclear RNAs (U snRNAs) and associated proteins. While trypanosomes possess all five 
U snRNAs, due to highly divergent amino acid sequences only a few splicing proteins were 
identified by standard genome annotation and most of the knowledge of splicing complexes 
comes from biochemical and functional characterizations. 
 
 
 
 
 
9
	   
 
 
 
 
 
 
 
 
 
Figure 1.2 Putative model for spliced leader (SL) trans splicing in trypanosomes. 
Analogous to cis splicing, SL trans splicing is achieved through two transesterification steps. Presumably, 
a pre-catalytic spliceosome is assembled on pre-mRNA that includes U1, U2, U5 andU4/U6 small nuclear 
ribo-nucleoproteins (snRNPs) as well as the SL snRNP. Subsequently, the spliceosome undergoes major 
structural and compositional changes to become activated during which U1 and U4 snRNAs leave the 
spliceosome. The activated spliceosome performs the first transesterification step which results in the 
release of the SL and the formation of a Y-structure intermediate. Thereafter, during the second catalytic 
step, mature spliced mRNA is generated that contains SL at its 5’ end. The intronic structure is rapidly 
degraded whereas the snRNPs are released and recycled for a new round of splicing. 
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  3. Splicing machinery in trypanosomes and other eukaryotes. 
3.1 Eukaryotic Spliceosome 
 The process of pre-mRNA splicing is catalyzed by a macromolecular, dynamic complex 
called the spliceosome, which is composed of five small nuclear ribo-nucleoproteins (snRNPs) 
U1, U2, U4, U5, and U6, as well as various non-snRNP proteins. Uridine-rich (U-rich) snRNPs, 
composed of U-rich snRNAs and stably interacting proteins, are the most important component 
of the spliceosome. In humans, there are ~45 snRNA associated proteins amongst a total of 
~170 proteins that are estimated to be associated with the spliceosome (Wahl et al., 2009). A 
large repertoire of spliceosome-associated proteins has regulatory roles while others serve to 
couple splicing to other processes of gene expression such as transcription and 
polyadenylation. Some are thought to provide flexibility and specificity to the spliceosome in 
order to rapidly respond to changes in cellular milieu. In accordance, several non-snRNP 
proteins are redundant and/or are loosely associated and most likely not needed for every 
splicing event (Hoskins and Moore, 2012; Matera and Wang, 2014; Wahl et al., 2009; Will and 
Luhrmann, 2001). 
 U snRNPs are the main building blocks of the spliceosome. Biogenesis of snRNPs 
occurs in a sequential manner in several distinct steps. In higher eukaryotes, all U snRNAs 
except U6 are transcribed by RNA pol II and acquire an m7G cap cotranscriptionally. These are 
then exported to cytoplasm, where they associate with seven common (Sm) proteins (B/B', D3, 
D2, D1, E, F and G) to form the core snRNP structure. These proteins form a heteromeric ring 
around the highly conserved Sm binding site in a process that is assisted by the survival of 
motor neurons (SMN) complex. Subsequently, the m7G cap is hypermethylated to 2,2,7-tri-
methylated guanosine (m3G) cap (Mouaikel et al., 2003) and the U snRNAs undergo 3′ end 
maturation (Seipelt et al., 1999). Thereafter, the core snRNPs are reimported into the nucleus 
where they bind to various snRNP-specific proteins in a special nuclear substructure called the 
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  Cajal body. In contrast to other U snRNPs, the U6 snRNP lacks a cytoplasmic phase. It is 
transcribed by RNA pol III and acquires a γ-monomethyl cap. The U6 snRNA lacks the Sm 
binding site and, instead, binds to seven Sm-like proteins (LSm2-8) (Achsel et al., 1999; Vidal et 
al., 1999).  
 In addition to the seven common Sm or Lsm proteins, there are additional snRNP-
specific proteins. Human U1 snRNP contains three U1 snRNP specific proteins namely, U1-
70K, U1-C and U1-A (Will and Luhrmann, 2001). U2 snRNP in humans consists of at least 14 
U2 snRNP-specific proteins including U2A' and U2B'' that directly bind to the U2 snRNA. U4 
snRNA and U6 snRNA extensively base pair with each other resulting in formation of stable 
U4/U6 di-snRNP. Five proteins in addition to the Sm and LSm proteins are stably associated 
with the U4/U6 di-snRNP. These are: Snu13 (aka 15.5K), CypH, Prp4 , Prp31, and Prp3 (Liu et 
al., 2006; Will and Luhrmann, 2001). The U5 snRNP contains at least eight specific proteins of 
which three are especially important for the RNA/RNP rearrangements that are crucial for 
activating the splicing reaction (Sander et al., 2006; van der Feltz et al., 2012). These proteins 
are helicase Brr2, GTPase Snu114 and the highly conserved and crucially important Prp8. 
 In addition to snRNP-specific proteins, there are several non-snRNP proteins that are 
essential for splicing reaction such as SF1 that binds to the BP (Berglund et al., 1997; Kramer 
and Utans, 1991), U2 auxiliary factor (U2AF) subunits U2A65 and U2A35 that bind 
polypyrimidine tract and the 3' SS respectively (Berglund et al., 1998; Wu et al., 1999), and the 
heteromeric  PRP19 complex (orthologous to the nineteen complex (NTC) in yeast) that is an 
integral part of the active spliceosome (Chan et al., 2003). 
 The spliceosome is assembled in a step-wise manner during RNA splicing. Firstly, the 
“early complex” or complex E is formed by the association of the U1 snRNP with the 5' SS via 
U1 snRNA base pairing. In addition, protein factor SF1 binds to the BP, and the U2AF 
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  associates at both the BP and 3' SS. Next, in an ATP-dependent step, the U2 snRNA 
recognizes the BP adenosine and interacts with U1 snRNP to form the pre-spliceosome or 
complex A. SF1 gets displaced during this process with the help of SF3a and SF3b complexes 
that are associated with the U2 snRNP. Subsequently, the preassembled tri-snRNP, consisting 
of the U4/U6 di-snRNP and the U5 snRNP, is recruited with the help of the helicase Prp28, to 
form the precatalytic complex B. Thereafter, complex B undergoes extensive rearrangements, 
both in composition as well as conformation to form the active complex B*. This activation 
requires the U5 snRNP-specific proteins Brr2 and Snu114, and the protein factor Prp2. During 
this process, U4/U6 base pairing is disrupted, U1 and U4 are released and U2-U6 base pairing 
is established. Complex B* catalyzes the first transesterification step of splicing, which results in 
the formation of complex C containing the lariat intermediate. Complex C undergoes further 
ATP dependent remodeling with the help of Prp8 and Prp16 to perform the second step of 
splicing. The resulting post-spliceosomal complex contains spliced exons and the lariat intron.  
Both the release of the spliced product and the disassembly of the post-spliceosomal complex is 
ATP driven and require additional RNA helicases. U2, U5 and U6 snRNPs are discharged and 
recycled for new rounds of splicing (reviewed in (Matera and Wang, 2014; Wahl et al., 2009)).  
 Most of our current knowledge for RNA splicing comes from biochemical and structural 
characterizations of snRNPs and different spliceosomal complexes in yeast and human 
systems, and is related to cis-splicing, e.g. intron removal.  In contrast to our detailed 
understanding of cis splicing, little is known about the particulars of the trypanosome trans 
splicing machinery. Previously, it was shown that U2, U4, U5 and U6 snRNAs are needed for 
trans splicing in T. brucei which indicated that the splicing machinery is similar for both forms of 
splicing (Tschudi and Ullu, 1990). On the other hand, it was shown in the nematode Ascaris that 
the U1 snRNP is dispensable for trans splicing in vitro (Hannon et al., 1991) and that the SL 
RNA, which is the SL donor, binds the Sm proteins and is assembled in a core snRNP itself 
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  (Bruzik et al., 1988; Palfi et al., 1991). This suggests that there are some important differences 
between cis and trans spliceosomes. Thus, the detailed understanding of the trans splicing 
machinery may reveal trans splicing-specific factors that can be potential antiparasitic drug 
targets. 
3.2 Splicing machinery of Trypanosomes 
 With the exception of two genes, trypanosomatid genes lack introns (Kolev et al., 2010). 
SL trans splicing is crucial for the maturation of each and every pre-mRNA in the cells. While 
trypanosomes harbor all five U-rich snRNAs, there are a few important differences between U 
snRNAs of humans and trypanosomatids. First, while in yeast and metazoans all U snRNAs 
with the exception of U6 snRNA, are synthesized by RNA pol II, in trypanosomatids all U 
snRNAs are transcribed by RNA pol III (Fantoni et al., 1994; Nakaar et al., 1994; Nakaar et al., 
1997). Unlike human and yeast U5, trypanosomatid U5 snRNA lacks the m3G cap (Dungan et 
al., 1996; Xu et al., 1997).  U1, U2 and U5 snRNAs in trypanosomatids are distinctively smaller 
than their counterparts in humans and yeasts, and lack the key stem-loop structures that are 
known to be important for RNA-protein interactions (Dungan et al., 1996; Hartshorne and 
Agabian, 1990; Tschudi et al., 1990; Xu et al., 1997). Lastly, the consensus Sm binding site that 
is typically well conserved in higher eukaryotes is relatively degenerate in trypanosomes 
(Preußer et al., 2012).  
 Since antibodies raised against the Sm core proteins that typically cross-react with Sm 
proteins in other organisms, did not recognize trypanosome Sm core, classical biochemistry and 
bioinformatics tools were used to identify the Sm and LSm core proteins in trypanosomes 
(Michaeli et al., 1990; Palfi and Bindereif, 1992; Palfi et al., 1991). Interestingly, while U1, U5 
and U6 are assembled in a canonical core snRNP with trypanosomatid orthologs of the seven 
Sm and Lsm proteins, U2 and U4 snRNP exhibit core variations. In U2 snRNP, paralogs of SmB 
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  and SmD3 called specific spliceosomal Sm2-1 (SSm2-1 a.k.a. Sm15k) and SSm2-2 (a.k.a. 
Sm16.5K) replace the canonical SmB and SmD3 respectively. Similarly paralogs SSm4 
replaces SmD3 in trypanosomatid U4 snRNP (Tkacz et al., 2007; Wang et al., 2006). While 
orthologs of U2 snRNP specific U2A' (Cross et al., 1993) and U5 snRNP specific PRP8 (Lucke 
et al., 1997) were characterized almost two decades ago, most of the other snRNP specific 
proteins have been identified only in recent years. One method that has significantly contributed 
in increasing the repertoire of identified splicing proteins in trypanosomes is tandem affinity 
purification (TAP) using the modified TAP tag called the PTP (protein C epitope-TEV protease 
cleavage site-protein A domains) tag (Schimanski et al., 2005a). With the help of TAP and 
bioinformatic approaches, trypanosome orthologs of almost all known snRNP proteins have 
been identified (Gunzl, 2010; Preußer et al., 2012).  
 However a majority of non snRNP spliceosomal proteins have not been identified yet 
and remain under represented in the current repertoire of known spliceosomal proteins in 
trypanosomes. In humans, only ~45 proteins of the estimated 170 spliceosomal proteins are 
snRNP proteins. Since orthologs of almost all snRNP proteins are present in trypanosomes, it is 
likely that a comparable number of non-snRNP proteins exist in trypanosomes and are yet to be 
discovered (Gunzl, 2010).  
3.3 The SL RNA and its assembly into the SL snRNP complex 
 One of the unique features of SL trans splicing is that the SL RNA, which is a splicing 
substrate itself, is assembled into a core snRNP and binds the common Sm proteins (Bruzik et 
al., 1988). Apart from the Sm proteins two other SL snRNP proteins, termed as SL175 and 
SL30 according to their molecular masses, were identified in the nematode Ascaris (Denker et 
al., 2002). These proteins are indispensable for trans splicing but are not required for cis 
splicing or non-SL trans splicing. SL RNA has the most extensively modified cap structure 
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  known in any system. This complex cap structure that is composed of a m7G residue (cap0) 
followed by four 2'-O-methylated nucleotides (AACU) and additional base methylations on the 
first and the fourth position (m7G pppm6,6AmpAmpCmpm3Um) is termed cap4 (Bangs et al., 
1992). The base methylations occurring on the first adenosine and the third uracil are unique to 
trypanosomes. The m7G cap is formed on nascent SL RNA cotranscriptionally by concerted 
action of two enzymes: the RNA triphosphatase TbCet1 (Ho and Shuman, 2001) and the 
bifunctional guanylytransferase/guanine N-7 methytransferase TbCgm1 (Ruan et al., 2007; 
Takagi et al., 2007). However it is not clear yet whether the remaining cap4 modifications occur 
cotranscriptionally. While it was thought initially that these modifications occur 
cotranscriptionally in a 5' to 3' direction and are independent of Sm binding (Hury et al., 2009; 
Mair et al., 2000b), it was shown subsequently that complete cap4 formation requires Sm core 
assembly (Zeiner et al., 2004a). In addition to cap4 methylations, SL RNA transcripts are also 
modified by pseudouridylation at nucleotide 28 (Liang et al., 2002) and 3' end trimming (Sturm 
et al., 1999). Pseudouridylation refers to the rotation of a uridine base relative to its ribose sugar 
ring.  Ψ28 formation on the SL RNA is directed by the SLA1 snoRNA (Hury et al., 2009; Liang et 
al., 2002; Watkins et al., 1994) and requires pseudouridine synthase TbCBF5 (Barth et al., 
2005).  Ψ28 is not essential for parasite survival since mutation of the base U at position 28 of 
the SL RNA was not lethal. (Liang et al., 2002; Sturm et al., 1998), Surprisingly, silencing of 
TbCBF5 resulted in elimination of Ψ28 as well as incomplete cap4 formation (Barth et al., 2005). 
TbMTR1, the enzyme responsible for the cap1 ribose methylation and TbCBF5 are part of a 
single RNP complex called the SLA1 small nucleolar RNP (snoRNP) complex (Zamudio et al., 
2009b). A knockout of TbMTR1 resulted in the specific loss of cap1 modification and 
accumulation of SL RNA intermediates with cap 0 and 3' end extension indicating a delay in 
downstream processing events (Zamudio et al., 2007). However, mRNAs from TbMTR1−/− cells 
had the remaining cap4 methylations, which clearly demonstrated that SL RNA lacking cap1 
can be trans spliced and methylations at the remaining cap4 positions are independent of cap1 
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  modification (Zamudio et al., 2009a). Two nuclear enzymes, TbMTR2 (a.k.a. TbMT48) and 
TbMTR3 (a.k.a. TbMT57) are responsible for ribose methylations at position 2 and 3 
respectively (Arhin et al., 2006a; Arhin et al., 2006b; Hall and Ho, 2006; Zamudio et al., 2006). It 
has been speculated that TbMTR3 also catalyzes the methylation at position 4 since cap3 
intermediates have not been detected yet.  It appears that modification at positions 2, 3 and 4 
requires binding of the Sm proteins to SL RNA. Knockout of either or both MTR2 and MTR3 did 
not affect culture growth and trans splicing (Zamudio et al., 2009a). However, neither MTR2 nor 
MTR3 could be deleted in TbMTR1−/− cells, indicating that at least a partly modified cap4 is 
essential for cell survival. Additionally cap4 also appears to be important for translation, but the 
mechanism for this remains to be determined (Zamudio et al., 2009a).   
 As mentioned above, assembly of the heptameric Sm proteins on SL RNA appears to 
occur after cap1 modification and prior to remaining cap modifications. It is not known if Sm 
assembly happens in the nucleus or cytoplasm and there are studies in support for both 
scenarios. Knockdown of Sm subunits or mutation of the Sm binding site results in an 
accumulation of immature SL RNA in the cytosol (Mandelboim et al., 2003; Zeiner et al., 2004a). 
These studies support the notion that the assembly of the SL RNP occurs in the cytoplasm in a 
manner that is similar to the association of Sm protein complex on U snRNAs in humans. On 
the contrary, nuclear colocalization of the SLA1 snoRNA with the SL RNA, SmE as well as the 
SL RNA transcription factor tSNAP42 suggests that SL RNA processing and Sm assembly 
occurs in a distinct site within the nucleus presumably at the site of SL RNA transcription (Hury 
et al., 2009; Tkacz et al., 2007). Nuclear localization of the Sm assembly factor SMN further 
supports this hypothesis (Jae et al., 2011; Palfi et al., 2009).  
 Finally, maturation of the SL RNA requires 3' end trimming of SL RNA, which involves 
removal of the last 4-6 nucleotides. Two nucleases are responsible for this, of which only one 
called SNIP is currently known (Zeiner et al., 2004b). The 3' end processing is dependent on the 
Sm-binding and is defined by the secondary structure of the SL RNA. SL RNA folds in a 
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  secondary structure containing three stem loops, with the second and the third loop flanking a 
single stranded Sm-binding site (Bruzik et al., 1988).  
4. SL RNA gene (SLRNA) transcription 
 Unlike other spilceosomal U snRNAs that are typically recycled, SL RNA is consumed in 
the trans splicing event. Consequently, it has a high turnover rate with a half life of ~4 minutes 
(Laird et al., 1987; Ullu and Tschudi, 1991). Most likely, to meet the constant high demand of SL 
RNA, there are ~100 SLRNA copies  organized in a 1.4 kb long tandem array on chromosome 9 
(Gilinger and Bellofatto, 2001). These genes are transcribed in a monocistronic fashion by RNA 
pol II, and SL RNA constitutes ~6% of total RNA synthesis in T. brucei (Campbell et al., 2000). 
Since a strong continuous supply of SL RNA is crucial for the survival of all trypanosomatid 
parasites, the processes of SL RNA synthesis and SL trans splicing are attractive targets for 
parasite control. Accordingly, proteins that are involved in SL RNA biosynthesis are typically 
encoded by essential genes. 
 SLRNA is the best-characterized transcription unit in trypanosomes. Unlike the protein 
coding genes, SLRNA units are transcribed in a monocistronic fashion from a definite 
transcription initiation site (TIS) (Hartree and Bellofatto, 1995) and transcription termination 
occurs at a poly T tract downstream of the SLRNA coding region (Sturm et al., 1999). 
Identification of the RNA pol that transcribes SLRNA has been controversial issue in the past. 
SL RNA has a m7G cap that is characteristic of RNA pol II transcripts (Laird et al., 1985) but 
termination of SLRNA transcription requires poly T tract (Sturm et al., 1999), which is a hallmark 
of RNA pol III transcription. While Tagetitoxin, a potent inhibitor of RNA pol III transcription, had 
no effect on SL RNA transcription (Grondal et al., 1989; Saito et al., 1994), α-amanitin that 
typically inhibits RNA pol II at low doses, did not affect SLRNA transcription in this manner 
(Crenshaw-Williams and Bellofatto, 1999; Gunzl et al., 1997; Saito et al., 1994). However, an in 
vitro transcription study unambiguously demonstrated that SLRNA is transcribed by RNA pol II 
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  and not by RNA pol III (Gilinger and Bellofatto, 2001).  
4.1 The SLRNA promoter 
 Mutational analyses in Trypanosoma brucei, Leptomonas seymouri and Leishmania 
tarentolae led to the identification of the tripartite SLRNA promoter elements that consist of two 
upstream sequence elements (USEs) and an initiator element (Inr) at the TIS (Gunzl et al., 
1997; Hartree and Bellofatto, 1995; Yu et al., 1998). The relative spacing between these three 
promoter elements is important for efficient transcription. Also, mutations within the Inr 
abolished correct transcription initiation (Luo et al., 1999). Thus, the SLRNA promoter has three 
important sequence elements called USE1, USE2 and Inr that are essential for accurate and 
efficient SLRNA transcription. 
4.2 Trans-acting factors binding to the SLRNA promoter 
 After characterization of the SLRNA promoter, the next obvious step was to identify a 
trans-acting factor that associates with it. Initial studies using conventional chromatography led 
to the purification of a tripartite complex that interacted specifically with USE1 of the SLRNA 
promoter (Luo et al., 1999). Of the two proteins that were identified in this study, one was a 
clear ortholog of the human snRNA-activating protein (SNAP)50 (Das and Bellofatto, 2003). 
SNAP50 is an essential subunit of the SNAP complex (SNAPc) which interacts with the 
proximal sequence element of the snRNA gene promoters to nucleate transcription pre-initiation 
complex formation in humans. Hence, this was the first evidence of a transcription factor in 
trypanosomes and suggested that a transcription pre-initiation complex (PIC), consisting of 
basal transcription factors (BTFs) and RNA pol II, is assembled at the SLRNA promoter. This 
was surprising since annotation of completed trypanosomatid genomes revealed only the 
trypanosome homolog of the TATA-binding protein (TBP), termed TBP-related factor 4 (TRF4) 
(Ruan et al., 2004), and the TFIIH helicases XPB and XPD as potential BTFs (Ivens et al., 
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  2005).  
4.3 Basal factors for RNA pol II mediated transcription in humans 
 Promoter-dependent transcription initiation by RNA pol II in eukaryotes invariably 
depends upon the formation of the PIC at the core promoter. PIC assembly for protein coding 
genes is typically initiated by binding of the basal transcription factor TFIID to the TATA box. 
This interaction is mediated by TBP, which is a part of the TFIID complex. This is followed by 
the binding of the bipartite TFIIA to TBP that serves to counteract repressors that might 
associate with TBP and to strengthen the DNA-protein interaction of the complex. DNA is 
severely bent upon TBP binding, allowing the single subunit TFIIB to enter the PIC. TFIIB 
directly interacts with RNA pol II and aids the recruitment of TFIIF-bound RNA pol II to the 
promoter, positioning it at the correct TIS and, thus, directing accurate start site selection. The 
bipartite, multi-functional TFIIF complex tightly associates with RNA pol II and facilitates the 
recruitment of the enzyme to the TFIID-TFIIB complex (Flores et al., 1991). It also aids the 
polymerase in start site selection (Ghazy et al., 2004) and promoter escape (Yan et al., 1999), 
and enhances the enzyme’s elongation efficiency (Price et al., 1989). TFIIF is also thought to 
recruit TFIIE to the PIC (Maxon et al., 1994). The two-subunit TFIIE complex brings TFIIH into 
the PIC and stimulates its helicase and kinase activity. TFIIH is a large complex consisting of a 
core of seven subunits, including the two helicases Xeroderma pigmentosum (XP)B and XPD, 
and a CDK-activating kinase (CAK) sub-complex of three subunits. The ATPase/helicase 
activity of XPB and XPD is needed for promoter opening and clearance and the kinase activity 
of CAK is required for CTD phosphorylation, facilitating promoter escape of RNA pol II 
[Reviewed in (Sikorski and Buratowski, 2009; Thomas and Chiang, 2006)]. 
 Transcription initiation by RNA pol II at the snRNA genes is less well characterized 
(Hernandez, 2001; Jawdekar and Henry, 2008). In the human system, PIC formation is initiated 
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  by SNAPc (Henry et al., 1995; Yoon et al., 1995). While human SNAPc consists of five subunits 
namely SNAP190, SNAP50, SNAP45, SNAP43 and SNAP19, only three of these factors: 
SNAP190, SNAP50 and SNAP43 are essential and conserved in other eukaryotes (Li et al., 
2004a). An in vitro study showed that TBP, TFIIA, TFIIB and TFIIF are also essential for snRNA 
gene transcription (Kuhlman et al., 1999), but the role of TFIIH although suggested, has not 
been conclusively established (Jawdekar and Henry, 2008; Kuhlman et al., 1999). Nevertheless, 
these findings indicate that, except for the DNA-protein contact by SNAPc, an RNA pol II PIC is 
formed at snRNA promoters that is largely congruent to that studied in much more detail at 
protein coding genes. 
4.4 Transcription factors essential for SLRNA transcription in trypanosomes 
As mentioned above, genomic annotation of the completed genome of the Trypanosoma 
brucei, Trypanosoma cruzi, and Leishmania major (also referred as Tritryp) did not identify 
orthologs of BTFs for RNA pol II other than the multifunctional TBP and TFIIH helicases XPB 
and XPD (Ivens et al., 2005). This was surprising since BTFs are typically highly conserved, and 
the apparent lack of the genes encoding for BTFs in the genome suggested that RNA pol II 
recruitment to DNA and transcription initiation does not require PIC formation in 
trypanosomatids. However, since these organisms diverged very early from the main eukaryotic 
lineage, it was possible that, due to sequence divergence, in silico identification of the 
corresponding BTF genes failed. Accordingly, BTF identification in trypanosomes relied on 
biochemical analysis. Since previous studies had identified SNAP50 (Das and Bellofatto, 2003) 
and TRF4 (Ruan et al., 2004) as transcription factors that bind to the SLRNA promoter and 
since both were needed for SLRNA transcription, these factors were tagged and tandem affinity-
purified to further characterize the transcription machinery. In both purifications, a complex 
consisting of tripartite SNAPc, TRF4, a clear ortholog of the smaller TFIIA subunit, and a sixth 
protein that is most likely a highly divergent ortholog of the larger TFIIA subunit, were identified 
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  (Das et al., 2005; Schimanski et al., 2005b). This complex bound to the SLRNA USE and its 
depletion from extract completely abolished SLRNA transcription activity while control 
transcription by RNA pol I remained unaffected (Schimanski et al., 2005b). Next, a highly 
divergent putative TFIIB ortholog was identified by a more thorough in silico search. Functional 
analysis showed that this protein was recruited to the PIC and interacted with both RNA pol II 
and TRF4. Expression silencing of TFIIB was lethal for the cells and clearly affected SLRNA 
transcription (Schimanski et al., 2006). Subsequent biochemical characterization of the TFIIH 
complex by tagging and TAP of the XPD helicase revealed a full core complex of seven 
subunits (Lee et al., 2007) and two additional bona fide subunits termed as trypanosomatid-
specific protein 1 (TSP1) and TSP2 that most likely represent divergent trypanosome orthologs 
of the two TFIIE subunits (Lee et al., 2009). Gene silencing of both TSP1 and 2 affected 
trypanosome culture growth and SL RNA abundance in the cells. Moreover, depletion of TSP2 
from extract completely abolished transcription from the SLRNA promoter (Lee et al., 2009). 
Interestingly, trypanosome TFIIH lacked the CAK complex, which consists of CDK7, cyclin H 
and MAT1. Potential homologs of these proteins did not co-purify with TFIIH subunits and  the 
electron microscopic structure of TFIIH in T. brucei lacked the characteristic knob-like structure 
that corresponds to the CAK complex in the human TFIIH. This suggested that, unlike in the 
model organisms, trypanosomatid TFIIH does not have kinase activity to phosphorylate the 
polymerase’s CTD (Lee et al., 2009). Nonetheless, the TFIIH complex was indispensable for 
SLRNA transcription, and localized to the putative sites of SLRNA synthesis (Lee et al., 2009; 
Lee et al., 2007). Finally, the trypanosome TFIIH complex associated with another protein 
complex of at least nine subunits termed Med-T that is essential for cell-survival, SLRNA 
transcription and PIC assembly. Molecular structure analysis by electron microscopy revealed 
that Med-T is similar to the head module of the mediator complex of higher eukaryotes. This 
was the first evidence that the mediator complex plays a role in the transcription of an snRNA 
gene (Lee et al., 2010).  
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   Taken together, the current repertoire of BTFs for SLRNA transcription in trypanosomes 
includes 25 unique proteins with orthologs of all known BTFs except TFIIF. Thus, the 
transcription machinery in trypanosomes is not as simplified as it was initially speculated. Since 
gene sequences in trypanosomes are highly divergent from those of the model organisms, 
standard genome annotations failed to identify these factors. However, functional 
characterizations have clearly demonstrated that a PIC is assembled at the SLRNA promoter 
that, albeit extremely divergent in amino acid sequence, closely resembles the PIC in other 
eukaryotes.  
 While a PIC is formed for SLRNA transcription in trypanosomes, there are some 
important distinctions between BTFs of trypanosomes and humans. For example, high-
resolution crystal structure of the C-terminal domain of trypanosome TFIIB revealed 
trypanosome specific structural attributes that are absent in human TFIIB (Ibrahim et al., 2009). 
Additionally, trypanosome TFIIH has unique features that distinguish it from human TFIIH. 
Firstly, while two divergent paralogs of the TFIIH helicase Xeroderma pigmentosum B (XPB) are 
present in the genome, only the larger of the two was identified as a TFIIH subunit. Secondly, 
trypanosome TFIIH lacks the CAK complex (Lee et al., 2009; Lee et al., 2007), which has 
essential function in RNA pol II CTD phosphorylation and promoter escape (Compe and Egly, 
2012). Despite the apparent lack of CAK complex, the CTD of trypanosome RPB1 is 
phosphorylated and important for SLRNA transcription (Chapman and Agabian, 1994; Das and 
Bellofatto, 2009).   
5. The TFIIH complex is essential for transcription and DNA repair 
5.1 The multifunctional TFIIH complex of eukaryotes 
 The multisubunit TFIIH is an essential component of the RNA pol II PIC amongst all 
eukaryotes. Apart from its essential role in transcription initiation by RNA pol II, it has also been 
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  shown to function as an elongation factor in RNA pol I transcription (Assfalg et al., 2012) and as 
a DNA repair factor for nucleotide excision repair of helix-distorting lesions that are generated 
after exposure to UV light or certain chemical agents (Compe and Egly, 2012). Conserved from 
yeast to mammals, TFIIH is composed of ten subunits that are present in two subcomplexes. 
The core complex consists of the two DNA helicases XPB & XPD, p62, p52, p44, p34 and the 
repair specific subunit TTDA. XPD connects the core to the tripartite CAK subcomplex of CDK7, 
cyclin H and MAT1.  
 Mutations in TFIIH subunits XPB, XPD and TTD-A are responsible for autosomal 
recessive disorders of Xeroderma pigmentosum (XP), Trichothiodystrophy (TTD) and Cockayne 
Syndrome. Patients with XP have a 1000-fold increase risk of developing skin cancer in addition 
to neurological and sexual developmental defects. Cockayne syndrome is associated with 
dwarfism, mental retardation, microcephaly etc. Lastly, patients with TTD experience 
neurological problems including retardation, tremors and ataxia, have short stature and develop 
sterility. For a long time clinical symptoms of these diseases were attributed to impairment of 
nucleotide excision repair (NER) of damaged DNA in patients, but it is now becoming clear that 
at least some of the symptoms are due to transcriptional defects of specific genes (Compe and 
Egly, 2012).  
 TFIIH was initially identified as a factor that is indispensable for basal transcription by 
RNA pol II (Flores et al., 1992). The enzymatic activities of the ATP dependent DNA helicase 
XPB and the cyclin dependent kinase CDK7 are essential for basal RNA pol II transcription. The 
ATPase activity of XPB facilitates melting of promoter DNA that allows RNA pol II to read the 
coding strand and initiate transcription. Subsequently, CDK7 of the CAK complex 
phosphorylates the CTD of RPB1, the largest subunit of RNA pol II (Compe and Egly, 2012). In 
most eukaryotes, the CTD is composed of 5-52 repeats of the heptad sequence motif 
‘YSPTSPS’. Post-translational modifications of the CTD regulate different stages of RNA pol II 
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  transcription (Buratowski, 2009). Specific post-translational modifications also facilitate 
association of the CTD with various mRNA processing factors. RNA pol II that is recruited to a 
promoter is typically hypo-phosphorylated at the CTD. Phosphorylation of the CTD at Serine 5 
of the heptad repeat by CDK7 enables promoter clearance of RNA pol II and allows the enzyme 
to dissociate from most BTFs (Egloff et al., 2010; Phatnani and Greenleaf, 2006). Additionally, 
CDK7 is implicated in the phosphorylation of the serine at position 7 of the CTD heptad repeat. 
The exact role of serine 7 phosphorylation for transcription of protein coding genes is not clear, 
although it is suggested that the bivalent marks might play a role in recruiting specific RNA 
processing factors (Akhtar et al., 2009; Glover-Cutter et al., 2009). On the other hand, serine 7 
phosphorylation by CDK7 at U snRNA genes is important for recruitment of the Integrator 
complex, which plays a role in 3′ processing of snRNAs (Egloff et al., 2007; Kim et al., 2009). In 
summary, TFIIH is a BTF that plays an essential role in transcription initiation, promoter 
clearance and recruitment of various processing factors during RNA pol II transcription. 
  Even before XPB and XPD helicases were identified as subunits of TFIIH, they 
were known to be important for NER of damaged DNA. Both of these helicases belong to the 
SF2 family of helicases and contain seven conserved helicase motifs. But while XPB is a 3/ - 5/ 
helicase, XPD is a 5/ - 3/ one. Interestingly, while ATPase activity of XPB is essential for both 
transcription and repair, its helicase activity is not required for DNA repair (Coin et al., 2007; Lin 
et al., 2005). Conversely, the helicase activity of XPD is essential for NER (Coin et al., 2007; 
Tirode et al., 1999). It is proposed that XPB is involved in anchoring of TFIIH complex to the 
sites of DNA damage (Oksenych et al., 2009) while XPD opens the damaged DNA that allows 
subsequent NER factors to repair the damage (Coin et al., 1998a; Coin et al., 1998b). Another 
subunit of TFIIH that is especially important for DNA repair is TTD-A (a.k.a. Tfb5). While 
recombinant TFIIH complex containing all nine subunits except for TTD-A, was competent in 
transcription assays, its repair activity was much reduced. Addition of TTD-A restored the in-
vitro repair activity of the recombinant TFIIH, clearly demonstrating the importance of TTD-A in 
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  NER (Coin et al., 2006). In addition to the XPB, XPD and TTD-A subunits that appear to have a 
direct role in DNA repair, other subunits of TFIIH perform regulatory functions. p52 and TTD-A 
stimulate the ATPase activity of XPB while p44 and p34 are known to stimulate the helicase 
activity of XPD.  
 The main function of TFIIH in NER is to unwind the DNA at the site of damage, allowing 
subsequent repair factors to access the damaged DNA and repair the defect (Compe and Egly, 
2012). NER is triggered when XPC-RAD23B recognizes the DNA lesions that are generated 
due to exposure to UV light or certain genotoxic chemicals such as cisplatin (Mocquet et al., 
2007; Sugasawa et al., 2001). These lesions include covalently linked bulky DNA adducts that 
distort the double helical structure. UV-induced lesions are also recognized by UV-damaged 
DNA binding (UV-DDB) proteins, which in turn, recruit XPC to the damage site (Fei et al., 2011; 
Fitch et al., 2003; Wang et al., 2004). In the transcription-coupled NER (TC-NER) pathway, 
which involves repair of DNA lesions on genes that are being transcribed, damage detection is 
mediated by stalled RNA pol II along with the Cockayne syndrome type B (CSB) protein 
(Hanawalt and Spivak, 2008). Subsequent to damage recognition, TFIIH enters the site of 
lesion, and unwinds the DNA with the help of XPB and XPD helicases (Compe and Egly, 2012; 
Oksenych and Coin, 2010). XPA and Replication Protein A (RPA) are then recruited to stabilize 
the TFIIH-XPC complex and protect the single-stranded DNA respectively (Aboussekhra et al., 
1995; Krasikova et al., 2010). Next, the NER endonucleases XPF and XPG incise the damaged 
DNA at 5′ and 3′ sides, respectively (Evans et al., 1997). This results in removal of an 
oligonucleotide that is about 27 nucleotides long, encompassing the DNA lesion. After XPF 
generates the 5′ incision, XPC, TFIIH and XPA are released from the reaction and recycled 
(Coin et al., 2008). Prior to the 3′ incision, RPC and Proliferating Cell Nuclear Antigen (PCNA) 
and DNA polymerases are recruited to the site of damage (Staresincic et al., 2009). 
Subsequently, DNA polymerases fill the gap and DNA ligases seal the newly synthesized DNA 
26
	  (Lehmann, 2011). It appears that in non-dividing cells, DNA polymerase δ (Pol δ) and Pol κ 
synthesize DNA (Ogi et al., 2010), and DNA ligase III–X-ray repair cross-complementing protein 
1 (XRCC1) performs ligation while in diving cells synthesis also needs Pol ɛ (Ogi et al., 2010) 
and ligation is mediated by both DNA ligase III–XRCC1 and DNA ligase I–flap endonuclease 1 
(FEN1) (Moser et al., 2007).  In a final step, chromatin assembly factor 1 (CAF1) repositions the 
nucleosomes on the repaired DNA (Gaillard et al., 1996) (Reviewed in (Compe and Egly, 
2012)).  
5.2 Unique features of trypanosome TFIIH 
 As mentioned earlier, trypanosome TFIIH is composed of the orthologs of XPD, XPB, 
p52, p62, p34, p44 and TTD-A, and two trypanosomatid specific subunits which are 
indispensable for SLRNA transcription (Lee et al., 2009; Lee et al., 2007). Surprisingly, 
annotation of completely sequenced genomes showed that trypanosomatids have two divergent 
XPB genes. The sequences of the XPB paralogs from T. brucei exhibit only 24.2% identity and 
37.1% similarity, indicating that this XPB dualism is not the result of a recent gene duplication 
event. Moreover, two divergent XPB genes are present in all kinetoplastids whose genome has 
been completed, suggesting that the XPB dualism is not restricted to trypanosomatid 
organisms. Interestingly, only the larger of the two XPB proteins co-purified with T. brucei TFIIH  
leaving the functional role of the smaller XPB paralog undetermined. 
 The study described in Chapter II is the functional characterization of the smaller 
XPB paralog termed XPB-R (R for repair). This study identified that while XPB-R  was 
dispensable for SLRNA and protein coding gene transcription, it was essential for NER in 
T. brucei. Our results also suggest that although XPB-R is not assembled in a TFIIH 
complex, it interacts with the p52 subunit of TFIIH. In other eukaryotes, it has been 
shown that p52 regulates XPB activity and interacts directly with XPB. Consistent with 
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  this, a knockdown of p52 also impaired NER in T. brucei. To our knowledge, this is the 
first study that demonstrates a TFIIH independent function of XPB for NER in any 
eukaryotic organism.  
 Another interesting feature of trypanosome TFIIH is the apparent lack of the CAK sub-
complex that is typically associated with TFIIH in all eukaryotes (Lee et al., 2009). As introduced 
above, the CAK enzyme CDK7 plays a crucial role in RNA pol II transcription by 
phosphorylating the CTD of RPB1. Interestingly, a comparative genomics study indicated that 
organisms that lack the heptad repeat motif in the CTD do not possess orthologs of CDK7 (Guo 
and Stiller, 2004). Accordingly, the finding that trypanosome TFIIH is not associated with a CAK 
complex was consistent with the fact that there are no heptad repeats in trypanosomatid 
RPB1s. Despite the absence of heptad repeats, the trypanosome CTD of RPB1 is 
phosphorylated (Chapman and Agabian, 1994; Das and Bellofatto, 2009). Moreover, it was 
shown that deletion of a major part of T. brucei CTD is lethal for cells and abolishes RNA pol II 
transcription (Das and Bellofatto, 2009). However, the kinase that phosphorylates the CTD and 
the functional significance of CTD phosphorylations in trypanosomes is not yet known although 
a recent study suggests that chromatin-associated RNA pol II is phosphorylated at the CTD 
(Rocha et al., 2014). In summary, these results indicated that trypanosomes possess a so-
called transcriptional CDK that controls RNA pol II phosphorylation and function. This prospect 
was exciting since CDKs, in contrast to almost all other transcription factors, are promising 
targets of chemotherapy. 
5.3 CDKs are essential regulators of the cell cycle and of gene expression 
 CDKs form a special class of serine-threonine kinases that require association with their 
regulatory partners called cyclins for kinase activity. CDK/cyclin complexes were first identified 
in yeast as key regulators of cell cycle progression (Beach et al., 1982; Nasmyth and Reed, 
1980). Although now it is well established that several CDK/cyclin complexes have crucial 
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  functions in transcription and RNA splicing (Lim and Kaldis, 2013; Loyer et al., 2005). CDKs 
share a conserved catalytic domain that consists of the ATP binding pocket, PSTAIRE-like helix 
domain responsible for cyclin binding and an activating T-loop motif. Association of cyclin to the 
PSTAIRE domain confers spatial reorientation of the T loop that enables substrate binding (Cao 
et al., 2014; Malumbres et al., 2009). While Saccharomyces cerevisiae encodes for six 
members of the CDK family and about 23 cyclins, the human CDK family is composed of 13 
established members that associate with 29 cyclins or cyclin-related proteins (Malumbres and 
Barbacid, 2009).  
  Pioneering studies in yeast showed that a single CDK − Cdc28p in Saccharomyces 
cerevisiae and cdc2 in S. pombe − controls the progression through the cell cycle by binding to 
specific cyclins at different stages (Beach et al., 1982; Evans et al., 1983; Nurse and Thuriaux, 
1980; Reed et al., 1982). In contrast to yeasts, many more CDKs and cyclins are involved in cell 
cycle regulation in mammals. These include CDK2, CDK4 and CDK6 also referred as 
interphase CDKs, CDK1 (a.k.a. cell division control protein 2 (CDC2)), and ten cyclins belonging 
to the classes of A-, B-, D- and E-type cyclins (Malumbres and Barbacid, 2009). According to 
the classical model, specific CDK-cyclin pairs control distinct events during the mammalian cell 
cycle. In response to mitogenic stimulus, D-type cyclins are expressed that preferentially bind to 
CDK4 and CDK6 during G1 phase. Activation of CDK4 and CDK6 stimulates the expression of 
E-type cyclins which bind and activate CDK2. The expression and availability of E-type cyclin is 
tightly restricted to the early stage of DNA replication. During the late stages, CDK2 interacts 
with cyclin A2 to drive the transition from S to G2 phase of cell cycle. Next, CDK1 activation by 
A-type cyclins drives initiation of mitosis. Subsequent to the breakdown of nuclear envelope, A-
type cyclins are rapidly degraded and CDK1 interacts with cyclin B to drive mitosis (reviewed in 
(Malumbres and Barbacid, 2009)). However, in recent years the classical model has been 
challenged by the studies that show that CDK2, CDK4 and CDK6 are not essential for the cell 
cycle (Berthet et al., 2003; Malumbres et al., 2004; Martin et al., 2003; Mettus and Rane, 2003; 
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  Ortega et al., 2003; Rane et al., 1999). Instead, they regulate specific functions in specialized 
cell types. For instance CDK4 is important for development of pancreatic β cells (Rane et al., 
1999) while CDK2 is essential for meiotic division in germ cells (Berthet et al., 2003; Ortega et 
al., 2003).  
 While CDKs that are important for the cell cycle are regulated by their sequential binding 
to different cyclins, each of which are transcribed and degraded at definite stages during the cell 
cycle, the CDKs and cyclins that are involved in gene expression appear to be constitutively 
expressed throughout the cell cycle. CDK7 is a unique CDK that has roles in both cell cycle and 
transcription regulation (Fisher, 2005). It associates stoichiometrically with Cyclin H and a RING 
finger domain containing protein, MAT1 forming a trimeric complex of CDK7/Cyclin H/MAT1 
called the CDK activating kinase (CAK) complex because of its ability to phosphorylate and 
activate key cell cycle CDKs at the T loop (Fisher, 2005; Roy et al., 1994; Serizawa et al., 1995; 
Shiekhattar et al., 1995). MAT1 functions as an assembly factor (Fisher et al., 1995; Tassan et 
al., 1995) and interacts directly with both Cyclin H and CDK7 (Busso et al., 2000).  
 Another CDK/cyclin complex that appears to function both in gene expression and cell 
cycle is the CDK11/cyclin L complex. As a result of alternative splicing and exon skipping, 
different isoforms of CDK11 are produced which are grouped as CDK11p110 and CDK11p58 
proteins based on their size. While CDK11p58 isoforms are only expressed during G2/M phase 
and are implicated in mitosis, CDK11p110 forms are constitutively expressed and have a role in 
transcription and pre-mRNA splicing (Hu et al., 2003; Loyer et al., 1998; Trembley et al., 2004). 
CDK11p110 associates with RNA pol II as well as the splicing factors RNPS1 and 9G8, and it was 
shown to phosphorylate the SR protein 9G8 (Hu et al., 2003). Phosphorylation of 9G8 is critical 
for its role in pre-mRNA splicing and export of mRNA from nucleus to cytoplasm. Thus, 
CDK11p110 might regulate splicing by controlling the phosphorylation status of 9G8 (Dickinson et 
al., 2002; Hu et al., 2003; Loyer et al., 2008; Loyer et al., 1998). 
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   Two other CDK/cyclin complexes known to function in transcription are CDK8/cyclin C 
and CDK9/cyclin T. CDK8/cyclin C associates with the Mediator complex and functions as a 
transcriptional repressor by phosphorylating cyclin H, which deceases the activity of TFIIH on 
the CTD (Akoulitchev et al., 2000). Conversely, CDK9/cyclin T, a.k.a. positive transcription 
elongation factor b (P-TEFb), promotes transcription elongation by RNA pol II by 
phosphorylating the CTD at Serine 2 of the heptad repeats (Ramanathan et al., 2001; Zhou et 
al., 2000).  
 In summary, CDKs are crucial regulators of the cell cycle and gene expression. CDKs as 
well as other kinases that control the cell cycle are often dysregulated during cancer leading to 
unrestricted cell proliferation (Malumbres and Barbacid, 2001). Since, kinases can be effectively 
inactivated by small molecule inhibitors, they are considered as relevant drug targets (Shapiro, 
2006). Pan-CDK inhibitor flavopiridol was the first CDK inhibitor to enter clinical trials.  It showed 
anti-tumor effects in leukemia cell and non-small cell lung cancer cell lines (Konig et al., 1997; 
Shapiro et al., 1999) as well as in patients with renal, prostate and colon cancer, metastatic 
gastric cancer and non-Hodgkin’s lymphoma during phase I clinical trials (Senderowicz et al., 
1998; Tan et al., 2002; Thomas et al., 2002). However it exhibited several adverse effects in 
patients and did not show significant advantages in phase II and III clinical trials (Aklilu et al., 
2003; Burdette-Radoux et al., 2004; Schwartz et al., 2001; Shapiro et al., 2001).  As of 2013, 
there were at least 40 ongoing clinical studies with several first and second-generation CDK 
inhibitors (Pitts et al., 2014). Currently, more attention is focused on the development of 
selective ATP-noncompetitive CDK inhibitors that do not exhibit toxicity that pan CDK showed in 
previous clinical trials (Abate et al., 2013). 
5.4 T. brucei CRK9 is a transcriptional CDK 
 T. brucei contains eleven CDKs, termed cdc2-related kinases (CRK)1-4 and CRK6-12 
and 10 cyclins (CYC2-11) (Hammarton, 2007; Naula et al., 2005). Due to high sequence 
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  divergence of trypanosome CDKs, it has been impossible to identify their putative orthologs in 
other eukaryotes without functional validation. Due to their potential druggability, trypanosomatid 
kinases have constantly been a subject of interest. A number of studies have been performed to 
identify essential CDKs in T. brucei (Jones et al., 2014; Mackey et al., 2011; Merritt and Stuart, 
2013). RNAi mediated gene knockdowns identified CRK1-4, CRK6, CRK9, and CRK12 as 
crucial for cell survival in T. brucei (Jones et al., 2014). CRK3 appears to be the functional 
homolog of CDK1 in trypanosomes. It partners with CYC6 (a.k.a. cyclin B2) and regulates 
mitosis (Hammarton et al., 2003; Li and Wang, 2003; Tu and Wang, 2004). CRK1 is important 
for G1/S progression and interacts with CYC2 in a yeast two-hybrid screen although interaction 
was not observed in vivo (Gourguechon et al., 2007; Tu and Wang, 2004; Van Hellemond et al., 
2000). In addition, CRK2, CRK4 and CRK6 appear to have accessory functions in the cell cycle 
although their cyclin partners are unknown (Tu and Wang, 2005). Recently CRK12 was shown 
to associate with CYC9 during TAP. Both CYC9 and CRK12 were essential in the human-
infective bloodstream stage of T. brucei, but gene silencing resulted in distinct phenotypes 
suggesting that while CYC9 is important for cytokinesis, CRK12 has a role in endocytosis 
(Monnerat et al., 2013).  
 In an attempt to identify the trypanosome CDK that is involved in CTD 
phosphorylation, we performed RNAi-mediated gene knockdowns of CRK1, CRK3, CRK7 
and CRK9 since CRK1, CRK3 and CRK9 were shown to be most important for 
trypanosome survival (Gourguechon and Wang, 2009; Tu and Wang, 2004) and CRK7 was 
speculated to be the ortholog of CDK7 based on sequence similarity (Parsons et al., 
2005). In a study described in chapter III, we identified that CRK9 is required for RPB1 
phosphorylation in T. brucei. Interestingly, CRK9 silencing did not lead to a specific 
defect in RNA pol II transcription; instead it caused SL RNA cap4 hypomethylation and a 
block at the first step of SL trans splicing. This study is the first identification of a 
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  trypanosome CDK that is essential for phosphorylation of RNA pol II and parasite 
specific process of trans splicing.  
 In a next step, I characterized the enzyme complex of this crucial CDK by TAP of 
CRK9. This led to identification of a putative tripartite complex comprised of CRK9, a 
previously unannotated cyclin termed CYC12, and a third protein termed CRK9AP with 
no obvious conserved sequence motifs. Gene silencing analysis identified CYC12 and 
CRK9AP as functional partners of CRK9 in vivo. A phylogenetic analysis suggested that 
CYC12 is an L-type cyclin, which, in other eukaryotes, associates with CDK11, a CDK that 
is involved in transcription and RNA splicing. However, the presence of CRK9AP in the 
enzyme complex distinguishes CRK9 from CDK11. CRK9AP appears to be important for 
enzyme complex assembly or stability, since its ablation led to rapid co-depletion of the 
other two proteins. Moreover, we validated in the mouse host that this unusual key 
enzyme is a suitable target for chemotherapy. This work is discussed in Chapter IV.  
 Lastly, due to CRK9’s putative role in the trans splicing process we renewed our 
interest in the trypanosome spliceosome, focusing on the non-snRNP PRP19 complex, 
which is important for the activation of the spliceosome. Most interestingly, we 
discovered that ablation of the PRP19 complex, in contrast to that of an essential U6 
snRNP protein, led to similar defects in trans splicing, cap4 formation and RPB1 
phosphorylation as we observed upon CRK9 depletion, indicating that CRK9 acts 
upstream of spliceosome activation. The functional and biochemical characterization of 
the trypanosome PRP19 complex was a collaborative study with Dr. Daniela Ambrósio 
and is described in Chapter V. 
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Chapter II 
 
Trypanosoma brucei harbors a divergent XPB helicase 
paralog that is specialized in nucleotide excision repair and 
conserved among kinetoplastid organisms 
 
 
1. Abstract 
 Conserved from yeast to humans, TFIIH is essential for RNA polymerase II transcription 
and nucleotide excision repair (NER). TFIIH consists of a core that includes the DNA helicase 
Xeroderma pigmentosum B (XPB) and a kinase subcomplex. Trypanosoma brucei TFIIH 
harbors all core complex components and is indispensable for RNA polymerase II transcription 
of spliced leader RNA genes (SLRNAs). Kinetoplastid organisms, however, possess two highly 
divergent XPB paralogs with only the larger being identified as a TFIIH subunit in T. brucei. 
Here we show that a knockout of the gene for the smaller paralog, termed XPB-R (R for repair) 
resulted in viable cultured trypanosomes that grew slower than normal. XPB-R depletion did not 
affect transcription in vivo or in vitro and XPB-R was not found to occupy the SLRNA promoter 
which assembles a RNA polymerase II transcription pre-initiation complex including TFIIH. 
However, XPB-R-/- cells were much less tolerant than wild-type cells to UV light- and cisplatin-
induced DNA damage, which require NER. Since XPB-R-/- cells were not impaired in DNA base 
excision repair, XPB-R appears to function specifically in NER. Interestingly, several other 
protists possess highly divergent XPB paralogs suggesting that XPBs specialized in 
transcription or NER exist beyond the Kinetoplastida. 
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  2. Introduction 
 The multi-subunit transcription factor TFIIH is of central importance to transcription 
initiation by RNA polymerase II and DNA nucleotide excision repair (NER) in yeast and 
mammalian systems (Compe and Egly, 2012; Feaver et al., 1993; Schaeffer et al., 1993). It 
consists of two sub-complexes: the core and the cyclin activating kinase (CAK) complex. The 
core complex includes the two ATP-dependent DNA helicases Xeroderma pigmentosum B 
(XPB, also known as ERCC3, RAD25, SSL2), and XPD (also known as ERCC2, RAD3), their 
respective regulators p52 and p44 along with p62, p34 and p8 (also known as TTDA, TFB5). 
XPD connects the core complex to the CAK complex which consists of cyclin-dependent kinase 
7 (CDK7), cyclin H and MAT1. Both XPB and XPD belong to the SF2 superfamily of helicases 
and contain seven characteristic helicase motifs, namely Walker motifs I, Ia, II, III, IV, V, and VI. 
While XPB is a 3/ - 5/ helicase, XPD exhibits 5/ - 3/ activity. Recent studies in human cells have 
demonstrated that these helicases have distinct roles in NER and transcription. The ATPase 
activity of XPB is essential for DNA opening in both repair and transcription while its helicase 
activity is specifically important for transcription: by unwinding DNA it facilitates RNA pol II 
escape from the promoter (Coin et al., 2007; Lin et al., 2005). The TFIIH subunit p52 directly 
interacts with an N-terminal region of XPB, termed XPB domain, and regulates its ATPase 
activity (Coin et al., 2007; Jawhari et al., 2002). In contrast, XPD helicase activity is essential for 
NER whereas it appears to be dispensable for transcription initiation (Coin et al., 2007; Tirode et 
al., 1999). Given the importance of these helicases in NER, it is not surprising that mutations in 
XPB and XPD cause deficiency in NER leading to the human diseases Xeroderma 
pigmentosum, Cockayne Syndrome and Trichothiodystrophy (Compe and Egly, 2012).  
 XPB homologs have been identified in both bacteria and archaea (Balasingham et al., 
2012; Biswas et al., 2009; Richards et al., 2008). Recent data suggest that archaeal XPB 
functions in NER. Crystal structure data of XPB from the archaeon Archaeoglobus fulgidus 
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  revealed a DNA damage recognition domain (Fan et al., 2006), and a functional analysis of the 
association between Sulfolobus solfataricus XPB and BAX1 endonuclease showed that this 
complex can recognize, unwind and cleave model NER substrates in vitro (Rouillon and White, 
2010). Moreover, homologs of other eukaryotic NER proteins have been identified in archaeal 
organisms as well (Rouillon and White, 2011). Conversely, the bacterial NER pathway is 
controlled by so-called Uvr proteins whose amino acid sequences are different from those of 
eukaryotic NER proteins (Truglio et al., 2006). Interestingly, bacterial and archaeal XPB appears 
to function independently of a TFIIH complex since, except for XPD, TFIIH subunit homologs 
have remained elusive in these organisms (Rouillon and White, 2011). 
 In eukaryotes, XPB exerts its dual function in transcription and DNA repair exclusively 
within a TFIIH complex (Compe and Egly, 2012). Notably, the completed genomes of members 
of the protistan family Trypanosomatidae, which include the human parasites Trypanosoma 
brucei, Trypanosoma cruzi and Leishmania major, harbor two distinct XPB genes that encode 
two divergent XPB paralogs (Ivens et al., 2005). The T. brucei TFIIH complex has been 
functionally, biochemically and structurally characterized, and has been shown to have a basal 
function in RNA polymerase II transcription as in other eukaryotes (Lecordier et al., 2007; Lee et 
al., 2010). This function, however, may be restricted to a single gene, namely the spliced leader 
(SL) RNA gene (SLRNA). In trypanosomatids, protein coding genes are arranged in long 
tandem arrays that are transcribed polycistronically. Individual mRNAs are then processed from 
precursor RNA by polyadenylation and SL trans splicing (Gunzl, 2010). Transcription of the 
gene arrays initiates predominantly in divergent strand-switch regions (dSSRs) in which the 
arrays are arranged head-to-head (Martinez-Calvillo et al., 2010; Martinez-Calvillo et al., 2003). 
While dSSRs typically harbor two peaks of open chromatin marks, it remains unclear whether 
basal transcription factors such as TFIIB or TFIIH are required for RNA pol II transcription 
initiation in these regions (see reviews by (Alsford et al., 2012) and Günzl, 2012) In contrast, 
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  SLRNA genes, which are tandemly linked on chromosome 9 and encode the SL donor in the 
trans splicing process, are transcribed monocistronically by RNA pol II from a concrete 
transcription initiation site. Accordingly, the SLRNA promoter assembles a conventional, albeit 
highly divergent, transcription pre-initiation complex which includes TFIIH (Preußer et al., 2012). 
The T. brucei TFIIH was characterized biochemically by tandem affinity purification revealing a 
full core of seven subunits and two additional subunits, termed TSP1 and TSP2, which most 
likely represent divergent subunit orthologs of the factor TFIIE (Lecordier et al., 2007; Lee et al., 
2009; Lee et al., 2007). Importantly, only the larger of the two XPB paralogs was identified in the 
TFIIH complex regardless of whether the complex was purified through tagging XPD or TSP2 
(Lecordier et al., 2007; Lee et al., 2009). 
 Here, we functionally characterized the smaller T. brucei XPB paralog which has 
previously been named XPBz (Lecordier et al., 2007). Our results showed that this helicase was 
neither important for transcription nor essential for the viability of the insect stage, procyclic form 
of the parasite in culture although the gene knockout did retard trypanosome proliferation. 
Instead, we found that the helicase specifically functioned in NER and, correspondingly, was 
localized throughout the nucleus. We therefore renamed this helicase XPB-R (R for repair). 
Furthermore, our results strongly indicate that XPB-R does not assemble into a TFIIH complex 
yet forms a repair complex with the trypanosome p52 ortholog. Interestingly, comparative 
genomics showed that the two divergent XPB orthologs are present in all kinetoplastids 
including the bodonid Bodo saltans and a phylogenetic analysis revealed that highly divergent 
XPB paralogs are present in distantly related protistan organisms suggesting that a bifunctional 
TFIIH complex is not the norm among deep branching eukaryotes. 
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  3. Materials and Methods 
3.1 DNAs 
 For XPB-R and p52 silencing, the coding region from position 8 to position 487 and from 
position 1 to 500, respectively, were integrated in a stem-loop arrangement (sense-stuffer-
antisense) into the pT7-stl construct (Brandenburg et al., 2007). For C-terminal PTP tagging of 
XPB-R, 499 bp of the 3/ terminal XPB-R coding sequence including an internal Bsgl linearization 
site were cloned into the pC-PTP-NEO vector using the vector’s ApaI and NotI restriction sites 
(Schimanski et al., 2005a). DNA oligonucleotides used for semi-quantitative RT-PCR or PCR 
are specified in Table S1 of the supplemental material. Plasmids used in dot blots were 
described previously and contained the complete coding regions of GPEET procyclin, α tubulin, 
actin, HSP70 and 18S rRNA or the threonine tRNA/U6 snRNA gene association (Schimanski et 
al., 2006). The template plasmids for in vitro transcription, GPEET-trm and SLins19, have been 
described previously (Gunzl et al., 1997; Laufer et al., 1999). 
3.2 Cells 
 T. brucei brucei 427 cell culture, stable transfection by electroporation, and the 
generation of clonal cell lines by selection and limiting dilution was carried out as described (Lee 
et al., 2007). In RNAi experiments, dsRNA synthesis was induced with 2 µg/ml of doxycycline. 
For measurement of procyclic and bloodstream form culture growth, cells were counted and 
diluted daily to 2 × 106 cells/ml and 2 × 105 cells/ml, respectively. The procyclic clonal XPB-R+/- 
cell line was generated by knocking out one of the XPB-R alleles with a PCR product in which 
101 bp of XPB-R 5/ and 3/ gene flanks were fused to the hygromycin phosphotransferase coding 
region. The clonal cell line that exclusively expressed XPB-R-PTP was obtained by targeted 
integration of the linearized plasmid XPB-R-PTP-NEO into the remaining XPB-R allele of the 
XPB-R+/- cell line. For HA tagging of p52, the construct p52-HA-BLA (Lee et al., 2007) was 
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  linearized with StuI and transfected into a clonal cell line that exclusively expressed XPB-R-
PTP. Immunoblotting was performed to confirm correct tagging of the protein in each clonal cell 
line. The XPB-R-/- KO-1 and KO-2 knockout cell lines were created by removing the remaining 
XPB-R allele in XPB-R+/- cells with a PCR product of the blasticidin-S deaminase coding region 
surrounded by 101 bp of XPB-R 5/ and 3/ gene flanks, and by limiting dilution of the cells 
immediately after transfection. Correct DNA integrations were ensured in clonal cell lines by 
PCR amplification of genomic DNA using oligonucleotides that hybridize outside of the 
transfected DNA constructs. 
3.3 RNA analysis 
 The relative abundance of RNAs in cells was determined by preparing total RNA from 8 
x 107 cells using Trizol reagent (Invitrogen), reverse transcription and semi-quantitative PCR. 
Reverse transcription was carried out with SuperScript II reverse transcriptase (Invitrogen) 
according to the manufacturer’s protocol using oligo-dT as primer. For semi-quantitative PCR, 
the number of cycles for the linear amplification range was determined empirically for each 
oligonucleotide pair. Labeling and analysis of nascent RNA using a permeabilized cell system 
was carried out as described previously (Schimanski et al., 2006). Quantification was performed 
by densitometry using ImageJ for SL RNA signals and by scintillation counting for dot blot 
signals. 
3.4 Protein Analysis 
 Immunoprecipitations (IPs) were performed as described previously (Lee et al., 2007). 
Briefly, for reciprocal co-IPs, 100 µl of crude extract was incubated with either 40 µl settled 
volume of IgG beads (Amersham, Piscataway, NJ) which interact with the PTP tag, or 25 µl 
settled volume of anti-HA antibody (Bedez et al., 2013) immobilized on protein G-Sepharose 
(Amersham). Once bound to protein G, the anti-HA antibody is unable to interact with the 
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  protein A domains of the PTP tag, ensuring that these beads precipitate HA-tagged protein only. 
After washing the beads six times with 700 µl of TET100 buffer (100 mM NaCl, 20 mM Tris-HCl, 
pH 8.0, 3 mM MgCl2, 0.05% Tween 20), PTP-tagged protein was released by AcTEV protease 
(Invitrogen) digestion, whereas HA-tagged protein was directly eluted into SDS loading buffer at 
100°C for 5 min. Precipitated complexes were analyzed by immunoblotting; PTP- and HA-
tagged proteins were detected on blots with the anti-protein C antibody HPC4 (Bedez et al.) or a 
monoclonal rat anti-HA antibody (Bedez et al.), and TSP2 with a polyclonal rat immune serum 
(Lee et al., 2009) in combination with the BM chemiluminescence blotting substrate (Bedez et 
al.) according to the manufacturer's specifications. 
 XPB-R-PTP was tandem affinity purified according to the standard PTP purification 
protocol (Schimanski et al., 2005a). Purified proteins were separated on a 10 to 20% SDS-
polyacrylamide gradient gel and stained with SYPRO Ruby (Invitrogen) according to the 
manufacturer's protocol. Proteins were trypsin digested, eluted from the gel and subjected to 
liquid chromatography-tandem mass spectrometry. 
 For sedimentation analysis, 200 µl of crude extract prepared from a clonal cell line 
expressing XPB-R-PTP and p52-HA was subjected to ultracentrifugation in 4 ml 10-40% linear 
sucrose gradients at 41,000 rpm for 16 h at 4°C as described previously (Lee et al., 2010). 
Twenty fractions were collected from top to bottom and protein in each fraction was collected 
with hydrophobic StrataClean resin (Stratagene, La Jolla, CA) as previously described 
(Schimanski et al., 2005a). Proteins were separated by denaturing PAGE and detected by 
immunoblotting. 
3.4 In vitro transcription 
 Preparation of extract active in transcription and the carrying out of in vitro transcription 
assays were performed as described previously (Laufer and Gunzl, 2001; Laufer et al., 1999). 
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  Newly synthesized RNAs of the GPEET-trm and SLins19 templates were detected by primer 
extension of 32P-end-labeled oligonucleotides Tag-PE and SLtag, which hybridize to unrelated 
oligonucleotide tags of the GPEET-trm and SLins19 RNAs. Primer extension products were 
resolved on 6% polyacrylamide-50% urea gels and visualized by autoradiography. 
3.5 Chromatin Immunoprecipitation 
 ChIP assays were performed as described previously (Lee et al., 2010). XPD-PTP- and 
XPB-R-PTP-bound chromatin fragments were immunoprecipitated overnight at 4°C with a 
polyclonal rabbit antibody directed against the protein A domains of the PTP tag (Kartalou and 
Essigmann). Immunoprecipitated DNA was analyzed by semiquantitative and quantitative real-
time PCR of the SLRNA promoter region (positions −90 to +63 relative to the transcription 
initiation site), the SLRNA intergenic region (+407 to +540), and the α-tubulin-coding region 
(+737 to +860 relative to the translation initiation codon) using the primer pairs listed in Table 
S1. For quantification of immunoprecipitated DNA, qPCR was performed using the SsoFast 
EvaGreen Supermix (BioRad) on a CFX96 cycler (BioRad) according to the manufacturer's 
recommendations. Two independent ChIP experiments were performed for both XPD-PTP and 
XPB-R-PTP cell lines. For each amplification and ChIP experiment, triplicate qPCR samples 
were analyzed using the Bio-Rad CFX Manager software package. The specificity of each 
amplification product was ensured by agarose gel electrophoresis and melting curve analysis. 
Standard curves for oligonucleotide pairs were obtained from serial dilution of input DNA. Their 
coefficient of determination (R2) value was above 0.98. Samples were standardized according to 
the starting quantities of tubulin DNA in each experiment and the fold enrichment values were 
calculated as the ratio between starting quantities of positive and control precipitations. 
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  3.6 Survival assays 
 Sensitivity of cells towards DNA damaging agents were tested at a cell density of 2 × 106 
cells/ml. For assessing UV irradiation effects, the wildtype (427) and knockout cells were 
exposed to doses of 300, 500 or 1000 J/m2 using the Stratalinker® UV Crosslinker (Stratagene). 
For Cisplatin (Kartalou and Essigmann) and MMS (Kartalou and Essigmann) sensitivity assays, 
cells were cultured with Cisplatin ranging from 0.5 to 10 µM and with MMS from 0.0001 to 
0.0004% for two days. In each case, treated and untreated control cell cultures were diluted 
daily to a concentration of 2 × 106 cells/ml. Total cell count was determined after two days and 
the survival was calculated as a percentage of untreated controls. In order to assess the 
sensitivity of RNAi cell lines towards UV irradiation, procyclic cell culture at the density of 2 × 
106 cells/ml was induced for dsRNA synthesis with 2 µg/ml of doxycycline. After 24 hours, 
induced and non-induced cells were diluted to a concentration 2 × 106 cells/ml and exposed to 
500 and 1000 J/m2 of UV light. The cells were counted 24 hours after exposure and the survival 
was determined as a percentage of untreated controls. 
 
3.7 Light Microscopy 
 
 Immunolocalizations were carried out as described previously (Luz Ambrósio et al., 
2009). XPB-R-PTP and XPD-PTP were detected with a rabbit polyclonal anti-protein A immune 
serum (Kartalou and Essigmann) followed by an Alexa 594-conjugated anti-rabbit secondary 
antibody (Invitrogen) whereas Tbp52-HA was visualized with a mouse monoclonal anti-HA 
antibody conjugated with fluorescein isothiocyanate (FITC; Sigma). Images were acquired on a 
Zeiss Axiovert 200 microscope equipped with DAPI (4′,6′-diamidino-2-phenylindole), EGFP, and 
Texas-Red filters using a 100× (1.3-numerical-aperture) oil immersion objective. 
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  4. Results 
4.1 XPB-specific domains are conserved in both trypanosome XPB and XPB-R. 
 Genome annotation of T. brucei identified two genes, Tb927.3.5100 and 
Tb927.11.16270 (accession numbers are from www.genedb.org; (Logan-Klumpler et al., 2012)), 
that encode XPB proteins with calculated masses of 105 kDa and 89 kDa, respectively 
(Berriman et al., 2005). The sequences of these two XPB paralogs are divergent, exhibiting only 
24.2% identity and 37.1% similarity between them according to a pair-wise alignment using the 
EMBOSS Needle server (http://www.ebi.ac.uk/Tools/psa/emboss_needle/). Despite this 
divergence both proteins are clearly XPB helicases: they harbor all seven Walker motifs of the 
SF2 superfamily of helicases and they possess an N-terminal XPB domain that interacts with 
the regulatory TFIIH subunit p52 (Coin et al., 2007; Jawhari et al., 2002), an XPB-specific R-E-D 
residue loop implicated in recognition of damaged DNA sites (Fan et al., 2006; Oksenych et al., 
2009), and an XPB signature sequence motif that was recently identified by a comparative 
genomics analysis (Figure. 2.1A and 2.1B) (Bedez et al., 2013). Both XPB paralogs are present 
in all sequenced kinetoplastid genomes, including that of the bodonid B. saltans, and a multiple 
sequence alignment showed that XPB domains are equally well conserved among the paralogs 
sequences (Attachment 1, Fig.S1). Moreover, the archaeal XPB structure revealed the 
presence of a Thumb-like domain (ThM) between Walker motifs III and IV that is structurally 
conserved in human XPB and thought to cooperate with the R-E-D loop in anchoring XPB to 
sites of DNA damage (Fan et al., 2006; Oksenych et al., 2009). While sequence conservation 
between human and archaeal ThM domains is very limited, there is clear sequence 
conservation between the human ThM sequence and the aligned kinetoplastid XPB sequences 
further supporting the notion that kinetoplastid organisms harbor two functional XPB paralogs 
(Attachment 1, Fig.S1). 
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   To further verify the nature of XPB-R, we tested whether this protein interacts with its 
functional partner p52. We created an insect-stage, procyclic T. brucei cell line in which XPB-R 
and p52 (accession number Tb927.10.5210) were C-terminally tagged with the composite PTP 
tag and the HA tag, respectively. Previously, we have shown that p52-HA interacted with XPD 
as part of the TFIIH complex and correctly localized to the nucleus, indicating that the tag does 
not interfere with p52 function (Lee et al., 2007). Similarly, cell proliferation assays (see below) 
indicated that XPB-R-PTP was functional as well. In whole cell lysates XPB-R-PTP was 
expressed as a single protein of correct size in two independently derived cell lines. However, in 
the extract sample, the appearance of a second band, which was 15 kDa smaller than the full 
length protein, suggested that some of XPB-R-PTP was cleaved at the N-terminus during 
extract preparation (Attachment 1, Fig.S4). Both bands were precipitated with IgG beads which 
bind to the protein A domains of the PTP tag (Figure 2.1C). p52-HA was co-precipitated but 
TSP2, a trypanosome TFIIH subunit partner of p52, was not. In the reciprocal anti-HA 
immunoprecipitation experiment, full length XPB-R-PTP was efficiently co-precipitated 
confirming the XPB-R/p52 interaction. The smaller, N-terminally degraded XPB-R-PTP form, 
however, did not interact with p52-HA which indicated that trypanosome XPB-R does possess a 
functional N-terminal p52 interaction domain. This negative co-precipitation result confirmed our 
previous finding (Nguyen et al., 2006) that protein G-bound anti-HA antibody does not co-
precipitate PTP-tagged protein non-specifically. As expected, TSP2 did co-precipitate with p52, 
verifying that both proteins are part of the same TFIIH complex. Together, these results showed 
that kinetoplastid organisms harbor two highly divergent XPB paralogs with conserved 
functional domains. Although T. brucei XPB-R was not detected in TFIIH complexes that were 
purified via tagged XPD or TSP2 (Lee et al., 2009), its interaction with p52 suggested that it is a 
functional enzyme in this parasite. 
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Figure 2.1 Trypanosomatids possess two different XPB helicases.  
A. Schematic (to scale) of human XPB (Hs XPB) and of T. brucei (Egloff et al.) XPB-R and XPB showing 
the XPB and RED domains, Walker motifs I, Ia, II-VI, and an XBP-specific sequence signature motif 
(Hegele et al.).  
B. Alignment of XPB and RED domain sequences from humans (Ivens et al.), Drosophila melanogaster 
(Ivens et al.), Caenorhabditis elegans (Ce), Saccharomyces cerevisiae (Sc), and T. brucei. Positions that 
are identical and similar across the model organisms are shaded in black and gray, respectively. Specific 
conservations in either TbXPB-R or TbXPB are shaded in pink and positions that are identical in 
trypanosome XPBs and different from those of the model organisms are shaded in cyan. Stars in the 
upper panel identify the phenylalanine and threonine residues found mutated in many Xeroderma 
pigmentosum patients. Stars in the lower panel identify Walker motif III and the R-E-D residue loop. 
C. Immunoprecipitation (IP) of either XPB-R-PTP (left panels) or p52-HA (right panels).Equivalent 
amounts of the input extract (Inp) and the supernatant (S) were analyzed whereas four times of the 
precipitate (4xP) were loaded. XPB-R-PTP was detected with the monoclonal anti-protein C epitope 
HPC4 antibody, p52-HA with a monoclonal anti-HA antibody, and the TFIIH subunit TSP2 with a 
polyclonal immune serum. Precipitated XPB-R-PTP was released from beads by TEV protease digest 
which removed the protein A domains, resulting in the smaller XPB-R-P protein. Asterisks identify the N-
terminally shortened XPB-R species seen in extract. 
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  4.2 Knockout of XPB-R retards trypanosome proliferation in culture. 
 
 Previously, XPB-R silencing in procyclic trypanosomes did not affect cell proliferation 
(Lecordier et al., 2007). We confirmed this result (data not shown) and, in addition, analyzed 
XPB-R silencing in bloodstream form trypanosomes by inducing synthesis of XPB-R dsRNA 
from a tetracycline operator-controlled stem-loop construct that had been integrated in 
tetracycline repressor-expressing single marker cells (Wirtz et al., 1999). Although semi-
quantitative reverse transcription (RT)-PCR showed that XPB-R mRNA was reduced after one 
and two days of induction, XPB-R silencing did not affect trypanosome proliferation suggesting 
that XPB-R is not an essential gene in either procyclic or bloodstream form trypanosomes 
(Attachment 1, Fig. S2). Accordingly, we succeeded in generating a procyclic XPB-R-/- knockout 
cell line in which the two XPB-R alleles were replaced by the hygromycin (HYGR) and blasticidin 
(BLAR) resistance markers (Figure 2.2A). After the second transfection of a single allele 
knockout XPB-R+/- cell line, we obtained two independently derived, double resistant XPB-R-/- 
cell lines which we termed KO-1 and KO-2. The gene knockouts were confirmed by a PCR of 
genomic DNA prepared from wild-type, XPB-R+/- and KO cell lines using primers that annealed 
to the 5/ and 3/ XPB-R gene flanks outside of the transfected, linear DNA constructs. While the 
KO cells gained HYGR- and BLAR-specific amplification products, they completely lost the wild-
type product (Figure 2.2B). Correspondingly, an RT-PCR analysis with oligonucleotides specific 
to the XPB-R coding region showed that the KO cells did not express XPB-R mRNA any longer 
(Figure 2.2C). The successful XPB-R knockout demonstrated that this gene was dispensable for 
cultured procyclics. However, the KO cell lines clearly grew slower than wild-type cells. While 
our wild-type strain had a doubling time of 8.5 hours, KO-1 and KO-2 cells doubled every 13.8 
and 15.6 hours, respectively (Figure 2.2D). This slow growth phenotype remained constant over 
a period of three months and was not affected by the presence or absence of antibiotics (data 
not shown). To determine whether the knockout delayed the cell cycle in a particular stage, we 
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  determined the number of kinetoplasts and nuclei in DAPI-stained wild-type and XPB-R-/- cells 
(n=100 for each cell line). Compared to the wild-type cell line, we found a strong accumulation 
of 2K2N cells (25% versus 6%) and a concomitant decrease of 1K1N trypanosomes (44% 
versus 68%) indicating a cell cycle-relevant function of XPB-R in late mitosis/cytokinesis 
(Attachment 1, Fig. S3) 
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Figure 2.2 A knockout of XPB-R increases the doubling time of trypanosomes in culture. 
A. Schematic (not to scale) of the XPB-R locus in wild-type and XPB-R-/- (KO) cells. In the latter, the XPB-
R coding regions of the two alleles were replaced with those of hygromycin phosphotransferase (HYGR) 
and blasticidin-S deaminase (BLAR). Oligonucleotides used for competitive PCR analysis of XPB-R, 
HYGR and BLAR alleles are indicated by arrows. 
B. Corresponding competitive PCR analysis of total DNA prepared from wild-type cells, cells in which one 
XPB-R allele was knocked out (XPB-R+/-), and two independently obtained XPB-R-/- knockout cell lines 
(KO-1, KO-2) 
C. RT-PCR of XPB-R and, as a control, of U2A/ mRNA. A control reaction with wild-type RNA in the 
absence of reverse transcriptase (-RT) demonstrated effective removal of genomic DNA from the RNA 
preparation. 
D. KO-1 and KO-2 cells have a prolonged doubling time versus wild-type cells. 
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  4.3 XPB-R does not function in transcription 
 To our knowledge eukaryotic XPB helicases function exclusively in transcription and 
NER. It was therefore possible that XPB-R had an important, albeit non-essential, function in 
transcription, possibly in a regulatory role. Since the SLRNA promoter is the only trypanosome 
promoter known to assemble an RNA pol II transcription pre-initiation complex including TFIIH 
(Lee et al., 2009), we first tested whether XPB-R occupies the SLRNA promoter by chromatin 
immunoprecipitation (ChIP). We previously showed that chromatin bound by PTP-tagged 
proteins can be highly enriched by a ChIP-grade, anti-protein A antibody (Lee et al., 2010). 
Accordingly, when we used a cell line that exclusively expressed functional XPD-PTP (Lee et 
al., 2007), we observed a 21 fold enrichment of the SLRNA promoter over a precipitation with a 
comparable non-specific immune serum (Figure 2.3A). This occupancy was strongly reduced in 
the SLRNA intergenic spacer approximately 500 bp downstream of the promoter, revealing the 
specificity of the ChIP assay. To analyze XPB-R in an equivalent way, we generated a cell line 
that exclusively expressed XPB-R-PTP. This was achieved by targeted integration of plasmid 
XPB-R-PTP-NEO into the remaining XPB-R allele of the single knockout XPB-R+/- cell line 
(Attachment 1, Fig. S4). To assess whether the PTP tag interferes with XPB-R function, we 
determined the doubling time of the XPB-R-PTP-expressing cells which, with 11.1 hours, was 
intermediate between wild-type and XPB-R-/- cells. Interestingly, single knockout XPB-R+/- cells 
exhibited a similarly prolonged doubling time (12 h) suggesting that maximal trypanosome 
proliferation requires a sufficiently high level of XPB-R and that the slower proliferation rate of 
XPB-R-PTP-expressing cells is due to haplo-insufficiency rather than a functionally deleterious 
PTP tag. Nevertheless, XPB-R-PTP did not occupy the SLRNA promoter, indicating that this 
helicase has no function in pre-initiation complex formation and RNA pol II transcription initiation 
(Figure 2.3A). 
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  To further validate this notion, we prepared transcriptionally active extract from XPB-R-PTP-
expressing cells and depleted the helicase by IgG affinity chromatography. Although the extract 
was almost fully depleted of XPB-R, it supported transcription of the SLRNA promoter template 
SLins19 equally well as mock-depleted extract did (Figure 2.3B). Accordingly, adding back 
tandem affinity-purified XPB-R (see below) to the extract had no impact on transcription 
efficiency. 
Finally, we employed permeabilization of wild-type and XPB-R-/- cells to label nascent RNA 
which, in this system, increases linearly for up to 20 minutes (Ullu and Tschudi, 1990). Due to a 
very strong synthesis rate, newly synthesized SL RNA can be directly visualized after 
separating labeled RNA by denaturing PAGE (Figure 2.3C). To assess protein coding gene 
transcription in these experiments, we hybridized the labeled RNA to dot blots of plasmids that 
contained whole coding regions (Figure 2.3D). Quantification of SL RNA bands by densitometry 
and of dots by scintillation counting in three independent experiments did not reveal any 
nascent RNA synthesis defect in XPB-R-/- cells in either KO cell line (Figure 2.3E). This was true 
for the RNA pol I transcripts 18S rRNA and GPEET procyclin mRNA, for the RNA pol II-
synthesized heat shock protein 70, actin and α tubulin mRNAs, and for the RNA pol III-derived 
threonine tRNA and U6 snRNA. Therefore, we concluded that XPB-R does not function in 
transcription. 
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Figure 2.3 XPB-R does not function in transcription. 
A. Anti-XPD-PTP and anti-XPB-R-PTP ChIP with a ChIP-grade, polyclonal anti-protein A antibody (α 
ProtA) and a comparable non-specific immune serum (nonsp. IS). Top panels, semiquantitative PCR of 
the SLRNA promoter (SL prom), the SLRNA intergenic region (SL intgen), and the α tubulin coding region 
(α tub cod). Lower panel, corresponding qPCR analysis showing the corrected fold difference of 
precipitated DNA over the nonspecific immunoprecipitation control. B. Co-transcription of the RNA pol I-
recruiting GPEET-trm template DNA and the SLRNA promoter template SLins19 in extract prepared from 
cells that exclusively express XPB-R-PTP. The extract was either mock-treated or depleted of XPB-R-
PTP by IgG affinity chromatography (depl). In a third reaction, tandem affinity-purified XPB-R was added 
to the XPB-R-PTP-depleted extract (depl + XPB-R elu). Main panel, transcription signals were obtained 
by primer extension of newly synthesized RNA with radiolabeled oligonucleotides specific for GPEET-trm 
or for SLins19 RNA. Left panel, detection of XPB-R-PTP including its partially degraded product (degrad 
prod) and, as a loading control, of U2A/ in mock-treated and XPB-R-PTP-depleted extract by 
immunoblotting. C. Nascent RNA was radiolabeled in permeabilized wild-type (Logan-Klumpler et al.), 
KO-1 and KO-2 cells, separated by denaturing PAGE, and visualized by autoradiography. Signals that 
correspond to tRNAs, the SL RNA, and pre-mRNA/pre-rRNA are indicated on the right. D. Labeled 
nascent RNA was hybridized to dot blots of plasmids containing the complete coding regions of GPEET 
procyclin, 18S rRNA, heat shock protein 70 (HSP70), actin and a tubulin. In addition, a plasmid harboring 
the coupled genes of threonine tRNA and U6 snRNA (tRNATHR/U6 snRNA) and a control plasmid without 
insert (ctrl) were analyzed. E. Quantification of RNA signals from three independent experiments. In each 
case the wild-type signal was set to 100. Error bars represent standard deviations. 
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  4.4  XPB-R is important for Nucleotide Excision Repair 
 NER is essential for the removal of covalently cross-linked bulky DNA adducts that 
cause a severe distortion of the DNA double helix. Formation of such DNA adducts can be 
induced by exposure to UV light or by treatment with cisplatin, strategies that have been 
employed in various systems (Kamileri et al., 2012) including trypanosomes (Sheader et al., 
2004). Ultraviolet (Van Hellemond et al.) radiation causes two major types of DNA lesions, 
namely cis-syn cyclobutane-pyrimidine dimers and 6,4 pyrimidine-pyrimidine photoproducts, 
both of which distort the helical structure of DNA (Thoma, 1999). To determine the role of XPB-
R in the repair of UV-induced DNA lesions, wild-type and XPB-R-/- cells were treated with 
increasing doses of UV radiation. (Figure 2.4A) Two days after the exposure, cell densities were 
determined and compared to those of untreated control cells. Even at the lowermost dose of 
300 J/m2, XPB-R-/- cells showed only 17.4% survival as compared to untreated XPB-R-/- cells 
while 75.3% of wild-type cells that had received the same dose survived relative to the 
untreated wild-type control. This indicated that the repair of DNA lesions that require NER is 
strongly impaired in XPB-R-/- cells. To validate this result, wild-type and XPB-R-/- cells were 
exposed to increasing concentrations of cisplatin, a chemical that induces the formation of bulky 
DNA lesions. The majority of cisplatin-induced lesions are 1,2-intrastrand crosslinks between 
adjacent guanines or between guanine and adenine both of which are efficiently removed by 
NER (Kartalou and Essigmann, 2001). As shown in figure 2.4B, XPB-R-/- cells were more 
sensitive towards cisplatin treatment than wild-type cells. For example, while treatment with 1 
µM of cisplatin reduced wild-type cell survival to 65.5%, only 33.5% of XPB-R-/- cells survived 
the same treatment. Taken together, the increased sensitivity of XPB-R-/- cells towards UV 
radiation and cisplatin strongly indicated direct involvement of XPB-R in NER. 
To assess whether XPB-R’s role in DNA repair is specific to NER, cells were treated with 
methylmethane sulfonate (MMS), an alkylating agent that methylates DNA on N7-deoxyguanine 
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  and N3-deoxyadenine. MMS causes formation of DNA base lesions that are repaired by the 
base excision repair (BER) pathway. If left unrepaired, these MMS-induced lesions can cause 
stalling of replication forks and lead to single or double strand DNA breaks (Brem et al., 2008). 
Despite using a range of different MMS concentrations, we did not detect a significant difference 
between XPB-R-/- cells and wild-type cells in their sensitivity towards MMS (Figure 2.4C). We 
therefore concluded that XPB-R is specifically important for NER and not required for BER. 
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Figure 2.4 XPB-R-/- cells are specifically sensitive to DNA lesions requiring NER. 
Wild-type (Logan-Klumpler et al.) and KO-1 cell survival after treatment with (A) UV light, (B) cisplatin or 
(C) methyl methanesulfonate (MMS) was determined relative to untreated wild-type and KO-1 cells, 
respectively. The results were obtained from three independent experiments. Error bars represent 
standard deviations. 
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  4.5  An XPB-R/p52 complex functions independently of a TFIIH complex 
 Previously, the T. brucei TFIIH complex was isolated and mass spectrometrically 
analyzed in four independent experiments: it was purified using XPD as bait by two different 
research groups (Lee et al., 2009; Lee et al., 2007) or through tagging TSP2 (Lee et al., 2009), 
and it was co-purified as an associated complex of the multi-subunit mediator complex (Lee et 
al., 2010). In each case, XPB was identified as a TFIIH subunit whereas XPB-R was never 
found. Although unlikely, it is possible that XPB-R is part of a distinct TFIIH complex of minor 
abundance that was not detected in these biochemical protein complex characterizations. To 
facilitate XPB-R detection in isolated TFIIH complexes, we tried unsuccessfully to raise a 
specific polyclonal immune serum in rats against two partial, recombinant XPB-R proteins that 
were fused to the GST tag and purified from Escherichia coli (data not shown). Next, we carried 
out a tandem affinity purification of XPB-R-PTP(Attachment 1, Fig. S4). Although the purification 
was efficient and the final eluate revealed several distinct protein bands, mass spectrometry 
identified only proteins that typically co-purify as contaminants such as α/β tubulin and HSP70 
but no other proteins (Attachment 1, Figs. S4C to S4E). Since p52, which did interact with XPB-
R-PTP in reciprocal co-IPs (Figure 2.1C), was not detected in this analysis, it was possible that 
tagging XPB-R at the C-terminus had a deleterious effect on the XPB-R/p52 interaction. It 
therefore appeared that either XPB-R tagging partially interfered with the XPB-R/p52 interaction, 
or that this interaction is weak and does not withstand purification. To obviate the latter concern, 
we sedimented crude extract, freshly prepared from cells expressing XPB-R-PTP and p52-HA, 
through a linear sucrose gradient by ultracentrifugation, a process which is much less stringent 
than tandem affinity purification. An immunoblot analysis of proteins collected from gradient 
fractions that were taken from top to bottom showed that p52-HA sedimentation peaked in 
fractions 6/7 and in fractions 14-16, between the 17S apoferritin and the 19S thyroglobulin 
markers (Figure 2.5A). The latter sedimentation peak corresponded to the previously 
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  determined ~17.5 S sedimentation coefficient of the TFIIH complex (Lee et al., 2009) and, 
accordingly, the TFIIH subunit TSP2 did co-peak with p52-HA in these fractions. The additional 
peak of TSP2 in fraction 11 likely corresponds to a XPB/TSP1/TSP2 subcomplex that we 
previously found missing from a partial TFIIH complex (Lee et al., 2009). Importantly though, 
neither band of XPB-R-PTP showed a peak in fractions 14-16 and they were, in fact, hardly 
detectable in these fractions, further supporting the notion that XPB-R does not function within a 
TFIIH complex. Its sedimentation in fractions 5 and 6 suggested that it peaks there by itself 
and/or in a complex with p52-HA. Together, these data strongly indicated that XPB-R is not part 
of a TFIIH complex comprising XPD and the other trypanosome TFIIH orthologs of p62, p44, 
and p34. 
 To corroborate these findings at the functional level, we generated procyclic cell lines for 
conditional p52 silencing by RNAi analogously to the XPB-R RNAi cell lines described above. 
Examination of three independently derived cell lines demonstrated that cultures stopped 
growing 3 days after induction of p52 dsRNA synthesis (Figure 2.5B). These growth defects 
closely resembled those observed previously upon silencing of XPD (Lee et al., 2007), 
indicating that p52 is an essential component of TFIIH. To assess whether RNAi-mediated 
depletion of either XPD, XPB-R or p52 in cells led to increased UV susceptibility, we silenced 
the expression of the respective genes in procyclic cell lines, exposed induced and non-induced 
cells to 500 or 1000 J/m2 UV light, and recorded cell survival one day after the treatment. While 
XPD silencing was as efficient as previously published (data not shown), UV exposure did not 
affect the survival rate of XPD-silenced cells (Figure 2.5C, top panel), strongly indicating that 
trypanosome TFIIH is specialized in transcription and, unlike its bifunctional counterparts in 
yeast and mammals, not involved in DNA repair. Conversely and as expected, XPB-R silencing 
significantly increased the UV susceptibility of trypanosomes (Figure 2.5C, middle panel). Since 
UV treatment was similarly lethal to p52-silenced cells (Figure 2.5C, bottom panel), these 
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  results identify p52 as a functional partner of XPB-R in DNA repair and as the only trypanosome 
protein so far that is likely involved in both RNA pol II transcription and NER. They also confirm 
our co-IP results (Figure 2.1C). 
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Figure 2.5 XPB-R and p52 but not XPD function together in NER. 
A. Crude extract from XPB-R-PTP-expressing trypanosomes was sedimented through a linear 10-40% 
sucrose gradient by ultracentrifugation. Fractions were taken from top to bottom and analyzed by 
immunoblotting as described above. As sedimentation markers IgG (6.6S), apoferritin (17S) and 
thyroglobulin (19S) were co-analyzed. 
B. Upper panel, growth curve of a representative, procyclic cell line (one out of three) in which 
doxycycline induces p52 silencing. Lower panel, semi-quantitative RT-PCR analysis of p52 mRNA and, 
as a control, of U2A/ mRNA in total RNA prepared from non-induced cells and from cells that were 
induced for one or two days. 
C. Diagrams showing the survival of cells treated with UV relative to untreated cells. Three cell lines were 
investigated in which XPD (upper panel), XPB-R (middle panel) or p52 (lower panel) were silenced (+ 
dox) or not (- dox). Each experiment was conducted three times, and the results were statistically 
analyzed by an unpaired, two-tailed student’s t test assuming unequal variances. One and two asterisks 
indicate p values that are smaller than 0.05 and 0.01, respectively. 
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  4.6 XPB-R-PTP is localized in the nucleus and partially co-localizes with p52-HA 
 NER factors including various TFIIH subunits typically exhibit a diffuse nuclear staining 
pattern (Hoogstraten et al., 2008; Vermeulen et al., 2000). We have previously shown that in T. 
brucei p52-HA localizes to the nucleus with the strongest accumulation in one or two 
perinucleolar foci. These foci most likely represent the ~100 tandemly linked SLRNA copies on 
chromosomes 9 that are transcribed monocistronically, thereby requiring the independent 
formation of transcription pre-initiation complexes on each and every SLRNA promoter (Lee et 
al., 2010). Accordingly, when we used a cell line in which the TFIIH helicase XPD and p52 were 
PTP- and HA-tagged, respectively (Lee et al., 2007), we observed that XPD-PTP predominantly 
localized to one or two perinucleolar foci in the nucleus with additional faint staining of other 
nuclear regions (Figure 2.6 and Attachment1 Fig.S5, left panels). p52-HA invariably co-localized 
with XPD-PTP in these foci presumably as part of the TFIIH complex, yet it also appeared to be 
more widely distributed than XPD within the nucleus. When we co-localized XPB-R-PTP with 
p52-HA in the cell line described above (Figure 2.6 and Attachment 1, Fig. S5, right panels), we 
detected a partial overlap of the two proteins which supports our finding that XPB-R and p52 do 
interact. On the other hand, the clearest difference from the XPD analysis was that XPB-R-PTP 
most often did not co-localize with the brightest p52-HA spots, supporting our finding that XPB-
R does not occupy the SLRNA promoter and is not required for RNA pol II transcription initiation 
at SLRNA genes. These results support a model in which trypanosomes possess a TFIIH 
complex with a basal function in RNA pol II transcription initiation, and an XPB-R/p52 complex 
specifically functioning in NER. 
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Figure 2.6 XPB-R-PTP co-localizes with p52-HA outside putative SLRNA expression foci in the 
nucleus. p52-HA (green) was co-localized with XPD-PTP (red; left panels) or with XPB-R-PTP (red, right 
panels). White bars represent 10 µm. 
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  4.7 Highly divergent XPB paralogs are present in other protistan lineages 
 We have shown that T. brucei possesses two highly divergent XPB paralogs. One 
participates in the transcriptionally active TFIIH complex while the other is important for DNA 
repair and, likely, functions independently of TFIIH. Since TFIIH analyses have mainly been 
restricted to yeast and higher eukaryotes, we wanted to know whether divergent XPB paralogs 
could be found in other eukaryotes. We carried out a phylogenetic analysis of XPB sequences 
of 33 species whose genomes were completely sequenced (Attachment 1, Fig. S6). Each XPB 
sequence that was retrieved gave an E value smaller than e-95 during a protein-protein BLAST 
analysis against the human XPB sequence and they all harbored the R-E-D motif, except for 
one of the two sequences found in the ciliate Paramecium tetraurelia that contained an R-Q-D 
motif instead (Attachment 1, Fig. S1). Despite the small E-values, multiple sequence alignment 
revealed several blocks of ambiguous alignment due to poorly conserved regions. To restrict 
our analysis to appropriately aligned sequences we applied the Gblock algorithm (Talavera and 
Castresana, 2007) in combination with maximum likelihood calculations. As expected, metazoa, 
yeasts and fungi have only a single XPB sequence which correlates with the dual function of 
TFIIH described in these organisms. The two plant species investigated, Oryza sativa and 
Arabidopsis thaliana, do possess two XPBs but their encoded sequences are nearly identical 
and more closely conserved within each species. This strongly suggests that these XPB genes 
stem from recent gene duplications that have not functionally diverged. In contrast, all 
kinetoplastid organisms possess two highly divergent XPBs that clearly segregate into two 
separate branches, one with T. brucei XPB and one with T. brucei XPB-R. Even the only 
bodonid species investigated, B. saltans, encoded unambiguously identifiable orthologs of these 
two helicases. The root of the two clusters is very deep, raising the possibility that the presence 
of two functionally distinct XPB helicases is an ancient eukaryotic trait. This hypothesis is 
supported by the presence of similarly divergent XPB paralogs in the ciliates Tetrahymena 
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  thermophila and P. tetraurelia although the ciliate XPB sequences do not form two separate 
clusters. Ciliates are grouped together with Apicomplexa in the supergroup Chromalveolata. 
However, all apicomplexan species investigated have only a single XPB gene. On the other 
hand, Entamoeba histolytica and Entamoeba dispar again have two highly divergent XPB genes 
that form two deeply rooted branches, while other members of the supergroup Amoebozoa, 
Dictyostelium discoideum and Acanthamoeba castellanii, have only a single XPB gene. Finally, 
among early diverged protists, the Giardia lamblia genome revealed only a single XPB gene 
whereas Trichomonas vaginalis and Naegleria gruberi encode two divergent XPB paralogs, 
although their roots are not as deep as those of ciliates and Entamoeba. 
 If distinct XPBs for transcription and DNA repair were a plesiomorphic trait in eukaryotes, 
we would expect a phylogenetic tree with separate XPB-R and XPB branches. This was never 
observed despite applying several different phylogenetic approaches (data not shown). On the 
other hand, the bootstrap values at the base of the tree in Attachment 1, fig. S6 are not high and 
it is possible that specific XPB-R and XPB branches do exist. Accordingly, when we carried out 
the same phylogenetic analysis with an archaeal sequence as an outgroup, the basal branching 
of the tree changed while the XPB and XPB-R dichotomies described here remained 
(Attachment 1, Fig. S7). Therefore, it will require more whole genome sequences from protistan 
organisms and a more comprehensive approach to solve the basal eukaryotic branching of the 
XPB tree unambiguously. Until then our data suggest that the presence of two functionally 
distinct XPBs is a phenomenon that exists beyond the Kinetoplastida. 
5. Discussion 
 This is the first report of a eukaryotic XPB paralog that is specialized in DNA repair while 
having no role in transcription. We showed that transcription of genes by all three nuclear RNA 
pols was not impaired in XPB-R-/- cells. Moreover and in contrast to TFIIH subunits, XPB-R did 
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  not occupy the SLRNA promoter, the only trypanosome promoter known to assemble a RNA pol 
II transcription pre-initiation complex, and depletion of XPB-R from extract did not affect SLRNA 
transcription in vitro. On the other hand, removal of the XPB-R gene rendered trypanosomes 
highly sensitive to UV irradiation and cisplatin, but not to methylmethane sulfonate, strongly 
indicating that XPB-R, like its XPB homologs from yeast to humans, specifically functions in 
NER and not in other DNA repair pathways. Interestingly, although not absolutely required for 
cell viability, the expression level of XPB-R directly influenced the trypanosome doubling time. 
Knockout of a single XPB-R allele increased the 8.5 h doubling time of wild-type to 12 h and a 
complete knockout to ~14.7 h. Given that a specific down-regulation of XPB-R would result in 
slow growth and impaired DNA repair, we speculate that regulation of its expression may play a 
role in pathways of programmed cell death that have been described in trypanosomes (Michaeli, 
2012; Welburn et al., 2006). 
 An interesting question emanating from our study is why XPB-R-/- cells take longer to 
double than wild-type cells. One possibility is that XPB-R-/- cells accumulate mutations that lead 
to increased cell death thus slowing culture growth. If this was the case, one would expect that 
XPB-R-/- cell lines would grow slower over time because all cells would accumulate mutations 
simultaneously. However, the doubling time of the knockout cells did not change over a period 
of ~150 generations. In addition, we did not detect a substantial increase of aberrant or dead 
cells in XPB-R-/- cell cultures when compared to wild-type cultures suggesting that accumulation 
of mutations is not the major cause of the growth defect (Attachment 1, Fig. S3 and data not 
shown). Instead, our results indicated that XPB-R-/- cells take substantially longer to complete 
mitosis and/or initiate cytokinesis because a quarter of XPB-R-/- cells, compared to 6% of wild-
type cells, was found to be in the precytokinesis stage with two kinetoplasts and two nuclei. 
Given that XPB-R is a DNA-dependent helicase, this finding suggests that XPB-R has a role in 
late mitosis. While this could be a trypanosome-specific function, a recent study did find human 
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  XPB but not other TFIIH subunits to be associated with centrosomes and adjacent parts of the 
mitotic spindle during mitosis (Weber et al., 2010). 
 Thus far, eukaryotic XPB function has exclusively been described in the context of the 
TFIIH complex (Compe and Egly, 2012; Naegeli and Sugasawa, 2011). The two TFIIH subunits 
that interact with XPB and modify its enzymatic activities are p52 and p8 (Coin et al., 2007; Coin 
et al., 2006; Fregoso et al., 2007). Accordingly, our analysis showed that trypanosome XPB-R 
does interact with p52, and while trypanosomes do possess a p8 ortholog that is part of the 
TFIIH complex (Lee et al., 2009), it remains to be determined whether it interacts with XPB-R. 
However, our study strongly indicates, in accordance with previous comprehensive TFIIH 
characterizations (Lecordier et al., 2007; Lee et al., 2009; Lee et al., 2007), that XPB-R does not 
assemble into a TFIIH complex. In the sedimentation analysis, tagged XPB-R was found almost 
exclusively near the top of the sucrose gradient and did not exhibit faster co-sedimentation with 
the TFIIH subunits p52-HA and TSP2. Accordingly, TSP2 did not co-immunoprecipitate with 
XPB-R from extract. Furthermore, isolation of XPB-R by tandem affinity purification did not co-
purify any TFIIH subunit suggesting that tagged XPB-R is not assembled into a stable protein 
complex. Finally, while the TFIIH subunits XPD and TSP2 were predominantly localized in one 
or two perinucleolar spots, XPB-R exhibited a more diffuse nuclear staining and rarely co-
localized with p52-HA in its perinucleolar spots, further indicating that XPD and XPB-R are not 
part of the same complex. 
 How does XPB-R function in NER in the absence of other TFIIH subunits? There are two 
distinct pathways of NER, namely transcription-coupled NER and global genome NER, which 
use different proteins to detect DNA lesions and recruit TFIIH to the sites of damage (Naegeli 
and Sugasawa, 2011). In the Tritryp genome projects, most of the factors involved in NER 
factors have been identified suggesting that both pathways are functional in trypanosomes 
(Berriman et al., 2005; Ivens et al., 2005); recently reviewed in (Passos-Silva et al., 2010). A key 
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  factor in global genome NER is XPC (accession number for the T. brucei ortholog is 
Tb927.9.11930) which, by directly interacting with XPB, recruits TFIIH to sites of DNA damage. 
Moreover, it was shown in the human system that the R-E-D residue loop, the ThM domain and 
the ATPase activity of XPB are important for recruitment of TFIIH to damaged sites (Oksenych 
et al., 2009). All of these domains are conserved in XPB-R suggesting that it can be recruited to 
DNA lesions by XPC in the absence of a TFIIH complex. Transcription-coupled NER removes 
DNA lesions that stall RNA pol II at actively transcribed genes (Hanawalt and Spivak, 2008; 
Laine and Egly, 2006). A key factor in this pathway is the so-called Cockayne syndrome type B 
or CSB protein (Tb927.7.4080), which is important for the recruitment of TFIIH and other NER 
factors to damaged DNA. Although it is not entirely clear how TFIIH is recruited in this pathway, 
early evidence revealed a direct link between CSB and XPB (Tantin, 1998), which would allow 
direct recruitment of XPB-R by trypanosome CSB for transcription-coupled NER. 
 After recruitment to DNA lesions, the function of TFIIH in global genome NER is to open 
up the site of damage by XPB ATPase and XPD helicase activity. The ATPase activity of XPB 
apparently drives the protein like a wedge into the damaged bubble enabling XPD, whose 
helicase activity alone is important for NER, to unwind the DNA (Coin et al., 2007). Since 
trypanosome XPB-R apparently does not function together with XPD, the XPB-R ATPase-driven 
opening of the damaged DNA site may be sufficient in trypanosomes for nucleotide repair. 
Alternatively, XPB-R may be a more processive helicase than its mammalian counterpart whose 
activity is important for NER. Mammalian XPD has also been implicated in DNA damage 
recognition and verification (Mathieu et al., 2010). Since there is no evidence that trypanosome 
XPB-R and XPD form a common complex, this function is either absent in trypanosomes or 
achieved independently of XPB-R. In the absence of a stable XPB-R complex, it appears that 
XPB-R functions like its archaeal ortholog. In vitro assays have shown that XPB of the archaeon 
Sulfolobus solfataricus can open up DNA lesions by 6-8 bp which is sufficient for the 
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  endonuclease Bax1 to cleave off the damaged DNA (Rouillon and White, 2010). Bax1 is thought 
to be the functional homolog of the eukaryotic NER endonuclease XPG (Rouillon and White, 
2010) which is encoded in the T. brucei genome (Tb927.9.11760; E value of 8e-20 derived from 
a protein-protein blast with the human XPG amino acid sequence) and likely functions together 
with XPB-R. In sum, it appears that trypanosomes have a simplified NER machinery that is 
separate from the transcriptionally essential TFIIH complex. 
 We have been able to combine gene silencing with UV exposure to assess the function 
of proteins in NER. This approach clearly demonstrated that XPD silencing did not alter cell 
survival after UV exposure whereas XPB-R and p52 silencing clearly increased the UV 
susceptibility of cells (Figure 2.5C). These data strongly support a model in which trypanosome 
TFIIH has an essential role in RNA pol II transcription while NER is carried out through a 
simplified, XPB-R-based machinery. This dichotomy in trypanosomes provides a unique 
opportunity to decipher specific DNA repair and transcription functions of XPB. For example, 
amino acids specifically required for DNA repair should be conserved in kinetoplastid XPB-R 
sequences as well as in the bifunctional XPBs of model organisms but not in kinetoplastid 
XPBs. Accordingly, several such positions were identified in the XPB multiple sequence 
alignment (Attachment 1, Fig. S1). Moreover, the bifunctional nature of human and yeast XPB 
has hampered XPB analysis in vivo since all mutations affecting the transcriptional function of 
XPB are lethal, an obstacle absent in future XPB-R analyses. 
 Finally, specific NER machinery may not be restricted to Kinetoplastida. Our survey of 
completely sequenced genomes revealed the presence of two highly divergent XPBs in several 
protistan taxa that belong to different supergroups (Dacks et al., 2008). In addition to the 
Excavata, the supergroup of kinetoplastids, highly divergent XPBs were found in the Ciliophora 
of the supergroup Chromalveolata and in the genus Entamoeba which is part of the Amoebozoa 
supergroup. Although our initial XPB phylogenetic analysis did not provide unambiguous 
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  branching at the base of the tree, which may be the reason why we did not observe an overall 
dichotomy of XPB and putative XPB-R sequences, our results raise the possibility that a DNA 
repair-dedicated XPB helicase is an ancestral eukaryotic trait. 
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  Chapter III 
 
Trypanosome cdc2-related kinase 9 controls  
spliced leader RNA cap4 methylation and  
phosphorylation of the RNA polymerase II subunit RPB1 
 
1. Abstract 
Conserved from yeast to mammals, phosphorylation of the heptad repeat sequence Tyr1-
Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 in the carboxy-terminal domain (CTD) of the largest RNA 
polymerase II subunit RPB1 mediates the enzyme’s promoter escape and binding of RNA 
processing factors such as the m7G capping enzymes. The first critical step, Ser5 
phosphorylation, is carried out by cyclin-dependent kinase 7 (CDK7), a subunit of the basal 
transcription factor TFIIH. Many early-diverged protists such as the lethal human parasite 
Trypanosoma brucei, however, lack the heptad repeats and, apparently, a CDK7 ortholog. 
Accordingly, characterization of trypanosome TFIIH did not identify a kinase component. The T. 
brucei CTD, however, is phosphorylated and essential for transcription. Here we show that 
silencing the expression of T. brucei cdc2-related kinase 9 (CRK9) led to a loss of RPB1 
phosphorylation. Surprisingly, this event did not impair RNA pol II transcription or co-
transcriptional m7G capping. Instead, we observed that CRK9 silencing led to a block of spliced 
leader (SL) trans splicing, an essential step in trypanosome mRNA maturation, that was caused 
by hypomethylation of the SL RNA’s unique cap4. 
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  2. Introduction 
 In eukaryotes, RNA polymerase II transcription of protein coding and small nuclear RNA 
genes is a highly conserved process involving a plethora of transcription and co-transcriptionally 
active RNA processing factors. A key regulatory structure in this process is the carboxy-terminal 
domain (CTD) of the largest RNA pol II subunit RPB1. Conserved from some protists to 
humans, the CTD consists of 5 to 52 repeats of the heptad sequence Tyr1-Ser2-Pro3-Thr4-Ser5-
Pro6-Ser7 whose regulated serine phosphorylation cycle is essential for RNA pol II function 
(Buratowski, 2009; Chapman et al., 2008; Hsin and Manley, 2012). RNA pol II that is recruited 
to the core promoter has hypophosphorylated heptad repeats. Transcription initiation and RNA 
pol II escape from the promoter then essentially depends on phosphorylation of Ser5 by cyclin-
dependent kinase 7 (CDK7; the yeast ortholog is termed Kin28) which is a component of the 
basal transcription factor TFIIH. The same phosphorylation event leads to binding of the m7G 
capping enzyme to the CTD and co-transcriptional capping of pre-mRNA (Fabrega et al., 2003). 
Further downstream of the transcription initiation site, phosphorylation of Ser2 by CDK9 (Bur1) 
and CDK12/13 (Ctk1) transform RNA pol II into an actively elongating enzyme (Karagiannis and 
Balasubramanian, 2007; Liu et al., 2009; Qiu et al., 2009). Finally, Ser7 phosphorylation appears 
to be particularly important for transcription of snRNA genes since it mediates the interaction of 
the integrator 3/ end RNA processing complex to RNA pol II. Ser7 is primarily phosphorylated by 
CDK7 (Akhtar et al., 2009; Glover-Cutter et al., 2009; Kim et al., 2009) although CDK9 (Kim et 
al., 2009; Tietjen et al., 2010) and DNA-activated protein kinase (Egloff et al., 2010) may play a 
role as well. 
The repetitive CTD structure, however, is not a universal feature of eukaryotes (Guo and 
Stiller, 2004). Notably, protistan organisms such as amoebozoa, kinetoplastids, trichomonads 
and diplomonads, which appear to have diverged very early from other eukaryotic lineages, lack 
repetitive CTD motifs. Moreover, comparative genomics suggested that these organisms also 
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  lack a CDK7 ortholog (Guo and Stiller, 2004). It therefore remains to be determined whether 
phosphorylation of non-repetitive CTDs is important for RNA pol II-mediated gene expression or 
whether the essential coordinating function of the canonical CTD has evolved later in evolution. 
The kinetoplastid Trypanosoma brucei is a lethal, vector borne parasite of humans and 
livestock in sub-Saharan Africa. It has emerged as a model organism for deviating gene 
expression mechanisms found in early-diverged eukaryotes. Its protein coding genes are 
arranged in long directional tandem arrays which are transcribed polycistronically. The resulting 
precursor RNAs are processed into individual mRNAs by spliced leader (SL) trans splicing and 
polyadenylation. The SL is derived from the small nuclear SL RNA and trans spliced onto each 
and every mRNA (Gunzl, 2010). The SL is 39 nt-long, pseudouridylated at position 28, and 
carries the most extensively modified cap found in any eukaryote. The cap structure is 
m7G(5/)ppp(5/)m6,6AmpAmpCmpm3Ump and was termed cap4 (Bangs et al., 1992). 
Trypanosome RNA pol II transcribes the protein coding gene arrays and the ~100 tandem 
copies of the SL RNA gene (SLRNA) on chromosome 9 whereas other small nuclear RNAs in 
trypanosomes are synthesized by RNA pol III. SLRNA transcription is monocistronic, initiates at 
a distinct initiation site, and requires the assembly of a conventional, albeit extremely divergent 
pre-initiation complex (Das et al., 2008; Lee et al., 2010; Lee et al., 2009). The T. brucei 
genome encodes a full set of RNA pol II subunits, termed RPB1 to RPB12 (Kelly et al., 2005), 
and biochemical characterization of the enzyme complex identified all subunits except RPB10 
(Das et al., 2006; Devaux et al., 2006; Martinez-Calvillo et al., 2007). In T. brucei there are two 
slightly different RPB1 genes (relevant T. brucei gene accession numbers are listed in 
supplementary Table S1) which appear to be functionally redundant since deletion of three 
RPB1 alleles did not impair trypanosome proliferation in culture (Ruan et al., 2004). All RPB1 
homologs possess eight highly conserved regions, termed A-H, and the sequence downstream 
of region H is generally considered to be the CTD (Chapman et al., 2008). The conserved 
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  regions can be clearly recognized in trypanosome RPB1 defining the CTD from residue 1481 to 
residue 1765. Despite the lack of the heptad repeat motif, this region is serine-rich, 
phosphorylated and essential for transcription (Chapman and Agabian, 1994; Das and 
Bellofatto, 2009). 
Characterization of the trypanosome phosphoproteome revealed 14 phosphorylated RPB1 
residues which all reside in the CTD (Nett et al., 2009), yet the functional significance of CTD 
phosphorylation in trypanosomes remains unclear. In accordance with the notion that organisms 
with a non-canonical CTD lack a CDK7 ortholog, biochemical and structural characterization of 
trypanosome TFIIH, which is a basal factor for SLRNA transcription, revealed a full core 
complex of seven subunits but no kinase component (Lee et al., 2009; Lee et al., 2007). These 
findings suggested that RNA pol II transcription initiation in trypanosomes does not depend on 
TFIIH-based CTD phosphorylation as it does in eukaryotes with canonical CTDs. Moreover, 
CTD phosphorylation seems not to be important for co-transcriptional RNA processing either. 
Since SL trans splicing uncouples mRNA capping from RNA pol II transcription, trypanosomes 
can utilize RNA pols other than RNA pol II to produce functional mRNA. T. brucei has evolved a 
multifunctional RNA pol I which transcribes the large ribosomal gene units as in other 
eukaryotes and, in addition, gene units that encode their major cell surface proteins procyclin 
and variant surface glycoprotein (Gunzl et al., 2003). In addition, genetically modified 
trypanosome cell lines that express T3 or T7 RNA polymerase are able to produce functional 
mRNA from the corresponding phage promoters (Wirtz et al., 1994). Thus, the use of promoters 
for different RNA pols showed that processing of a reporter pre-mRNA was not coupled to RNA 
pol II (Stewart et al., 2010). On the other hand, there is strong evidence that m7G capping and 
cap4 formation of the SL RNA occurs co-transcriptionally (Hury et al., 2009; Mair et al., 2000b). 
 Canonical CTDs are primarily phosphorylated by CDKs. T. brucei harbors 11 enzymes 
of this class termed cdc2-related kinase (CRK)1-4 and CRK6-12. Sequence divergence 
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  prevents an unambiguous assignment of these enzymes to putative counterparts in other 
eukaryotes although CRK3 appears to be the functional homolog of CDK1 (Hammarton, 2007; 
Parsons et al., 2005). Here, we show that silencing CRK9 expression leads to both a loss of 
RPB1 phosphorylation and a trans splicing defect due to hypomethylation of the first four SL 
RNA nucleotides. Most interestingly and consistent with a CDK7-less TFIIH, loss of RPB1 
phosphorylation did not impair RNA pol II transcription or m7G capping of SL RNA. 
3. Materials and methods 
3.1 DNAs 
 For CRK9, CRK1, CRK3 and CRK7 silencing, the coding regions from position 9 to 
position 508, from position 5 to position 505, from position 431 to position 930, and from position 
6 to 506, respectively, were integrated in a stem-loop arrangement (sense-stuffer-antisense) 
into the pT7-stl construct (Brandenburg et al., 2007). The RNAi vector targeting the CRK9 3/ 
UTR was generated by inserting 501 bp of the CRK9 3/ UTR from positions 2326 to 2827 
relative to the translation initiation codon into pT7-stl. For HA tagging of RPB1, 1077 bp of the 
3/-terminal RPB1 coding sequence was inserted into the pC-HA-BLA vector (Lee et al., 2007) 
utilizing the vector's ApaI and NotI restriction sites. The resulting vector was named pRPB1-HA-
BLA. pCRK9-PTP-NEO was generated by inserting 1,532 bp of the CRK9 coding region 
(position 791 to position 2322) into the ApaI and NotI sites of pC-PTP-NEO (Schimanski et al., 
2005a). pCRK9-HA-BLA and pCRK9-HAT533A-BLA were generated by inserting 1,532 bp of the 
CRK9 coding region (position 791 to position 2322) into the ApaI and NotI sites of pC-HA-BLA. 
An A1597G transition was generated through overlapping PCR which changed the threonine 
codon 533 to an alanine codon. For transfection, pRPB1-HA-BLA, pCRK9-PTP-NEO, pCRK9-
HA-BLA, and pCRK9-HAT533A-BLA were linearized with restriction enzymes NarI, XhoI, SphI, 
and SgrA1, respectively. DNA oligonucleotides that were used in semi-quantitative and 
quantitative reverse transcription (RT)-PCR and in primer extension assays are specified in 
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  supplementary Table S2. Plasmids used in dot blots were described previously and contained 
the complete coding regions of GPEET procyclin, α tubulin, HSP70, and 18S rRNA or the 
tRNAThr/U6 snRNA gene association (Schimanski et al., 2006). 
3.2 Cells 
 T. brucei cell culture, transfection, and the generation of stable cell lines by selection and 
limiting dilution was carried out as described (Lee et al., 2007; Park et al., 2011). In RNAi 
experiments, dsRNA synthesis was induced with 2 µg/ml of doxycycline. Cells were counted 
and diluted daily to 2 × 106 cells/ml for procyclic cell culture and to 2 × 105 cells/ml for 
bloodstream form culture. A procyclic clonal cell line that exclusively expressed CRK9 with a C-
terminally fused PTP tag, was generated by targeted integration of linearized pCRK9-PTP-NEO 
in one CRK9 allele and by knocking out the remaining allele with a PCR product in which 101 bp 
of CRK9 5/ and 3/ gene flanks were fused to the hygromycin phosphotransferase coding region. 
Clonal CRK9 RNAi cell lines that expressed RPB1 with a C-terminal HA tag were generated by 
transfection of linearized pRPB1-HA-BLA. 
3.3 RNA analysis 
 To determine the relative abundance of RNAs in RNAi cells, total RNA prepared from 8 x 
107 cells using TRIzol reagent (Invitrogen) was analyzed by semi-quantitative and quantitative 
RT-PCR. Reverse transcriptions were carried out with SuperScript II reverse transcriptase 
(Invitrogen) according to the manufacturer’s protocol and with oligo-dT and random 
hexanucleotides (Roche) for the analysis of mature and pre- mRNAs, respectively. For each 
semi-quantitative PCR, the number of cycles for the linear amplification range was determined 
empirically. For RNA quantifications, cDNA preparations from two independent RNAi 
experiments were analyzed by qPCR assays using the SsoFast EvaGreen Supermix (BioRad) 
on a CFX96 cycler (BioRad) according to the manufacturer’s recommendations. For each 
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  amplification and RNAi experiment, triplicate qPCR samples were analyzed using the CFX 
Manager software package (BioRad). Each amplification product was evaluated for specificity 
by both agarose gel electrophoresis and melting curve analysis. Standard curves for 
oligonucleotide pairs were obtained from serial dilutions of non-induced cDNA samples and 
ranged in their coefficient of determination (R2) value from 0.98 to 1.0. Samples were 
standardized with the 18S rDNA result from random hexamer-derived cDNA. 
 Labeling and analysis of nascent RNA using a permeabilized cell system was carried out 
as described previously (Schimanski et al., 2006). For steady state analysis of SL RNA and U2 
snRNA abundances 10 µg of total RNA prepared from induced or non-induced trypanosomes 
was assayed by primer extension using the 5/ 32P-endlabeled oligonucleotides SLf and U2f 
(Gunzl et al., 1992). The methylation status of SL RNA cap4 was analyzed by a modified primer 
extension assay in which 4 µg of total RNA was reverse transcribed by unmodified Moloney 
murine leukemia virus reverse transcriptase (Invitrogen) at a concentration of individual dNTPs 
that was reduced from 0.5 mM to 0.1 mM. DNA sequence ladders were generated by using the 
Thermo Sequenase Cycle sequencing kit (USB) and radiolabeled SLf according to the 
manufacturer’s specifications. Sequencing ladder and cap4-specific primer extension products 
were separated on high resolution 50% urea-6% polyacrylamide gels and visualized by 
autoradiography. 
 The m7G capping status of SL RNA was analyzed by immunoprecipitation with a mouse 
monoclonal anti-2,2,7-trimethylguanosine antibody coupled to agarose beads that also 
recognizes the m7G cap nucleotide but not an unmethylated guanosine cap (Calbiochem). In 
immunoprecipitations, 5 µg of total RNA were diluted in 220 µl of buffer PA-150 (20 mM Tris-
HCl, pH 7.7; 150 mM NaCl; 3 mM MgCl2, 0.5 mM dithiothreitol; 0.1% Tween 20), mixed with a 
30 µl of a 1:1 slurry of beads, and incubated for 1 h at 4 °C. Immunoprecipitates were washed 
six times with 0.8 ml of PA-150 buffer. Bound RNA was extracted from the beads using the 
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  TRIzol reagent and resuspended in 20 µl of RNase-free water. 10 µl of bound and unbound 
fractions (equal amounts) were used for primer extension analysis using Superscript II reverse 
transcriptase as described above. 
3.4 Protein analysis 
 For the generation of a polyclonal anti-RPB1 immune serum, the CTD portion of RPB1, 
comprising the C-terminal 228 amino acids, was expressed with an N-terminal glutathione S-
transferase tag in Escherichia coli, purified by glutathione affinity chromatography, and used as 
a GST fusion protein to immunize rats according to a previously published protocol (Schimanski 
et al., 2006). 
 RPB1 was detected on immunoblots by 1:2000 dilution of the anti-RPB1 immune serum 
followed by a 1:5000 dilution of a monoclonal, peroxidase-labeled anti-rat IgG secondary 
antibody (Vector Laboratories). HA-tagged protein was detected with a commercial monoclonal 
rat anti-HA antibody (Roche) and RPA1 with a polyclonal rabbit immune serum as described 
previously (Schimanski et al., 2003). Blots were developed with BM chemiluminescence blotting 
substrate (Roche) according to the manufacturer's protocol. 
 To demonstrate that the upper RPB1 band detected in immunoblots with anti-HA or anti-
RPB1 antibodies corresponded to phosphorylated RPB1, 8 x 107 parasites were resuspended in 
25 µl of lysis buffer (2% SDS; 100 mM Tris-HCl, pH 6.8) and boiled for 5 min. To enable alkaline 
phosphatase treatment the lysate was diluted twentyfold with tryp wash solution (100 mM NaCl; 
3 mM MgCl2, 20 mM Tris–HCl, pH 7.5) to reduce the SDS concentration to 0.05% and 
subsequently reduced to a volume of 100 µl using an Amicon ultra 0.5 ml filter device (Millipore). 
The phosphatase reaction was carried out in a volume of 30 µl containing 20 µl of sample, 1x 
NEB3 buffer, and 10 units of calf intestinal phosphatase (New England Biolabs), and by 
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  incubation at 37 °C for one hour. To block the phosphatase, 0.5 µl of phosphatase inhibitor 
cocktail 2 (Sigma Co.) were added to the reaction. 
4. Results 
4.1 CRK9 silencing blocked SL trans splicing.  
 The research group of Dr. C.C. Wang (University of California San Francisco) had 
previously studied all eleven T. brucei CRKs by RNAi-mediated gene knockdown. Their data 
indicated that CRK1, CRK3 and CRK9 were the most important CRKs for trypanosome viability 
(Gourguechon and Wang, 2009; Tu and Wang, 2004). Moreover, based on sequence similarity 
it was previously proposed that CRK3 (Ivens et al., 2005) or CRK7 (Parsons et al., 2005) may 
represent CDK7 orthologs. To explore the possibility that these CRKs regulate gene expression 
and/or are involved in CTD phosphorylation, we generated clonal cell lines of the insect-stage, 
procyclic form of T. brucei, in which each of these four CRK genes can be conditionally silenced 
by doxycycline-induced dsRNA expression (Wirtz et al., 1999). The knockdowns of CRK9 
(Figure 3.1A) and of CRK1 and CRK3 (Attachment 2, Fig. S1) were lethal, halting culture growth 
after the first or second day of induction. While these growth defects were consistent with 
previous results (Gourguechon and Wang, 2009; Tu and Wang, 2004), the much stronger 
growth inhibition in our experiments was likely the consequence of our use of the well-regulated 
pT7-stl RNAi construct (Brandenburg et al., 2007) which caused a rapid drop of the target 
mRNA levels within 24 hours of induction (boxed panels in Figures 3.1B and Attachment 2, Fig. 
S1). Analysis of RNAs synthesized by all three RNA pols showed that the CRK1 and CRK3 
knockdowns had no strong effects on RNA abundances (Attachment 2, Fig. S1) whereas CRK9 
silencing consistently resulted in a clear reduction of α tubulin and GPEET procyclin mRNA 
abundances and a concomitant increase of the corresponding pre-mRNAs. Since procyclin and 
α tubulin genes are transcribed by RNA pols I and II, respectively, it was unlikely that these 
effects were connected to the transcription of these genes. In addition to these changes in pre- 
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  and mature mRNA levels, we found that SL RNA abundance sharply increased 48 hours after 
induction of CRK9 silencing whereas there was no consistent effect on the abundances of rRNA 
and U2 snRNA which, in trypanosomes, are synthesized by RNA pols I and III, respectively 
(Figure 3.1B). According to reverse transcription-quantitative real-time (RT-q)PCR experiments 
these were strong effects: after three days of induction the pools of mature α tubulin and 
GPEET mRNA were reduced to approximately one quarter while the levels of SL RNA and pre-
mRNA were increased up to ~nine-fold (Figure 3.1C). Since SL RNA is consumed in the first 
transesterification step of the splicing process, these findings strongly indicated that CRK9 
silencing led to inhibition of SL trans splicing before the first step. In accordance with this notion, 
a primer extension assay showed that the SL intron, the product of the first splicing step, 
disappeared specifically upon CRK9 silencing (Figure 3.1B, bottom panel; compare with the 
corresponding panels in Attachment 2, Fig. S1) CRK9 appears to have the same important 
functional role in gene expression in the mammalian-infective bloodstream trypanosome 
because a CRK9 knockdown in this life cycle stage was as lethal as in the procyclic form and 
also led to a decrease of α tubulin mRNA and a concomitant increase of the corresponding pre-
mRNA (Attachment 2, Fig. S2). Importantly, this result is in direct contrast to a previous report 
which found CRK9 to be essential only in the procyclic form (Gourguechon and Wang, 2009). 
Again, this discrepancy may be explained by our use of the more suitable pT7-stl RNAi vector 
(Brandenburg et al., 2007). 
 In accordance with previously published results (Gourguechon and Wang, 2009), 
silencing of CRK7 did not impair trypanosome proliferation in culture, and abundances of rRNA, 
GPEET mRNA and α tubulin mRNA remained unaffected by the knockdown (Attachment 2, Fig. 
S3). Since these results strongly suggested that CRK7 is not a functional homolog of eukaryotic 
CDK7 we did not further analyze this kinase. It should be noted though that these results are in 
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  contrast to a genome-wide RNAi screen which found CRK7 to be important for trypanosome 
viability across different life cycle stages (Alsford et al., 2011). 
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Figure 3.1 CRK9 expression silencing caused a decrease of mature mRNA levels and concomitant 
accumulations of SL RNA and pre-mRNAs.  
(A) A representative growth curve from one of three independently derived clonal cell lines was obtained 
in the absence and presence of the dsRNA synthesis-inducing reagent doxycycline (-/+ dox).  
(B) Relative CRK9 mRNA levels were determined by semi-quantitative RT-PCR of total RNA prepared 
from non-induced (ni) cells and in cells that were silenced for 1, 2 or 3 days (boxed panel). In the same 
RNA preparations, the relative abundances of α tubulin (α TUB) and of GPEET procyclin mature and pre-
mRNAs were determined by semi-quantitative RT-PCR, those of the large ribosomal RNAs by ethidium 
bromide staining, and those of the SL RNA, the U2 snRNA, and the SL intron by primer extension assays. 
Note that the SL intron signals were obtained through overexposure of the same gels; the asterisk 
indicates overexposed U2 signal just above the SL intron signal.  
(C) Corresponding RT-qPCR analyses. The relative level of the analyzed RNAs in non-induced cells was 
arbitrarily set to 100. The quantitative data were calculated from two independent experiments each of 
which was analyzed three times by qPCR. The boxed panel shows the silenced CRK9 mRNA levels. 
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  4.2 CRK9 silencing led to a loss of RPB1 phosphorylation.  
 Since we had speculated that RPB1 CTD phosphorylation is mediated by a CDK, we 
wanted first to know whether CRK9 silencing did affect the phosphorylation status of the CTD. 
We expressed a GST-CTD fusion protein in Escherichia coli and raised a rat polyclonal anti-
CTD immune serum against the purified recombinant protein. On immunoblots, the antibody 
specifically detected two specific protein bands in the range of 200 kDa in whole cell lysates. 
However, the larger band was consistently absent in cell-free extract suggesting that in extract 
RPB1 is rapidly dephosphorylated (Figure 3.2A). This finding was in accordance with previous 
studies in which detection of RPB1 phosphorylation in extract proved to be difficult (Chapman 
and Agabian, 1994; Das and Bellofatto, 2009). Although we tested several phosphatase 
inhibitor cocktails, the loss of the upper band in extract could not be prevented (data not shown). 
To prove that the upper band detected with our anti-CTD antibody represented phosphorylated 
RPB1, we lysed trypanosomes in an SDS buffer and then reduced the detergent concentration 
to enable alkaline phosphatase treatment. As shown in Figure 3.2B, the upper band was 
retained after mock incubation without enzyme while addition of alkaline phosphatase converted 
the upper band into the lower band, and this conversion was completely blocked with 
phosphatase inhibitor. Therefore, we concluded that the upper and lower bands in our 
immunodetections represented phosphorylated (pRPB1) and dephosphorylated RPB1, 
respectively. Immunoblotting of whole lysates from non-induced and induced cells then clearly 
showed that the pRPB1 signal became diminished upon CRK9 silencing whereas 
dephosphorylated RPB1 increased (Figure 3.2C). Quantification of immunoblot signals revealed 
that the pRPB1 signal decreased to 31% and 21% of non-induced levels on days 2 and 3, 
respectively, whereas the signal of dephosphorylated RPB1 increased to ~2.5 fold during the 
same period (Figure 3.2D). To confirm this result, we generated a clonal procyclic cell line that 
expressed RPB1 with a C-terminal HA tag. Anti-HA immunoblotting detected the same two 
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  RPB1 bands as our polyclonal antibody and CRK9 silencing again led to a signal decrease of 
the upper band and a concomitant signal increase of the lower band (Figure 3.2D). To make 
sure that loss of RPB1 phosphorylation is a specific CRK9-dependent effect and not a general 
phenotype of dying trypanosomes, we analyzed RPB1 in CRK3-silenced cells which, like CRK9-
silenced cells, ceased to proliferate after the first day of induction (Attachment 2, Fig. S1). 
Although we noted a general loss of RPB1 on day 3 of induction, the relative amounts of upper 
and lower bands remained at a similar level during the course of this experiment (Figure 3.2E) 
and allowed us to conclude that CRK9 is essential for the majority of, if not all, RPB1 
phosphorylations. 
 Although our data showed that RPB1 phosphorylation depended on CRK9 they did not 
show whether CRK9 directly phosphorylates the CTD. To detect a physical link between CRK9 
and RNA pol II we generated a cell line which exclusively expressed CRK9 C-terminally tagged 
with the composite PTP tag (Schimanski et al., 2005a). Since CRK9 is essential for 
trypanosome viability we concluded that the tag did not interfere with the function of the kinase. 
A pull-down of CRK9 under low stringency conditions, however, did not co-precipitate 
detectable amounts of RPB1 (data not shown). Since this result may be due to a transient or 
low affinity interaction between the kinase and RPB1, we speculated that if RPB1 was 
phosphorylated at SLRNAs then the kinase should be cross-linkable to SLRNA chromatin. 
However, chromatin immunoprecipitation (ChIP) of PTP-tagged CRK9 or equivalently tagged 
RPB9, a specific subunit of RNA pol II, showed high occupancy of the SLRNA promoter by 
RPB9 whereas a CRK9 association with this promoter could not be detected (Attachment 2, Fig. 
S4). Although these experiments do not rule out that CRK9 directly phosphorylates RPB1 they 
raise the possibility that a different, CRK9-dependent kinase carries out these phosphorylations. 
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Figure 3.2 CRK9 silencing caused a loss of RPB1 phosphorylation.  
(A) Cell-free extract (EXTR) or whole cell lysate (WCL) was separated by SDS-PAGE, blotted and probed 
with anti-RPB1 pre-immune (pre-IS) or immune serum (IS). The immune serum specifically detected 
phosphorylated (pRPB1) and dephosphorylated RPB1.  
(B) Diluted whole cell lysate was mock-treated or incubated with alkaline phosphatase (alk pho) in the 
absence or presence (+inh) of a phosphatase inhibitor cocktail.  
(C) Anti-RPB1 immunoblot analysis of whole cell lysates prepared from CRK9-silenced cells. Detection of 
the similar-sized RNA pol I subunit RPA1 served as a loading control.  
(D) Densitometric quantification of the phosphorylated (phos.) and dephosphorylated (dephos.) RPB1 
bands upon CRK9 silencing from three independent experiments. The signal of non-induced cells was 
arbitrarily set to 100.  
(E) Anti-HA immunoblot of a corresponding experiment with CRK9 RNAi cells that expressed RPB1-HA.  
(F) Anti-RPB1 immunoblot analysis of whole cell lysates prepared from CRK3-silenced cells. 
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  4.3 CRK9 silencing does not impair RNA pol II transcription.  
 Since CTD phosphorylation is essential for transcription initiation in yeast and mammals, 
we explored whether CRK9-dependent RPB1 phosphorylation is required for RNA pol II 
transcription in trypanosomes. We employed a permeabilized cell system which supports 
labeling of nascent RNA in a linearly increasing fashion for a period of 15-20 min (Ullu and 
Tschudi, 1990). Upon separation of labeled RNA by denaturing PAGE, the 142 nt-long SL RNA 
can be readily detected due to its strong overall synthesis rate (Figure 3.3A). The amount of SL 
RNA was roughly the same in non-induced cells and in cells in which the CRK9 knockdown was 
induced for one day. After two days of induction, the SL RNA was reduced by approximately 
one half but the signals for tRNA and larger RNAs were similarly reduced, most likely due to an 
increasing number of dying cells. Accordingly, when we used densitometry to adjust the tRNA 
signal, labeled SL RNA remained at the same high level two days after induction (Figure 3.3A, 
right panel). Signal quantification from independent experiments confirmed that nascent SL 
RNA synthesis is not perturbed upon CRK9 silencing (Figure 3.3C). Due to a large number of 
dead or dying cells, the experiment could not be performed meaningfully with cells that were 
CRK9-silenced for three days. However, since trypanosome growth ceased already after one 
day of CRK9 silencing and since the levels of pre-mRNA, mature mRNA and SL RNA were 
already clearly perturbed after two days of induction (Figure 3.1), we concluded that the loss of 
CRK9-dependent RPB1 phosphorylation did not impair SL RNA synthesis. Importantly, the 
SLRNA promoter is the only characterized RNA pol II promoter in trypanosomes that assembles 
a transcription pre-initiation complex including TFIIH, the factor responsible for initial CTD 
phosphorylation in other eukaryotes. Therefore, this finding strongly indicated that, in 
trypanosomes, TFIIH-mediated CTD phosphorylation is not required for RNA pol II escape from 
the SLRNA promoter. 
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   To explore the possibility that RPB1 phosphorylation is important for transcription of 
protein coding genes, we hybridized labeled nascent RNA to dot blots of plasmids carrying 
trypanosome gene inserts (Figure 3.3B). The experiment was repeated three times and 
revealed that labeling efficiency was reduced throughout the array two days after induction. For 
comparison, we normalized all signals with the signal of the RNA pol III-transcribed threonine 
tRNA/U6 snRNA gene association (Nakaar et al., 1997) which on day 2 was reduced on 
average by ~35%. Quantification of hybridization signals did not detect a specific defect in RNA 
pol II-mediated transcription of protein coding genes. Two days after induction, the α tubulin and 
HSP70 signals were reduced by 14% and 3% respectively, RNA pol I-synthesized GPEET 
procyclin RNA was reduced by 21%. While none of these reductions proved to be significant 
(unpaired Student’s T test assuming equal variance and two-tailed distribution), the strongest 
signal reduction of 33% was observed in RRNA transcription. Since it is well-known from other 
systems that inhibition of rRNA synthesis in stationary or stressed cells is often a first measure 
to down-regulate gene expression, this signal reduction could reflect the poor health of CRK9-
silencend cells. 
 In summary, these experiments failed to detect a specific defect in RNA pol II 
transcription and thus strongly indicate that CRK9-dependent RPB1 phosphorylation is neither 
required for transcription initiation at the SLRNA promoter nor an essential modification for 
transcription elongation within the protein coding gene arrays. 
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Figure 3.3 CRK9 silencing does not affect RNA pol II transcription.  
(A) Nascent RNA of cells that were non-induced (ni) or CRK9-silenced for 1 or 2 days, was radio-labeled 
in a permeabilized cell system, extracted, separated on a 50% urea-6% polyacrylamide gel, and 
visualized by autoradiography. In the left panel, the loading of RNA was standardized to the number of 
cells and on the right panel, the loading was standardized according to the tRNA signal as indicated. The 
arrow points to an RNA band that most likely represents a previously described SL RNA that is extended 
at the 3/ end.  
(B) The same labeled RNA preparations were used to probe dot blots of plasmids containing the coding 
regions of T. brucei GPEET procyclin, α tubulin (α TUB), heat shock protein 70 (HSP70), and 18S rRNA 
as well as the associated threonine tRNA/U6 snRNA genes (tRNATHR/U6 snRNA). The plasmid without 
insert (pTZ18U) served as a negative control. For each lane, upper and lower panels are from the same 
image.  
(C) The radioactive signals from four independent experiments were quantified by scintillation counting 
and normalized to the RNA pol III-mediated tRNATHR/U6 snRNA signal because CRK9 silencing did not 
affect the abundance of the RNA pol III-synthesized U2 transcript. The SL RNA signal was quantified by 
densitometry and normalized to the tRNA signal as shown in (A). The error bars represent standard 
deviations. 
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  4.4 CRK9 silencing impairs cap4 formation of the SL RNA.  
 As detailed above, reporter gene expression by different RNA pols demonstrated that 
pre-mRNA processing in trypanosomes is uncoupled from RNA pol II transcription (Stewart et 
al., 2010). In accordance with these results, CRK9 silencing affected RNA pol I-synthesized 
GPEET procyclin RNA in the same way as it did RNA pol II-synthesized α tubulin mRNA (Figure 
3.1). However, these results did not exclude the possibility that SL RNA modification depended 
on RNA pol II because SL trans splicing is an essential maturation step for all trypanosome 
mRNAs independent of the transcribing RNA pol. Since trans splicing depends on the 
methylation status of the SL RNA cap4 structure (McNally and Agabian, 1992; Ullu and Tschudi, 
1991) and since there is evidence that SL RNA cap4 formation occurs co-transcriptionally (Mair 
et al., 2000b), it was possible that the trans splicing block observed upon CRK9 silencing was 
due to inappropriate cap4 formation. To monitor cap4 methylations on the SL RNA we 
employed a modified primer extension assay with a reduced concentration of 
deoxyribonucleotides and with unmodified MMLV reverse transcriptase that terminates 
polymerization before the methylated nucleotide under these conditions (Mandelboim et al., 
2002; Zamudio et al., 2006). In non-induced cells, the SL RNA-specific extension products 
spanned six positions: cap0 - cap4 in which, as previously noted (Zamudio et al., 2007), a cap3-
specific extension product is typically not observed because MTR3 methylates positions 3 and 
4, and cap4 can generate two extension products (Figure 3.4A). The cap4 signals were the 
strongest in these cells and the pattern did not change after one day of CRK9 silencing. 
Conversely, on days two and three, the cap4 signals faded whereas the main extension product 
of the accumulating SL RNA was the cap0 product indicating a complete loss of cap4 
methylations (Figure 3.4A). Furthermore, loss of cap1 modification was previously shown to 
correlate with ineffective trimming of the SL RNA 3/ end by the nuclease TbSNIP leading to 
slightly larger SL RNAs (Zamudio et al., 2007). In accordance with this finding, we detected an 
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  accumulating signal above the correct SL RNA band in labeled nascent RNA (Figure 3.4A, 
arrow). In summary, we concluded that CRK9 silencing caused a degree of cap4 
hypomethylation that impaired SL trans splicing leading to SL RNA and pre-mRNA 
accumulations and decreasing levels of mature mRNAs. 
Next, we addressed the question whether cap4 hypomethylation is linked to the loss of 
RPB1 dephosphorylation. We first analyzed the U1 snRNA cap. While the T. brucei U1 gene 
appears to be transcribed by RNA pol III (Djikeng et al., 2001), the U1 snRNA has a cap1 
structure consisting of a trimethylguanosine (TMG) cap and a methylated adenosine at position 
1 that leads to a premature primer extension stop at position 2 (Djikeng et al., 2001; Zamudio et 
al., 2007). Importantly, cap1 methylation of both SL RNA and U1 snRNA is carried out by the 
same methyltransferase termed MTR1 (Zamudio et al., 2007). Hence, if CRK9 silencing led to a 
direct deactivation of MTR1 we would expect to see a loss of cap1 in U1 snRNA. To test this, 
we carried out the modified primer extension assay with total RNA prepared from CRK9- and 
CRK3-silenced cells using a U1-complementary oligonucleotide (Figure 3.4B). We reproducibly 
detected three U1-specific products in our assay: the two lower bands were specific for cap1 
and unmodified cap0 whereas the fainter product with an extra nucleotide (position -1) was 
possibly generated due to the TMG cap (as opposed to the SL RNA m7G cap). As expected, 
treating the cells for six hours with sinefungin resulted in a signal shift from cap1 to cap0/pos-1 
products. This shift was not observed in CRK9- or CRK3-silenced cells even after RNAi 
induction for three days indicating that the MTR1 enzyme activity remained active. 
Consequently, the specific loss of SL RNA cap1 methylation upon CRK9 silencing may be due 
to a failure in MTR1 recruitment to the SL RNA 5/ end. 
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Figure 3.4 CRK9 silencing resulted in specific hypomethylation of SL RNA cap4.  
(A) Primer extension analysis with MMLV reverse transcriptase and reduced dNTP concentration (100 
nM) of total RNA prepared from non-induced (ni) or CRK9-silenced cells using 32P-5/ end-labeled 
oligonucleotides SLf and U2f that are complementary to SL RNA and U2 snRNA, respectively. The 
extension products were separated on a high resolution 6% sequencing gel and visualized by 
autoradiography. The lower exposure of the SL RNA extension products at the bottom reveals that CRK9 
silencing led to accumulation of larger extension products, particularly that of the cap0 product. For 
comparison, a SL RNA-specific sequencing ladder was generated by linear amplification sequencing 
using labeled SLf; the nucleotide specification for each lane corresponds to the coding strand sequence. 
The sequencing ladder was co-separated on the same gel but required a longer exposure.  
(B) A corresponding analysis of the U1 snRNA cap1 in CRK9- and CRK3-silenced cells. The first four U1 
nucleotides of the sequencing ladder are marked by asterisks and the partial loss of cap1 in sinefungin-
treated cells (sin) is denoted by the arrow. 
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  To support this notion, we evaluated pseudouridylation of SL RNA at position 28 which is 
carried out by the SLA1 ribonucleoprotein particle (RNP) that comprises several proteins 
including the pseudouridine synthase CBF5 (54) and MTR1 (Zamudio et al., 2009b). We 
hypothesized that if MTR1 is not recruited to the SL RNA cap in CRK9-silenced cells then 
pseudouridylation may also be impaired because MTR1 and CBF5 belong to the same RNA-
protein complex. However, the accumulating SL RNA in CRK9-silenced cells was clearly 
pseudouridylated (Attachment 2, Fig. S5) indicating that the SLA1 RNP can interact with SL 
RNA independent of CRK9-controlled RPB1 phosphorylations. As follows, our data do not 
unequivocally support the notion that RPB1 phosphorylation mediates cap4 formation. Testing 
this hypothesis is beyond the scope of this study because it requires the simultaneous 
knockdown of the two T. brucei RPB1 genes and the ectopic expression of a tagged, RNAi-
resistant version of the large RPB1 gene carrying mutations of phosphorylated CTD residues. 
Nevertheless, the results presented here strongly indicate that the unique methylations of cap4 
that are essential for trans splicing depend on CRK9. 
4.5 CRK9 silencing does not affect m7G capping of SL RNA.  
 The previous demonstration that prematurely terminated SL RNA transcripts as short as 
30 nt were capped with an m7G residue led to the conclusion that m7G capping of T. brucei SL 
RNA occurs cotranscriptionally (Mair et al., 2000b). It was therefore possible that CRK9 
silencing and the resulting CTD dephosphorylation abrogated m7G capping of the SL RNA. To 
analyze the SL RNA capping status in CRK9-silenced cells we performed immunoprecipitations 
with an antibody directed against a TMG cap that also recognizes the m7G cap but does not 
interact with an unmethylated guanosine cap or uncapped RNAs. As shown in figure 3.5, the SL 
RNA was efficiently precipitated from total RNA of non-induced cells as well as of cells in which 
CRK9 was silenced for up to three days. In contrast, SL RNA from sinefungin-treated cells that 
lacked methylations and the uncapped U5 snRNA, which served as an internal negative control, 
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  were not precipitated. These results clearly demonstrated that CRK9-dependent CTD 
phosphorylation is not required for SL RNA m7G capping indicating that a potential interaction 
between trypanosome RNA pol II and the capping enzyme is independent of RPB1 
phosphorylation. 
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Figure 3.5 CRK9 silencing does not affect m7G capping of SL RNA.  
Total RNA preparations from non-induced cells (ni), cells in which CRK9 was silenced for 1, 2 or 3 days, 
or cells which were treated with the methylation inhibitor sinefungin (sin) were immunoprecipitated with an 
antibody that recognizes both m2,2,7G and m7G caps. Equal amounts of supernatants (S) and 
immunoprecipitates (P) were analyzed by primer extension with oligonucleotides complementary to the 
SL RNA (m7G cap), the U2 snRNA (m2,2,7G cap), and the uncapped U5 snRNA. 
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  4.5 RPB1 phosphorylation and SL RNA cap4 formation depend on CRK9 kinase activity.  
 Thus far, we have shown that inducible expression of dsRNA that targets the 5/-terminal 
CRK9 coding region led to an efficient knockdown of CRK9 mRNA and to RPB1 
dephosphorylation, SL RNA cap4 hypomethylation, and the described RNA processing defects. 
To unequivocally demonstrate that these effects depended on CRK9 and its enzymatic activity 
and not to an off-target effect of the 500 bp-long dsRNA, we generated a new procyclic RNAi 
cell line in which we targeted the 3/ UTR of the CRK9 mRNA (Figure 3.6A). The corresponding 
knockdown led to a similar, rapid decline of cell numbers as observed previously and, as 
expected, the levels of mature and pre-mature α tubulin mRNA decreased and increased upon 
induction of dsRNA synthesis, respectively. The cap4 methylation defect and RPB1 
dephosphorylation were similarly obvious (Figure 3.6A). Moreover, when we integrated a 
plasmid into an endogenous CRK9 allele that fused an HA tag sequence and the RPA1 3/ UTR 
to the CRK9 coding region, we could rescue culture growth and all the defects (Figure 3.6B). 
The corresponding RNA analysis showed that endogenous CRK9 mRNA was effectively 
knocked down whereas CRK9-HA mRNA was resistant to the RNAi response. Correspondingly 
CRK9-HA protein abundance remained unaffected upon doxycycline induction. These results 
unequivocally demonstrated that RPB1 phosphorylation and SL RNA cap4 formation are 
controlled by CRK9. In a final step, we wanted to make sure that the kinase activity of CRK9 is 
important for this control. In general, phosphorylation of the T loop threonine residue (T161 in 
human CDK1) leads to activation of a CDK/cyclin complex. The corresponding threonine 
residue in CRK9 of T. brucei had been mapped to position 533 (Hammarton, 2007). We 
therefore repeated the rescue experiment but this time we mutated the T533 to an alanine in the 
CRK9-HA protein (Figure 3.6C). RNAi induction showed a growth defect after 24 h similar to the 
other (non-rescued) CRK9 silencing experiments. However, these cells recovered after 2-3 days 
to normal growth and this was observed with three independently obtained clonal cell lines. 
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  Concomitant with recovery we reproducibly noticed a slightly higher migrating band of CRK9-
HAT553A 3 days after induction (Figure 3.6C, arrow in CRK9-HAT553A immunoblot) suggesting that 
compensatory phosphorylations or other post-translational modifications led to an 
unconventional activation of CRK9-HAT553A. Nevertheless, while only a minor perturbation of α 
tubulin (pre-)mRNA was apparent 3 days after induction, cap4 hypomethylation and RPB1 
dephosphorylation were clearly detectable 2 days after induction. These data strongly indicated 
that CRK9 enzyme activity is required for RPB1 phosphorylation and SL RNA cap4 formation. 
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Figure 3.6 RPB1 phosphorylation and SL RNA cap4 formation depend on CRK9 kinase activity.  
A CRK9 RNAi parent cell line (A) was generated in which the inducibly expressed dsRNA targets the 3/ 
UTR of CRK9 mRNA. This cell line was further modified by targeted integration of a plasmid into an 
endogenous allele that fused an HA tag sequence and the 3 /UTR of the largest RNA pol I subunit RPA1 
to the 3/ end of the gene (B). A third cell line was generated analogously except that the threonine codon 
at position 533 was mutated to an alanine codon (C). For each cell line, culture growth curves were 
obtained in the presence or absence of doxycycline and RNA and protein analyses were conducted with 
non-induced cells (ni) and with cells that were induced for 1, 2, or 3 days. Semi-quantitative RT-PCR 
analyses demonstrated efficient knockdown of endogenous (Castillo et al.) CRK9 RNA and RNAi 
resistance of CRK9-HA RNA (boxed results). The CRK9 silencing effect on α tubulin mRNA (α Tub) and 
pre-mRNA (pre-αTub) was assessed by semi-quantitative RT-PCR, and on SL RNA by primer extension 
assays. Detection of rRNA (RRNA) by ethidium bromide staining served as a control for RNA amount. 
Asterisks identify increased hypomethylated cap4 signals. Anti-HA and anti-RPB1 immunoblot analyses 
confirmed RNAi resistance of CRK9-HA (boxed) and revealed the effects of CRK9 silencing on RBP1 
phosphorylation. Detection of RPA1 served as a loading control. The arrow on the right identifies a slower 
migrating band of CRK9-HAT553A protein. 
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  5. Discussion 
 We have analyzed the role in gene expression of four out of the eleven trypanosome 
CDKs. Our hypothesis was that, in line with phosphorylation of heptad repeats, this type of 
kinase phosphorylates the non-canonical RPB1 of trypanosomes and is of central importance 
for gene expression in this early-diverged eukaryote. Accordingly, we could demonstrate that 
silencing of trypanosome CRK9 led to a loss of RPB1 phosphorylation. Since it was shown that 
the RPB1 CTD is phosphorylated (Chapman and Agabian, 1994; Das and Bellofatto, 2009) and 
phosphoproteomics exclusively detected phosphorylated residues in the CTD of the large RPB1 
protein (Nett et al., 2009), it is likely that most if not all RPB1 phosphorylations are located in the 
CTD. It seems that all of these phosphorylations depend on CRK9 because silencing of its gene 
led to a loss of the pRPB1 band in immunoblots and to a concomitant increase of 
unphosphorylated RPB1 without the appearance of an intermediate band. Although we have not 
been able to show so far that CRK9 directly phosphorylates the CTD, our results are informative 
about the function of the non-canonical CTD. We found that reducing phosphorylated RPB1 to 
30% on day 2 of CRK9 silencing, did not impact transcription of protein coding and SLRNA 
genes indicating a mechanistic difference in transcription initiation between trypanosomes and 
eukaryotes with a canonical CTD. In the latter, RNA pol II recruitment into the PIC involves the 
mediator complex which binds to hypophosphorylated RNA pol II. TFIIH/CDK7-mediated CTD 
phosphorylation disrupts this interaction, presumably facilitating promoter escape of the 
polymerase (Sogaard and Svejstrup, 2007). Trypanosomes do possess a mediator complex that 
is essential for SLRNA transcription, interacts with TFIIH, and is required for the formation of a 
transcription pre-initiation complex at the SLRNA promoter (Lee et al., 2010). However, whereas 
eukaryotic mediator consists of head, middle, tail and CDK8 modules, EM structure analysis of 
the trypanosome complex indicated that it is confined to the head module (Lee et al., 2010). 
Thus, the absence of a TFIIH kinase (Lee et al., 2009) and the presence of a minimal mediator 
complex suggest that, in trypanosomes, a mediator-CTD interaction does not occur and a 
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  release of RNA pol II from mediator is not a prerequisite for promoter escape of the enzyme. 
Accordingly, tandem affinity purification of trypanosome mediator did not co-purify detectable 
amounts of RNA pol II subunits (Lee et al., 2010) and vice versa (Das et al., 2006; Devaux et 
al., 2006). 
Furthermore, RPB1 dephosphorylation did not impact m7G capping of SL RNA. In higher 
eukaryotes, the capping enzyme binds to the CTD after Ser5 of the heptad repeat motif is 
phosphorylated by CDK7 (Fabrega et al., 2003); capping then occurs co-transcriptionally. Since 
in trypanosomes, SL RNA capping does occur co-transcriptionally as well (Mair et al., 2000b), 
our results strongly suggest that the trypanosome capping enzyme interacts with the 
transcription machinery in a trypanosome-specific manner independent of CTD phosphorylation. 
Nevertheless, CRK9 silencing resulted in a striking defect in trypanosome gene 
expression, namely a block of trans splicing before the first transesterification reaction caused 
by hypomethylation of SL RNA cap4. Formation of the unique cap4 structure involves seven 
methylations on the first four nucleotides by three or more different methyltransferases. Thus, 
the most intriguing aspect of our work is the demonstration that cap4 formation is controlled by a 
single enzyme. Since the trypanosome cap4 structure is unique, essential for trans splicing 
(McNally and Agabian, 1992; Ullu and Tschudi, 1990), and important for translation (Zamudio et 
al., 2009b), identification of the methyltransferases has been a priority and, thus far, the three 2/-
O-ribose methyltransferases MTR1, MTR2 (aka COM1, MT48) and MTR3 (aka MT57) which 
methylate positions 1, 2 and 3/4, respectively, have been identified (Arhin et al., 2006a; Arhin et 
al., 2006b; Hall and Ho, 2006; Zamudio et al., 2007; Zamudio et al., 2006). Surprisingly, 
however, elimination of individual MTR genes left trypanosomes viable and did not impair trans 
splicing. This functional redundancy of the known MTRs has dampened enthusiasm for these 
enzymes being potential chemotherapeutic targets. However, the dependence of a critical 
number of cap4 methylations on CRK9 alone reinstates cap4 formation as a target. CRK9 
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  appears to be particularly promising in this respect. Firstly, CRK9 has an essential central role in 
trypanosome gene expression controlling RPB1 phosphorylation and SL RNA cap4 formation. 
Secondly, SL trans splicing does not occur in mammals and, thus, the block of SL RNA 
maturation is a parasite-specific defect. Thirdly, since SL RNA is consumed in trans splicing of 
every mRNA, partial inhibition of SL RNA biogenesis may already be lethal. This notion is 
backed up by independent observations that a reduction of SL RNA synthesis to ~30% is 
already lethal to cultured trypanosomes (Ruan et al., 2004; Schimanski et al., 2006). Fourthly, 
cyclin-dependent kinases in general are considered to be among the most promising drug 
targets due to their key function in cell proliferation (Malumbres and Barbacid, 2009). 
Accordingly, CRK9 silencing was shown to affect trypanosome mitosis and cytokinesis 
(Gourguechon and Wang, 2009; Li, 2012). 
How does CRK9 enable cap4 formation? A plausible explanation is that cap4 
methylations occur co-transcriptionally requiring a phosphorylated CTD. This would be 
consistent with previous observations that cap4 methylations can be detected on newly 
synthesized, prematurely terminated SL RNA transcripts (Mair et al., 2000b). Part of our results 
support this scenario: CRK9 silencing did not cause a detectable defect of cap1 formation in the 
RNA pol III-synthesized U1 snRNA suggesting that MTR1, the methyltransferase that forms 
cap1 in both U1 and SL RNA, remains functional during the CRK9 knockdown. Thus, the loss of 
SL RNA cap1 may be explained by failed recruitment of MTR1 by dephosphorylated RNA pol II. 
Although MTRs did not co-purify with T. brucei RNA pol II (Das et al., 2006; Devaux et al., 
2006), the interaction may have been lost due to rapid RPB1 dephosphorylation in extract. As 
our data show (Fig. 3.2A), the phosphorylated form of RPB1 was only detected in whole cell 
lysates and rapidly converted to the dephosphorylated form during extract preparation, possibly 
due to the presence of 15 putative homologs of the CTD phosphatase FCP1 in the T. brucei 
genome (www.TritrypDB.org). 
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  On the other hand, there are findings which suggest that the T. brucei 
methyltransferases do not require RNA pol II for recruitment. T. brucei MTR1 was found to be in 
a complex with the SLA1 RNP that contains several subunits including the pseudouridine 
synthase CBF5, and which guides pseudouridylation of SL RNA position 28 (Zamudio et al., 
2009b). While SL RNA pseudouridylation is not essential for trypanosome viability (Hury et al., 
2009), CBF5 silencing affected cap4 formation indicating that the SLA1 RNP is important for 
MTR1 function (Barth et al., 2005). Accordingly, we found that pseudouridylation was not 
impaired during CRK9 silencing which indicates that the SLA1 RNP can interact with the SL 
RNA independent of phosphorylated RNA pol II. Furthermore, MTR2 and MTR3 cap4 
methylations depend on Sm protein binding to the SL RNA 3/ terminal domain (Mandelboim et 
al., 2003; Zeiner et al., 2004a), suggesting that the SL RNP possesses RNA pol II-independent 
determinants for MTR2 and MTR3 recruitment. However, these arguments are not conclusive 
and there are other findings which are more in line with co-transcriptional cap4 formation. 
Firstly, the interaction between SLA1 and SL RNA appears to be weak and transient since 
purification of the SLA1 RNP did not co-purify detectable amounts of SL RNA, indicating that 
base pairing alone may not be enough for SLA1 recruitment to the SL RNA (Zamudio et al., 
2009b). Taken together, it will require a dedicated study to decipher whether CTD 
phosphorylation is directly linked to SL RNA cap4 formation or whether RPB1 phosphorylation 
and cap4 formation are independent processes. 
Overall, our study has identified a cyclin-dependent kinase that is of central importance to 
trypanosome gene expression being essential for SL RNA maturation and RPB1 
phosphorylation. Together with previous TFIIH and mediator characterizations, it has provided 
compelling evidence for RNA pol II transcription initiation and m7G capping functioning 
independently of a TFIIH-based, CDK7-mediated CTD phosphorylation event. Our data strongly 
suggest that the essential CTD function in RNA pol II transcription initiation has evolved after 
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  the divergence of major protistan lineages because it appears to be coupled to the canonical 
CTD with heptad repeat motifs. 
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  Chapter IV 
The cyclin-dependent kinase CRK9, a new L-type cyclin and 
a CRK9-associated protein cooperate in facilitating  
spliced leader trans splicing in Trypanosoma brucei 
 
 
1. Abstract 
 In eukaryotes, cyclin-dependent kinases (CDKs) control the cell cycle and critical steps 
in gene expression. The lethal parasite Trypanosoma brucei, member of the phylogenetic order 
Kinetoplastida, possesses eleven CDKs which, due to high sequence divergence, were 
generically termed CDC2-related kinases (CRKs). While several CRKs have been implied in the 
cell cycle, CRK9 is the first trypanosome CDK that was shown to control the unusual mode of 
gene expression found in kinetoplastids. In these organisms, protein-coding genes are arranged 
in tandem arrays which are transcribed polycistronically. Individual mRNAs are processed from 
precursor RNA by spliced leader (SL) trans splicing and polyadenylation. CRK9 ablation was 
lethal in cultured trypanosomes, causing a block of trans splicing at the first transesterification 
step. Additionally, CRK9 silencing led to dephosphorylation of RNA polymerase II and to 
hypomethylation of the SL cap structure. Here, we tandem affinity-purified CRK9 and, among 
potential CRK9 substrates and modifying enzymes, discovered an unusual tripartite complex of 
CRK9, a new L-type cyclin (CYC12) and a protein, termed CRK9-associated protein (CRK9AP), 
that is only conserved among kinetoplastids. Silencing of either CYC12 or CRK9AP reproduced 
the effects of depleting CRK9, identifying these proteins as functional partners of CRK9 in vivo. 
While mammalian cyclin L binds to CDK11, the CRK9 complex deviates substantially from that 
of CDK11, requiring CRK9AP for CRK9 complex integrity. Interference with this unusual CDK 
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  rescued mice from lethal trypanosome infections, validating CRK9 as a potential 
chemotherapeutic target. 
 
2. Introduction 
 Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are unicellular, vector 
borne, human parasites belonging to the early-diverged phylogenetic order Kinetoplastida. 
These parasites collectively affect millions of people worldwide primarily in developing countries, 
causing debilitating to fatal human diseases. There is no preventive vaccine for these diseases 
and the current medications are unsatisfactory due to poor efficacy, toxicity and developing drug 
resistance (Barrett and Croft, 2012). Trypanosomatid parasites share a unique mode of protein 
coding gene expression that is distinct from their hosts. A trypanosomatid genome is organized 
in large gene clusters, containing tandemly linked protein coding genes which are transcribed 
polycistronically. Individual mRNAs are resolved from pre-mRNA by spliced leader (SL) trans 
splicing and polyadenylation. In SL trans splicing, the SL, derived from the small nuclear SL 
RNA, is spliced onto the 5/ end of each mRNA (Gunzl, 2010; Michaeli, 2011). Like cis splicing, 
e.g. the removal of introns, SL trans splicing comprises two transesterifications, generating a Y-
shaped structural intermediate after the first splicing step that is analogous to the lariat structure 
in cis splicing (Murphy et al., 1986; Sutton and Boothroyd, 1986). The 39 nt-long SL harbors an 
extensively modified cap structure, called cap4, that consists of a standard 7-methylguanosine 
cap nucleotide followed by four methylated nucleotides (Bangs et al., 1992). Cap4 is important 
for SL trans splicing (McNally and Agabian, 1992; Ullu and Tschudi, 1991) and for efficient 
translation (Zamudio et al., 2009a). Since each and every mRNA carries a SL, trans splicing is 
absolutely essential for the survival of kinetoplastids. In T. brucei, the cdc2-related kinase 9 
(CRK9) appears to be of crucial importance for this unusual mode of gene expression since 
depletion of this cyclin-dependent kinase (CDK) led to a lethal block of trans splicing (Badjatia et 
al., 2013a). 
101
	   CDKs are serine/threonine kinases that require association with a cyclin for enzymatic 
activity (Pines, 1995). CDKs were first identified as key regulators of cell cycle progression 
(Beach et al., 1982; Nasmyth and Reed, 1980), although now it is well established that there is 
a second group of CDK/cyclin complexes that have crucial functions in transcription and RNA 
splicing (Lim and Kaldis, 2013; Loyer et al., 2005). There are 13 CDKs in humans all of which 
share a conserved catalytic domain containing an ATP binding pocket, a PSTAIRE-like helix 
domain responsible for cyclin binding and an activating T-loop motif (Cao et al., 2014; 
Malumbres et al., 2009). While CDKs that are important for the cell cycle are regulated by their 
sequential binding to different cyclins, each of which are transcribed and degraded at defined 
cell cycle stages, the CDKs and cyclins that are involved in gene expression are constitutively 
expressed throughout the cell cycle, typically forming a single CDK-cyclin complex (Lim and 
Kaldis, 2013; Loyer et al., 2005). In metazoans, CDK7 has a dual role in both cell cycle and 
transcription. Uniquely, CDK7 forms a trimeric complex with Cyclin H and the RING finger 
domain protein MAT1 (ménage a trois 1) that phosphorylates and activates cell cycle CDKs in 
their T-loops and, therefore, has been termed the CDK-activating kinase (CAK). CAK is also 
part of the basal transcription factor TFIIH and, in this association, phosphorylates the carboxy-
terminal domain of RPB1 during transcription initiation, promoting promoter clearance of RNA 
pol II (Akoulitchev et al., 1995; Dahmus, 1996; Serizawa et al., 1995; Shiekhattar et al., 1995) 
and recruitment of RNA processing factors including the capping enzyme (Rodriguez et al., 
2000) reviewed in . The PITSLRE kinase CDK11 is another CDK that has a dual role (Loyer et 
al., 2005; Satyanarayana and Kaldis, 2009). In murine and human cells it is present as two 
isoforms, CDK11p110 and CDK11p58 (Cornelis et al., 2000; Gururajan et al., 1998; Li et al., 2004b; 
Xiang et al., 1994). While CDK11p58 is implicated in mitosis, and is expressed due to a G2/M-
specific internal ribosome entry site present in the CDK11p110 mRNA (Cornelis et al., 2000; Li et 
al., 2004b); CDK11p110 is constitutively expressed and involved in transcription and pre-mRNA 
splicing (Hu et al., 2003; Loyer et al., 1998; Trembley et al., 2004). Orthologs of CDK11 are 
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  present in all metazoans and fission yeast but absent from budding yeast (Guo and Stiller, 
2004; Liu and Kipreos, 2000). 
 Trypanosoma brucei harbors eleven CDKs that were generically termed CRK1-4 and 
CRK6-12 since their high sequence divergence has prevented orthologous assignments with 
CDKs of other eukaryotes. In addition, ten cyclins (CYC2-11) have been identified in T. brucei 
so far (Hammarton, 2007; Naula et al., 2005). Due to their crucial importance for gene 
expression and cell proliferation, CDKs are generally considered to be promising drug targets 
and, therefore, trypanosomatid CRKs have been a research focus. RNAi-mediated gene 
knockdowns identified CRK1-3, CRK6, CRK9 and CRK12 as essential CDKs in T. brucei 
(Badjatia et al., 2013a; Gourguechon and Wang, 2009; Jones et al., 2014; Mackey et al., 2011; 
Merritt and Stuart, 2013; Monnerat et al., 2013; Tu and Wang, 2004). Less is known about the 
specific functions of these important enzymes. CRK3 was shown to be the functional homolog 
of human CDK1; it partners with CYC6 (also referred to as Cyclin B2) and regulates mitosis 
(Hammarton et al., 2003; Li and Wang, 2003; Tu and Wang, 2004). Depletion of both CRK3 (Tu 
and Wang, 2004) and CYC6 (Hammarton et al., 2003; Li and Wang, 2003) results in a block of 
G2/M progression and cell death in the PF as well as BF. Interestingly, CRK3 also forms a pair 
with CYC2 (aka cyclin E1) in vivo (Van Hellemond et al., 2000). The knockdown of CYC2 is 
lethal and causes a G1 arrest in cells (Hammarton et al., 2004; Li and Wang, 2003), but a 
function of CRK3 in G1 phase if any, is yet unknown. CRK1 is important for G1/S progression 
and interacts with CYC2 in a yeast two-hybrid screen but this interaction was not observed in 
vivo (Gourguechon et al., 2007; Tu and Wang, 2004; Van Hellemond et al., 2000). CRK2, CRK4 
and CRK6 appear to have accessory functions in the cell cycle although their cyclin partners are 
unknown (Tu and Wang, 2005). Recently, CYC9 was shown to associate with CRK12 during a 
tandem affinity purification of CRK12. Both CYC9 and CRK12 were essential in BF, but gene 
silencing resulted in distinct phenotypes, suggesting that while CYC9 is important for 
cytokinesis, CRK12 has a role in endocytosis (Monnerat et al., 2013). 
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   CRK9 is the first trypanosome CDK shown to have an essential role in gene expression. 
In addition, like mammalian CDK7 and CDK11, this CDK seems to function in the cell cycle, too, 
since ablation of CRK9 in insect-stage, procyclic form (PF) trypanosomes led to a defect in 
basal body segregation during cytokinesis (Gourguechon and Wang, 2009). CRK9’s essential 
function in gene expression became apparent by RNA analysis of CRK9-silenced PFs and BFs 
both of which revealed a strong decline of mature mRNA and a concomitant increase of 
unspliced pre-mRNA. Similarly, while the trans splicing substrate SL RNA was dramatically 
increased in CRK9-silenced cells, the Y structure splicing intermediate exhibited a strong 
decline in abundance (Badjatia et al., 2013a). Moreover, introduction of an RNAi-resistant CRK9 
wild-type gene into these cells completely rescued this phenotype whereas introduction of an 
equivalent CRK9 gene carrying a mutation in its T-loop sequence did not. Together, these 
results showed that CRK9 enzyme activity is crucial for the first step of splicing. 
 Interestingly, CRK9 ablation also caused dephosphorylation of RPB1 and 
hypomethylation of the SL cap, raising the possibility that CRK9 is a functional homolog of 
mammalian CDK7, directly phosphorylating the CTD of RPB1. However, biochemical and 
structural characterization of trypanosome TFIIH did not reveal a kinase sub-complex (Lee et 
al., 2010; Lee et al., 2009) and CRK9 silencing did not lead to a RNA pol II-specific transcription 
defect (Badjatia et al., 2013a). Conversely, the CRK9 silencing defects could be quantitatively 
reproduced by depleting a subunit of the spliceosomal PRP19 complex that, in other systems, 
was shown to be essential for spliceosome activation, indicating a potential role of CRK9 in the 
RNA processing branch of gene expression (Ambrosio et al., 2015). Thus, while its importance 
for trypanosome gene expression and viability has been clearly demonstrated, the nature of 
CRK9 remains undetermined. 
 Here we have characterized the enzyme complex and validated CRK9 enzyme activity 
as a potential drug target in the mouse. CRK9 forms a tripartite complex together with a novel, 
previously unannotated L-type cyclin that we termed CYC12 and a kinetoplastid-specific protein 
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  that we call CRK9-associated protein (CRK9AP). CYC12 and CRK9AP silencing reproduced the 
CRK9 silencing phenotypes, identifying them as essential, functional partners of CRK9 in vivo. 
This is highly unusual as with the exception of CDK7, CDKs typically function in be reconstituted 
in active form in vitro and do not require additional protein partners for their kinase activity. 
Interestingly, CRK9AP appears to be important for the integrity of the complex as the 
knockdown of CRK9AP resulted in a concomitant loss of both CRK9 and CYC12. 
3. Results 
3.1 Characterization of the CRK9 enzyme complex 
 Since trypanosome CRK9 enzyme activity was required for spliced leader trans splicing, 
a parasite-specific step in the maturation of all mRNAs, we tagged and tandem affinity-purified 
the enzyme to identify its cyclin partner and other co-purifying proteins by liquid 
chromatography-tandem mass spectrometry (LC/MS/MS). By two consecutive transfections, we 
generated the clonal PF cell line TbC9ee, in which the hygromycin phosphotransferase gene 
(HYGR) replaced one CRK9 allele and targeted insertion of plasmid CRK9-PTP-NEO fused the 
sequence of the composite PTP tag, which encodes the protein C epitope (ProtC), a tobacco 
etch virus (TEV) protease cleavage site and a tandem protein A domain (ProtA), to the 3/ end of 
the CRK9 coding region (Fig. 4.1A). To confirm that TbC9ee cells exclusively expressed tagged 
CRK9, we raised a specific anti-CRK9 immune serum in rats against a partial recombinant GST-
tagged CRK9 protein that was expressed and purified from Escherichia coli. In an immunoblot 
of whole cell lysates, the immune serum detected a single protein band of ~100 kDa in wild-type 
trypanosomes which is slightly larger than the predicted CRK9 mass of 85.6 kDa (Fig. 4.1B). 
Accordingly to the molecular mass of 19 kDa for the PTP tag, in TbC9ee cells, this band was 
replaced by a ~120 kDa band that was also detected by a ProtA-specific probe, confirming 
exclusive expression of CRK9-PTP in TbC9ee cells. TbC9ee cells did not exhibit reduced 
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  culture growth as compared to the wild-type cells. Additionally, the phosphorylation status of 
RPB1, which has been linked to CRK9 function, was comparable in wild-type and TbC9ee cells 
(Fig. 4.1B, bottom panel). Hence, we concluded that the PTP tag did not interfere with CRK9 
function. 
 Facilitated by the PTP tag, we purified CRK9-PTP by IgG affinity chromatography, TEV 
protease cleavage and anti-ProtC immunoaffinity chromatography. An anti-ProtC immunoblot 
analysis revealed efficient capture of the tagged protein in all steps of the tandem affinity 
purification (Fig. 4.1C). Separation of the final eluate and, as controls, of the input material and 
the TEV protease fraction, by SDS-PAGE and staining of proteins by Sypro Ruby and 
Coomassie Blue, revealed a dominant band of ~105 kDa, representing CRK9-P (note that 
CRK9-PTP was reduced by ~15 kDa to CRK9-P by TEV protease cleavage), and, 
unexpectedly, many co-purified protein bands (Fig. 4.1D). Mass spectrometry of two 
independent CRK9-PTP purifications revealed a total of 162 proteins that were identified with an 
expect value smaller than 0.01 and at least by two unique peptides (Attachment 3, S1 Table). 
The majority of proteins, including those with very high Mascot Scores, were proteins of both 
ribosomal subunits. This massive co-purification of ribosomal proteins was surprising because 
CRK9 is a nuclear protein and not enriched in the nucleolus (Gourguechon and Wang, 2009), 
and previous PTP purifications of various nuclear complexes contained only few, low scoring 
ribosomal proteins. Since the functional association of CRK9 with ribosomal complexes remains 
unclear, we focused on non-ribosomal proteins. Table 4.1 lists the most significant 
identifications. While no annotated cyclin was detected in the purification, the protein with the 
second highest score is a new trypanosome cyclin (see below) which we termed CYC12 
(Tb927.10.9160). Among the top scoring proteins are three dual specificity protein kinases 
capable of phosphorylating serines and threonines as well as tyrosines. While these kinases 
may be substrates of CRK9, it is equally possible that they modify CRK9 since phospho-
proteomic studies revealed that residues threonine 533, serine 746, serine 750 and threonine 
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  752 of CRK9 are phosphorylated in the cell (Nett et al., 2009; Urbaniak et al., 2013).The list also 
contains four proteins that are only conserved within the genus Trypanosoma, indicating that, in 
addition to CRK9’s fundamental role in gene expression, there may be additional, trypanosome-
specific functions associated with this kinase. Finally, as potential direct links to the trans 
splicing mechanism, polyubiquitin-binding protein 2 (PABP2) and the SR protein TSR1 were 
identified. 
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Figure 4.1. Tandem affinity purification of CRK9.  
 
(A) Schematic depiction (not to scale) of the CRK9 locus in procyclic TbC9ee cells that exclusively 
express CRK9-PTP and no untagged CRK9. In these cells one wild-type CRK9 allele (open box) was 
knocked out by a hygromycin phosphotransferase gene (HYGR, striped box). Integration of plasmid 
CRK9-PTP-NEO introduced the PTP sequence (black box) and the neomycin phosphotransferase 
(NEOR) to the second allele. Smaller gray boxes indicate gene flanks for RNA processing signals and 
checkered boxes depict CRK9 sequences encoded in the plasmid.  
(B) Immunoblot of whole cell lysates of wild-type trypanosomes and of TbC9ee cells, detecting CRK9 and 
CRK9-PTP, respectively, with the newly generated anti-CRK9 polyclonal immune serum. On the same 
blot, phosphorylated (p) and unphosphorylated RPB1 was detected as a loading control with a polyclonal 
antibody, and CRK9-PTP specifically with the peroxidase anti-peroxidase reagent (PAP) that binds to the 
ProtA domains of the PTP tag.  
(C) Immunoblot monitoring of the CRK9-PTP purification detecting CRK9-PTP in crude extract (Inp) and 
the flowthrough of IgG affinity chromatography (FT-IgG), and CRK9-P in TEV protease eluate, the 
flowthrough of the anti-ProtC immunoaffinity chromatography (FT-ProtC) and the final eluate (Elu) with 
the monoclonal HCPC4 anti-ProtC antibody. The x-values indicate relative amounts analyzed.  
(D) Protein analysis of the CRK9-PTP purification. Proteins of crude extract, the TEV eluate and the final 
eluate were separated on 10-20% SDS polyacrylamide gel and first stained with Sypro Ruby and, 
subsequently, with Coomassie blue (right panel). Marker sizes in kDa are indicated on the left. 
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  Table 4.1 Mass spectrometric identification of CRK9 co-purified proteins 
 
Rank Annotation 1 Accession # 1 Mr (kDa) Score 2 % Coverage emPAI 3 
. 1 CRK9 Tb927.2.4510 85.5 13,418 73.9 10.3 . 
. 2 CYC12 Tb927.10.9160 71.2 9,956 43.3 8.1 . 
 6 protein kinase 4 Tb927.7.3880 87.0 1,797 49.7 2.1 
 19 hypothetical, conserved 5 Tb927.9.13970 36.8 805 47.3 2.8 
 22 protein kinase 4 Tb927.10.350 58.6 795 35.5 1.5 
 24 PABP2 Tb927.9.10770 62.2 724 37.8 1.7 
 28 protein kinase 4 Tb927.3.1610 74.2 661 34.1 1.0 
. 37 CRK9AP Tb927.3.4170 13.0 568 37.2 5.5 . 
 46 hypothetical, conserved Tb927.3.3740 69.1 525 34.4 0.8 
 50 hypothetical, conserved 5 Tb927.1.4680 37.3 474 36.3 1.2 
 59 hypothetical, conserved Tb927.10.11600 66.0 382 21.7 0.7 
 62 MRB1-assoc. protein Tb927.11.6320 53.2 353 29.3 0.6 
 69 NRBD1 (RNA-binding) Tb927.11.14000 28.8 299 37.8 1.7 
 73 hypo. conserved 5 Tb927.7.3080 47.3 285 31.9 1.0 
 74 RACK1 (kinase receptor) Tb927.11.11360 34.7 285 18.7 1.0 
 77 hypothetical, conserved 5 Tb927.4.3150 38.1 275 27.7 0.7 
 84 PNO1 (pre-rRNA process.) Tb927.9.11840 24.1 257 32.5 1.3 
 93 TSR1, splicing factor Tb927.8.900 37.4 226 22.1 0.6 
List of CRK9-PTP co-purified proteins, identified by LC/MS/MS, that were not a common contaminant of 
previous tandem affinity purifications, not annotated a ribosomal protein, had a Mascot Score of at least 
200 and an emPAI value equal or greater than 0.5. The rank number is according to the complete 
protein list in S1 Table. The CRK9 kinase complex subunits are highlighted in gray. 
1 Protein annotation and accession numbers are from the T. b. brucei 927 database at 
www.TriTrypDB.org, although proteins were identified through the T. b. brucei 427 Lister genome 
database whose annotation and assembly is not as complete. 
2 The Mascot Score corresponds to -10 x LOG10(P), where P is the absolute probability that the observed 
match is a random event. 
3 The emPAI (exponentially modified Protein Abundance Index) is a measure for the relative amount of 
an identified protein in the final eluate (Ishihama et al., 2005). 
4 Dual specificity kinases for tyrosine and serine/threonine phosphorylation. 
5 These proteins appear to be conserved only in the genus Trypanosoma. 
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   To potentially separate the kinase complex from co-purifying proteins, we sedimented 
the eluate of a CRK9-PTP purification through a sucrose gradient by ultracentrifugation. While 
part of the enzyme and nearly all other co-purified proteins migrated to the bottom of the 
gradient, CRK9-P exhibited a strong sedimentation peak in fractions 9-11 (Fig. 4.2A). Protein 
bands of ~80, 37 and 15 kDa co-sedimented in these fractions. Since transcriptional CDKs of 
other systems are capable of autophosphorylating their T-loop motifs, we carried out a kinase 
assay with fractions 9, 11, 13, and 20 detecting disproportionately high CRK9-P phosphorylation 
in fractions 9 and 11, indicating that fractions 9-11 contain the active CDK9 complex (Fig. 4.2B). 
Mass spectrometry identified the protein of the 37 kDa band, which exhibited a slightly different 
sedimentation profile than the other two bands, as a putative ribosomal protein 
(Tb927.11.2050); it may be a direct interactor of CRK9 within the ribosome. The two other 
bands were non-ribosomal proteins: The 80 kDa band contained CYC12 whereas the 15 kDa 
band revealed a protein (Tb927.3.4170) whose conservation is conserved only among 
kinetoplastid organisms and which we termed CRK9-associated protein or CRK9AP 
(Attachment 3, S2 Figure). To enable verification of these protein identifications by reciprocal 
co-immunoprecipitation, we manipulated one CYC12 allele in TbC9ee cells, fusing an HA tag C-
terminally to CYC12, and raised a polyclonal immune serum in rats against recombinant, GST-
tagged CRK9AP (Attachment 3, S3 Figure). As shown in figure 2C, precipitation of either CRK9-
PTP, CYC12-HA or CRK9AP specifically co-precipitated the other two proteins, indicating the 
presence of a tripartite enzyme complex. 
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Figure 4.2 CRK9 interacts and co-sediments with two unannotated proteins.  
(A) CRK9-PTP tandem affinity-purified material was sedimented through a 10-40% linear sucrose 
gradient by ultracentrifugation and fractionated into 20 aliquots from top to bottom. Proteins from each 
fraction were separated by SDS-PAGE and stained with sypro ruby. Protein bands were excised and 
identified by LC/MS/MS. Arrows point to the CYC12 and CRK9AP bands which co-sediment with CRK9 in 
fractions 9/10. The 35 kDa band with a peak in fractions 10/11 was found to be the putative ribosomal 
protein L5 (Tb927.9.15110/15150).  
(B) Kinase assay with materials from indicated fractions suggest autophosphorylation of CRK9.  
(C) Reciprocal co-IP assays of extracts prepared from a cell line in which CRK9 was exclusively PTP-
tagged and an HA tag sequence was inserted at the 3’end of one CYC12 allele. The precipitate (P) was 
loaded at a fourfold excess relative to extract (Inp) and supernatant (S). Detection of the RNA pol II 
transcription factor TFIIB served as a negative precipitation control. 
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  3.2 CYC12 is a new L-type cyclin 
 Mammalian cyclin L homologues exclusively partner with CDK11. There are two human 
cyclin L paralogs, L1 and L2, which share 60% identity. These proteins have a ~200 amino acid-
long N-terminal composite CCL1 domain that comprises the highly conserved Cyclin_N domain, 
the less conserved Cyclin_C domain (Nugent et al. 1991) and additional sequence 
conservation, characteristic for transcriptional cyclins, around these domains. In addition, cyclin 
L is an SR-related protein that features a conserved, C-terminal, highly positively charged 
arginine/serine-rich RS domain with repetitive “SR” dipeptide motifs (Fig. 4.3A). A standard 
protein-protein BLAST search of the human proteome with the T. brucei CYC12 sequence 
returned L1 and L2 cyclins (E=2e-09) but no other cyclins. A multiple sequence alignment of the 
CCL1 domain of cyclin L orthologs from model organisms and of kinetoplastid CYC12 
sequences showed convincing sequence conservation across the whole domain, although, as 
expected, the Cyclin_C domain was less well conserved (Attachment 3, S4 Figure). 
Interestingly, both cyclin domains were disrupted by extensive kinetoplastid-specific sequence 
insertions which likely prevented recognition of CYC12 as a cyclin in trypanosomatid genome 
annotations and of the cyclin domains by the NCBI BLAST algorithm (Fig. 4.3A, Attachment 3, 
S4 figure). Analysis of the C-terminus of CYC12 revealed a strong reduction of SR dipeptide 
motifs when compared to the human cyclin L domain (21 versus 7). However, conserved among 
all kinetoplastid CYC12 orthologs, the C-terminal domain has a similarly high isoelectric point of 
~12 as its counterparts in other eukaryotes. 
 To substantiate the notion that CYC12 is an L-type cyclin, we generated a phylogenetic 
tree with the sequence alignment of all human cyclin sequences and four representative 
kinetoplastid CYC12 sequences. To avoid a potential bias of the charged cyclin L/CYC12 C-
terminal domain, we restricted the analysis to the CCL1 domain. As expected, CYC12 
sequences unambiguously partitioned with the transcriptional cyclins and formed a branch with 
human L cyclins with a bootstrap value of 87% (Fig. 4.3B). A more extensive phylogenetic 
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  analysis of complete sequence alignments of cyclins of model organisms and all known 
kinetoplastid CYC12 orthologs revealed a similar tree although the bootstrap value of the cyclin 
L/CYC12 cluster was reduced to 53% (Attachment 3, S5 Figure). Taken together, these data 
strongly indicate that kinetoplastid CYC12 represents a L-type cyclin. 
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Figure 4.3 Cyclin CYC12 is an L-type cyclin.  
(A) Schematic drawing to scale of the human L1 and T. brucei CYC12 cyclins. The two cyclin folds (blue) 
are embedded in the CCL1 domain (green). The charged RS domain (red) was defined by a hydrophilicity 
Kyte & Doolittle blot score of < -2. Black lines indicate SR or RS dipeptides. Both cyclin domains of 
CYC12 are disrupted by insertions.  
(B) Phylogenetic tree, generated by the maximum likelihood algorithm and based on a multiple sequence 
alignment of the cyclin domains of human cyclins and of CYC12s from T. brucei (Tb), T. cruzi (Tc), L. 
major (Lm) and the bodonid Bodo saltans (Bs) (for accession numbers see Figure S5). Cyclins involved in 
the cell cycle and in transcriptional control are indicated. Bootstrap values are indicated in percentages 
and were derived from 1000 replicates. The common branch of human cyclins L and kinetoplastid 
CYC12s is drawn in red. 
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  3.3 CYC12 and CRK9AP are functional partners of CRK9 
 To test whether CYC12 and CRK9AP are of similar importance as CRK9 for 
trypanosome gene expression, we generated PF and BF cell lines for conditional silencing of 
each gene. Since the culture growth defects upon gene silencing were very similar between the 
lines for each gene (data not shown), we analyzed the knockdown phenotype in detail in one of 
those cell lines. In PFs, CYC12- and CRK9AP-silencing strongly affected culture growth two 
days after induction of the gene knockdown. Although the defects were delayed by one day 
when compared to the CRK9 knockdown (Badjatia et al., 2013a), trypanosome numbers 
diminished after the second day of induction (Figure 4.4A). The decline of PF trypanosome 
numbers was not as strong in CYC12-silenced cells as it was with CRK9- and CRK9AP-
silenced cells, indicating a different dynamic of the lethal defect. In BFs, this variation of gene 
silencing was not observed and the knockdown of each of the three genes was even more lethal 
than in PFs. As was observed previously in the CRK9 knockdown (Badjatia et al., 2013a), 
CYC12 or CRK9AP silencing caused a culture growth defect within 24 hours of induction and, 
subsequently, cell numbers rapidly declined with no viable cells left on day 4 after induction 
(Attachment 3, S6 figure, (Badjatia et al., 2013a). Thus, we concluded that CYC12 and CRK9AP 
are generally essential genes in T. brucei. 
 The trans splicing block upon CRK9 silencing became apparent by a decrease of mature 
mRNA and the Y structure intermediate, the concomitant increase of unspliced pre-mRNA, and 
the accumulation of SL RNA with a hypomethylated cap structure (Badjatia et al., 2013a). 
Analyses of total RNA from CYC12- and CRK9AP-silenced cells revealed similar defects 
(Figure 4.4B). As analyzed for α tubulin and RPB7 (RPB7 encodes a subunit of RNA pol II) by 
RT-PCR, the total coding RNA declined upon gene silencing whereas the abundance of 
unspliced RNA from these genes strongly increased during this period. Furthermore, primer 
extension assays of the same RNA preparations showed that, in both knockdowns, SL RNA 
increased, predominantly in its hypomethylated form, whereas the Y structure intermediate 
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  declined during the time course experiments (Figure 4.4B). These experiments clearly indicated 
a block of trans splicing before the first transesterification step in both gene knockdowns. 
Analysis of α tubulin RNA in BFs revealed the same trans splicing defect (Attachment 3, S6 
Figure). 
 Another specific effect of CRK9 silencing was dephosphorylation of the RNA pol II 
subunit RPB1 (Badjatia et al., 2013a). To monitor the phosphorylation status of this RNA pol II 
subunit, we probed an immunoblot of whole cell lysates with a specific immune serum raised 
against the C-terminal domain of RPB1 (Badjatia et al., 2013a). As shown in Figure 4.4C, the 
signal for phosphorylated RPB1 clearly decreased upon both CYC12- and CRK9AP-silencing 
whereas the dephosphorylated signal concomitantly increased. Note that the disproportional 
increase of the unphosphorylated RPB1 signal likely is due to an increase of antibody-
recognizable epitopes since the immune serum was raised against unphosphorylated protein. 
 Finally, as described previously, CRK9 silencing leads to an atypical rounding up of cells 
(Badjatia et al., 2013a; Gourguechon and Wang, 2009). Virtually all PFs that survive 3 days of 
CRK9 silencing exhibit a round shape (Attachment 3, S7 figure) reminiscent of FAT cells that 
were observed in the discovery of the RNA interference pathway upon tubulin gene knockdowns 
(Ngo). Silencing of CYC12 and of CRK9AP resulted to the same extent in the same 
characteristic phenotype (Attachment 3, S7 figure). Rounding up of cells was also observed in 
BFs in all three gene knockdowns although the number of round cells detected after three days 
of induction was limited to 81%, 55%, and 50% (n = 50) in CRK9-, CYC12-, and CRK9AP-
silenced cells, respectively. Possibly, the rapid onset of the deleterious effect in BFs prevented 
rounding up of all cultured cells. 
 Taken together, CYC12 and CRK9AP silencing resulted in the same block of trans 
splicing and RPB1 dephosphorylation in both PFs and BFs as observed previously upon CRK9 
silencing. Moreover, all three gene knockdowns caused cells to round up, an atypical death 
phenotype. These data demonstrate that CRK9, CYC12 and CRK9AP are functional partners in 
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  facilitating SL trans splicing in trypanosomes. Moreover, since this function requires an intact T-
loop of CRK9 (Badjatia et al., 2013a), our data indicate that all three proteins are required in 
vivo for CRK9-dependent phosphorylation. 
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Figure 4.4 CYC12 and CRK9AP are functional partners of CRK9.  
(A) Cumulative culture growth curves were obtained for CYC12 and CRK9AP silencing in the absence 
and presence of doxycyline (dox), the gene knockdown-inducing compound. For each knockdown a 
representative growth curve is shown.  
(B) Analysis of total RNA prepared from non-induced cells and cells in which CYC12 or CRK9AP were 
silenced for 1, 2 or 3 days. CYC12 or CRK9AP mRNA as well as α tubulin and RPB7 mRNA were 
analyzed by reverse transcription of oligo-dT and semi-quantitative PCR, whereas unspliced, pre-mRNA 
of α tubulin and RPB7 were analyzed by reverse transcription of random hexamers and by PCR using an 
oligonucleotide upstream of the SL addition site. rRNA was visualized by ethidium bromide staining after 
separation in an agarose gel. SL RNA, U2 snRNA and the Y structure intermediate were detected by 
primer extension assays using a SL RNA and a U2 snRNA-specific primer in the same reactions.  
(C) Anti-RPB1 immunoblot analysis of whole-cell lysates prepared from CRK9AP-silenced cells. Detection 
of the similar-sized RNA pol I subunit RPA1 served as a loading control. 
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  3.4 CRK9AP silencing causes rapid co-loss of CRK9 and CYC12 
 
 A tripartite CRK9 enzyme complex would be highly unusual since, to our knowledge, 
eukaryotic CDK7 is the only CDK whose enzyme activity depends on three proteins. Thus, to 
understand the specific function of CRK9AP, we investigated the effect of CRK9AP ablation on 
the expression of its functional partners. While the CRK9 and CYC12 RNA abundances were 
unaffected by CRK9AP silencing in both PFs and BFs (data not shown), both proteins were 
rapidly lost upon CRK9AP depletion (Figure 4.5). This result indicates that CRK9AP is important 
for CRK9 complex assembly and/or integrity. Alternatively, CRK9AP may mediate nuclear 
import of the complex, although the amino acid sequence did not reveal a conventional nuclear 
localization signal (data not shown). 
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Figure 4.5 CRK9AP depletion results in rapid co-loss of CRK9 and CYC12. Immunoblot of whole cell 
lysates derived from non-induced (n.i.) and CRK9AP-silenced PF and BF trypanosomes. The arrow 
indicates the gene knockdown or CRK9AP. Detection of the class I transcription factor I subunit 6 
(CITFA6) served as a loading control. 
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  3.5 Validation of CRK9 as a potential chemotherapeutic target in the mouse model 
 Since CRK9 enzyme activity is essential for SL trans splicing in T. brucei (Badjatia et al., 
2013a) and assembles into a unique complex with its functional CYC12 and CRK9AP partners, 
this CDK is a promising chemotherapeutic target for trypanosomatid parasites. Thus, we 
validated CRK9 as a drug target in the mouse host. We first used so-called single marker BF 
(smBF) trypanosomes, the parent line for conditional gene silencing experiments (Wirtz et al., 
1999), to determine their lethal dose in intraperitoneal BALB/c mouse infections. Injection of 2 
million smBFs was lethal to all mice tested within 3-5 days (data not shown). Accordingly, when 
we repeated the mouse infections with a cell line in which doxycycline induced the expression of 
CRK9 3/ UTR dsRNA (Badjatia et al., 2013a), mice died on days 4 and 5 in the absence of 
doxycycline (n=15). However, when mice (n=16) obtained doxycycline in their drinking water, 
they all survived for two weeks, the time doxycycline was administered (Figure 4.6A). 
Interestingly, once doxycycline was removed from the drinking water, six out of sixteen mice 
survived for another month until the experiment was terminated, indicating that they were fully 
cured by the doxycycline treatment (data not shown). To control that this effect was due to 
CRK9 ablation and not an off-target effect, we introduced a CRK9 transgene, which was 
resistant to RNAi due to a different 3/ UTR sequence, into the CRK9 knockdown cell line. As 
expected, these cells were not affected by doxycycline and were lethal to all mice in the 
absence (n=15) and presence (n=15) of doxycycline (Figure 4.6B). Thus, we concluded that 
inhibition of CRK9 is a valid strategy to combat trypanosome infections of mammalian hosts. 
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Figure 4.6 Validation of CRK9 as a drug target in the mouse.  
(A and B) Two cell lines derived from the T. brucei brucei 427 smBF cell line were used for mouse 
infection studies. The line on the left (A) harbored a construct for conditional expression of dsRNA that 
targets the 3/ UTR of the CRK9 mRNA. This line was further modified (B) by targeted integration of a 
plasmid into the endogenous CRK9 locus that fused a functional HA tag sequence and the 3/ UTR of 
RPA1 to the 3/ end of one CRK9 allele, making the corresponding mRNA resistant to the RNAi response. 
As the survival graphs of infected mice show in the bottom panels, doxycycline treatment rescued every 
single mouse when CRK9 was depleted. This effect was completely abolished upon generating an RNAi-
resistant CRK9 gene in the same trypanosomes. 
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  4. Discussion 
 CRK9 is the first CDK of trypanosomes known to be crucial for the parasite-specific path 
of gene expression. Ablation of CRK9 blocks SL trans splicing, leads to an accumulation of SL 
RNA with a hypomethylated cap structure and causes dephosphorylation of RPB1, the largest 
subunit of RNA pol II, indicating that CRK9 is a gene expression regulator of central importance 
(Badjatia et al., 2013a). Here we identified two un-annotated proteins that co-purified and co-
sedimented with CRK9. Moreover, silencing of the respective genes was lethal and 
recapitulated the defects seen upon CRK9 ablation, identifying these two proteins as functional 
partners of CRK9 in vivo and suggesting that CRK9 may function in a tripartite enzyme 
complex. Multiple sequence alignments and phylogenetic evidence suggests that the larger 
protein is an L-type cyclin that was not recognized before due to unique sequence insertions in 
both its Cyclin_N and Cyclin_C domains. The smaller protein, CRK9AP, is conserved only 
among kinetoplastids without an established sequence motif. 
 CRK9 functionally partners with CYC12, which most likely is the kinetoplastid ortholog of 
human cyclin L. Interestingly, a standard protein-protein BLAST search of the human or 
Drosophila melanogaster proteome with the T. brucei CRK9 sequence returned various 
isoforms of CDK11 (E=5e-43 & 2e-37 respectively). Since Cyclin L is a known functional partner of 
CDK11 (Loyer et al., 2008), this together with the phylogenetic clustering of CRK9 with 
CDK10/CDK11 in a previous study with a bootstrap of 45% (Monnerat et al., 2013), suggests 
that CRK9 is a divergent kinetoplastid ortholog of CDK11 kinase of higher eukaryotes. The 
members of CDK10/11 family have a conserved PIT/SSLRE-helix motif (Trembley et al., 2004) 
instead of the PSTAIRE-helix box that is characteristic of the cell cycle-related CDKs (Morgan 
and De Bondt, 1994) . This helix box is crucial for CDK-cyclin interaction and the activation of 
kinase subsequent to cyclin binding (Jeffrey et al., 1995; Morgan and De Bondt, 1994). 
Interestingly, while CRK9 appears to be related to CDK10/11 clade in phylogenetic analyses 
(Monnerat et al., 2013), all CRK9 orthologs from kinetoplastids have a conserved PPYLLRE (or 
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  PPYMLRE for Leishmania species) motif instead of PITSLRE motif that is characteristic of 
CDK10/CDK11 branch.  
 CDK11p110 isoform is essential for pre- mRNA splicing both in vivo and in vitro splicing 
assays (Choi et al., 2014; Hu et al., 2003). CDK11p110 /cyclin L associates with RNA pol II, CK2, 
transcription elongation factors as well as several splicing factors including PRP19 and the SR 
proteins: RNPS1, 9G8 and ASF/SF1 (Choi et al., 2014; Trembley et al., 2002; Trembley et al., 
2003). In addition, 9G8, which is a crucial splicing factor (Cavaloc et al., 1994), was identified as 
a substrate for CDK11p110 both in vitro and in vivo (Trembley et al., 2003).  Our data clearly 
shows that CRK9 and the associated L-type cyclin, CYC12 are crucial for trans splicing in T. 
brucei and this suggests some functional overlap between trypanosome CRK9 and metazoan 
CDK11. Consistent with this several SR proteins including TSR1 that functions in splicing in 
trypanosomes and the trypanosome ortholog of ASF/SF1 were co-purified with CRK9. Since the 
function of SR proteins in splicing is typically regulated by phosphorylations (Shepard and 
Hertel, 2009), it will be interesting to find out if one of these co-purified SR proteins is a 
substrate of CRK9.  Interestingly, a recent study shows that CDK11 homolog in S. pombe 
regulates transcription by phosphorylating mediator subunits (Drogat et al., 2012). These 
phosphorylations determined the assembly of the Mediator complex, an essential PIC 
component. This function of CDK11 appears to be unique to budding yeast, since it is either 
absent or yet to be identified for CDK11 from other eukaryotes. Nonetheless, all characterized 
CDK11 orthologs are implicated in the regulation of gene expression but during evolution they 
seem to have acquired specialized roles in gene expression in different organisms. 
 CRK9 is an unusual CDK since unlike most other CDKs that require only cyclin as a 
functional partner, CRK9’s specific function seems to be dependent on both CYC12 and 
CRK9AP and it consistently associates with both proteins during purifications. To the best of our 
knowledge, CDK7 is the only other CDK that forms a bona fide tripartite complex called the CAK 
complex, which is crucial for both gene expression and the cell cycle (Fisher, 2005). Could 
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  CRK9/CYC12/CRK9AP trimeric complex represent a divergent CAK complex? Similar to CAK’s 
function in phosphorylation of RPB1’s CTD, we show that CRK9 as well as CYC12 and 
CRK9AP are essential for RPB1 phosphorylations in T. brucei. However, while CAK mediated 
CTD phosphorylations are important for RNA pol II transcription, we did not observe a specific 
defect in RNA pol II transcription in CRK9-depleted cells. Moreover, CRK9 appears not to 
interact with TFIIH because our long list of CRK9 co-purified proteins did not reveal a single 
TFIIH subunit (Table S1), CRK9 was not discovered in eluates of several independent TFIIH 
tandem affinity purifications (Lecordier et al., 2007; Lee et al., 2010; Lee et al., 2009), and CRK9 
was not found to occupy the SLRNA promoter in vivo, the only known T. brucei promoter that 
assembles a RNA pol II PIC (Badjatia et al., 2013a). Another function of CAK is to 
phosphorylate and activate the CDKs involved in cell cycle control (Fisher, 2005). If the trimeric 
CRK9 complex is important for activation of cell cycle-relevant CDKs of trypanosomes is yet to 
be tested. Interestingly, CRK9 does seem to function in the cell cycle, and was shown to be 
important for proper basal body segregation during cytokinesis (Gourguechon and Wang, 2009). 
However, further work is required to understand the role of CRK9 in cell cycle regulation in 
trypanosomes. 
 What is the functional role of CRK9AP in the trimeric CRK9 complex? In the CAK 
complex, the presence of MAT1 significantly stimulates the kinase activity of CDK7 towards 
CTD. MAT1 interacts directly with both Cyclin H and CDK7 (Busso et al., 2000), and functions 
as an assembly factor (Fisher et al., 1995; Tassan et al., 1995) Interestingly, in MAT1 deficient 
cells, the levels of CDK7 and cyclin H are significantly reduced (Korsisaari et al., 2002; Rossi et 
al., 2001; Sano et al., 2007).  In this context, CRK9AP appears to function in a similar manner to 
MAT1, since presence of CRK9AP is crucial for the stability of both CRK9 and CYC12. 
However, while a N-terminal RING finger motif is a conserved feature of MAT1 proteins from 
different organisms (Busso et al., 2000), CRK9AP lacks any obvious functional motif and it is 
conserved only amongst kinetoplastids. Another group of small proteins that are implicated in 
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  assembly of CDK-cyclin complexes is the Cip/Kip family of CDK inhibitor (CKI), which was 
shown to important for assembly and activation of CDK4/6 - cyclin D complexes (Cheng et al., 
1999; LaBaer et al., 1997). Future work will determine if CRK9AP is a divergent ortholog of 
MAT1 or Cip/Kip proteins or it is a unique kinetoplastid-specific protein dedicated for the 
assembly/stability of CRK9 complex. 
 In summary, CRK9 assembles in a unique complex together with CYC12 and CRK9AP 
and regulates trans splicing and possibly cell cycle in trypanosomes. We also show that CRK9 
is crucial for trypanosomes to establish infection in a mouse model. Since trans splicing is a 
parasite-specific process, and kinases including CDKs are considered suitable drug targets, 
CRK9 is an attractive drug target against trypanosomatid parasites. It is interesting to note that 
both CRK9 and CYC12 have large kinetoplastid specific insertions in their kinase and cyclin 
domain respectively. These insertions could be a result of the complex’s specialized function in 
trans splicing and might mediate association with trypanosome specific splicing proteins. 
Nonetheless, the unique features of CRK9 complex may be exploited to selectively inhibit this 
CDK in a parasite-specific manner.  In the future, identification of a substrate(s) of CRK9 would 
help to delineate the mechanism by which CRK9 affects gene expression. Potential substrate 
candidates, including TSR1, are listed in Table 1. 
5. Methods 
5.1 DNAs 
 For gene silencing of CYC12 and CRK9AP, their coding regions from position 21 to 
position 520 and from position 1 to position 414, were integrated in stem-loop arrangements into 
the pT7-stl vector (Brandenburg et al., 2007) to reveal plasmids T7-CYC12-stl and T7-CRK9AP-
stl, respectively. For HA-tagging of CYC12, 1140 bp of the 3/-terminal CYC12 coding sequence 
was inserted into the pC-HA-BLA vector (Lee et al., 2007), utilizing the vector's ApaI and NotI 
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  restriction sites. The resulting vector, named pCYC12-HA-BLA, was linearized with BamHI 
before transfection. DNA oligonucleotides that were used in semi-quantitative and quantitative 
reverse transcription (RT)-PCR and in primer extension assays are specified in (Ambrosio et al., 
2015; Badjatia et al., 2013a). 
5.2 Cells 
 BF and PF Trypanosoma brucei cell culture was maintained, transfected, and cloned as 
described before (Lee et al., 2007; Park et al., 2011). Clonal cell lines for conditional CYC12 
and CRK9AP silencing experiments were generated by transfection of linearized and RRNA 
locus-targeted T7-CYC12-stl and T7-CRK9AP-stl constructs, respectively. For PF and BF lines, 
the constructs were transfected into 29-13 and smBF cells, respectively (Wirtz et al., 1999). 
dsRNA synthesis for gene knockdowns was induced with 2 µg/ml of doxycycline during RNAi 
experiments. Cells were counted and diluted daily to 2 × 106 cells/ml for PF culture and to 2 × 
105 cells/ml for BF culture. CYC12 was fused C-terminally with an HA tag in CRK9AP PF and 
BF knockdown cell lines by transfection of pCYC12-HA-BLA. 
5.3 RNA analysis 
 Semi-quantitative and quantitative RT-PCR was performed to determine relative 
amounts of various RNAs during gene silencing experiments. Total RNA was prepared from 8 x 
107 PF or 1 x 108 BF cells using the TRIzol reagent (Invitrogen) or the hot-phenol method 
(Nguyen et al., 2007) respectively. Reverse transcription reactions were carried out with 
SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer’s specifications. 
Oligo-dT and random hexanucleotides (Roche) were used in reverse transcription for the 
analysis of mature mRNA and unspliced pre-mRNA, respectively. For each semi-quantitative 
PCR, the number of cycles for the linear amplification range was determined empirically. For 
RNA quantifications, cDNA preparations were analyzed by qPCR assays using the SsoFast 
EvaGreen Supermix (BioRad) on a CFX96 cycler (BioRad) according to the manufacturer’s 
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  recommendations. For each amplification, triplicate qPCR samples were analyzed. 
Oligonucleotide pairs that were used in qPCR reactions were evaluated for specificity by both 
agarose gel electrophoresis and melting curve analysis. Standard curves for oligonucleotide 
pairs were obtained from serial dilutions of non-induced cDNA samples and ranged in their 
coefficient of determination (R2) value from 0.98 to 1.0. Samples were standardized with the 
18S rDNA result from random hexamer-derived cDNA. The methylation status of SL RNA cap4 
was analyzed by a modified primer extension as described previously (Badjatia et al., 2013a). 
5.4 Protein analysis 
 The polyclonal anti-CRK9 and anti-CRK9AP immune sera were generated by 
immunization of rats (Schimanski et al., 2006) with N-terminal glutathione S-transferase fusion 
proteins, either comprising amino acids 100 to 300 of CRK9 or the entire coding region for 
CRK9AP that were expressed in Escherichia coli strain BL21Star(DE3) and purified by 
glutathione affinity chromatography (GE Healthcare). The CRK9 sequence was chosen due to 
its  hydrophilic nature  as determined by a hydrophilicity blot using the Kyte & Doolittle algorithm 
on the ProtScale server at http://web.expasy.org/protscale/. 
 CRK9 and CRK9AP were detected on immunoblots by 1:1000 dilution of the respective 
immune sera followed by a 1:5000 dilution of a monoclonal, peroxidase-labeled anti-rat IgG 
secondary antibody (Vector Laboratories). HA-tagged protein was detected with a commercial 
monoclonal rat anti-HA antibody (Roche), RPA1 with a polyclonal rabbit immune serum and 
CITFA6 with a polyclonal rat immune serum as described previously (Nguyen et al., 2012; 
Schimanski et al., 2003). Blots were developed with BM chemiluminescence blotting substrate 
(Roche) according to the manufacturer's protocol. PTP-tagged proteins were detected either 
with the peroxidase anti-peroxidase reagent (Sigma) or the monoclonal anti-ProtC antibody 
HPC4 (Roche). 
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   Extract preparation and tandem affinity purification of PTP-tagged CRK9 was carried out 
according to the standard PTP purification protocol (Schimanski et al., 2005a). Purified proteins 
were separated on SDS–10 to 20% polyacrylamide gradient gels (BioRad) and stained either 
with Sypro ruby (BioRad) or with Coomassie blue (Gelcode Coomassie stain; Thermo Fisher 
Scientific). For the sedimentation analysis of the CRK9 complex, the final eluate of the CRK9 
PTP purification was concentrated, dialyzed against E-80 buffer and sedimented in a linear 10-
40% sucrose gradient as described before (Ambrosio et al., 2015). Briefly, the gradient was 
fractionated from top to bottom in twenty aliquots of 200µl each. Proteins from 150µl of each 
fraction were collected by a hydrophobic resin (StrataClean, Stratagene), and resuspended in 
SDS loading buffer for electrophoresis. The remaining 50µl aliquots  were dialyzed against E-20 
buffer (20 mM HEPES-KOH pH 7.7, 20 mM potassium glutamate, 20 mM potassium chloride, 3 
mM magnesium chloride, 0.2 mM EDTA, 0.5 mM EGTA and 4 mM DTT) and used for in vitro 
kinase assays. Proteins that co-purified with CRK9-P were analyzed by LC/MS/MSfrom the gel 
lane of the final eluate by the Keck facility of Yale University as described previously (Ambrosio 
et al., 2015). Individual protein bands obtained after sucrose gradient sedimentation were 
analyzed equivalently. 
5.5 Phylogenetic analysis 
 Amino acid sequences spanning  the CCL1 domain (COG5333) of various human 
cyclins and of CYC12 from T. brucei, T. cruzi, Leishmania major and Bodo saltans were aligned 
using the multiple sequence alignment tool ClustalW at the EMBL European Bioinformatics 
Institute (http://www.ebi.ac.uk/Tools/msa/muscle/). The alignment was uploaded onto the 
graphical user interface Seaview (Gouy et al., 2010) (http://pbil.univ-
lyon1.fr/software/seaview.html) to perform the phylogenetic analysis. A maximum likelihood tree 
was generated employing the LG empirical matrix (Le and Gascuel, 2008) with optimized 
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  invariable sites, substitution rate categories of 4, estimated gamma distribution and model 
equilibrium frequencies. Bootstrapping was performed with 1000 replicates. 
5.6 Mouse infections 
 6-10 weeks old female BALB/c mice (The Jackson Laboratory, Bar Harbor, ME), were 
injected intraperitoneally with 2 × 106 cells in 0.1 ml of cold phosphate buffer saline (PBS) that 
was supplemented with 1% glucose.  To ensure cell viability, the parasites and syringes were 
kept on ice prior to injections. To induce RNAi, mice were given 1 mg/ml doxycycline in their 
drinking water 2 days prior to injection and for up to 2 weeks post-injection. Drinking water was 
replaced daily with fresh doxycycline solution. Mice were monitored daily and sacrificed upon 
signs of distress Blood samples, randomly taken from sick mice, were investigated 
microscopically, revealing, in each case, parasitemia ranging from 0.8 to 1 x 109 trypanosomes 
per ml of blood. 
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  Chapter V 
The spliceosomal PRP19 complex of trypanosomes 
 
1. Abstract 
 In trypanosomes, mRNAs are processed by spliced leader (SL) trans splicing, in which a 
capped SL, derived from SL RNA, is spliced onto the 5/ end of each mRNA. This process is 
mediated by the spliceosome, a large and dynamic RNA-protein machinery consisting of small 
nuclear ribonucleoproteins (snRNPs) and non-snRNP proteins. Due to early evolutionary 
divergence, the amino acid sequences of trypanosome splicing factors exhibit limited similarity 
to those of their eukaryotic orthologs making their bioinformatic identification challenging. Most 
of the ~60 protein components that have been characterized thus far are snRNP proteins 
because, in contrast to individual snRNPs, purification of intact spliceosomes has not been 
achieved yet. Here, we characterize the non-snRNP PRP19 complex of trypanosomes. We 
identified a complex that contained the core subunits PRP19, CDC5, PRL1, and SPF27, as well 
as PRP17, SKIP and PPIL1. Three of these proteins were newly annotated. The PRP19 
complex was associated primarily with the activated spliceosome and, accordingly, SPF27 
silencing blocked the first splicing step. Interestingly, SPF27 silencing caused an accumulation 
of SL RNA with a hypomethylated cap that closely resembled the defect observed previously 
upon depletion of the cyclin-dependent kinase CRK9, indicating that both proteins may function 
in spliceosome activation. 
 
2. Introduction 
 Nuclear pre-mRNA splicing, in which introns are removed from exonic sequences, is an 
essential step for the expression of many eukaryotic genes. The splicing process, which occurs 
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  by two consecutive transesterifications, is carried out by the spliceosome, a large and highly 
dynamic complex of the U1, U2, U4/U6 and U5 small nuclear ribonucleoproteins (snRNPs) and 
non-snRNP proteins (Smith et al., 2008; Wahl et al., 2009). After recognition of the splice sites 
and before the splicing process, a large spliceosomal complex is formed on the pre-mRNA that 
is known as the B complex, which contains all five snRNPs and many non-snRNP proteins. 
Subsequently, substantial structural and compositional alterations, including the exit of the U1 
and U4 snRNAs and the exchange of protein components, leads to spliceosome activation. The 
first transesterification generates spliceosomal complex C which, after additional 
rearrangements, carries out the second splicing step. While it has recently been established that 
RNA catalyzes the splicing reaction (Fica et al., 2013), there are more than 200 spliceosome-
associated proteins known in the human system several of which are indispensable for the 
splicing process (Hegele et al., 2012; Wahl et al., 2009). Among those is PRP19, a highly 
conserved splicing factor that is essential for the activation of the spliceosome (Chan et al., 
2003; Makarova et al., 2004; Ohi and Gould, 2002). PRP19’s role in RNA splicing is through a 
heteromeric protein complex known as the Nineteen Complex (NTC) in the budding yeast 
Saccharomyces cerevisiae (Tarn et al., 1994) and the PRP19/CDC5L complex in humans 
(Grote et al., 2010; Makarova et al., 2004). Although the protein composition of the human and 
yeast complexes differ, they share the subunits PRP19, CDC5L/Cef1p (human/yeast 
nomenclature), SPF27/Snt309, and PRL1/Prp46. In the human system, these subunits were 
shown to form a salt stable core complex (Grote et al., 2010). Additionally, there are 3-4 non-
homologous proteins in each system that are considered bona fide subunits of these complexes 
(Chanarat and Strasser, 2013) which, from here on, will be generally referred to as “PRP19 
complexes”. Moreover, several other spliceosomal proteins were found to consistently co-purify 
with the PRP19 complex, although their association appears to be less stable than that of the 
bona fide subunits (Makarov et al., 2002; Ohi et al., 2002). In the human system, these proteins 
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  have been termed “PRP19-related” proteins, and they include factors such as SKIP, SYF1, 
CRN, ISY1, etc. (Wahl et al., 2009). 
 Pre-mRNA splicing has been a focus in the protozoan parasites Trypanosoma brucei, 
Trypanosoma cruzi, and Leishmania spp., which cause devastating human diseases, because 
maturation of each and every mRNA in these organisms requires spliced leader (SL) trans 
splicing (Gunzl, 2010; Michaeli, 2011; Preußer et al., 2012). Protein coding genes in these 
trypanosomatids are arranged in long tandem arrays that are polycistronically transcribed. 
Individual mRNAs are then processed from precursor RNA by SL trans splicing and 
polyadenylation. In trans splicing, the SL is derived from the 5/ end of the small nuclear SL RNA 
and spliced onto the 5/ end of each mRNA. The SL carries a so-called cap4 structure which 
comprises a standard m7G cap nucleotide and methylations of the first four SL nucleotides 
(Bangs et al., 1992). Cap4 formation appears to be a pre-requisite for trans splicing (McNally 
and Agabian, 1992; Ullu and Tschudi, 1991) although individual methylations are dispensable 
for the process (Arhin et al., 2006a; Arhin et al., 2006b; Zamudio et al., 2007; Zamudio et al., 
2006). SL trans splicing is achieved by the same two transesterification reactions as in “cis 
splicing” (Murphy et al., 1986; Sutton and Boothroyd, 1986). Furthermore, dependence of trans 
splicing on U snRNAs (Tschudi and Ullu, 1990) and on orthologs of various spliceosomal factors 
(Liang et al., 2006; Luz Ambrósio et al., 2009; Tkacz et al., 2008; Tkacz et al., 2010) 
demonstrated that trans splicing in trypanosomes is carried out by a spliceosomal complex that 
is similar to its human and yeast counterparts. However, characterization of the trypanosomal 
spliceosome has been difficult because, so far, a larger spliceosomal complex could not be 
quantitatively purified from trypanosomatids. Furthermore, trypanosome protein sequences are 
highly divergent from their human and yeast counterparts, making bioinformatic annotation of 
proteins and their genes challenging in some cases. Nevertheless, tandem affinity purification of 
the T. brucei snRNP proteins SmD1 (Luz Ambrósio et al., 2009), SmB (Palfi et al., 2009), and 
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  the Leishmania tarentolae snRNP proteins SmD3, LSm3 and U1A (Tkacz et al., 2010) led to the 
identification of several new splicing factors increasing the trypanosomatid repertoire of known 
spliceosomal proteins to ~60 (Gunzl, 2010; Preußer et al., 2012). Most of these proteins are 
snRNP proteins and relatively few non-snRNP proteins have been identified so far, suggesting 
that mainly individual snRNPs were purified and that many non-snRNP proteins remained 
undetected in these purifications (Gunzl, 2010). PRP19 is such a spliceosomal non-snRNP 
protein that was identified by sequence homology and shown to be essential for cell viability, 
trans splicing and removal of the PAP (poly A polymerase) intron in T. brucei (Tkacz et al., 
2010). In addition, PRP19 silencing led to hypomethylation of the SL RNA cap. Little is known, 
however, about PRP19 complex subunits. While CDC5 (Gunzl, 2010) and PRL1 (Tkacz et al., 
2010) co-purified with splicing complexes and were then identified bioinformatically, an SPF27 
ortholog has been elusive. Furthermore, only a few homologs of PRP19-related proteins have 
been identified so far (Gunzl, 2010). (Please note that since T. brucei is a parasite of humans, 
when possible, we prefer to use the nomenclature of the human system for trypanosome 
splicing factors). 
 Here we have tandem affinity-purified T. brucei PRP19 and mass spectrometrically 
identified 47 co-purifying proteins. Among those were 35 spliceosomal orthologs, which included 
the three newly annotated proteins SPF27, SKIP, and PPIL1, as well as six proteins which 
appear to be conserved only among trypanosomatids. A sedimentation analysis revealed a 
stable PRP19 complex of seven subunits that, although containing the four core subunits, 
deviated in protein composition from its human and yeast counterparts. As expected, PRP19 
complex subunits were primarily associated with the activated spliceosome. Finally, silencing of 
SPF27 affected SL RNA cap methylation similarly to the previous PRP19 knockdown. However, 
as our data indicate, cap4 methylation defects may be a general phenomenon of blocking 
spliceosome activation in trypanosomes. 
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  3. Materials and Methods 
3.1 DNAs 
 pPRP19-PTP-NEO was generated by inserting 627 bp of the C-terminal PRP19 coding 
region (position 901 to position 1527 relative to the translation initiation codon) into the pC-PTP-
NEO tagging construct (Schimanski et al., 2005a) using the ApaI and NotI restriction sites. 
pCDC5-PTP-NEO, pSPF27-PTP-NEO, and pORC1-PTP-NEO were obtained analogously by 
cloning 519 bp (position 1663 to position 2181), 695 bp position -53 to position 642) and 326 bp 
(position 983 to position 1308) of the CDC5, SPF27 and ORC1 genes into pC-PTP-NEO, 
respectively. For pSPF27-HA-BLA, the 695 bp DNA fragment was cloned into pC-HA-BLA 
(Nguyen et al., 2007), again using the ApaI and NotI restriction sites. The conditional 
knockdown constructs pT7-SPF27-stl and pT7-ORC1-stl were obtained by cloning, respectively, 
571 bp (position 7 to position 577) and 526 bp (position 7 to position 532) of the SPF27 and 
ORC1 coding regions in a stem-loop arrangement into the vector pT7-stl (Brandenburg et al., 
2007). The constructs for conditional knockdown of LSm2 and CRK9 have been described 
previously (Badjatia et al., 2013a; Luz Ambrósio et al., 2009). 
3.2 Cells 
 Cell culturing and stable transfection of procyclic T. brucei brucei strain 427 and of cell 
line 29-13 (Wirtz et al., 1999) was carried out as described previously (Laufer et al., 1999). After 
each transfection, cell lines were cloned by limiting dilution. Cell line TbP19ee was generated by 
inserting BmgBI-linearized pPRP19-PTP-NEO into one PRP19 allele and deleting the remaining 
wild-type allele with a PCR product in which 100 bp of the PRP19 5/ and 3/ gene flanks were 
fused to the hygromycin phosphotransferase (HYG) coding region. Cell lines that express 
CDC5-PTP, SPF27-PTP or ORC1-PTP were generated by transfecting SnaBI-linearized 
pCDC5-PTP-NEO, BsmI-linearized pSPF27-PTP-NEO, and XhoI-linearized pORC1-PTP-NEO, 
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  respectively. Cells that express both PRP19-PTP and SPF27-HA were obtained by two 
consecutive transfections, first with linearized pPRP19-PTP-NEO and then with BsmI-linearized 
pSPF27-HA-BLA. Cell lines for conditional gene knockdowns were generated by targeting the 
T7-stl constructs to the RRNA spacer region. For each transfection correct integration of DNA 
was verified by PCR with at least one oligonucleotide hybridizing outside the transfected DNA 
sequence. After selection, 427 cells with antibiotic resistance markers were grown in 40 µg/ml 
hygromycin, 40 µg/ml G418, and/or 10 µg/ml blasticidin whereas 29-13 cell lines were kept in 50 
µg/ml hygromycin, 15 µg/ml G418, and 4 µg/ml phleomycin. Conditional gene silencing 
experiments were induced by adding doxycycline to a final concentration of 1 µg/ml. Cells were 
counted and diluted to a density of 2 x 106 cells/ml daily. 
3.3 Protein analysis 
 PTP-tagged proteins on immunoblots were detected either with the peroxidase anti-
peroxidase reagent (Kartalou and Essigmann) or a monoclonal anti-protein C epitope antibody 
(Roche). Extract preparation and tandem affinity purification of PTP-tagged proteins were 
carried out according to the standard protocol (Schimanski et al., 2005a) Purified proteins were 
separated on SDS–10 to 20% polyacrylamide gradient gels (BioRad) and stained either with 
sypro ruby (BioRad) or with Coomassie blue (Gelcode Coomassie stain; Thermo Fisher 
Scientific). For the sedimentation analysis of PRP19 and CDC5 complexes, the final eluate of a 
standard tandem affinity purification (~1.8 ml) was vacuum concentrated to ~100 µl, dialyzed 
overnight against E-80 buffer (150 mM sucrose, 20 mM HEPES-KOH pH 7.7, 20 mM potassium 
glutamate, 80 mM potassium chloride, 3 mM magnesium chloride, 0.2 mM EDTA, 0.5 mM 
EGTA), loaded onto a 4 ml linear 10-40% sucrose gradient in E-80 buffer, and ultracentrifuged 
at 41,000 rpm in a Beckman Sw55Ti rotor for 19 h at 4 °C. Subsequently, the gradient was 
fractionated from top to bottom in 20 aliquots. Proteins in each aliquot were collected by a 
hydrophobic resin (StrataClean, Stratagene), and resuspended in SDS loading buffer for 
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  electrophoresis. Proteins that co-purified with PRP19-P were analyzed from a gel lane of the 
final eluate by the Proteomic Core facility of the Rockefeller University. The gel lane was cut into 
multiple pieces and peptides, derived from trypsin-digested proteins, were separated by liquid 
chromatography and analyzed by tandem mass spectrometry (LC/MS/MS) using an Ultimate 
3000 HPLC system (Dionex) and a nanospray LTQ Orbitrap XL (Thermo Scientific) mass 
spectrometer. Individual protein bands obtained after sucrose gradient sedimentation were 
analyzed equivalently by the Keck facility (Yale University). Proteins were identified using 
Mascot and NCBI non-redundant protein sequence database of eukaryotes, with 
carbamidomethyl (C) as static and oxidation (M) as variable modifications. Peptide Mass 
tolerance was set to ±25 ppm and fragment mass tolerance to ±0.8 Da. Peptides were 
considered as identified when their score was ≥22 and expectation values were ≤0.05. 
3.4 RNA analysis 
 To analyze gene silencing effects on RNA abundances, total RNA was prepared from 
non-induced or doxycycline-induced cells by the hot phenol method as described previously 
(Nguyen et al., 2007). rRNA was separated by gel electrophoresis on reliant precast 1.25% 
SeaKem Gold agarose RNA gels (Lonza) and detected by ethidium bromide staining. For the 
analysis of mRNA and unspliced pre-mRNA, total RNA was first reverse transcribed with 
SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer’s protocol using, 
respectively, oligo(dT) and random hexamers as primers. Secondly, the cDNAs were subjected 
to semi-quantitative and quantitative (q)PCR analysis. Semi-quantitative PCR was performed 
using cycle numbers that were empirically determined to be within the linear amplification range 
for each oligonucleotide pair. The specificity of oligonucleotide pairs used in qPCR was first 
verified in analyzing their products by standard agarose gel electrophoresis. To further confirm 
the validity of the qPCR reactions, a melt curve analysis was included for each qPCR to ensure 
that only a single product was amplified. In addition, a linear regression analysis of a serial 
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  dilution of input material was performed to make sure that the coefficient of determination (r2) 
was within the 0.98 to 1.0 range. 
Spliceosomal U snRNAs, SL RNA and, as a control, 7SL RNA were detected by primer 
extension assays using 10 µg of total RNA, 5/-32P-end-labeled oligonucleotides and SuperScript 
II reverse transcriptase. Primers SL_PE and SL40, 7SL_PE, U1_PE, U2f, U4_PE, U5_PE, and 
U6_PE were used to detect SL RNA, 7SL RNA, U1, U2, U4, U5 and U6 snRNA, respectively. 
Primer extension products were separated on 8% polyacrylamide – 50% urea gels and 
visualized by autoradiography. The modified primer extension assay for characterizing the 
methylation status of the SL RNA cap and generation of the sequencing ladder was conducted 
with unmodified Moloney’s murine leukemia virus (MMLV) reverse transcriptase (Invitrogen) and 
the Thermo Sequenase cycle sequencing kit (USB), as previously described (Badjatia et al., 
2013a). For the analysis of PRP19 complex-associated U snRNAs, PTP-tagged proteins were 
precipitated by immunoglobulin G (Djikeng et al.) beads (GE Healthcare), and total RNA was 
prepared and analzyed by primer extension assays as previously published (Luz Ambrósio et 
al., 2009). DNA oligonucleotides that were used in primer extension assays and in competitive 
and [semi-]quantitative reverse transcription (RT-)PCR reactions are specified in Attachment 4, 
Supplementary Table S1. 
3.5 Light microscopy 
 Immunofluorescence microscopy was performed as previously described (Luz Ambrósio 
et al., 2009). For the detection of PRP19-PTP, a rabbit polyclonal anti-ProtA immune serum 
(Kartalou and Essigmann) followed by an Alexa 594-conjugated anti-rabbit secondary antibody 
(Invitrogen) was used, while HA-tagged SPF27 was detected by a rat monoclonal anti-HA 
antibody (Roche) and an Alexa 488-conjugated anti-rat secondary antibody (Invitrogen). We 
excluded the possibility that anti-HA antibodies were non-specifically bound by ProtA by 
analyzing cells that expressed only PRP19-PTP with the antibody mix described above (data 
138
	  not shown). Images were taken on a Zeiss Axiovert 200 microscope equipped with DAPI (4′,6′-
diamidino-2-phenylindole), EGFP and Texas-Red filters using a 100x (1.3-numerical-aperture) 
oil immersion objective. Quantification of the co-localization was done using the Zeiss Axiovision 
4.6.3.0 software program for co-localization. 
 
4. Results 
4.1 Tandem affinity purification of PRP19 and identification of co-purified proteins 
 For tandem affinity purification (Biswas et al.) of PRP19 (accession number 
Tb927.2.5240 at www.GeneDB.org or www.TriTrypDB.org) we generated the insect-stage, 
procyclic T. brucei cell line TbP19ee which expressed PRP19 with a C-terminal PTP tag 
(PRP19-PTP) and no untagged PRP19. The PTP tag is a composite tag consisting of a protein 
C epitope (ProtC) followed by a tobacco etch virus (TEV) protease cleavage site and tandem 
protein A domains (ProtA) (Schimanski et al., 2005a). The cell line was obtained by replacing 
one PRP19 allele of wild-type procyclics with the coding region of the selectable marker 
hygromycin phosphotransferase (HYG) and by targeted integration of plasmid PRP19-PTP-
NEO into the remaining PRP19 allele, thereby fusing the PTP sequence to the PRP19 gene 
(Figure 5.1A). Since TbP19ee cell cultures did not exhibit a growth defect (data not shown) and 
PRP19 is an essential gene in T. brucei (Tkacz et al., 2010), we inferred that the tag did not 
disrupt PRP19 function. We then prepared extract from 5 x 1010 trypanosomes and performed 
PTP tandem affinity purification of PRP19-PTP. While the expected size of PRP19-PTP is 74 
kDa, anti-ProtC immunoblotting of extract revealed a single band of ~80 kDa (Figure 5.1B, lane 
1). PTP-based TAP involves IgG affinity chromatography through ProtA, release of the tagged 
protein by TEV protease cleavage, and recapture of the tagged protein by anti-ProtC 
immunoaffinity chromatography (Schimanski et al., 2005a). Immunoblot monitoring of the TAP 
procedure showed that both chromatography steps led to efficient depletion of the tagged 
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  protein from extract and from TEV protease eluate (lanes 2 and 4) and that the final eluate 
contained a substantial amount of purified PRP19 (lane 5). Note, that removal of ProtA 
decreased the molecular mass of PRP19-P by ~15 kDa. The final eluate was then separated on 
a SDS-polyacrylamide gel and stained with Coomassie blue (Figure 5.1C). The profile of protein 
bands exhibited a massive protein enrichment in the 55-65 kDa range, which included PRP19-
P, and three major protein bands with apparent sizes of ~85, 26 and 22 kDa. In addition, many 
bands of minor abundance and different size were detected which could be components of the 
spliceosome. 
 To identify co-purified proteins, we performed liquid chromatography-tandem mass 
spectrometry (LC/MS/MS) with the final TAP eluate that was not separated electrophoretically. 
By limiting the analysis to proteins that were identified by at least two unique peptides and 
excluding recurrent PTP purification contaminants, we identified 47 proteins (Table 5.1). Of 
those, 35 proteins were homologs of known spliceosomal proteins, two of the six proteins 
without annotation (conserved hypothetical) were previously co-purified with trypanosomatid 
splicing complexes (Luz Ambrósio et al., 2009; Palfi et al., 2009), and only six of the annotated 
proteins did not have a known splicing function. Moreover, the list contains several orthologs of 
human and yeast PRP19 complex subunits as well as PRP-related proteins (see below) 
confirming that the tagged PRP19 was functionally incorporated into RNA splicing complexes 
and indicating that the PRP19 purification was highly specific. 
4.2 Identification of a stable T. brucei PRP19 complex of seven subunits 
 To determine the proteins that form a stable PRP19 complex, we sedimented PRP19-
PTP-purified proteins through a linear sucrose gradient by ultracentrifugation. We took 20 
fractions of the gradient from top to bottom, collected the proteins from each fraction with a 
hydrophobic resin and stained the proteins after electrophoretic separation in the gel with sypro 
ruby (Figure 5.1D). The major protein bands of the purification co-sedimented with peak signals 
140
	  in fractions 14 and 15 which is between the ~230 kDa-large T. brucei SNAPc/TRF4/TFIIA 
transcription factor complex (Schimanski et al., 2005b) and the 444 kDa-large apoferritin 
marker. Furthermore, in fraction 20, major and minor bands were co-detected indicating that the 
purified material contained larger complexes that sedimented to the bottom of the gradient. 
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Figure 5.1 Trypanosoma brucei has a stable PRP19 complex of seven subunits A.Schematic (not to 
scale) of a PRP19 wild-type allele and the PRP19 locus in procyclic TbP19ee cells that exclusively 
express PRP19-PTP and no untagged PRP19. PRP19, HYG/NEO coding regions and PTP tag are 
indicated by open, striped and black boxes, respectively. Gene flanks for RNA processing signals are 
drawn as smaller gray boxes. Checkered boxes indicate plasmid-derived portions of the PRP19 coding 
region. B. Immunoblot monitoring of the PRP19-PTP tandem affinity purification. PRP19-PTP and 
PRP19-P (after removal of the ProtA domains) were detected with the monoclonal anti-ProtC antibody 
HPC4 in crude extract (Inp), flowthrough of the IgG column (FT-IgG), TEV protease eluate (TEV), 
flowthrough of the anti-ProtC column (FT-ProtC) and the final eluate (Elu). x-Values indicate relative 
amounts loaded. C. Aliquots of extract, the TEV protease eluate and the final eluate were separated on a 
10-20% SDS-polyacrylamide gradient gel and stained with Coomassie blue. Percentages indicate relative 
amounts analyzed. D. The eluate of a PRP19-PTP tandem affinity purification was sedimented through a 
10-40% linear sucrose gradient by ultracentrifugation and 20 fractions were taken from top to bottom. 
Proteins from each fraction were separated on a 10-20% SDS-polyacrylamide gradient gel and stained 
with Sypro Ruby. Proteins specified on the right were identified by excision of individual protein bands 
and LC/MS/MS analysis. For comparison, sedimentations of Taq DNA polymerase (95 kDa), IgG (150 
kDa, 6.6S), apoferritin (444 kDa, 17S) and thyroglobin (660 kDa, 19S) were analyzed in parallel gradients 
(arrowheads). In addition, sedimentation peaks from previous, comparable experiments of TEV protease 
(29 kDa) and the SNAPc/TRF4/TFIIA transcription factor complex (230 kDa) are indicated as well. 
Asterisks indicate the sedimentation peak. 
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  Table 5.1 Mass spectrometric identification of PRP19 co-purified proteins 
Annotation 1 Accession # Mr (kDa) Protein score # Unique pept. % Coverage # Pept. 
PRP19 Tb927.2.5240  54.2 65,296 32 75.1 39  
CDC5 / Cef1 Tb927.5.2060  80.1 31,713 57 82.0 64  
CDC40 / PRP17 Tb927.3.1930  52.8 9,959 33 83.7 37  
SKIP / Prp45 2,3 Tb927.9.5880 50.4 8,862 25 50.3 30  
PRL1 / Prp46 Tb927.10.10170 48.8 6,349 23 68.2 23  
SPF27 / Snt309 2,3 Tb927.11.14150 24.5 5,775 16 74.8 23  
PPIL1 2 Tb927.8.2090 21.7 5,615 11 67.0 13  
DHX38 / Prp16 Tb927.10.7280 121.2 4,398 63 66.6 63  
U5-200K / Brr2 Tb927.5.2290 249.3 3,936 67 37.2 67  
[U5-]PRP8 Tb927.9.11110 276.8 3,811 79 36.0 79  
HSP73 (HSP70) Tb927.11.11330 76.0 3,523 36 65.1 40  
CRN / Clf1, Syf3 Tb927.10.9660 87.6 2,654 25 45.8 25  
CACTIN 3 Tb927.11.11610 64.6 2,303 24 57.2 24  
U5-116K / Snu114 Tb927.11.15430 105.4 2,165 33 43.8 33  
SYF1 Tb927.5.1340 92.1 1,846 21 35.9 21  
KIAA1604 / Cwc22 Tb927.11.10750 66.8 1,737 20 35.3 20  
Conserved hypoth. 3 Tb927.8.5650 103.2 1,233 22 34.8 22  
Conserved hypoth. Tb927.2.3400 36.6 852 10 32.9 10  
U5-CWC21 Tb927.9.3480 20.4 693 10 55.2 10  
U2A/ (U2-40K) Tb927.10.14360 36.5 662 15 65.3 15  
Conserved hypoth. 3 Tb927.10.11230 34.7 567 11 42.7 11  
SmD1 Tb927.7.3120 11.7 528 4 45.3 4  
LSm2 Tb927.8.5180 13.3 507 5 44.8 5  
LSm8 Tb927.3.1780 14.0 435 6 43.4 6  
VSG pseudogene Tb927.5.4980 48.5 428 5 20.0 5  
aminopeptidase Tb927.11.3570 98.0 408 9 15.5 9  
AD002 / CWC15 Tb927.10.11950 22.4 403 6 33.2 6  
U5-40K Tb927.11.11150 35.0 398 5 18.7 5  
SmF Tb927.9.10250 8.4 394 4 56.0 4  
PRP31 Tb927.10.10700 39.6 371 4 13.2 4  
SSm2-1 (Sm15K) Tb927.6.4340 12.8 342 3 33.3 3  
ISY1 Tb927.8.1930 31.7 313 5 29.0 5  
SmD2 Tb927.2.5850 12.5 282 4 35.1 4  
PABP2 (PABP1) Tb927.9.10770 62.2 282 7 15.5 7  
Conserved hypoth. Tb927.11.2960 12.0 280 5 40.7 5  
Actin A Tb927.9.8850 41.9 266 3 11.4 3  
SSm2-2 (Sm16.5K) Tb927.10.4950 14.7 255 4 31.3 4  
SmE Tb927.6.2700 9.7 217 3 37.2 3  
SmB Tb927.2.4540 12.3 169 5 40.4 5  
U2B// Tb927.3.3480 13.6 167 5 27.4 5  
Argonaute AGO1 Tb927.10.10850 99.2 162 3 3.7 3  
ALBA3 Tb927.4.2040 20.8 153 2 10.5 2  
Conserved hypoth. 3 Tb927.4.3540 41.2 136 3 12.9 3  
Pumilo PUF2 Tb927.10.12660 92.2 126 2 4.5 2  
LSm4 Tb927.11.13960 14.2 122 2 15.0 2  
Conserved hypoth. 3 Tb927.8.5840 21.5 118 2 10.7 2  
Cyclophilin (PPlase) Tb927.9.11740 20.3 103 3 24.0 3  
PRP19 co-purifying proteins, identified by LC/MS/MS, are ranked according to protein score. Listed proteins have a 
score of >100 and were identified by 2 or more unique peptides. Proteins that co-sedimented with PRP19 in linear 
sucrose gradients are highlighted in yellow, proteins denoted as PRP19 subunits or PRP19-related proteins in other 
systems in green, un-annotated proteins in blue, and [putative] spliceosome components in gray. Annotated proteins 
without a known role in RNA splicing were not highlighted. In addition, standard contaminants of trypanosome TAPs 
such as a/b  tubulin, translation elongation factor, retrotransposon hot spot proteins, histones, low scoring ribosomal 
proteins, and chaperones were eliminated from this list, although it should be noted that prefoldin chaperones were 
particularly enriched in these purifications. 
1 Annotation is according to the human/yeast systems unless there is a trypanosome-specific name. Names in 
parentheses refer to alternative names published for T. brucei. 
2 Proteins that were annotated in this study. 
3 [putative] Spliceosomal proteins that co-purified in a trypanosome splicing complex for the first time. 
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  To identify the proteins in the bands seen in fractions 14 and 15, gel slices were excised and 
their protein content analyzed by LC/MS/MS. We identified seven proteins which coincided with 
the seven proteins that obtained the highest protein score listed in Table 5.1. The largest protein 
was identified as trypanosome CDC5. The strong bands of 65 and 55 kD contained tagged 
PRP19-P and PRP17 (Palfi et al., 2009), respectively. The strong PRP19 signal is consistent 
with PRP19 forming a tetramer within a single PRP19 complex (Ohi et al., 2005). In contrast, 
PRP17 was not a component of previously characterized human and S. cerevisiae PRP19 
complexes and, therefore, has not been considered a bona fide component of the PRP19 
complex (Chanarat and Strasser, 2013; Wahl et al., 2009). On the other hand, systematic yeast-
2-hybrid screens have identified PRP17 as a direct interactor of the PRP19 WD40 domain 
(Figure 5.2A) in human and yeast systems (Hegele et al., 2012; Ren et al., 2011). Moreover, in 
Schizosaccharomyces pombe, PRP17 was consistently detected in tandem affinity purifications 
of PRP19 complexes, and it was determined that there are four PRP17 molecules per complex 
(Ren et al., 2011). Our results corroborate these findings. In T. brucei, PRP17 co-purified and 
co-sedimented with PRP19 identifying it as a bona fide subunit of the trypanosome PRP19 
complex. Moreover, the strong signals of the 65 and 55 kDa bands suggest that there is more 
than one PRP17 molecule present in the trypanosome complex. However, the strong 55 kDa 
signal appears to be not confined to PRP17 alone because we detected a second protein in this 
band. This protein is encoded in gene Tb927.9.5880 which has been annotated as a 
“conserved, hypothetical protein” indicating that its sequence is conserved only among 
kinetoplastids. A standard BLAST search identified an internal SKIP/SNW domain strongly 
indicating that this protein is the ortholog of the spliceosomal Ski-binding protein (SKIP) and 
PRP45p of mammals and S. cerevisiae, respectively (Figs. 5.2A, B). Interestingly, in the human 
and yeast systems, SKIP/PRP45p is not considered to be a PRP19 complex subunit but a 
PRP19-related/associated protein (Fabrizio et al., 2009; Makarova et al., 2004). 
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   The band of ~50 kDa has a lower strength signal and contained only a single protein, 
namely the trypanosome ortholog of human PRL1 and yeast PRP46p. It is considered a core 
component of the yeast and human PRP19 complexes (Fabrizio et al., 2009; Makarova et al., 
2004). Trypanosomatid PRL1 had been identified previously, co-purifying with LSm3 in 
Leishmania tarentolae (Tkacz et al., 2010). Accordingly, T. brucei PRL1 shares clear sequence 
homology to human PRL1 (E = e-80) including a C-terminal WD40 protein-protein interaction 
domain (Figure 5.2A). 
 The sixth protein, with an apparent size of 25 kDa, was found to be encoded by gene 
Tb927.11.14150. The corresponding amino acid sequence was conserved only among 
kinetoplastid organisms and, in contrast to the SKIP identification, did not reveal a conserved 
sequence motif. However, a key subunit of similar size of PRP19 complexes across systems is 
SPF27. To analyze whether this trypanosomatid protein could be a SPF27 ortholog, we 
performed a multiple sequence alignment of SPF27 orthologs from model organisms and of the 
kinetoplastid orthologs of Tb927.11.14150. As shown in Figure 5.2C, we found four short 
domains of sequence conservation between the two orthologous groups including a nearly 
invariant LPY motif near the N-terminus of the protein. Although this degree of sequence 
conservation is not strong, the findings that SPF27 is a bona fide PRP19 complex subunit in all 
systems and that Tb927.11.14150 was a major protein in the PRP19 purification co-regimenting 
with the PRP19 complex subunits argue that this protein is trypanosome SPF27. 
 Analysis of the smallest band of 21 kDa revealed a protein that is encoded by gene 
Tb927.8.2090 and had been annotated as a cyclophilin-type peptidyl-prolyl cis-trans isomerase 
in the genome data base because it harbors the conserved domain of this enzyme class (Figure 
5.2A). The protein was identified previously co-purifying with SmB and annotated as cyclophilin 
CYP2 (Palfi et al., 2009). However, a search for the closest homolog of this protein in the 
human genome returned the PRP19-related factor PPIL1. A multiple sequence alignment of the 
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  trypanosomatid orthologs of this protein and PPIL1 sequences from different model organisms 
showed sequence conservation along the whole protein (Attachment 4, Fig. S1). Moreover, 
human PPIL1 binds to a 21 amino acid-long region in the N-terminal part of SKIP (Wang et al., 
2010). This region is highly conserved in trypanosome SKIP sequences including two key 
residues (Figure 5.2D). Further support for Tb927.8.2090 being a PPIL1 ortholog comes from a 
comparison with yeast genome databases. While S. pombe harbors PPIL1 and full-length SKIP 
orthologs, S. cerevisiae does not have a PPIL1 ortholog (spliceosome database; (Cvitkovic and 
Jurica, 2013) and its SKIP protein lacks the N-terminal domain including the PPIL1 binding site 
(Wang et al., 2010). Accordingly, a blastp search of the S. pombe genome database with the 
Tb927.8.2090-encoded amino acid sequence identified the PPIL1 ortholog Cyp1 as the most 
similar sequence with a low Expect Value (E = 2e-25) whereas the same search of the S. 
cerevisiae database returned the mitochondrial peptidylprolyl isomerase CPR3 as the most 
similar sequence with a considerably higher Expect Value (E = 9e-14). We therefore concluded 
that gene Tb927.8.2090 encodes T. brucei PPIL1. 
 Finally, to confirm the characterization of the PRP19 complex, we generated a cell line 
that expressed CDC5 with a C-terminal PTP tag. Tandem affinity-purification of CDC5-PTP and 
sedimentation analysis revealed a protein complex with similar banding pattern and 
sedimentation property as the PRP19-purified complex (Attachment 4, Fig. S2). Accordingly, 
mass spectrometry of the excised protein bands revealed the same seven proteins as in the 
PRP19-PTP-purified complex. Thus, we have identified a stable PRP19 complex in T. brucei 
consisting of seven subunits.  
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  Figure 5.2 Domain structure and sequence conservation in PRP19 complex subunits 
A. Domain structure drawn to scale of trypanosome PRP19 complex subunits and their human 
orthologues. The protein domains were identified by NCBI blastp searches of the Conserved Domain 
Database (Marchler-Bauer et al., 2011) (E-values are specified for T. brucei protein domains): CDC5: 
SANT domain (cd00167), E=1.03e-08 ; SANT/myb-like domain (cd11659), E=8.07e-10; the very limited 
sequence similarity between the human Myb_Cef domain (pfam11831) and the corresponding region 
of trypanosomatid CDC5 sequences is indicated by the dashed box. PRP19: U-Box (smart00504), 
E=1.06e-14; PRP19 domain (coiled-coiled [C-C] protein interaction domain, pfam08606), E=4.87e-20; 
WD40 (cd00200), E=5.77e-18. PRL1: WD40 (cd00200), E=1.4e-75. SPF27: while the LPY motif is 
present in T. brucei SPF27, the human BCAS2 domain (pfam05700) was not recognized. PRP17: 
WD40 (cd00200), E=2e-37. SKIP: PPIL1-binding domain (PBD); SKIP_SNW domain (pfam02731), 
E=7.51e-08. PPIL1: cyclophilin domain [cd00317], E= 2.18e-27 (note that while the trypanosome 
sequence returned the general cyclophilin domain, the more specific SpCYP2_like cyclophilin domain 
(cd01922) was identified in the human ortholog. 
B. Multiple sequence alignment of the SKIP/SNW domain of Homo sapiens (Hs, accession number 
NP_036377), Drosophila melanogaster (Dm, AGB95213), Caenorhabditis elegans (Ce, CAA98552), 
Arabidopsis thaliana (At, AEE35947), Schizosaccharomyces pombe (Sp, CAB41231), 
Saccharomyces cerevisiae (Sc, P28004), and the kinetoplastids Leishmania major (Lm, 
LmjF.15.1030), Leishmania braziliensis (Lbr, LbrM.15.1070), Trypanosoma cruzi (Tc, 
TcCLB.509445.20), T. brucei (Tb, Tb927.9.5880), Trypanosoma vivax (Tv, TvY486_0902160), and 
Bodo saltans (Bs, ACI16065). Since the N-terminal ~50 amino acids of the domain are only weakly 
conserved among kinetoplastids, they were omitted from the alignment. Numbers indicate the 
position within the SKIP/SNW domain. Positions with more than 50% similarity or identity are shaded 
in gray and black, respectively. Identical positions in model organisms without any conservation in 
kinetoplastids are shaded blue and identical position in kinetoplastids without conservation in model 
organisms are shaded in red. A hyphen indicates lack of an amino acid at this position. Numbers in 
parentheses specify lengths of non-conserved insertions. The highly conserved SNWKN motif is 
indicated by asterisks. 
C. Corresponding alignment of four short conserved domains in SPF27 orthologues. Asterisks mark the 
highly conserved LPY motif which, among Leishmania species, is only present in L. tarentolae as 
LPF. Accession numbers: Hs, NP_005863; Dr (Danio rerio), NP_001007775; Dm, NP_651596; Ce, 
NP_498360; At, NP_566599; Sp, CAB57933; Sc, EEU07188; Ddis (Dictyostelium discoideum), 
XP_640072; Tb, Tb927.11.14150; Tcon (Trypanosoma congolense), TcIL3000.11.14450; Tv, 
TvY486_1114990; Tc, TcCLB.511727.110; Lta (Leishmania tarentolae), LtaP32.0970; Lm, 
LmjF.32.0900. 
D. Multiple sequence alignment of the 21 amino acid-long PPIL1 binding domain in SKIP orthologues. 
Numbers indicate positions relative to the starting methionine. The two key residues for PPIL1 binding 
are marked by asterisks. 
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  4.3 SPF27 silencing affects trans and cis splicing of pre-mRNA 
 Next, we wanted to verify for one co-purified subunit whether its depletion in cells had 
effects on cell viability, RNA splicing and SL cap4 formation which corresponded with the 
previous PRP19 silencing experiment (Tkacz et al., 2010). We chose SPF27 since it was the 
least conserved subunit of the PRP19 complex. By stable integration of a tetracycline repressor-
regulated SPF27 stem-loop construct into procyclic 29-13 cells, which constitutively express the 
tetracycline repressor and T7 RNA polymerase (Wirtz et al., 1999), we generated a cell line for 
conditional SPF27 silencing. Induction of the SPF27 knockdown with the more stable 
tetracycline derivative doxycycline, which was added to the medium, stopped culture growth 
between one and two days of induction (Figure 5.3A). Subsequently, the cell density remained 
nearly constant until day 5 of the experiment strongly indicating that SPF27 is an essential gene 
(Figure 5.3A). Interestingly, while the previous PRP19 knockdown generated a similar growth 
defect (Tkacz et al., 2010), depletion of the essential snRNP proteins LSm2 and U5-Cwc21 led 
to rapidly declining cell numbers in our hands (Luz Ambrósio et al., 2009), suggesting that 
disabling the PRP19 complex affected trypanosomes differently than depletion of snRNP 
proteins. This difference appears not to be a consequence of inefficient gene knockdown 
because a semi-quantitative RT-PCR analysis showed that SPF27 mRNA was rapidly and 
strongly reduced in the presence of doxycycline (Figure 5.3B). Analyzing total RNA prepared 
from non-induced cells and from cells in which SPF27 was silenced for 1 to 3 days clearly 
revealed pre-mRNA splicing defects. While the amounts of the control RNAs, rRNA and the 
non-spliceosomal 7SL RNA, which is the RNA component of the signal recognition particle 
(Michaeli et al., 1992), did not change in these RNA preparations, semi-quantitative RT-PCR 
analysis clearly indicated that the abundance of mature α tubulin mRNA decreased upon SPF27 
silencing whereas, in random hexamer-derived cDNA of the same RNA preparations, the signal 
of unspliced α tubulin pre-mRNA, lacking the SL, clearly increased (Figure 5.3B). Similarly, a 
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  competitive PCR of cDNA across the PAP intron showed a relative increase and decrease of 
unspliced and mature PAP RNA, respectively (Figure 5.3B). Together, these results revealed a 
splicing defect both in SL trans splicing (α tubulin mRNA) and in cis splicing (PAP mRNA). 
 To confirm that these changes in RNA abundances are specific to SPF27 silencing and 
not due to pathways of death, we co-analyzed the knockdown of a non-spliceosomal gene that 
affected trypanosome culture growth similar to SPF27 silencing. We chose the ORC1 gene 
encoding subunit 1 of the origin recognition complex (Godoy et al., 2009) because, in our 
hands, the ORC1 knockdown arrested culture growth after the second day of induction 
(Attachment 4, Fig. S3). The RNA analysis showed that, while ORC1 mRNA abundance was 
very strongly reduced after 1 day of induction, the level of α tubulin mRNA was unaffected even 
after 3 days of ORC1 silencing (Figure 5.3C). Together, these results confirmed that SPF27 is a 
spliceosomal protein. 
 Since the PRP19 complex is known to be important for spliceosome activation, we 
expected that SPF27 silencing would affect the first step of splicing. In trans splicing such a 
defect should lead to an increase of the SL RNA splicing substrate and a decline of the Y 
structure intermediate that is formed after the first transesterification (Luz Ambrósio et al., 2009; 
Tkacz et al., 2010). To test this we conducted a primer extension assay with three radiolabeled 
oligonucleotides that specifically hybridize to the intronic sequence of the SL RNA and, as 
controls, to the U2 snRNA and the 7SL RNA. In the Y structure, the 5/ end of the intron is 
covalently linked to the branch site which forms a barrier for reverse transcriptase, leading to an 
intron-specific primer extension product. Indeed, in SPF27-silenced cells, primer extension 
showed a strong increase of SL RNA abundance on day 2 and 3 of induction and a concomitant 
reduction of the Y structure signal in these total RNA preparations, a phenotype that was not 
observed in ORC1-silenced cells (Figure 5.3D, left panel). 
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   To substantiate these findings, we carried out quantitative RT-PCR analyses with three 
independently derived RNA preparations for each time point of SPF27 silencing. On days two 
and three after induction, the amount of SL RNA increased ~6 to ~9-fold over the un-induced 
level, respectively (Figure 5.3D, right panel). These numbers were in accordance with those of a 
previous study in which silencing the gene of CDC2-related kinase 9 (CRK9) also resulted in a 
block of trans splicing before the first step (Badjatia et al., 2013a). In agreement with such a 
block, we found a ~3-fold increase of α tubulin pre-mRNA abundance in SPF27-silenced cells 
which coincided with a ~50% reduction of the mature mRNA level on day three of induction 
(Figure 5.3E, left panel; note that our analysis of mature mRNA did not discriminate between a 
correct mRNA and a polyadenylated, unspliced mRNA). Comparable results were obtained 
when we analyzed a second mRNA encoding the RPB7 subunit of RNA polymerase II (RNAPII; 
Figure 5.3E, middle panel). Finally, while the PAP mRNA level strongly decreased upon SPF27 
silencing as expected, a PAP intron-dependent qPCR detected only a small, insignificant 
increase of PAP pre-mRNA in induced cells (Figure 5.3E, right panel). Possibly, unspliced PAP 
mRNA is highly unstable, preventing an accumulation of this RNA in splicing-impaired cells. 
 In summary, the increase of SL RNA and unprocessed pre-mRNA levels paralleled by 
the concomitant decrease of the Y structure intermediate and mature mRNA abundances 
demonstrated that SPF27 depletion caused a block of the first trans splicing step, further 
indicating a role of the PRP19 complex for spliceosome activation in trypanosomes and 
corroborating SPF27 as a bona fide subunit of this complex. 
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Figure  5.3 SPF27 silencing halted trypanosome proliferation and inhibited splicing of pre-mRNA. 
A. Procyclic trypanosome culture growth in the absence and presence of doxycycline, which induced 
SPF27 silencing. 
B. Analysis of total RNA prepared from non-induced cells (n.i.) and cells in which SPF27 was silenced 
for 1, 2 or 3 days. rRNA was detected by ethidium bromide staining,7SL RNA and [pre-]mRNA of α 
tubulin (α tub) by semi-quantitative PCR and [pre-]mRNA of poly-A polymerase (PAP) by competitive 
PCR. 
C. Corresponding analysis of rRNA, ORC1 mRNA and α tubulin mRNA in ORC1-silenced cells. 
D. Left panels, primer extension of total RNA prepared from SPF27- and ORC1-silenced cells with three 
32P-5/-endlabeled oligonucleotides detecting SL RNA, U2 snRNA, the SL intron after the first step of 
SL trans splicing in the Y structure, and the 7SL RNA by denaturing PAGE and autoradiography. 
Arrows indicate the loss of the Y structure intermediate in SPF27-silenced cells. The lower panel is a 
lower exposure the SL RNA-specific product that better shows the increase of the SL RNA signal 
upon SPF27 silencing. Right panel, RT-qPCR analysis of SL RNA abundance in SPF27-silenced 
cells. The amounts are relative to that of non-induced cells which was arbitrarily set to 100. Averages 
were derived from three independently conducted gene knockdown experiments. 
E. Corresponding RT-qPCR analyses of pre-mRNA and of mature mRNA of α tubulin, RPB7 and PAP. 
For pre-mRNA analyses, random hexamer-derived cDNA was amplified with a sense oligonucleotide 
that hybridized upstream of the SL trans splice site (α tubulin and RPB7) or with an antisense 
oligonucleotide that hybridized within the PAP intron. 
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  4.4 PRP19 and SPF27 co-localize in the nucleus 
 To further validate SPF27 as a component of the PRP19 complex, we examined if 
SPF27 co-localizes with PRP19 in trypanosomes. We generated a procyclic cell line in which 
PRP19 and SPF27 were C-terminally tagged with PTP and HA, respectively. Detection of both 
proteins by indirect immunofluorescence microscopy revealed that both proteins localized to the 
nucleus, exhibiting a speckle-like distribution that is characteristic of spliceosomal proteins, 
including trypanosome and human PRP19 (Figure 5.4) (Marechal et al., 2014; Spector and 
Lamond, 2011; Tkacz et al., 2010). Consistently, both proteins co-localized to a large extent 
(Pearson coefficient of 0.73, n = 53), supporting our findings that both proteins are subunits of 
the same spliceosomal protein complex. In comparison, PRP19 localization was previously 
found to be not as widespread in the nucleus as in our analysis but more focused at the so-
called SL RNP factory in which SL RNA is synthesized (Tkacz et al., 2010). This discrepancy 
could be due to using different tags (PTP versus YFP), tagging different ends (C- versus N-
terminus) or detecting PRP19 by indirect versus direct immunofluorescence microscopy. 
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Figure 5.4 PRP19 and SPF27 co-localize predominantly in nuclear speckles 
PRP19-PTP (red) was co-localized with SPF27-HA (green) in procyclic trypanosomes by indirect 
immunofluorescence. DNA detected by DAPI staining revealed the large nucleus and the smaller 
kinetoplast of trypanosomes. The black bar represents 10 µm. 
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  4.5 SPF27 silencing leads to SL cap hypomethylation 
 SL cap4 methylations at positions 1, 2 and 3/4 are carried out by the methyl transferases 
MTR1 (Zamudio et al., 2007), MTR2 (also known as MT47 or COM1) (Arhin et al., 2006b; Hall 
and Ho, 2006) and MTR3 (also known as MT57) (Arhin et al., 2006a; Zamudio et al., 2006), 
respectively, and they occur sequentially from position 1 to 4 (Mair et al., 2000b) recently 
reviewed by (Sturm et al., 2012). Previously, Tkacz et al. (2010) reported that PRP19 silencing 
led to a loss of cap3/4 and an accumulation of SL RNAs with cap2 indicating a functional link 
between PRP19 and MTR3. To test whether SPF27 silencing led to a comparable defect, we 
performed a modified primer extension assay with MMLV reverse transcriptase and reduced 
ribonucleotide concentrations, both of which promote polymerization stops at methylated 
residues. We first extended oligonucleotide SL_PE which hybridizes to the single-stranded Sm 
binding region of the SL RNA (positions 111 to 130) and which we had used previously to show 
that CRK9 silencing caused the loss of all cap4 methylations (Badjatia et al., 2013a). As shown 
in figure 5.5A, we found that the shorter extension product, indicative of SL RNA with a fully 
methylated cap4 structure, disappeared after 2 days of SPF27 silencing and that the 
accumulated SL RNA signal was found almost exclusively in the top band instead, suggesting 
the predominant presence of SL RNA with a hypomethylated cap. Since a nearly congruent 
primer extension pattern was obtained when CRK9 was silenced (Badjatia et al., 2013a), this 
result suggested a complete loss of cap4 methylations instead of a specific cap3/4 loss upon 
SPF27 silencing. However, Tkacz et al. had used an oligonucleotide that hybridized further 
upstream of the SL RNA, precisely up to the GU splice site nucleotides of the SL RNA intron. 
Since it was possible that the use of different primers led to different extension results, we 
repeated the primer extension assay with oligonucleotide SL40 (Zamudio et al., 2006) that also 
hybridized up to GU splice site. Although the same assay conditions and RNA preparations 
were used, primer extension of SL40, in contrast to that of SL_PE, was different revealing cap4 
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  products on days 2 and 3, and a cap2-specific product that was clearly detectable on 
accumulated SL RNA 2 days into the SPF27 knockdown (Figure 5.5B). Possibly, the shorter 
extension of SL40 made reverse transcription more sensitive to methylated residues, resulting 
in a better detection of methylated and partially methylated SL RNA caps. Nonetheless, 
consistent with the SL_PE extension results, the cap4 product diminished over the time course, 
the cap2 product disappeared on day 3, and the accumulating SL RNA predominantly had a 
cap0. Thus, these findings did not reveal a specific cap3/4 defect but they clearly indicated that 
SPF27 silencing led to an accumulation of SL RNA that is progressively hypomethylated with 
most SL RNA having a cap0 structure. 
 Since SPF27 and CRK9 silencing led to similarly strong accumulations of SL RNA and, 
according to the SL_PE primer extension results, to a similar loss of cap4 methylation, we co-
analyzed total RNA from both gene knockdowns with primer SL40. In addition, we analyzed 
RNA from the ORC1 knockdown as a negative control and repeated an LSm2 silencing 
experiment which was shown previously to also affect the first step of trans splicing (Luz 
Ambrósio et al., 2009). As shown in figure 5.5C, depletion of the U6 snRNP-specific LSm2 
protein caused only a mild increase of SL RNA that did not exhibit any methylation defect. This 
result is not due to ineffective gene silencing because LSm2 silencing rapidly and strongly 
affected trypanosome proliferation in culture (Luz Ambrósio et al., 2009); data not shown). In 
contrast, the extent of SL RNA accumulation and the very strong cap0 signal were nearly 
identical in SPF27 and CRK9 knockdowns. The similarity of these phenotypes, despite the fact 
that SPF27 silencing merely halted culture growth (Figure 5.1A) while CRK9 silencing led to a 
strong decline of cell numbers (Badjatia et al., 2013), suggests that SPF27 and CRK9 function 
in the same step of RNA splicing. LSm2 silencing led to a loss of U6 snRNA (Luz Ambrósio et 
al., 2009; Tkacz et al., 2008) which should affect the formation of the B complex before 
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  spliceosome activation. Therefore, strong SL RNA accumulation and cap hypomethylation may 
be specific consequences of interference with spliceosome activation. 
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Figure 5.5 Accumulated SL RNA in SPF27-silenced cells is hypomethylated 
A. SL RNA and, as a loading control, U2 snRNA primer extension products of total RNA, prepared from 
non-induced (n.i.) cells and cells in which SPF27 was silenced for 1 to 3 days, were analyzed on a 
sequencing gel that separates SL RNA cap4–derived signals from signals of hypomethylated SL RNA 
caps (SL cap0). On the left, marker bands are indicated. 
B. Corresponding primer extension analysis of the same RNA with oligonucleotide SL40 which 
hybridizes just downstream of the 5/ splice site in the SL RNA (position 40 to position 59 relative to SL 
RNA 5’ end). For comparison, a sequencing ladder, which was obtained by linear amplification 
sequencing with the same oligonucleotide, was co-analyzed. Each lane is marked with the 
complementary base of the chain-terminating nucleotide used, so that the SL RNA sequence can be 
directly inferred from top to bottom. The starting A residue is marked with an asterisk. M, marker. On 
the left, the SL starting sequence 5/-AACTAA-3/ is indicated while specific cap products and the signal 
of the 7SL RNA, which was co-analyzed as a loading control, are specified on the right. Note that 
primer extension of SL40 generated a product with an extra nucleotide (position -1) that has been 
observed before and may be due to terminal transferase activity of reverse transcriptase (Zamudio 
et al., 2009a). 
C. SL RNA primer extension analysis, using primer SL40, of total RNA which was prepared from 
uninduced cells or from cells in which ORC1, LSm2, SPF27, or CRK9 was silenced for three days. 
Co-detection of U2 snRNA served as a loading control. 
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  4.6 The trypanosome PRP19 complex is associated with U2, U5 and U6 snRNAs 
 In a final step, we wanted to see whether the trypanosome PRP19 complex is 
associated with a complex comparable to the activated spliceosome in the yeast and human 
systems, which is characterized by the presence of U2, U5 and U6 snRNAs and the absence of 
U4 and U1 snRNAs. For this analysis, we prepared extract from TbP19ee cells, and efficiently 
pulled down PRP19-PTP by IgG beads (Figure 5.6A). Total RNA, prepared from the precipitated 
material, was then analyzed by two distinct primer extension assays. In assay A, four 
oligonucleotides were used to detect SL RNA and the Y structure intermediate as well as U2, 
U4 and U6 snRNA, whereas assay B contained two oligonucleotides complementary to U1 and 
U5 snRNAs (Figure 5.6B). In a positive control precipitation of the PTP-tagged SmD1 core 
snRNP protein (Luz Ambrósio et al., 2009) all six snRNAs were efficiently detected by correctly 
sized primer extension products (lanes 1 and 2) while in a negative control precipitation of PTP-
tagged ORC1 none of these RNAs co-precipitated (lanes 7 and 8). Since all PTP-mediated pull-
downs were of similar efficiency (Figure 5.6A), these results confirmed the specificity of the 
primer extension assays. In comparison, the pull-down of PRP19 mainly co-precipitated U2 and 
U5 snRNA as well as the Y structure intermediate (Figure 5.6B, lanes 3 and 4). In addition, full 
length SL RNA and U6 snRNA were co-precipitated although with a reduction in relative signal 
strength whereas U4 and U1-specific products were hardly detectable. This snRNA pattern 
shows that the PRP19 complex is predominantly associated with a complex that resembles an 
activated spliceosome and it suggests that the trypanosome PRP19 complex assembles into 
the spliceosome after the discard of U1 and U4 snRNA has been initiated. Moreover, the clear 
detection of the Y structure in PRP19-precipitated material confirms that the trypanosome 
PRP19 remains associated with spliceosome after the first step of splicing. Since SmD1 binds 
directly to the SL RNA (Palfi et al., 2000) and PRP19 is associated with snRNAs only through 
the spliceosome, the reduction of SL RNA signal versus the positive control is expected. 
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  Similarly, the reduction of the U6 signal is likely due to the presence of free U4/U6 snRNP in 
extract that is not assembled into the spliceosome and, therefore, is precipitated with SmD1 but 
not with a non-snRNP protein. When we repeated this experiment with two different cell lines 
that expressed either PTP-tagged CDC5 (lanes 6 and 7) or PTP-tagged SPF27 (lanes 9 and 10) 
the results were congruent with those for PRP19, further validating CDC5 and SPF27 as bona 
fide subunits of the trypanosome PRP19 complex. Overall, we found that only minor amounts of 
snRNPs co-precipitated with the PRP19 complex because, in contrast to the SmD1 precipitation 
in which snRNAs were efficiently co-depleted from the supernatant, the pull down of SPF27 did 
not detectably reduce the abundance of snRNAs in extract (Attachment 4, Fig. S4). This result 
is consistent with the finding that in trypanosomal extracts the majority of snRNAs are 
assembled in individual snRNPs rather than in large spliceosomes (Cross et al., 1991). 
 Finally, depletion of Sm and LSm proteins as well as of other snRNP proteins in 
trypanosomes led to a loss of the cognate U snRNA (Liu et al., 2004; Luz Ambrósio et al., 2009; 
Tkacz et al., 2008; Tkacz et al., 2010). In contrast, SPF27 silencing for three days did not alter 
the abundance of spliceosomal snRNAs, verifying the non-snRNP nature of the trypanosome 
PRP19 complex (Attachment 4, Fig. S5). Thus, the effective co-precipitation of the U snRNAs 
with PRP19 complex components suggests that trypanosomes form splicing complexes that are 
comparable to the B and C complexes described in other organisms and that these complexes 
remained stable in our extracts. 
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Figure 5.6 The trypanosome PRP19 complex specifically associates with U2, U5 and U6 snRNAs 
A. Extract was prepared from procyclic cell lines that express SmD1, PRP19, CDC5, ORC1 or 
SPF27 with a functional, C-terminal PTP tag. PTP-tagged proteins were precipitated by IgG 
beads that bind the protein A domain of PTP and were detected with the peroxidase anti-
peroxidase complex that is bound by protein A. Inp, input; Sn, supernatant; P, precipitate. x-
Values indicate relative amounts analyzed. 
B. Total RNA was prepared from the precipitates and analyzed by two primer extension reactions. In 
reaction A, oligonucleotides were used that are specific to SL RNA, U2 snRNA, U4 snRNA and 
U6 snRNA, whereas in reaction B, a U5- and a U1-specfic oligonucleotide were combined. The 
SmD1 and ORC1 pull-downs served as positive and negative controls, respectively. Note that the 
exposure time of the SmD1 analysis was much shorter than those of the other assays. 
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  5. Discussion 
 In this study we have characterized the spliceosomal non-snRNP PRP19 complex of T. 
brucei. Since trypanosomes and the model organisms from yeast to humans belong to different 
phylogenetic lineages, e.g. the Excavata and Opisthokonta, respectively (Katz, 2012), a 
comparison of these complexes can distinguish between properties that are highly conserved 
over extended evolutionary time and those that vary between species. Accordingly, the subunits 
PRP19, CDC5, PRL1 and SPF27 are invariably present in the human, yeast and trypanosome 
complexes indicating that these four proteins form the conserved core of the complex (Table 
5.2). 
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Table 5.2 PRP19 complex subunits in H. sapiens, T. brucei and S. cerevisiae 
 
H. sapiens T. brucei S. cerevisiae 
 PRP19 PRP19 Prp19 
 CDC5L CDC5 Cef1 
 PRL1 PRL1 Prp46 
 SPF27 SPF27 Snt309 
 AD002 assoc. assoc. (Cwc15) 
 CTNNB1 n.k.h. n.k.h. 
 HSP73 assoc. - 
 - PRP17 assoc. 
 assoc. SKIP assoc. 
 assoc. PPIL1 n.k.h. 
 assoc. assoc. Isy1 
 assoc. assoc. Syf1 
 assoc. n.k.h. Syf2 
 assoc. assoc. Clf1 (Syf3) 
assoc. associated; proteins that were co-purified 
with PRP19 complexes but not considered 
bona fide subunits. In humans they are 
referred to as “PRP19-related” (Chanarat 
and Strasser, 2013; Wahl et al., 2009) 
n.k.h. no known homologue 
- protein was not co-purified 
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  PRP17 is not a subunit of the human PRP19 complex and it is considered to be associated 
with the S. cerevisiae PRP19 complex. Trypanosome PRP17, however, stably co-purified and 
co-sedimented with the PRP19 complex independent of whether the complex was purified 
through PRP19 or CDC5 (Fig. 5.1D). This finding confirmed the association of S. pombe PRP17 
and PRP19 (Ren et al., 2011), and it strongly suggested that PRP17 functions in the 
spliceosome through association with PRP19 across eukaryotes. In the model of the S. pombe 
PRP19 complex, a PRP19 tetramer binds four PRP17 molecules through interaction of the 
PRP17 N-terminus with the PRP19 WD40 domain (Ren et al., 2011). These domains are 
conserved in the trypanosome orthologs (Fig. 5.2A) and the strong protein bands that contained 
PRP19 and PRP17 (Fig. 5.1D) may indicate that this model does fit the trypanosome complex. 
However, our sedimentation analysis revealed a complex of ~350 kDa which is substantially 
smaller than the expected 675 kDa of a complex containing a PRP19 tetramer, four PRP17 
molecules and monomers of each of the other subunits. Possibly, tandem purification and 
sedimentation led to a partial disruption of the PRP19 complex. Alternatively, we cannot rule out 
that there are two distinct PRP19 complexes of different composition that were not separated 
during sedimentation. 
 An interesting deviation from the yeast and human system was the finding that SKIP and 
PPIL1 were stably associated with trypanosome PRP19. Identification of these two proteins in 
trypanosomes implies an early evolutionary origin of the SKIP-PPIL1 sub-complex (Wang et al., 
2010). Furthermore, although previous work demonstrated a direct interaction between the 
yeast SKIP ortholog and PRP46p (PRL1) in vitro (Albers et al., 2003), these proteins have not 
been considered bona fide subunits of the PRP19 complex and were classified as PRP19-
related proteins (Chanarat and Strasser, 2013; Wahl et al., 2009). Since organization of PRP19-
related proteins is in general not well understood, our finding suggests that the SKIP/PPIL1 sub-
complex functions within the PRP19 complex independent of other PRP19-related proteins. This 
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  seems to be at least true for trypanosomes since we recently succeeded in characterizing a 
distinct complex of PRP19-related proteins that does not contain PRP19 complex subunits 
including SKIP and PPIL1 (DL Ambrósio and A Günzl, unpublished data). 
 Another important aspect of our study was the discovery that depletion of SPF27 led to a 
strong accumulation of SL RNA with a hypomethylated cap. The extent of SL RNA accumulation 
and the pattern of cap hypomethylation closely resembled the effects seen upon CRK9 silencing 
but not those of the LSm2 knockdown which also affected trans splicing (Fig. 5.5C) (Badjatia et 
al., 2013a; Luz Ambrósio et al., 2009). Thus, these findings suggested that CRK9 functions in 
spliceosome activation. Originally, our interest in CRK9 stemmed from its apparent role in the 
phosphorylation of RPB1, the largest subunit of RNAPII. In other systems, RPB1 
phosphorylation is critically important for RNAPII transcription initiation and elongation 
(Buratowski, 2009). However, in trypanosomes the loss of RPB1 phosphorylation upon CRK9 
silencing did not lead to an RNAPII-specific transcription block but, instead, coincided with SL 
RNA cap hypomethylation and the trans splicing block. Since cap4 formation was thought to be 
co-transcriptional (Mair et al., 2000b) and cap4 methylations a pre-requisite for SL trans splicing 
(McNally and Agabian, 1992; Ullu and Tschudi, 1991), we had speculated that CRK9’s primary 
substrate is RPB1, and that cap methylation and splicing defects are downstream 
consequences of RPB1 de-phosphorylation (Badjatia et al., 2013a). However, the possibility 
that CRK9 functions directly in spliceosome activation may point to a regulatory loop in 
trypanosomes in which the status of RNAPII phosphorylation is directly linked to the trans 
splicing mechanism. Accordingly, it will be interesting to analyze whether blocking spliceosome 
activation independent of CRK9 affects RNAPII phosphorylation. 
 Overall, this is the first characterization of a spliceosomal non-snRNP protein complex in 
trypanosomes. It is an important step towards understanding the spliceosome of T. brucei and 
related parasites. The human spliceosome is a validated anti-cancer drug with the first inhibitor 
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  in clinical trial (Eskens et al., 2013; van Alphen et al., 2009). Given the special use of this RNA-
protein machinery in trypanosome SL trans splicing, and considering the great evolutionary 
distance between trypanosomes and humans, a trypanosome-specific splicing inhibitor may 
wait to be discovered. 
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  Chapter VI 
 
Discussion and Future Directions 
 
 
 
 
1. The conserved kinetoplastid XPB-R paralog is specialized in Nucleotide 
Excision Repair (NER) 
 The multi-subunit and multi-functional transcription factor TFIIH is an important 
component of the RNA pol II transcription pre-initiation complex (PIC) as well as the NER 
machinery in eukaryotes (Compe and Egly, 2012). The TFIIH core complex includes the DNA 
helicase XPB, which is essential for TFIIH’s function in both transcription initiation and DNA 
repair. While model organisms such as yeast and humans have a single, bifunctional XPB that 
functions exclusively within TFIIH, kinetoplastids harbor two divergent XPB helicases. Our 
previous work showed that the larger of the two XPB paralogs is part of the trypanosome TFIIH 
complex that is crucial for SLRNA transcription (Lee et al., 2009; Lee et al., 2007). However, the 
functional significance of the smaller XPB paralog was unclear.  
 In this study, we functionally characterized the smaller XPB paralog that was termed 
XPB-R (R for repair) due to its essential role for NER in T. brucei (Badjatia et al., 2013b). We 
show that while XPB-R is dispensable of cell viability and transcription, it is important for NER in 
cells. Our results also indicate that XPB-R is not assembled in a TFIIH complex but that it does 
interact with the trypanosome p52 ortholog. p52 is a known regulator of XPB function in higher 
eukaryotes (Coin et al., 2007). Furthermore, gene silencing of p52 but not of XPD rendered 
trypanosomes susceptible to UV light in a manner comparable to XPB-R silencing. This strongly 
indicates that the interaction of XPB-R with p52 is important for its function in NER. Consistent 
with our results, in a parallel study it was shown that RNAi of XPB-R increases the susceptibility 
of cells towards UV and cisplatin-induced DNA lesions that are repaired by NER (Machado et 
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  al., 2014). Furthermore, this study also demonstrated that XPD and the larger XPB paralog do 
not function in DNA repair in trypanosome. 
 To the best of our knowledge, this is the first study that demonstrates a role of the XPB 
helicase in repair independent of the TFIIH complex. Our data support a model in which 
trypanosome TFIIH complex including the DNA helicases XPD and the larger XPB paralog is 
crucial for RNA pol II transcription but not required for DNA repair while XPB-R and its functional 
partner p52 are part of a TFIIH independent NER machinery (Figure 6.1). Since a similar XPB 
dualism is also found in other phylogenetically early-diverged eukaryotes such as ciliates and 
species of Entamoeba, it is possible that a repair-specialized XPB helicase is an ancient 
eukaryotic trait and that combining the repair and transcriptional functions in a single XPB 
helicase occurred later during evolution. 
 While our results clearly demonstrate that XPB-R is not essential for cell survival in T 
brucei, the XPB-R−/− knockout cell lines exhibited consistent slow growth when monitored for a 
period of over three months. This slow growth could be a result of accumulating DNA mutations 
in culture or it is possible that XPB-R has other functions in cells. Nonetheless, successful 
generation of clonal XPB-R−/− cell lines shows that XPB-R is not essential for culture growth of 
T. brucei. However, XPB-R could still be an important virulence factor in T. brucei for 
establishing successful infections in its host where growth conditions are very distinct from 
those in culture. This can be tested in a mouse model by injecting equal number of wild-type 
and XPB-R−/− parasites into mice and monitoring parasitemia and survival over a period of time. 
This will determine if XPB-R plays a role in virulence of the parasites.  
 Our results show that XPB-R−/− cells are more susceptible to NER inducing agents such 
as UV light and cisplatin as compared to the wild-type cells. This susceptibility is dose 
dependent. In order to further strengthen this finding, we can perform IF to determine if XPB-R 
localizes to the site of DNA damage specifically at DNA lesions induced by UV light and 
cisplatin. This can be done by colocalizing XPB-R and DNA lesions in cells that have been 
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  exposed to UV or cisplatin. Commercially available monoclonal antibodies against 6-4 
photoproducts and cyclobutane pyrimidine dimers (CPD) can be used to detect DNA lesions 
that are generated after UV exposure and anti-cisplatin antibody can be used to visualize 
cisplatin adducts. Since we have already established a clonal cell in which XPB-R is exclusively 
expressed as a fusion with the PTP tag, XPB-R and DNA lesions can be co-detected in this cell 
line using our established IF protocol. We would expect XPB-R to accumulate at the sites of 
DNA lesions after exposure to DNA damaging agents. This will be a strong support for our 
previous results that demonstrate XPB-R’s involvement in NER.  
 Furthermore, IF can be used to determine if absence of XPB-R impedes the repair of 
Cisplatin- or UV-induced DNA lesions. DNA lesions can be visualized in wild type and XPB-R−/− 
cells at different time points after exposure to DNA damaging agents. We would expect to see a 
delay/loss in the repair of the lesions in XPB-R−/− cells. This will demonstrate a direct role of 
XPB-R in NER in trypanosomes.  
 Alternatively, a recently established more sensitive and quantitative NER assay termed 
Oligonucleotide Retrieval Assay (ORA) can be employed to compare repair efficiency in XPB-
R−/− and wild-type cell lines (Shen et al., 2014). In this assay, 5′-biotinylated duplex DNA that 
contains a CPD adduct is transiently transfected into cells to serve as a substrate for NER. 
Thereafter, DNA is extracted from cells and the transfected oligonucleotide is isolated using 
capture by streptavidin beads. Finally, qPCR can be used to quantify the proportion of CPD 
lesions that were repaired in vivo. This sensitive assay can be employed to quantify the 
differences in NER efficiency in XPB-R−/− and wild-type cell lines. 
 A detailed analysis of NER in T. brucei showed that the trypanosome orthologs of CSB 
and XPG as well as XPB-R are crucial for the trypanosome NER pathway (Machado et al., 
2014). In other eukaryotes, CSB is known to function in detection of DNA lesions specifically in 
the TC-NER pathway while XPC detects damage in the non-transcription coupled genomic NER 
pathway (Compe and Egly, 2012). XPG is one of the two endonucleases that mediate excision 
169
	  of damaged DNA (Compe and Egly, 2012). Interestingly, while CSB seems to be important for 
NER in T. brucei, XPC appears to be dispensable. It is possible that trypanosome CSB detects 
DNA lesions in both TC-NER and genomic NER. However, since the crystal structure of archeal 
XPB revealed a DNA damage recognition domain, it can also be speculated that trypanosome 
XPB-R is capable of damage detection independent of XPC or CSB. In the archeon Sulfolobus 
solfataricus, a complex of XPB and Bax1 endonuclease (functional equivalent of XPG), can 
recognize, unwind and cleave NER substrates in vitro (Rouillon and White, 2010). If XPB-R and 
trypanosome XPG form a similar complex is not yet clear. This possibility can be tested by 
tandem affinity purification of XPG and/or by reciprocal co-immunoprecipitation analysis of XPB-
R and XPG. Furthermore, NER efficiency of cellular extracts that are immmunodepleted of 
either XPB-R or XPG can be measured in vitro NER assays such as the ORA described above. 
Recombinant XPB-R and/or XPG can be added back to the extracts for reconstitution of the 
NER activity. Moreover, interaction of recombinant XPG with XPB-R can be examined in pull-
down experiments. Lastly, it can be tested if recombinant XPB-R and XPG complex can 
recognize, open and cleave model NER substrates in vitro in a manner similar to repair by the 
archaeal XPB/Bax1 doublet. 
 Finally, the role of XPB-R in TC-NER, if any, can be tested in similar experiments as 
described above. TAP of CSB can potentially reveal novel factors that are important for TC-NER 
in T. brucei. Whether or not XPB-R interacts with CSB can be analyzed by reciprocal 
immunoprecipitations in extracts and in vitro pull-down experiments. Also, whether or not CSB 
specifically functions in TC-NER can be tested by measuring the NER activity of extracts 
depleted of CSB in vitro. However, since repair of model NER substrates is not coupled to 
transcription, depletion of CSB should not affect repair of in vitro substrates.  
 In conclusion, various experiments described above can help to further delineate the 
NER pathway in trypanosomes which is not well-characterized. It will also help us to understand 
the precise role of XPB-R in NER. These analyses can reveal unique features of trypanosome 
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  NER machinery that are distinct from the NER machinery of the model organisms and they may 
elucidate the evolution of this important pathway in the eukaryotic kingdom. 
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Figure 6.1 A model for the comparison of TFIIH composition and function in human and T. brucei.  
 
The human TFIIH complex (model modified from (Compe and Egly, 2012)) consists of two structural 
and functional sub-complexes, namely the core complex, which includes the DNA helicases XPB and 
XPD, and the cyclin-dependent kinase (CDK)-activating kinase (CAK) complex. The XPB subunit of TFIIH 
has essential functions in both RNA pol II transcription and DNA repair. Trypanosomes contain two 
divergent paralogs of the XPB helicase of which only the larger termed XPB-T (T for transcription) is 
associated in a TFIIH complex together with orthologs of all core subunits as well as two trypanosome 
specific subunits called TSP1 and TSP2. T. brucei TFIIH is essential for SLRNA transcription by RNA pol 
II but lacks the CAK complex that is conserved amongst model eukaryotes.  The smaller XPB paralog 
termed XPB-R (R for repair) in T. brucei is specialized in nucleotide excision repair (NER), and has no 
role in RNA pol II and RNA pol I transcription. It interacts with the p52 subunit of TFIIH, a known regulator 
of XPB in other systems, but does not appear to assemble in a TFIIH complex. This suggests a model in 
which trypanosomes possess a TFIIH, containing XPB-T, that is specialized in RNA pol II transcription 
while NER is carried out via a XPB-R based machinery.  
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  2.  Characterization of the unique CRK9 complex, which is crucial for SL trans 
splicing 
 Our biochemical and structural characterization of TFIIH revealed that trypanosome 
TFIIH lacks the CAK sub-complex (Lee et al., 2009; Lee et al., 2007; Rouillon and White, 2010), 
composed of CDK7, cyclin H and MAT1, which is typically conserved in all model eukaryotes. 
Given CDK7’s essential role in the phosphorylation of the RPB1 CTD (Fisher, 2005), and the 
finding that the corresponding trypanosome CTD is phosphorylated as well (Chapman and 
Agabian, 1994; Das and Bellofatto, 2009), we analyzed the four most essential trypanosome 
CDKs, namely CRK1, CRK3, CRK7 and CRK9,  in an attempt to identify the trypanosome CDK 
that is involved in CTD phosphorylation. Indeed, our study showed that ablation of CRK9 
resulted in a loss of CTD phosphorylation. In addition, we found that this kinase is indispensable 
for the essential parasite-specific process of SL trans splicing in T. brucei. Silencing of CRK9 
led to the inhibition of SL trans splicing before the first transesterification step and it resulted in 
SL RNA cap hypomethylation and loss of RPB1 phosphorylation (Badjatia et al., 2013a). 
 Since trypanosomatids transcribe their protein coding genes in a polycistronic fashion, 
the processes of SL trans splicing and polyadenylation are required for resolving individual 
mRNAs from polycistronic pre-mRNA. Thus, SL trans splicing is a crucial RNA processing step 
for the maturation of each and every mRNA in these parasites. Accordingly, factors that are 
involved in SL trans splicing are typically essential for parasite survival. In this study, we found 
that CRK9 is vital for parasite survival and that CRK9 silencing led to  arrest in culture growth 
just after one day of inducing the gene knockdown (Badjatia et al., 2013a). Furthermore, we 
showed that CRK9 is crucial for trypanosomes to establish infection in a mouse model (Chapter 
V). This is important since CDKs are considered to be suitable drug targets for dividing cells and 
several CDK inhibitors such as Flavopiridol have been tested or are in clinical trials for cancer 
therapy (Cicenas et al., 2014; Peyressatre et al., 2015).  Since we have validated CRK9 as a 
173
	  potential chemotherapeutic target for trypanosomes in a mouse model, characterization of the 
CRK9 complex is an important next step for the development of specific small molecule 
inhibitors of this enzyme in the future.  
 For this, we tandem affinity-purified CRK9 and sedimented the final eluate in a sucrose 
gradient. The sedimentation profile led to identification of a putative tripartite complex of CRK9 
together with a previously unannotated cyclin, termed CYC12, and the novel protein CRK9AP. 
Expression silencing of both CYC12 and CRK9AP recapitulated the phenotypes of the CRK9 
knockdown, confirming that CYC12 and CRK9AP are functional partners of CRK9 in vivo. 
 The newly identified cyclin CYC12 is conserved amongst all kinetoplastids. Our 
bioinformatic and phylogenetic analyses strongly indicated that CYC12 is a L-type cyclin with a 
C-terminal arginine/serine-rich RS domain of high positive charge that is characteristic of L-type 
cyclins in other eukaryotes with the exception of S. pombe L-type cyclin that lacks this domain 
(Dickinson et al., 2002). Thus far, CYC12 is the only known ‘transcriptional’ cyclin of 
trypanosomes that is crucial for the parasite-specific mode of gene expression. Interestingly, 
kinetoplastid CYC12 deviates from known cyclins by  large insertions in both of its cyclin 
domains, e.g. Cyclin_N and Cylin_C. It is likely that these sequence insertions prevented 
recognition of CYC12 as a cyclin in the annotation of the genome (Parsons et al., 2005). These 
insertions might reflect functionally important enzyme features that are kinetoplastid-specific . 
However, this remains to be tested. 
 Consistent with the identification of CYC12 as a putative L-type cyclin, a standard 
protein-protein BLAST search of the human or Drosophila melanogaster proteome with the T. 
brucei CRK9 sequence returned various isoforms of CDK11 (E=5e-43 & 2e-37 respectively). 
Cyclin L is a known functional partner of CDK11 in model organisms (Loyer et al., 2008). 
CDK11p110 isoform is implicated in the regulation of gene expression in eukaryotes, and was 
shown to be essential for pre-mRNA splicing in both in vivo and in vitro splicing assays (Choi et 
al., 2014; Hu et al., 2003). Since our results demonstrate CRK9’s indispensable role in SL trans 
174
	  splicing, this finding together with the association of CRK9 with an L-type cyclin, strongly 
suggests that CRK9 is a divergent ortholog of CDK11. 
 Our study also identified a small 15 KDa protein termed CRK9AP that is required for 
trans splicing in vivo. CRK9AP appears to be kinetoplastid-specific with no recognizable 
orthologs in other systems and no identifiable functional motifs. Nonetheless, knockdown of 
CRK9AP mirrored the defects observed in CRK9 and CYC12 silencing. Our studies indicate that 
CRK9AP associates with CYC12 and CRK9 to form a stable tripartite complex. This is unique 
since with the exception of CDK7’s CAK complex, CDKs function in heterodimeric complexes 
together with their cyclin partner. Silencing of CRK9AP leads to co-loss of CRK9 and CYC12 
from cells strongly indicating that CRK9AP is important for stability and/or assembly of the 
complex. Interestingly, similar to the phenotype we observe upon CRK9AP silencing, in MAT1 
deficient cells, the levels of CDK7 and cyclin H are significantly reduced (Korsisaari et al., 2002; 
Rossi et al., 2001; Sano et al., 2007). It is possible to speculate that CRK9AP’s function in 
CRK9 complex is similar to that of MAT1 in CAK complex. However, it remains to be tested if 
CRK9AP is essential for CRK9’s kinase activity in vitro. Previously, it has been shown that the 
C-terminal hydrophobic domain of MAT1 is sufficient for its association in the CAK complex and 
for activation of the kinase activity of CDK7 (Busso et al., 2000). It is interesting to note that 
CRK9AP also has a large hydrophobic region at the C-terminus. In the future, a mutational 
analysis of CRK9AP may help to decipher important domains/residues  that mediate CRK9AP’s  
interaction with CRK9 and CYC12. 
 Another family of small proteins that are implicated in assembly of CDK-cyclin 
complexes is the Cip/Kip family of CDK inhibitors (CKI). Although members of this protein  
family are typically considered as inhibitors of cell cycle-related CDKs, they were also shown to 
be important for the assembly and activation of CDK4/6 - cyclin D complexes (Cheng et al., 
1999; LaBaer et al., 1997). However, the function of Cip/Kip family is restricted to CDKs 
involved in the regulation of the cell cycle and so far no study has demonstrated their role in 
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  activation or inhibition of transcriptional CDKs. Nonetheless, future work will determine if 
CRK9AP is a divergent ortholog of MAT1 or Cip/Kip proteins or if it is a unique kinetoplastid-
specific protein dedicated for the assembly/stability of CRK9 complex.  
 Our infection studies in mice with cells where CRK9’s expression can be silenced by 
induction with doxycycline validated CRK9 as a suitable chemotherapeutic target. However, in 
order to screen for a large number of small molecule inhibitors of CRK9, a functional 
recombinant enzyme is required. Although our initial attempts to express full-length CRK9 and 
CYC12 in E. coli were not successful, recently we have effectively expressed CRK9, CYC12 
and CRK9AP in vitro in wheat-germ extracts. This is very promising as this system can allow us 
to tether the interactions of individual proteins with the others. Our preliminary results indicate 
that CRK9AP can interact with both CRK9 and CYC12 independently. Future pull-down 
experiments will determine if CRK9 can interact with CYC12 independent of CRK9AP or if 
CRK9AP functions as an assembly factor to mediate interaction between CYC12 and CRK9. 
Additionally, this system can be utilized to perform mutational analysis for identification of 
domains/regions of ALP or CYC12 that mediate interaction with CRK9 and each other. For 
example, pull down experiments after deletion of the RS domain of CYC12 and C-terminal 
hydrophobic region of ALP will determine if these regions are important for protein-protein 
interactions. 
 We do not yet know if CRK9 can assemble in a functional kinase complex in wheat-germ 
extracts. This can be tested by purifying the CRK9 complex from wheat-germ extract in which all 
three proteins are co-expressed and by subjecting the purified enzyme complex to 
autophosphorylation in kinase assays. If autophosphorylation of CRK9 is observed, then we can 
test if CRK9AP is essential for this phosphorylation. However, the CRK9 complex purified from 
wheat-germ may not be competent in autophosphorylation of CRK9. One possible reason for 
this could be that activation of CRK9 is dependent on post-translational modifications that are 
absent in wheat-germ extracts. Previous phospho-proteomic studies of T. brucei have identified 
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  phosphorylations of CRK9 threonine 533 (T533), serine 746 (S746), S750 and T752 (Nett et al., 
2009; Urbaniak et al., 2013). While our results showed that mutation of T533, which resides in 
the activating T-loop of the kinase, is deleterious to CRK9’s function in cells, the significance of 
the remaining phosphorylations remains unknown. Phosphomimetic mutations of these four 
residues can determine if these phosphorylations are crucial or inhibitory for CRK9 kinase 
activity. Finally if we could establish a functional CRK9 complex from wheat germ extract, a 
small-scale screen of inhibitors can be performed which can give some leads for establishing a 
high-throughput screening (HTS) assay in the future.  
 In order to measure the activity of CRK9 in vitro kinase assays, we need to first identify 
the substrates(s) of CRK9 enzyme. Not only will this allow us to develop a robust in vitro kinase 
assay for CRK9 activity but it will also help delineate the mechanism by which CRK9 functions 
in SL trans splicing in vivo. A number of proteins were co-purified with CRK9 during TAP. Most 
significant proteins with high Mascot Scores are listed in Table 4.1. These are potential 
substrate candidates, including TSR1, which is a trypanosome SR protein shown to be 
important of splicing in Trypanosoma brucei (Gupta et al., 2014).   
 Expression of an analog-sensitive mutant of CRK9 in cells is another powerful strategy 
to identify its targets in vivo (Gregan et al., 2007). Methionine at position 438 was identified as 
the gatekeeper residue of CRK9 by bioinformatic analysis (data not shown). The gatekeeper 
residue is a conserved bulky hydrophobic amino acid that resides in the ATP binding pocket of a 
kinase. Mutation of this amino acid to small residue such as alanine or glycine enlarges the ATP 
binding site such that the kinase can accommodate a hydrolysable ATP analog (e.g. N6-
(benzyl)ATP) or specific cell-permeable inhibitors (e.g. 1-NA-PP1, 3-MB-PP1) (Gregan et al., 
2007). These analogs or inhibitors can only bind to the mutant kinase and not to any other wild-
type kinase. Thus, analog-sensitized CRK9 can be used to identify its substrates in two 
independent approaches. First, in an indirect approach, cells that exclusively express analog 
sensitive CRK9 (asCRK9) will be grown in a medium containing cell permeable inhibitors such 
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  as 1-NA-PP1 that specifically inhibits asCRK9. In a control experiment cells will be grown in 
medium lacking the inhibitor but containing amino acids labeled with heavy isotopes. 
Subsequently, equal number of cells will be harvested from both cultures, combined and 
analyzed by mass spectrometry to identify phosphoproteins in the sample. This SILAC based 
mass spectrometry approach will determine relative abundance of phosphoproteins in the two 
cell populations analyzed. In this approach we will be able to identify candidate proteins whose 
phosphorylation is directly or indirectly dependent on CRK9 kinase activity. In a second, more 
direct approach, cellular extract prepared from cells that express asCRK9 will be subjected to 
an in vitro kinase assay with an ATP analog carrying a thio-phosphate group (N6B-ATPγS) 
(Blasius et al., 2011). Subsequently, proteins will be digested with trypsin and thio-
phosphorylated peptides will be enriched with iodo-acetyl agarose beads (SulfoLink Coupling 
Resin, Thermo Scientific). Subsequently, the thio-phosphorylated peptides will be eluted with an 
oxidizing agent and analyzed by mass spectrometry. This approach will allow identification of 
direct CRK9 substrates. Commercially available antibodies against thiophosphate-ester (e.g. 
from Epitomics Inc., Burlingame, CA, USA) can be used in immunoblotting experiments  to 
validate potential substrates or autophosphorylation of asCRK9. 
 In order to perform a HTS for specific CRK9 inhibitors we might need functional 
recombinant enzyme in large amounts. For this a Baculovirus-insect cell expression system can 
be established. Insect cell expression systems have been used in the past to purify active CDK-
cyclin complexes in large quantities for structural analysis. Thus, this system might be useful to 
obtain functional CRK9 enzyme in amounts needed for HTS. Once a functional recombinant 
CRK9 enzyme can be obtained, it will be possible to establish a sensitive fluorescence-based 
HTS assay to screen for a wide range of (potential) kinase inhibitors. We will collaborate with 
drug screening centers to test for lead compounds. An important candidate is the Drug 
Discovery Unit in Dundee, UK which is led by Dr. Micheal Ferguson, a well-known 
trypanosomatid researcher. 
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   In summary, different approaches described above can be used to further characterize 
the CRK9 complex, identify substrates of CRK9 and to discover specific small molecule 
inhibitors against CRK9. This study has significant medical implications for the treatment of 
trypanosomatid diseases since we have validated CRK9 as potential chemotherapeutic target. 
Furthermore, identification of CRK9 substrates in vivo will elucidate the mechanism by which 
CRK9 regulates the essential parasite-specific process of SL trans splicing and it may reveal 
other potential targets upstream or downstream of CRK9 function in this essential gene 
expression pathway. 
 
3. Characterization of the trypanosome PRP19 complex 
 Having identified CRK9’s crucial role in SL trans splicing, we wanted to further 
characterize the splicing machinery of trypanosomes. In recent years, biochemical 
characterizations of protein complexes and bioinformatics approaches have led to the 
identification of orthologs of almost all known spliceosomal snRNP proteins in trypanosomes. 
However a majority of non-snRNP splicing proteins remain unidentified (Gunzl, 2010; Preußer 
et al., 2012). In this study, we biochemically and functionally characterized the non-snRNP 
PRP19 complex of trypanosomes, which in other eukaryotes is essential for spliceosome 
activation (Ambrosio et al., 2015). By TAP and subsequent sedimentation of the purified PRP19 
complex in a sucrose gradient and mass spectrometry of co-sedimented proteins, we identified 
a PRP19 complex that contained the orthologs of the known core subunits PRP19, CDC5, 
PRL1, and SPF27 that are also invariably present in yeast and human PRP19 complexes as 
well as PRP17, SKIP and PPIL1 orthologs which are not considered bona fide subunits of the 
PRP19 complex in the model organisms. This demonstrated that the trypanosome PRP19 
complex consists of a conserved, albeit divergent core but, otherwise,  deviates substantially in 
protein composition from its human and yeast counterparts. Moreover, this study is the first 
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  characterization of a non-snRNP protein complex in trypanosomes. In the future, further 
biochemical characterizations, for example by TAP, will help to expand the repertoire of non-
snRNP splicing factors in trypanosomes. These analyses may eventually lead to the 
identification of a trans splicing-specific protein that can be targeted in an antiparasitic strategy.  
 Recently, the human PRP19 complex was characterized by electron microscopy (EM) 
after TAP (Grote et al., 2010). This work revealed that the PRP19 complex has an asymmetric 
and elongated structure with a maximum dimension of ~20 nm and width of ~9 nm. 
Interestingly, the yeast PRP19 complex also has a similarly elongated morphology but a larger 
size with a side length of 40 nm (Ohi et al., 2005), indicating differences in the composition of 
the two complexes. In the future, we can perform EM analysis of the structure of the 
trypanosome PRP19 complex which might reveal unique structural features of the PRP19 
complex in trypanosomatids. 
 Interestingly, gene silencing of components of the PRP19 complex led not only to 
defects in trans splicing but also to hypomethylation of cap4 and a loss of RPB1 
phosphorylation. These phenotypes were very similar qualitatively and quantitatively to those 
we observed upon CRK9 silencing. This suggests that CRK9 and PRP19 depletion affects trans 
splicing in a similar fashion and that cap4 hypomethylation and RPB1 dephosphorylation are a 
consequence of a block of trans splicing. Since PRP19 is important for activation of the 
spliceosome and our results strongly suggest that trypanosome PRP19 associates with the 
active spliceosome, it is possible that both PRP19 and CRK9 function in spliceosome activation. 
These findings also allude to a cross-talk between SL trans splicing and the status of RNA pol II 
phosphorylations. It will be interesting to decipher the signaling pathway that leads to the co-
regulation of transcription, SL RNA biogenesis and trans splicing. Potential proteins involved in 
this pathway may have purified either with CRK9 (see above) or with the PRP19 complex. 
 Finally, our previous PTP purifications of SmD1 and PRP19 co-purified several so called 
‘conserved hypothetical’ proteins. These are proteins that are conserved only amongst 
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  trypanosomatids with no known ortholog in other systems. One of these conserved hypothetical 
proteins is encoded by a gene with the accession number Tb927.11.2960 and it was found to be 
enriched in the PRP19-PTP purification with a high protein score. Tb927.11.2960 is an essential 
gene and silencing of its expression led to comparable defects in trans splicing and cap4 
methylations as observed upon silencing of PRP19 or CRK9. Our preliminary TAP analysis of 
this protein co-purified  several proteins which, in the human system, have been termed PRP19-
related proteins because they consistently co-purify with PRP19 subunits but are not stably 
associated with the PRP19 complex (Wahl et al., 2009). Most interestingly, a sedimentation 
analysis discovered a distinct complex of these proteins that has not been described in any 
other organisms and our initial analysis revealed that the complex enters the spliceosome 
before the PRP19 complex (data not shown). Thus, it is possible that the “PRP19-related” 
complex facilitates recruitment of the PRP19 complex into the spliceosome. This can be 
investigated by a conditional knockdown of genes encoding subunits of the newly identified 
complex and the parallel assessment of the snRNA profile that co-precipitates with PRP19. If 
the proposed functional relationship between these two distinct complexes can be established, 
this would provide new insight into spliceosome activation for the RNA splicing field in general. 
Overall, the spliceosome is difficult to investigate because it is such a huge and dynamic 
machinery. However, the methodology established in the laboratory and employed and further 
developed in this thesis project provides the means for a comprehensive analysis of the 
spliceosome and its signaling pathways to the other essential processes of gene expression. 
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Hs     -------------------------PDVIQHLLQDPVIRECRLRNSEGEATELITETFT------------------------------- Mm     -------------------------PDVIQHLLQDPVIRECRLRNAEGEATELITETFT------------------------------- Drer   -------------------------PDVIQRLLQDTVIRDCRLRSAEGEETELITETIS------------------------------- Dm     -------------------------PEVLQKLLKDPVIQKCRLIRSEGEDF--IQGTLD------------------------------- Ce     -------------------------SDVMQKLLKDSVIQSCILDDRVQPAQQT---ELP------------------------------- Sc     -------------------------ADILQMLLNDSVIGPLRIDSDHQVQPPEDVLQQQ------------------------------- Sp     -------------------------ASVLRLLLRDPVIGPLRIDYSTQSSKQKSSKP--------------------------------- Ca     -------------------------ADILQMLLKDPVIGPLRIQSSENIVTSNGLITSA------------------------------- Nc     -------------------------AELLQKLLRDEVIGKWRVQGSGDITTSYAPTM--------------------------------- 
Tb-1   DVKAEEG--------------------------------CEEATDELSPLAG--------QVKKEETKEVAAEPRRRFLSL--------- Tco-1  SSDAEQE--------------------------------ECEGTEALSPCGE---FASPKRFKRDPGGGGAAPPKHRVLSL--------- Tv-1   ATLENGG--------------------------------TCHSEPAVKKL--KKEDEEFVPEVKVNSLENTEKPRRRFLSL--------- Tc-1   K--KQQK--------------------------------QEEDEDGLGPKRAKKENGERVSLVKQEATEETAAPSRRFFSL--------- Lm-1   TILASLNRTSADDAPSPAVTAHHVGNDSLETLVKREKVEEEEMGDRLSAGGAAASALKTVSSRSAAPSG---SPTSRLLQLFRPLLPTPA Li-1   TILASLNRTGADDVASPAVSAPHVSNDSWKTLVKREKVEEEAVGDRLSAGDAAASALETVSSRAAAPSG---SPTSRLLQLFRPLLPTPA Lb-1   TLLASLNRPSADDAASSTLFSPHMRNDTLKTRIKSEKVEEE-EGELLSAGGEGASALEPVLPRTAAPFPRPRSPATRVLQLFRPSSPAPA Lmx-1  TILASLNGASADGVTSPAVPTPHVSNDRLKSLVKRENVEEEEVGDRLSAADAAASASETVSSRTAAPSS---SPTSRLLQLFRPLLPTPA Bs-1   ------------------------------------------------------------------------------------------ 
Tb-R   -------------------------IVTAKTLLKDRVVRSLCCQPKETVGE--------------------------------------- Tco-2  -------------------------IETANILLRDLTVRSLCAEPPEIVTT--------------------------------------- Tv-2*  -------------------------ASTAKALLEDRVVRSLCAHPPKASRT--------------------------------------- Tc-2   -------------------------VETAETLLLDPVVRSLCAEPPQIVPV--------------------------------------- Lm-2   -------------------------EETAQMLLRDAVIASVAATPLRIFYEESS------------------------------------ Li-2   -------------------------EETAQMLLRDAVIASVAVTPLRIFYEKSS------------------------------------ Lb-2   -------------------------EETAQMLLCDAVITSVAATPPQIFYETSS------------------------------------ Lmx-2  -------------------------EETAQMLLRDAVIASVAATPLRIFYEESS------------------------------------ Bs-2   ------G------------------RRLAEAILRDQRIVSLCAVRDTSVGATAAAT---VRNRQQQT----------------------- 
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Hs     --------------------------------------------------------------------SKSAI----------------S Mm     --------------------------------------------------------------------SKSAI----------------S Drer   --------------------------------------------------------------------SKSAI----------------S Dm     --------------------------------------------------------------------GKAIT----------------Q Ce     --------------------------------------------------------------------AQEKI--------------KFS Sc     --------------------------------------------------------------------LQQT------------------ Sp     --------------------------------------------------------------------SNEDN--------------VED Ca     --------------------------------------------------------------------SEPSN--------------IVI Nc     -----------------------------------------------------------------------GG--------------LVI 
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Tb-R   -----------------------DA----------------------------------------------------------------- Tco-2  -----------------------SA----------------------------------------------------------------- Tv-2*  -----------------------EA----------------------------------------------------------------- Tc-2   -----------------------VP----------------------------------------------------------------- Lm-2   --------------WEE----SPAP----------------------------------------------------------------- Li-2   --------------WEE----SPAP----------------------------------------------------------------- Lb-2   --------------WAE----NPAP----------------------------------------------------------------- Lmx-2  --------------WDE----NPAP----------------------------------------------------------------- Bs-2   ------STKTSDKKIEE----GDES-------------------L---------SHLYITR---------RII----------------R 
Ng-1   ---------------------------------------------------------------------KRFI--------------IKS Ng-2   ---------------------------------------------------------------------KRFI--------------IRT Trva-1 -----------------------------------------------------------------------KI--------------M-I Trva-2 -----------------------------------------------------------------------KF--------------L-K Gl     ---------------EQGVQS-DQS--------------------------LWYTQSFKIASIPKLKRYFFPL----------------- Ehis-1 ------------------------------------------------------------------------------------------ Ehis-2 ----------------------------------------------------------------------ECI--------------T-- Edis-1 ------------------------------------------------------------------------------------------ Edis-2 ----------------------------------------------------------------------EFI--------------I-- Dd     ---------------------------------------------------------------------KTGF----------------I Ac**   -----------------------------------------------------------------------NF----------------S Pf     -----KNNNDDNNNIDK----TTSN-------------------LLN--EDQKGKDCYVTYEAPVLDTTQLGF--------------KIS Toxg   ---------------AS----GSSS-------------------LLKSLPSPSNDGLYVIANAPTLDASQLAF--------------QVS Eimt** ------------------------------------------------------------------------------------------ Ta     ----------------------------------------------N--STSNRNNEYVTISVPT---SDFSF--------------VFN Tett-1 -----------------------------------------------------------IQK--DLQSFFQNIKTENNQQSSKKNQ-KMI Tett-2 -----------------------------------------------------------MEQNPPQQLLQT------------------- Part-1 -----------------------------------------------------------IQVNPQLKNFEQQIEL--------------- Part-2 ----------------------------------------------------------------SIENYER------------------- At-1   ---------------------------------------------------------------------GDGF----------------S At-2   ---------------------------------------------------------------------GDGF----------------T Orys-1 ---------------------------------------------------------------------APSF----------------T Orys-2 ---------------------------------------------------------------------APSF----------------T 
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Tb-R   -----------------------------------------------------CPHFLLKSR--AAARVVAER-C-VL--LGYPLQQQYE Tco-2  -----------------------------------------------------RPYSLLRNR--AVTKVVAER-C-AA--LGYPLQQQYD Tv-2*  -----------------------------------------------------CSF-LLRSR--AAARPVAER-C-VA--LGFPLQQQYD Tc-2   -----------------------------------------------------HSLLVLRSR--AVARRVAER-C-VL--LGFPLQQQYD Lm-2   -----------------------------------------------------YPSFLLQSR--AMSKVVAAQ-C-VV--LGLPIQQQYD Li-2   -----------------------------------------------------YPSFLLQSR--AMSKVVAAQ-C-VV--LGLPIQQQYD Lb-2   -----------------------------------------------------YPSFLLQSR--AMSKVVAAR-C-MV--LGFPIQQQYD Lmx-2  -----------------------------------------------------YPSFLLQSR--VMSKVVAAQ-C-VV--LGLPIQQQYD Bs-2   --SEAKNAAI-----------VA-----------DKEEHDDDG-------ELEEVQVLLQDH--AASRLVSDVLW-AH--HHLPICQVYH 
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                                                                                         WM I                                                                                              *****    Hs     FRNDS--------------------------VNPDINI-DLKPTAVLRPYQEKSLRKMFGNG---------RARSGVIVLPCGAGKSLVG Mm     FRNDT--------------------------LNPDINI-DLKPTAVLRPYQEKSLRKMFGNG---------RARSGVIVLPCGAGKSLVG Drer   FRNDT--------------------------VNPDINM-DLKPTAVLRPYQEKSLRKMFGNG---------RARSGVIVLPCGAGKSLVG Dm     FRNDT--------------------------NNPDINI-DLKPAAVLRPYQEKSLRKMFGNG---------RARSGVIVLPCGAGKSLVG Ce     FRNDT--------------------------LNPNLGI-DLKPSTTLRPYQEKSLRKMFGNS---------RARSGVIVLPCGAGKTLVG Sc     FRNDH--------------------------RNPDLDI-DLKPSTQIRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKTLVG Sp     FRNDN--------------------------INPDLPI-DLKPSTQIRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKTLVG Ca     FRHDA--------------------------RNPDLEI-DLKPSTQIRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKTLVG Nc     FRNDS--------------------------NNADLEI-DLRPNTQIRPYQEQSLSKMFGNG---------RAKSGIIVLPCGAGKTLVG 
Tb-1   YVQDH---------------------------SLHVCDLELSENVRLRPYQVASLERFRSGN---------KAHQGVIVLPCGAGKTLTG Tco-1  YLQDQ---------------------------SLHVCGLELSENVRLRPYQVASLERFRSGN---------KAHQGVIVLPCGAGKTLTG Tv-1   YNEDC---------------------------TLHVCDLELAGHARLRPYQVASLERFRSGN---------KAHQGIIVLPCGAGKTLTG Tc-1   YVQDG---------------------------TLDVRDLALAEHVRLRPYQVASLERFRCGN---------KAHQGVIVLPCGAGKTLTG Lm-1   YMQDH---------------------------TLYVPNLSLASHVRLRPYQVASLERFRRGR---------KAHQGVIVLPCGAGKTLTG Li-1   YMQDR---------------------------TLHVPNLNLASHVRLRPYQVASLERFCRGR---------KAHQGVIVLPCGAGKTLTG Lb-1   YVQDR---------------------------TLYVPNLTLARHVRLRPYQVASLERFRRGQ---------RAHQGVIVLPCGAGKTLTG Lmx-1  YMQDR---------------------------TLHVPNLHLASHVRLRPYQVASLERFRRGQ---------KAHQGVVVLPCGAGKTLTG Bs-1   YMRDL--------------------------QTPTVANFSLRLGVRLRPYQAASLERFRRDD---------KAHHGVVVLPCGAGKTLTG 
Tb-R   YEK--------------------------DTSIRNVNI-ALKSQTRPRPYQIAAVDAAASDG---------ALRSGCIVLPCGSGKTLVG Tco-2  YER--------------------------DTTIRNVNI-ALKAQTKPRPYQIDAVDAATADG---------SLRSGCIVLPCGAGKTLVG Tv-2*  YER--------------------------DMSIRSINI-MLKTQTKPRPYQIDAVDAAVSDG---------FLRSGCIVLPCGAGKTLVG Tc-2   YER--------------------------DSGVRNINV-MLKTQTKPRPYQIDAVNAAATEG---------SLRSGCIVLPCGAGKTLVG Lm-2   FEN--------------------------DTSVRTAHI-SLRTQTKPRRYQIEAVDAAIHDG---------TLNSGCLLLPCGAGKTLLG Li-2   FEN--------------------------DTSVRTAHI-SLRTQTKPRRYQIEAVDAAIHDG---------TLNSGCLLLPCGAGKTLLG Lb-2   FEN--------------------------DTSVRKAHI-SLRTQTKPRRYQIEAVDAAIHDG---------TLNSGCILLPCGAGKTLLG Lmx-2  FEK--------------------------DTSVRTAHI-SLRTQTKPRRYQIEAVDAAIHDG---------TLNSGCLLLPCGAGKTLLG Bs-2   FSASDDSVVHDDKGGADHVLNSAASRDHAANDVRSINL-VLRPQCRPRPYQIAAVEAALAHG-------GTAVRSGVLLLPCGAGKTLVG 
Ng-1   FRNDK--------------------------RNSSLVI-DLKPTTTIRSYQEKSLNKMFSNG---------RARSGIIVLPCGAGKTLVG Ng-2   ------------------------------------------------------------------------------------------ Trva-1 FMNDK--------------------------SLKNLNI-RLRTETNIRPYQEKALSKMFSGG---------RAKSGIIVLPCGAGKTLVG Trva-2 FMNDK--------------------------TIDNLGI-QLKNTTRIRPYQEKALTKMFSGG---------RSISGIIVLPCGAGKTLVG Gl     -----------------------------QVKAPQINA-QLKPTTDLRDYQDHASKKVISEVQLDTSQIVKRCNSGLVVLPCGAGKSLLG Ehis-1 FLRDK--------------------------QKE-LPI-QLR-KDCLRPHQERALQQIFDNE---------MARSGIVVLPCGAGKTLTA Ehis-2 I------------------------------GEKTIPI-ALKDDTVLRKYQISGISSVFRKG---------FAQSGIIILPCGAGKTLMT Edis-1 FLRDK--------------------------QKE-LPI-QLR-KDCLRPHQERALQQIFDNE---------MARSGIVVLPCGAGKTLTA Edis-2 I------------------------------GKKRINI-SLKDDTVLRTYQIKGINSVFKKG---------FAQSGIIILPCGSGKTLMS Dd     FRNDT--------------------------VNPNLNI-DLKPTTMIRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKSLSG Ac**   FLTNRWSEK----------------------ACANLAI-NLKEGTGVRPYQKRAAFSLFWDN---------KAHSSILVLPCGAGKTLVG Pf     FRRDK--------------------------KNPNLIC-SLKSHVQIRYYQEKALRKMFSNG---------RSRSGIIVLPCGVGKTLTG Toxg   FRRDK--------------------------TNKNLSSLLLKSSTKIRYYQERALRKMFSNG---------RARSGIIVLPCGAGKTLTG Eimt** ---------------------------------------------------------MFSNG---------RARSGIIVLPCGAGKTLTG Ta     FRKDN--------------------------NSPSLNC-CIRSNIKIRYYQERALRRMFSNG---------RARSGIIVLPCGAGKTLTG Tett-1 FENK---------------------------SFKQLEI-ELKPKIKVRYYQERALKNIFIQK---------KARSGLIILPCGAGKTIVG Tett-2 DDKESQNDLSSN----------------VQIPYKKLDI-ELRQITQPRIYQQKALKNIFVCE---------KPRSATIVLPCGAGKTLLG Part-1 FTKE---------------------------K-QKLDI-NLKPSTKPRLYQLRAAKTVIMGD---------YAKSGLIVLPCGAGKTLVG Part-2 YLKDLENTKQ-D----------------I--QKKLQQF-RMKAIYQLYSHQNRALKKIFQND---------KAHSGVIILPCGAGKTLLG At-1   FRNDN--------------------------VNPDLDM-ELKPHAQPRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKSLVG At-2   FRNDN--------------------------VNPDLDM-ELKPHAQPRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKSLVG Orys-1 FRNDT--------------------------VNPDLEM-ELKPQARPRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKSLVG Orys-2 FRNDT--------------------------VNPDLEM-ELKPQARPRPYQEKSLSKMFGNG---------RARSGIIVLPCGAGKSLVG                                  WM IA                                                                                             ****                                                                  Hs     VTAACTVRKRCLVLGNSAVSVEQWKAQFKMWSTIDD-----------------------------------SQICRFTSDAKDK-PIG-- Mm     VTAACTVRKRCLVLGNSAVSVEQWKAQFKMWSTIDD-----------------------------------SQICRFTSDAKDK-PIG-- Drer   VTAACTVRKRCLVLGNSSVSVEQWKAQFKMWSTIDD-----------------------------------SQICRFTSDAKDK-PIG-- Dm     VTACCTVRKRALVLCNSGVSVEQWKQQFKMWSTADD-----------------------------------SMICRFTSEAKDK-PMG-- Ce     VTAVTTVNKRCLVLANSNVSVEQWRAQFKLWSTIQD-----------------------------------KQLVRFTREAKDP-APSGA Sc     ITAACTIKKSVIVLCTSSVSVMQWRQQFLQWCTLQP-----------------------------------ENCAVFTSDNKEM-FQT-- Sp     ITAACTIKKSVIVLCTSSVSVMQWRQQFLQWSNIKP-----------------------------------DHIAVFTADHKER-FHS-- Ca     ITAACTIRKSVIVLCTSSVSVMQWRQQFLQWCTIQP-----------------------------------ENVAVFTSENKEM-FAS-- Nc     ITAACTIKKGVIVLCTSSMSVVQWRQEFLKWSNINP-----------------------------------DDIAVFTAESKNK-FSG-- 
Tb-1   IGAAATVKKRTIVMCINVMSVLQWQREFIRWTNLSE-----------------------------------DQVTVCIADKKQM------ Tco-1  IGAAATVKKRTIVMCINVMSVLQWQREFLRWTNLTE-----------------------------------EQVTVCISDKKQM------ Tv-1   IGAATIVKKRTIVMCINVMSVLQWQQEFVRWTNLTE-----------------------------------DQVTVCISDKKQM------ Tc-1   IGAATILKKRTIVMCINVISVLQWQREFFRWTDLSE-----------------------------------DQVTVCISDKKQM------ Lm-1   IGAAATMQTTTIVMCINHMSVFQWQREFLRWTNLAE-----------------------------------EEVTVCTAKVKQR------ Li-1   IGAAATMQTTTIVMCINNMSVFQWQREFLRWTDLAE-----------------------------------DEVTVCTAKVKQR------ Lb-1   IGAAATMQTTTIVMCINNMSVFQWKREFLRWTDLTE-----------------------------------DEVTVCTAKVKQR------ Lmx-1  IGAAATMQTTTIVMCINNMSVFQWQREFLRWTDLAE-----------------------------------DEVTVCTAKVKQR------ Bs-1   IAASSIVSKKTIVMCCNVLSVMQWRKEFLRWTDLRE-----------------------------------DQVTVCVRGMKQR------ 
Tb-R   IMLLCKVKKPTLILCAGGVSVEQWRNQILEFASVCAPANNEEGDPSNS-----T-----TGEKVRTAAVGAARISCLTGKQKDE-I---- Tco-2  VMLLCKVKKPTLILCTGGISVEQWRNQILEFASLSAPSGGEEGSSSTAC----A-----TSKRARPPAVGAARISCLTGKQKDE-I---- Tv-2*  IMLLCKVKKPTLILCAGSVSVEQWKNQILEFSTLGCSLGNDENRSSSGS---GT-----ASGRQRTRIEGVARISCLTAKQKDD-I---- Tc-2   IMLLCKVKKPTLILCAGSVSVEQWKNQILEFASICAHDTDDEM----------A-----AAEKHRSRLEGAARIACLTGKQKDP-V---- Lm-2   IMLMCKVKKPTLVLCAGSVSVEQWKSQILDYATLETPPRTDDGDASDAH-----------GGRPHQIKDGAARIACLTGKQKDP-I---- Li-2   IMLMCKVKKPTLVVCAGSVSVEQWKSQILDYATLEAPPPTDDGDAANAH-----------SGRSHQIKNGAARIACLTGKQKDP-I---- Lb-2   IMLMCKVKKPTLVVCAGSVSVEQWRSQILDYATLEAPPPTDNDDAADTQ-----------GGCSHQIKSGATRIACLTGKQKDP-I---- Lmx-2  IMLMCKVKKPTLVVCAGGVSVEQWKSQILDYAVLEAPPPTDDGDAADAH-----------GGRPHQIKNGAARIACLTGKQKDP-I---- Bs-2   VLLAAVVKKRTIIVCAGSISVEQWKNQLLEWADLTPLDEEDTATTHNIAARGGRGGGRGGSRGGQGRAVGGDRVACLTGKHKDP-I---- 
Ng-1   VTAASTIKKHTLVLCINTVSVFQWKNQFRLWSTIDD-----------------------------------DSILVHTSQQKAT-LPK-- Ng-2   -----SAVETFYLFEINPTECIEWKNQFKLWSTIDE-----------------------------------NRVVVFTSQEKDA-LPK-- Trva-1 ITAVATINKPAVVVCNSVEPVKQWANQFNLWTNVPG-----------------------------------GVVVVLTSENKQA-LP--- Trva-2 IAALATINKPTVIVCNNRLTVKQWYNQILQYATMDM-----------------------------------KKIFLFSDTEKQA-LPQ-- Gl     VACACRLGHSCIVVTNGNLSSKQWKSQFLQFSTVES-----------------------------------DRVYIFSANKDEETEFI-- Ehis-1 IAACSKIKRSTIVLTHTTQSVFQWKEEFLKWSTIKP-----------------------------------DAIKLCVSSKKEQ-LGD-- Ehis-2 IGIICTFQQPTIIICTTTISIEQWRDEIRKWSTIPL-----------------------------------NKIKCFSSIIKET------ Edis-1 IAACSKIKRSTIVLTHTTQSVFQWKEEFLKWSTIKP-----------------------------------DAIKLCVSSKKEQ-LGD-- Edis-2 IGIICKFQEPTIIICTTTISIEQWRDEIRKWTNIPL-----------------------------------NKIKCFSSIIKEE------ Dd     ITAACTVKKSILVLCTSAVSVEQWKYQFKLWSNIEE-----------------------------------RQISKFTSDNKEK-ISN-- Ac**   ITVSSIIKKCILVFCTSMMAVNQWREQFLKWSDIEP-----------------------------------SRISRFISDTRKKGEWD-- Pf     ITAASTIKKSALFLTTSAVAVEQWKKQFEDFTNIHP-----------------------------------RHIRILTSDYKLD-LWP-- Toxg   ITAACTLRKSVMILTTSAVAVDQWRKQFEEYTTIDS-----------------------------------SRLLTLTAETKQT-LWP-- Eimt** ITAVCTLQRSAVVLTTSAVAVEQWKRQFLENSSIKE-----------------------------------KEIMLLTAESKQQ-LWG-- Ta     IVAACTVRKSIFVLTTSAVAVEQWIKQFLDFTNISR-----------------------------------TNLISLTSEHKTD-LWD-- Tett-1 VIAIERIKQSTVIICDSDVSVDQWRDELERWTTINK-----------------------------------NKIVRLTGRIVDE--WPTR Tett-2 IIVTEKIKGNTIVICDIDTATKQWKNEFIRWTTVKP-----------------------------------DRIKIYTGKTKNL--QE-- Part-1 VLCMSLIKSSTVIICDSNVSVEQWKREIEGYTTIDN-----------------------------------RRIIRVTGFAKDK--WQG- Part-2 INVALKIKRKTLIICDQVNDVYQWQKSFIKFTEMDK-----------------------------------NNLAIILRTQQEV--PMAV At-1   VSAAARIKKSCLCLATNAVSVDQWAFQFKLWSTIRD-----------------------------------DQICRFTSDSKER-FRG-- At-2   VSAAARIKKSCLCLATNAVSVDQWAYQFKLWSTIKD-----------------------------------DQICRFTSDSKER-FRG-- Orys-1 VSAACRIKKSCLCLATNAVSVDQWAFQFKLWSTIKD-----------------------------------EHISRFTSDNKEK-FRG-- Orys-2 VSAACRIKKSCLCLATNAVSVDQWAFQFKLWSTIKD-----------------------------------EHISRFTSDNKEK-FRG--                     .        :*  .:                                                                
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WM II                                                                                             ****     Hs     ----CSVAISTYSMLGHTTKR----------------------------------------SWEAERVMEWLKTQEWGLMILDEVHTIPA Mm     ----CSVAISTYSMLGHTTKR----------------------------------------SWEAERVMEWLKTQEWGLMILDEVHTIPA Drer   ----CSVAISTYSMLGHTTKR----------------------------------------SWEAERVMEWMKSQEWGLIILDEVHTIPA Dm     ----CGILVTTYSMITHTQKR----------------------------------------SWEAEQTMRWLQEQEWGIMVLDEVHTIPA Ce     DATKPVVCISTYSMVAYSGRR----------------------------------------TLQAEEAMKFIEKQEWGLLLLDEVHTIPA Sc     ---ESGLVVSTYSMVANTRNR----------------------------------------SHDSQKVMDFLTGREWGFIILDEVHVVPA Sp     ---EAGVVVSTYSMVANTRNR----------------------------------------SYDSQKMMDFLTGREWGFILLDEVHVVPA Ca     ---ESGLVVSTYSMVANTRNR----------------------------------------SHDSQKVMDFLRSREWGFIILDEVHVVPA Nc     ---NTGIIVTTYSMVTNNRER----------------------------------------SHDSKKMMDFLKSREWGLMLLDEVHVVPA 
Tb-1   ---PGDVFITTYSMLIARRSNVPEM-EQSAD------------------------------AKLTAKILASVGEQPWGLLLLDEVHTALA Tco-1  ---PGDVFITTYSMLIAKRPNVSDQ-EQSAD------------------------------AKLTSKILASVSEQPWGLLLLDEVHTALA Tv-1   ---PGDVFITTYSMLIARRTSNLGQ-EQGED------------------------------AKLTSKILFAVEEQPWGLLLLDEVHTALA Tc-1   ---PGDVFITTYSMLVAKRPTAPEQ-EQGED------------------------------ARLTSRILASVEEQAWGLLLLDEVHAALA Lm-1   ---PGKVFITTYSMVVAKRGSADG-----AA------------------------------AEESRAILQVMTAQPWGLLLLDEVHTALA Li-1   ---PGKVFITTYSMVVAKRGSTDG-----AA------------------------------AEESRAILQAMTAQPWGLLLLDEVHTALA Lb-1   ---PGKVFITTYSMVIAKRGNADG-----AA------------------------------AEESRAILQAMAAQPWGLLLLDEVHTALA Lmx-1  ---PGKVFITTYSMVVAKRGNADG-----AA------------------------------AEESRAILQAMTAQPWGLLLLDEVHTALA Bs-1   ---PGDVFITTYSMLTAQRATRPADAVVTED------------------------------ALLTKEILSDIANSTWGMLLLDEVHIAPA 
Tb-R   -TDETDIVLTTYSMLVTAHKAQARCQVEGFE----------M------------NADGRGRNPRRANPKERLFQ-PYGLLIMDEVHMMPATco-2  -TDDTDIVLTTYNMLVTAHKMQRRQQCSSAG----------G------------ATGEQRAKTRRPNPKERLFQ-PYGLLIMDEVHVMPATv-2*  -TDDTDIVLTTYNMLVTAHKAQARYHAEHCK----------V------------AVDTQRKRGRRSNPKERLFQ-PYGLLIMDEVHVMPATc-2   -TEETDIVLTTYSMLVTAHRAQMRQRAAHAS----------G------------LADDRHQKRRRANPKEKLFQ-PYGLLIMDEVHVMPALm-2   -TEETDVVLTTYSMLVTAHRAKMRQQATTTS-------SEDG------------LFTGRGLRKRKENPKEKLFA-PYGLLILDEVHVMPALi-2   -TEETDVVLTTYSMLVTAHKAKMRQQATTTS-------SEDG------------LFTERGLRKRKENPKEKLFA-PYGLLILDEVHVMPALb-2   -TEETDVVLTTYSMLVTAHKAKLRQHATTTA-------GEDD------------LFTGRGLRKRKENPKEKLFA-PYGLLILDEVHVMPALmx-2  -TEETDVVLTTYSMLVTAHKAKMRQQATAIS-------SEDG------------LFTGRGLRKRKENPKEKLFA-PYGLLILDEVHVMPABs-2   -TEDTDVVITTYTMLGVAQEHYRREQQQRLERRKLQNRGEDDDDMTRRSCGAAPDRRSSAQSKRSRNPKEALFDTTWGLMILDEVHMAPA
Ng-1   DPNKAVVLITTYSMISFKGRR----------------------------------------SEESKQMMEYIENREWGLLMFDEVQVYPA Ng-2   DDD-PLIIITTYTMITHTRKR----------------------------------------SGEAKEVMDYIQSREWGLLILDEVHVVPA Trva-1 --DKPCILVTTYGMLTSSARR----------------------------------------SAESQKVIDQITGRDWGILVMDEVQEAAA Trva-2 --TGPCIVISTYSMLSNPNKR----------------------------------------SDKSQQIIDQIKSRDWGLLILDEVQDSAA Gl     -PGYHIVFISTYQMLTNAKSA------------------------------------------KSKETLNKVHSLMWGIVLFDEAHQVMA Ehis-1 ---DACVLITSYSMLSHTGER----------------------------------------EYAGQRIIDDLLKREWGFIIFDEVHGSTT Ehis-2 -IEESYIVITTYQMIQS-------------------------------------------------KEIEEIRKKKYGMMILDEVHSSVA Edis-1 ---DACVLITSYSMLSHTGER----------------------------------------EYAGQRIIDDLLKREWGFIIFDEVHGSTT Edis-2 -IX-XYIIITTYQMIQS-------------------------------------------------KEIEEINKKRYGMMILDEVHSSVA Dd     ---VAGVTITTYTMVAFGGRR----------------------------------------SAESLKIMNEITNREWGLVLLDEVHVVPA Ac**   --HTCGLLITTYNMFTS-EKR----------------------------------------AEHSTRMIEKCKERTWGLMILDEVHLAPA Pf     -INEAGVLISTYTMLSYSGKR----------------------------------------SEQSLRIVNDIRRREWGLLVFDEVQFAPA Toxg   -VDEAGVLVSTYTMLAFSGRR----------------------------------------SLAAERIMQQIREREWGLLIFDEVQFAPA Eimt** -PAAAGVLLSTYTMLAFSGRR----------------------------------------SAAAAAVLSQIQSREWGILIFDEVQFAPA Ta     -EKDAGVLISTYTMMSYTRKH----------------------------------------RENTERILNQIKQREWGMLIFDEVQFVPA Tett-1 TTDEPIIVITTYYMLVKKREDLPPT-----Q-------------I---------AQKS---K--KRQYIDSMKERKWGVCVIDEVHKLPA Tett-2 KQTKPFILITTFKQLSSIIKSNKLQKEKRQD-------------M---------DTSS---KYETKMDHYIQEEMEWDLCIADETQYSAA Part-1 --EQPIVILTTYSWLIAQFRNN----------------------------------SS---S--TKTVWNQISEVSWGICIVDEVHRLPA Part-2 LGREHIIVITNKDMISS-----------------------------------------------NRKDIKHVTTLEWPLLIMDEVHGLPA At-1   ---NAGVVVTTYNMVAFGGKR----------------------------------------SEESEKIIEEMRNREWGLLLMDEVHVVPA At-2   ---NAGVVVTTYNMIAFGGKR----------------------------------------SEEAEKIIEEMRNREWGLLLMDEVHVVPA Orys-1 ---MAGVVVTTYNMVAFGGKR----------------------------------------SEDSEKIIEEIRNREWGLLLMDEVHVVPA Orys-2 ---MAGVVVTTYNMVAFGGKR----------------------------------------SEDSEKIIEEIRNREWGLLLMDEVHVVPA : ::.   .                                                             : . : **.:   : 
WM III RED                                       ThM domain*****  ***                                       ************  * Hs     KMFRRVL----------TIVQAHCKLGLTATLVREDDKIVDLNFLIGPKLYEANWMELQNNGYIAKVQCAEVWCPMSPEFYREYVAI--K Mm     RMFRRVL----------TIVQAHCKLGLTATLVREDDKIVDLNFLIGPKLYEANWMELQNNGYIAKVQCAEVWCPMSPEFYREYVAI--K Drer   KMFRRVL----------TIVQAHCKLGLTATLVREDDKIVDLNFLIGPKLYEANWMELQNNGYIAKVQCAEVWCPMSPEFYREYVAI--K Dm     KMFRRVL----------TIVQSHCKLGLTATLLREDDKIADLNFLIGPKLYEANWLELQKKGYIARVQCAEVWCPMSPEFYREYLTT--K Ce     KMFRRVL----------TIVQAHCKLGLTATLVREDDKITDLNFLIGPKIYEANWMELQKAGHIAKVQCAEVWCPMTSAFYSYYLRS--Q Sc     AMFRRVV----------STIAAHAKLGLTATLVREDDKIGDLNFLIGPKLYEANWMELSQKGHIANVQCAEVWCPMTAEFYQEYLRE--T Sp     AMFRRVV----------TTIAAHTKLGLTATLVREDDKIDDLNFLIGPKMYEANWMDLAQKGHIAKVQCAEVWCAMTTEFYNEYLRE--N Ca     QMFRRVV----------TTIAAHAKLGLTATLVREDDKIDDLNFLIGPKLYEANWMDLAQKGHIANVQCAEVWCPMTAEFYQEYLRE--N Nc     DVFRRVI----------SSIKSHSKLGLTATLLREDDKISHLNFLIGPKLYEANWMELSEKGHIAKVQCAEVWCPMPTEFYDEYLRA--N 
Tb-1   HNFQEVL----------NKVKYKCVIGLSATLLREDDKIGDLRHLVGPKLYEANWLDLTRAGFLARVECAEIQCPLPKAFLTEYLESQSD Tco-1  HNFREVL----------NKVKFKCVVGLSATLLREDDKIGDLRHLVGPKLYEANWLDLTRAGFLARVECAEVQCPLPRPFLVAYLDNQKQ Tv-1   QNFQEVL----------NKVKYKCVVGLSATLLREDGRIDDLRHLVGPKLYEANWLDLTNAGFLARVECAEVQCPLPISFFSEYLIAQQE Tc-1   HHFQEVL----------NKVKYKCVVGLSATLLREDDKIGDLRHLVGPKLYEANWLELTRAGFLARVECAEVQCPLPLPFFREYLDSQAE Lm-1   HHFQDVL----------NTIKYKCVLGLSATLLREDDKIGDLRHLVGPKLYEANWLDLTRAGFLANVECAEVQCPMPPLFLQEYYGIQRT Li-1   HHFQDVL----------NTIKYKCVLGLSATLLREDDKIGDLRHLVGPKLYEANWLDLTCAGFLANVECAEVQCPMPPLFLQEYHDIQST Lb-1   HHFQDVL----------NTIKYKCVLGLSATLLREDDKIGDLRHLVGPKLYEANWLDLTRAGFLANVECAEVQCPMPPLFLQEYRDIQRT Lmx-1  HHFQDVL----------NTIKYKCVLGLSATLLREDDKIGDLRHLVGPKLYEANWLDLTRAGFLANVECAEVQCPMPPLFLEEYHAIQRT Bs-1   QRFQEVI----------NCVKHHCVLGLSATLLREDQRIDNLRFLVGPKLYEANWLELTNQGFLADVVCVDVRCPMPPAYLRMYLDPQST 
Tb-R   DAYKDSL----------GFINAKGVVGLTATYVREDSKIRDLFHLVGPKLFDISWERLASSGYLAHVTCIEVLTPLARRFSLEYLERSSE Tco-2  DVYKESL----------GYVNSKGVIGLTATYVREDAKIRDLFYLVGPKLFDMSWERLASSGYLANVTCVEVLTPLTRQFNLEYMERSGS Tv-2*  ETYKESL----------GFINAKGVIGLTATYVREDAKIRDLFHLVGPKLFDVSWETLASSGYLANVTCVEILTPLTRQFSLEYMERSSS Tc-2   EAYKESL----------SLVDAKGVVGLTATYVREDAKIQDLFHLVGPKLYDVSWETLASSGYLANVTCIEVLTPLTRQFSLEYMQRSGE Lm-2   ESFRGSL----------GFVDAKGVIGLTATYVREDHKILDLFHLVGPKLYDISMETLASQGYLAKVHCVEVRTPMTKEFGLEYMQRSSK Li-2   ESFRGSL----------GFVDAKGVIGLTATYVREDHKILDLFHLVGPKLYDISMETLASQGYLAKVHCVEVRTPMTKEFGLEYMHRSSK Lb-2   ESFRGSL----------GFIDAKGIVGLTATYVREDHKILDLFHLVGPKLYDISMEALASQGYLANVHCVEVRTPMTKEFGLEYMDHRRR Lmx-2  ESFRESL----------GFVDAKGVVGLTATYVREDHKILDLFHLVGPKLYDISMETLASQGYLSKVHCVEVRTPMTKEFGLEYMDRSSK Bs-2   AGVRESI----------SHVVSKAVVGLTATYVREDHRIRDTFHVVGPKLFDISWEELHQQGFLASITCVEVHCPMTPDFMVEYTQRLHT 
Ng-1   DSFRA------------SHLKAHCKLGLTATLLREDNKQEDLNFLIGPKLYEANWLDLQKKGHLANVQCVEVWCPMTAEFYAEYLSS--N Ng-2   NMFRHV-----------ASVKSHCKLGLTATLLREDNKTDDLYFLIGPKLYEANWLDLQQKGHLANVQCVEVWCPMTAEFFAEYLTA--N Trva-1 EKFRNVT----------DMVKAHTRLGLTATMVREDGKIDDLKYLVGPKLYEANWIELSESGYLARVKCFEILVTMSQEFYKKYLTLDKD Trva-2 NTFRNVT----------DIAKAHTRLGLTATLIREDDKISDLRYLVGPKLYEANWLELSEQGYLARVKCFEVTVPMTASFYKYYLLS--D Gl     ETYRTLFVTDNVNTKANLFLRSYCKIGLTATPLREDDEMTNL-YLLGNKLYESNWSDLAKRGFIAKLQCAEIRCPMHHIFYDDWLDQNTA Ehis-1 DNIEKFV----------CKIKAQCKLGLTATLIREDDRIRDLEFMIGPMLYEASWQELAKQGYIANAKCFEVICPMTKTYYSAYVEAD-D Ehis-2 KEFRKIY----------YLIEARCRIGITATPIREDCKIKDLDYLIGPILYQESWKELIKEKYIANVQCIDIKCPMTIPFYEEYINNS-N Edis-1 DNIEKFV----------CKIKAQCKLGLTATLIREDDRIRDLEFMIGPMLYEASWQELAKQGYIANAKCFEVICPMTKTYYSAYVEAD-D Edis-2 KEFRKIY----------YLIETRCKIGITATPIREDYKIKDLDYLIGPILYQENWKDLIKEKYIAKVQCIEIKCPMTIPFYEEYINNS-K Dd     AMFRKVL----------TVTKAHCKLGLTATLLREDEKIQDLNFLIGPKLYEANWLDLQKAGFLANVSCSEVWCPMTAEFYKEYLIND-S Ac**   TTFKRVT----------TEFRAHVKLGLTATMVREDELIAELPTLVGPRLDEVDLLSLKIHNHVANVHCYRIVCPLTSAFGAAYRTAR-S Pf     PSFRRIN----------DIVKSHCKLGLTATLVREDLLIRDLHWIIGPKLYEANWVELQNKGFLAKALCKEIWCSMPCSFYKYYLKS--N Toxg   PAFRRIN----------DLVKSHCRLGLTATLVREDDLIKDLQWLIGPKLFEANWIELQDQGFLARVSCQEVWCPMTADFYREYLRC--S Eimt** PAFRKIN----------ALVRAHCRLGLTATLVREDDLIKDLQWIIGPKLYEANWIDLQNQGYLAKVSCQEVWCPMTAEFYREYLRA--P Ta     PAFRRIN----------EIIRSHCKLGLTATLVREDDLIRDLQWLIGPKLYEANWLELQQKGYLAKVICKEIWCPMTAPFYREYLRS--S Tett-1 NTFQNVL----------KQYKFHFKLGLTATPYREDEKIINLFYMIGPKLYEENWYDLVSQGFLAKPYCVEIRCEMSQLWMSEYNKKDLK Tett-2 STYKKIF----------EEFNFKLKIGLTATPYREDNKIDDLFHVIGPKLYEANISELIQDSYLAKPYCVVFRCKMHECCEDFMKDR--- Part-1 VQFQNVL----------KQIKCAIKIGLTATLLREDQKLDNLYFMIGPKLYEENLIDLMTQGFLAKPHIIEIQCDMPPIFLQEYQTKNNM Part-2 EQINAEI----------SKLKANMKIGLTATPYRQDNKIKEIFYKVGPKLHESMIVDLKQMGYVSKIYCIQVYVGMQDLYKQKYEEYRRV At-1   HMFRKVI----------SITKSHCKLGLTATLVREDERITDLNFLIGPKLYEANWLDLVKGGFIANVQCAEVWCPMTKEFFAEYLKKE-N At-2   HMFRKVI----------SITKSHCKLGLTATLVREDEKITDLNFLIGPKLYEANWLDLVKGGFIANVQCAEVWCPMTKEFFAEYLKKE-N Orys-1 HMFRKVI----------SITKSHCKLGLTATLVREDERITDLNFLIGPKLYEANWLDLVKGGFIANVQCAEVWCPMTKEFFAEYLKKE-N Orys-2 HMFRKVI----------SITKSHCKLGLTATLVREDERITDLNFLIGPKLYEANWLDLVKGGFIANVQCAEVWCPMTKEFFAEYLKKE-N .                     :*::**  *:*    .    :*  : :     *    .::      .   :
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                                                                     ***********                   Hs     -------------------------------------------------------------TKKRILLYTMNPNKFRACQFLIKFHE-RR Mm     -------------------------------------------------------------TKKRILLYTMNPNKFRACQFLIKFHE-RR Drer   -------------------------------------------------------------TKKRILLYTMNPNKFRACQFLIRFHE-RR Dm     -------------------------------------------------------------TSKKMLLYVMNPSKFRSCQFLIKYHE-QR Ce     -------------------------------------------------------------IARKLLLAVMNPNKFRICQFLIKFHE-RR Sc     -------------------------------------------------------------ARKRMLLYIMNPTKFQACQFLIQYHE-RR Sp     -------------------------------------------------------------SRKRMLLYIMNPKKFQACQFLIDYHE-KR Ca     -------------------------------------------------------------ARKRMLLYIMNPTKFQACQFLIHYHE-KR Nc     -------------------------------------------------------------SRMKRTLYAMNPRKFQACQYLINYHE-AR 
Tb-1   GDPFA--------------------------------------------RRGT--------TRMAHSVVCLNPYKLWCTQALLEFHR-NR Tco-1  GDLST--------------------------------------------RRGT--------SPMARAVVCYNPYKLWCAQALLEFHR-NR Tv-1   EDPSA--------------------------------------------RRGT--------SSLARALVCLNPYKLWCTQALLEFHR-NR Tc-1   EDPFA--------------------------------------------RRGT--------SSLARAVVCFNPYKLWCTQALLEFHR-NR Lm-1   RALLGAHARRNHRGGCGGNGKRCRESVFQDDEDAGEDGDSDGEDNGARGGRGRGHDAYGPLTSRSLRLASCNPYKLWCAQALLAFHQ-QR Li-1   RALLGAHARLNHRGGRRGNGKRCRESVFQDDEDAGEDGDSDGEDNGARGGRGRGHDAYGSLTSRSLRLASCNPYKLWCTQALLAFHQ-QR Lb-1   RTLLGTHAHRSHSGSRAGNGKRRRESVFQDDEDAREDEDHDEENGGAYRGRGRGHDLCGYLPSRSLRLASCNPYKLWCTQALLAFHQ-QR Lmx-1  RALLGAHARCNHRR---GNGKRRRESVFQDDEDASEDGDGNGEDNGAYGRRGRGHDSCGPLTSRSLRLASCNPYKLWCTQALLAFHQ-QR Bs-1   DESLC-------------------------------------------------------------DISSVNPHKLWATQALLHFHG-SR 
Tb-R   L------------------------------------------------------TSPQHGTPLLVMLAAANPNKMLCVMEIVKRHV-AE Tco-2  GF-----------------------------------------------------TVQRRKVPLLVMLAAANPNKMLCVAELVQRHI-VE Tv-2*  DS-----------------------------------------------------TGAHRRIPLLVMLAAANPNKMLCVMELIRRHL-AE Tc-2   DH-----------------------------------------------------TLQQRKMPLLVMLAAANPNKMLCVLELVRRHV-AD Lm-2   V-------------------------------------------------------ARAGTAPVLVMLAAANPNKMMCVRELVRQHL-DA Li-2   T-------------------------------------------------------ARARTAPVLVMLAAANPNKMMCVRELVRQHL-DA Lb-2   A-------------------------------------------------------AGTSKTSVLVMLAAANPNKMMCVRELVWQHL-DV Lmx-2  A-------------------------------------------------------ARAGKAPALVMLAAANPNKMMCVRELVWQHL-DA Bs-2   SLSSRSNSSKSSSA-------------------------------------G---VSALAAAPMLQAIAASNPNKMLCVWELVHRHL-HQ 
Ng-1   -------------------------------------------------------------YAKQSLYYVMNPNKFRACEFLIRYHE-KH Ng-2   -------------------------------------------------------------AKKKTLLYVMNPNKFRACEFLIRYHE-KQ Trva-1 -------------------------------------------------------------PIKRRVLAASNPNKIDVLESLLQYHE-AR Trva-2 -------------------------------------------------------------HFRQRILCSSNPNKIRTVAGIIKFHE-RR Gl     QATNQ---DR--T-------TVCV------------------------------NDVMITRKTYMKYLTILNPYKVQTAWYLKEYHT-RR Ehis-1 -------------------------------------------------------------SKLKQCLAQLNPNKIDACKYLLEQHK-AH Ehis-2 -------------------------------------------------------------YRHKIILSALNPNKIEVTKFLIKQHL-KR Edis-1 -------------------------------------------------------------SKLKQCLAQLNPNKIDACKYLLEQHK-AH Edis-2 -------------------------------------------------------------YRHKIILTALNPNKIEVIKFLIKEHL-KR Dd     -------------------------------------------------------------QGKKKLLYTMNPNKFRACEYLIRFHE-QR Ac**   -------------------------------------------------------------PAEKRLLHITNPNKARIVFTLLKRHL-RR Pf     -------------------------------------------------------------SFIKRRLYTCNPRKLMMCEYLIKYHE-QN Toxg   -------------------------------------------------------------HAKQRKLWVCNPTKLMTCEWLLRYHE-AR Eimt** -------------------------------------------------------------YAKQRKLWVCNPSKLMVCEFLLKFHE-AK Ta     -------------------------------------------------------------SVKKRRLWSCNPVKLITCEYLLRFHE-SR Tett-1 TG------------------------------------------------------KNYYRGPQRELIHTSNPRKFKTLEYLIKVHE-ER Tett-2 ---------------------------------------------------------KF---KNKPSLQSGNPEKFKLLYYLIKFHE-SR Part-1 --------------------------------------------------------------TVRQLLHTGNPGKYKALQFLIKNHE-ML Part-2 NN-----------------------------------------------------------QFVTNTLYQMNPKKFEVLQSLINIHR-TR At-1   -------------------------------------------------------------SKKKQALYVMNPNKFRACEFLIRFHEQQR At-2   -------------------------------------------------------------SKKKQALYVMNPNKFRACEFLIRFHEQQR Orys-1 -------------------------------------------------------------SKKKQVLYAMNPNKFRACEFLIRFHEQQR Orys-2 -------------------------------------------------------------SKKKQVLYAMNPNKFRACEFLIRFHEQQR                                                                               ** *      :   *                                                         WM IV                                                                                             *******                                            Hs     ----NDKIIVFADNVFAL------KEYA--IRLNKPYIYGPTSQGERMQILQNFKHNPKINTIFISKVGD-------------------- Mm     ----NDKIIVFADNVFAL------KEYA--IRLNKPYIYGPTSQGERMQILQNFKHNPKINTIFISKVGD-------------------- Drer   ----NDKIIVFADNVFAL------KEYA--IRLNKPYIYGPTSQGERMQILQNFKHNPKINTIFISKVGD-------------------- Dm     ----GDKTIVFSDNVFAL------KHYA--IKMNKPFIYGPTSQNERIQILQNFKFNSKVNTIFVSKVAD-------------------- Ce     ----NDKIIVFSDNVFAL------KRYA--IEMQKPFLYGETSQNERMKILQNFQYNPRVNTIFVSKVAD-------------------- Sc     ----GDKIIVFSDNVYAL------QEYA--LKMGKPFIYGSTPQQERMNILQNFQYNDQINTIFLSKVGD-------------------- Sp     ----GDKIIVFSDNVYAL------RAYA--IKLGKYFIYGGTPQQERMRILENFQYNELVNTIFLSKVGD-------------------- Ca     ----GDKIIVFSDNVYAL------QEYA--LRLGKPFIYGSTPQQERMKILQNFQHNDQINTIFLSKVGD-------------------- Nc     ----GDKIIVFSDELYSL------KQYA--LKLNKVFIYGGTGQAERMQVLENFQHNPQVNTLFLSKIGD-------------------- 
Tb-1   --SPPDKVIIFCDQIDGI------QYYA--QHLHVPFMDGKTSDMERENLLQYFQHSDNINAIILSRVGD-------------------- Tco-1  --SPPDKVIIFCDQIDGV------QYYA--QHLNVPFMDGRTSDAERANLLQYFQHSSDINAIILSRVGD-------------------- Tv-1   --SPPDKVIIFCDDVEGV------QYYA--QHLHVPFMDGKTSDSERANVLQHFKNSSKTNAIILSRIGD-------------------- Tc-1   --SPPDKVIIFCDDLEGV------QYYA--RHLNVPFMDGKTTEVERENLLQYFQHSNDINAIILSRVGD-------------------- Lm-1   --SPPDKVIIFCDYLADV------RFFA--HHLHLPFMDQRTSEAERTNLLQYFQHSDGVNAIILTRVGD-------------------- Li-1   --SPPDKVIIFCDYLADV------RFFA--HHLHLPFMDRRTSEAERTNLLQYFQHSDSVNAIVLTRVGD-------------------- Lb-1   --SPPDKAIIFCDYLADV------RFFA--HHLHLPFMDQRTSEAERANLLQYFQHSNDVNAIILTRVGD-------------------- Lmx-1  --SPPDKVIIFCDYLSDV------RFFA--HHLHLPFMDQRTSEAERTNLLQYFQHSSGVNAIILTRVGD-------------------- Bs-1   --SPPDKTIIFCDSIPAL------QFYA--TQLCIPFMDGRTPEDERAKLLEYFKTSPNVNTIILSRVGD-------------------- 
Tb-R   ----SSKILVFCDHIMLL------KEYS--KLLGAPVVCGDTPHRERLMIFSDFQSTSKVNVVCLSRVGD-------------------- Tco-2  ----SSKILVFCDHIVLL------MEYG--KFLGAPVICGDTPHRERLMIFSDFQSTSKVNVICLSRVGD-------------------- Tv-2*  ----SSKILVFCDHIALL------KEYS--KVLNAPVICGETPHRERLMIFSDFQSTSKVNVICISRVGD-------------------- Tc-2   ----SSKILVFCDHLLLL------REYG--TLLHAPVICGQTPHRERLMIFSDFQSTSKLNVICLSRVGD-------------------- Lm-2   ----GAKILLCCDHIMLL------KEYG--ELLNAPVICGSTQHKERLMIFSDFQSTSKINVICVSRVGD-------------------- Li-2   ----GAKILLCCDHITLL------KEYG--ELLNAPVICGTTQHKERLMIFSDFQSTSKINVICVSRVGD-------------------- Lb-2   ----GAKILVCCDHIMLL------KEYG--ELLNAPVICGSTQHKERLMIFSDFQSTSKINVICVSRVGD-------------------- Lmx-2  ----GAKILLCCDHIMLL------KEYG--ELLNAPVICGSTQHKERLMIFSDFQSTSKINVICVSRVGD-------------------- Bs-2   QEHHTAKILVFCDHIALL------KEYA--KLLGAPLVHGETSHAERMAIFSEFQSTRRVNVICISRVGD-------------------- 
Ng-1   ----GDKIIVFSDNTFTL------EQYA--IKLKLPYIYGKTRESERLDVLNRFKS-GNFNTVFLSKVGD-------------------- Ng-2   ----GDKIIVFSDNVFAL------QEYA--EKLGVPYIFGNTKQQERVYYLNQFRNTNHYNTIFISKVGD-------------------- Trva-1 ----GDKILVFCDYLQII------EKLA--RRLDRPHLHGGISNNERTKLFNKFKTTKKVNTIILSKIGD-------------------- Trva-2 ----GDKVLVFCDIIHIL------IHLA--GLLHCPEIHGETPENVRSSIFHEFKNGSKVNTLILSSVGD-------------------- Gl     ----GDQVLLFCDTIMAA------KMYA--RMFDVPFIMGACSDDERECLVNAFA-TRTISCLMLSSVGD-------------------- Ehis-1 ----GDKIIIFCNELKPA------GFYKEKLKLQKCYMDGNTSEEHRRNLLDQFRR-DEISVIFCSKIGD-------------------- Ehis-2 ----NEQIILFCDSIIVL------KEIG--YQINCPIFFGESPNKERLDILNKFKL-KDINCIGMSSVGD-------------------- Edis-1 ----GDKIIIFCNELKPA------GFYKEKLKLQKCYMDGNTSEEHRRNLLDQFRR-DEISVIFCSKIGD-------------------- Edis-2 ----KEQIIIFCDSIIVL------KEIS--YQINCPIFFGESPNKERIDILNKFKL-KEINYIGMSSVGD-------------------- Dd     ----GDKIIVFSDNVYAL------QKYA--KGLGRYFIYGPTSGHERMSILSKFQHDPTVRTIFISKVGD-------------------- Ac**   ----GHKCLVFCDDLFGL------QWFS--QVLGSPYIDGETKNEDREKSLNMFRTTKSSAYVLISKVGD-------------------- Pf     ----NDKIIVFSDNIFAL------LHIA--KTLNKPFIYGKLSPIERIAIINKFKHDSSINTILLSKVGD-------------------- Toxg   ----GDKILVFSDNVFAL------LHTA--KALNRPFIYGQVSAVERVAILNKFKHESTFNSLFLSKVGD-------------------- Eimt** ----GDKIIVFSDNVFAL------LHAA--RALNRPFIYGKVCPPERMAILTKMKAPSTPF--FFRKSETMQLTFRAQTSSYKSPSTLLP Ta     ----GDKVIVFSDNLFAL------LHAA--KLLNRPFIYGKVSSAERIVILNKFKNETTFNTIFLSKVGD-------------------- Tett-1 ----GDKILVFCDRPMII------DYYG--NILKYPVIYGDVSQDERKKIFNLFKVSNQINTIFLSRVGD-------------------- Tett-2 ----KDKILVFCDQIPVL------KYYS--QKMGYPAIYGEVGLLEKLVWLDLFR-KGEINTLFLSRVGD-------------------- Part-1 ----GHKIIVFCDSLLIL------NYYA--LLLGYPVIDGDLNTDEKNKIFSIFKNSNEIKTIFVSRVGD-------------------- Part-2 ----KDKILVFCEKVNKLADTGTLEKFA--KLNNCPIISQKVEQTERSAIYKLYQ-EDKLDVIIFGQIAD-------------------- At-1   ----GDKIIVFADNLFAL------TEYA--MKLRKPMIYGATSHIERTKILEAFKTSKDVNTVFLSKVGD-------------------- At-2   ----GDKIIVFADNLFAL------TEYA--MKLRKPMIYGATSHIERTKILEAFKTSKTVNTVFLSKVGD-------------------- Orys-1 ----GDKIIVFADNLFAL------TSYA--MKLRKPMIYGSTSHVERTRILHQFKNSSDVNTIFLSKVGD-------------------- Orys-2 ----GDKIIVFADNLFAL------TSYA--MKLRKPMIYGSTSHVERTRILHQFKNSSDVNTIFLSKVGD--------------------              : :: .:                        .        :                                           
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                                WM V                                           WM VI                                              *********                                      ********           Hs     -----------------------TSFDLPEANVL------------------------IQISSHGGSRRQEAQRLGRVLRAKKGMV---- Mm     -----------------------TSFDLPEANVL------------------------IQISSHGGSRRQEAQRLGRVLRAKKGMV---- Drer   -----------------------TSFDLPEANVL------------------------IQISSHGGSRRQEAQRLGRVLRAKKGMV---- Dm     -----------------------TSFDLPEANVL------------------------IQISSHGGSRRQEAQRLGRILRAKKGAI---- Ce     -----------------------TSFDLPEANVL------------------------IQISAHGGSRRQEAQRLGRILRAKKHS----- Sc     -----------------------TSIDLPEATCL------------------------IQISSHYGSRRQEAQRLGRILRAKRRN----- Sp     -----------------------TSIDLPEATCL------------------------IQISSHYGSRRQEAQRLGRILRAKRRN----- Ca     -----------------------TSIDLPEATCL------------------------IQISSHYGSRRQEAQRLGRILRAKRRN----- Nc     -----------------------TSLDLPEATCL------------------------IQISSHFGSRRQEAQRLGRILRAKRRN----- 
Tb-1   -----------------------VALDIPCASVV------------------------IQISGLGASRRQEAQRLGRILRPKPAS----- Tco-1  -----------------------VALDIPCASVV------------------------IQISGLGASRRQEAQRLGRILRPKPPS----- Tv-1   -----------------------VALDIPCASVV------------------------IQISGLGASRRQEAQRLGRILRPKPPS----- Tc-1   -----------------------VALDIPCASVI------------------------IQVSGLGASRRQEAQRLGRILRPKPPS----- Lm-1   -----------------------VALDLPCASVV------------------------IQVSGLGASRRQEAQRLGRILRPKPPS----- Li-1   -----------------------VALDLPCASVV------------------------IQVSGLGASRRQEAQRLGRILRPKPPS----- Lb-1   -----------------------VALDLPCASVV------------------------IQVSGLGASRRQEAQRLGRILRPKPPS----- Lmx-1  -----------------------VALDLPCASVV------------------------IQVSGLGASRRQEAQRLGRILRPKPLS----- Bs-1   -----------------------IALDIPEASVI------------------------IQLSGLGASRRQEAQRLGRILRPKPAS----- 
Tb-R   -----------------------VSVNLPSANVV------------------------VQVSSHGGSRRQEAQRLGRILRPKEKAS---- Tco-2  -----------------------VSVNLPSANVV------------------------IQVSSHGGSRRQEAQRLGRILRPKAKAG---- Tv-2*  -----------------------VTVNLP------------------------------------------------------------- Tc-2   -----------------------VSVNLPSANVV------------------------IQVSSHGGSRRQEAQRLGRILRPKARAS---- Lm-2   -----------------------VSVNLPNANIV------------------------IQVSSHGGSRRQEAQRLGRILRPKERAA---- Li-2   -----------------------VSVNLPNANVV------------------------IQVSSHGGSRRQEAQRLGRILRPKERAA---- Lb-2   -----------------------VSVNLPNANVV------------------------IQVSSHGGSRRQEAQRLGRILRPKERAA---- Lmx-2  -----------------------VSVNLPNANVV------------------------IQVSSHGGSRRQEAQRLGRILRPKERAA---- Bs-2   -----------------------VSVNLPCANVV------------------------IQVSSHGGSRRQEAQRLGRILRPKQQND---- 
Ng-1   -----------------------TAIDIPEATVI------------------------IQISSHFGSRRQEAQRLGRILRPKNGT----- Ng-2   -----------------------TAIDIPEATVI------------------------IQISSHFGSRRQEAQRLGRILRPKGGG----- Trva-1 -----------------------KAIDLPSANVL------------------------IQLCSHFGARMQESQRLGRVLRPKPGR----- Trva-2 -----------------------KAIDLPSASVV------------------------VQVCSNYGARMQESQRLGRVLRPKSGN----- Gl     -----------------------TSLDLPDANVI------------------------IELDWQERSRRQEAQRMGRISRPKSGD----- Ehis-1 -----------------------VGLDLPDASVA------------------------IQLSSSSGSRRQEAQRLGRILRAKDGT----- Ehis-2 -----------------------TSLDIPDASVI------------------------IQISTNNGSRKQQLQRLGRISRIKKNE----- Edis-1 -----------------------VGLDLPDASVA------------------------IQLSSSSGSRRQEAQRLGRILRAKDGT----- Edis-2 -----------------------TSIDIPDASVI------------------------IQISTNNGSRKQQLQRLGRISRIKKNE----- Dd     -----------------------TSIDIPEATVI------------------------IQVSSHYGSRRQEAQRLGRILRPKPKS----- Ac**   -----------------------HSIDLPEANVV------------------------IQVGVVDGSRMQEAQRLGRVQRKKPGA----- Pf     -----------------------NAIDIPIANVV------------------------IQISFNFASRRQEAQRLGRIIRPKNKANEKKN Toxg   -----------------------NAIDIPCANVV------------------------IQISFNFASRRQEAQRLGRILRAKPQAGDE-- Eimt** GQQQQQQHSSSSSTSSTAAAAAPARVAAPAARAAVALEGVAAGLAPKNEQEHHHQQQQQQQQQQQRGVRQEAQRLGRILRAKPRGAEE-- Ta     -----------------------NALDIPCANVV------------------------IQISFNFASRRQEAQRLGRILRPKSKTDEH-- Tett-1 -----------------------TAIDLPQANVG------------------------IQIGMHFKSRRQEVQRLGRIMRAKENY----- Tett-2 -----------------------TALDLPIANVC------------------------IQIGFQFGSRRQEVQRLGRIMRRKEGQ----- Part-1 -----------------------TGIDIPSASVG------------------------IEIGYLGGSRRQKVQRLGRVMRPKQNT----- Part-2 -----------------------QGLDLPSANVG------------------------IQISFNFKSVRQEFQRMGRIQRKKENQ----- At-1   -----------------------NSIDIPEANVI------------------------IQISSHAGSRRQEAQRLGRILRAKGKLEDRMA At-2   -----------------------NSIDIPEANVI------------------------IQISSHAGSRRQEAQRLGRILRAKGKLEDRMA Orys-1 -----------------------NSIDIPEANVI------------------------IQISSHAGSRRQEAQRLGRILRAKGKHQDRMA Orys-2 -----------------------NSIDIPEANVI------------------------IQISSHAGSRRQEAQRLGRILRAKGKHQDRMA                                 .  *                                                                                 XPB signature                                                                                     ****************                                                                    Hs     --AEEYNAFFYSLVSQDTQEMAYSTKRQRFLVD-QGYSFKVITKLAGMEE--------E-----------------D-----------LA Mm     --AEEYNAFFYSLVSQDTQEMAYSTKRQRFLVD-QGYSFKVITKLAGMEE--------E-----------------E-----------LA Drer   --AEEYNAYFYSLVSQDTQEMAYSTKRQRFLVD-QGYSFKVITKLAGMEE--------E-----------------D-----------LM Dm     --AEEYNAFFYTLVSQDTMEMSYSRKRQRFLVN-QGYSYKVITHLKGMDTD-------S-----------------D-----------LM Ce     --TDQFNAFFYSLVSQDTVEMGYSRKRQRFLVN-QGYAYKVVNNLPGMEL--------E-----------------D-----------LK Sc     --DEGFNAFFYSLVSKDTQEMYYSTKRQAFLVD-QGYAFKVITHLHGMENI-------P-----------------N-----------LA Sp     --DEGFNAFFYSLVSKDTQEMYYSSKRQAFLID-QGYAFKVITNLKGMENL-------P-----------------N-----------LA Ca     --DEGFNAFFYSLVSKDTQEMYYSTKRQAFLVD-QGYAFKVITHLSGMEQL-------P-----------------D-----------LA Nc     --DVGFNAFFYSLVSKDTQEMYYSSKRQAFLVD-QGYAFKVITQLANIENT-------P-----------------D-----------LA 
Tb-1   --LDNVCSYFYTLVSQDTHEISQSYERQSWLRD-QGFSYRVLQSDMVLQHFL-------------------------RTGGKLCCVGPPR Tco-1  --LDNSCSFFYTLVSQDTHEISQSYSRQSWLRD-QGFSYRVLQSDTVLQHFQ-------------------------KTGGRLCCVGHPK Tv-1   --LDSSCSYFYTLVSQDTYEMSQSYERQSWLRD-QGFSYRVLQCETVFGHLL-------------------------RTGGKPCCVGAPR Tc-1   --LDNTCSYFYTLVSQDTHEVQQSYGRQSWLRD-QGFAYRVLQCDSLLKELR-------------------------RTGGKPCCVGHPQ Lm-1   --LDNTCAYFYTLVSQDTADVSTSYKRQSWLRD-QGFAYRILHCDRVLSEFA-------------------------RVGGQPCCVGPPQ Li-1   --LDNTCAYFYTLVSQDTADVSTSYKRQSWLRD-QGFAYRILHCDRVLSEFA-------------------------RVGGQPCCVGPPQ Lb-1   --LDNTCAYFYTLVSQDTADVSTSYKRQSWLRD-QGFAYRILHCDRVLHEFV-------------------------RVGGRLCCVGPPQ Lmx-1  --LDNTCAYFYTLVSQDTADVSTSYKRQSWLRD-QGFAYRILHCDRVLSEFA-------------------------RVGGQPCCVGPPQ Bs-1   --VDSTTAYFYTLVSEDTDESRNAFGRQEWLRD-QGFAYRMMSFRDILQHYAPNSKMFLDNGQGRAPSTMQPSNDCNRRRSRLLCVGPPK 
Tb-R   -NGKPTDAWFYTVISTDTVEMSYAAHRTAFLVD-QGYTCSVTEFNPDGAPEAA------------------------------------- Tco-2  -NGKAVDAWFYSVISTDTVEMSFAARRTAFLVD-QGYTCRVMEFYPDDVAQTA------------------------------------- Tv-2*  ------------------------------------------------------------------------------------------ Tc-2   -NGKMVDAWFYTIISTDTLEMAYAAHRTAFLVD-QGYTCRIIEFQPDELSNDE------------------------------------- Lm-2   -NGRTVDAWFYSIISTDTVEINYAAHRTAFLVD-QGYTCRIMEYSPFTSSVDT------------------------------------- Li-2   -NGRTVDAWFYSIISIDTVEMNYAAHRTAFLVD-QGYTCRVMEYNPFTSSVDT------------------------------------- Lb-2   -NGRAVDAWFYSIISMDTIEMNYAAHRTAFLVD-QGYACRVMEYIPFESSANT------------------------------------- Lmx-2  -NGRTVDAWFYSIISMDTVEMNYAAHRTAFLVD-QGYACRVMEYNPFASSVNT------------------------------------- Bs-2   -SAGPVDAFFYSLISRDTMEVAYAAHRSEFLVD-QGYRCRFIVFEPPPPVHENDEEEEG-----------------NTTGGGGAVVVVAA 
Ng-1   ----NKQAYFYSLVSQDTKEMFFATKRQQFLTN-QGYSFRVLADIQKYYSSNRVE---------------------T-----------KF Ng-2   --LKNQQAYFYTLVSQDTQEMFFSTKRQQFLIN-QGYSFRVLPDIQKYYRQGANEMGLT-----------------L-----------KH Trva-1 --TDEYNAFFYTLVSQDTEEIYYSAKRQQFLVD-QGYSYEPVVNAMERWPN------SA-----------------P-----------LS Trva-2 --REEFNAFFYSCISDMTTDLKYSARRQQFLVD-QGYVYEPVSDARERWPW------PE-----------------D-----------LL Gl     -----QNAYFYILVSEDTNEQHTAAERRTYLSYNQGYPYSIMNCKEIWETCNLSEL----------------FNDCE--------FTRFD Ehis-1 -----NSAYFYTLTSKDTREMYFSQRRQRVMRQ-NGYTFKVIDSAVIKPLR-------------------------K-----------ED Ehis-2 -----RIGYFYTLTSIDTHEEYFIHKKQIYMQN-LGFGFECINSTIITHMN--------------------------------------- Edis-1 -----NSAYFYTLTSKDTREMYFSQRRQRVMRQ-NGYTFKVIDSAVIKPLR-------------------------K-----------ED Edis-2 -----GIGYFYTLTSIDTHEEYFIYKRQIYMEN-LGFEFENIISKLITNMN--------------------------------------- Dd     --DGLYNAFFYSLVSKDTQEMYYSTKRQQFLID-QGYSFKVISELPGIDQE-------V-----------------N-----------LK Ac**   ----DVSAYFYTIVSEGTDEVGYSDRRREFMEE-HGYLYHEYDYKHFMHAE-------------------------T-----------EE Pf     --INDPDSFFYSLVSKDTIEMCYSDKRQRFLIN-QGYAYNVLSDNIVDFNK-------L-----------------N-----------LV Toxg   --GENFNAFFYSLISKDTLEMVYADKRQQFIID-QGYAYKVIHSRDLPMQP-------D-----------------K-----------LI Eimt** --DGGFNAYFYSLISKDTLEMVYADKRQQFIID-QGYSYKVLHCRDLPLQQ-------Q-----------------T-----------LV Ta     ----GFNAFFYSLVSKDTQEMVFADKRQQFIID-QGYAYNVTSFSTIVKDT-------S-----------------N-----------LL Tett-1 --DGQYNAFWYTLVSKGTDETSYCLARQKCLIN-QGFKYEIIDEKDLPYSQNPQK---------------------------------FK Tett-2 --KGEYNAFFYTIVSKNTEQAQFYYRRQKSLMD-LGINFEVIDIDE----QNGNK---------------------------------FK Part-1 --NHEIQAFFYSLASKDTTESEYSYKRQKYITEQLGLNTELILEGDLPYNKNPQK---------------------------------YK Part-2 --IGEYDCFFYSIVTKGTREVEIQFERQIAVIN-QGYPYEIISADELKPPQSEAD---K-----------------K-----------LQ At-1   GGKEEYNAFFYSLVSTDTQEMYYSTKRQQFLID-QGYSFKVITSLPPPDAG-------S-----------------S-----------LS At-2   GGKEEYNAFFYSLVSTDTQEMYYSTKRQQFLID-QGYSFKVITSLPPPDAG-------S-----------------S-----------LG Orys-1 GGKEEYNAFFYSLVSTDTQEMYYSTKRQQFLID-QGYSFKVITSLPPPEEL-------P-----------------N-----------LK Orys-2 GGKEEYNAFFYSLVSTDTQEMYYSTKRQQFLID-QGYSFKVITSLPPPEEL-------P-----------------N-----------LK  
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Tb-R   ----------------------------VEG-VDDTAPGDVVSIRQAKLRGTFKK-QELKCS-------------VA-----SP-TAQGS Tco-2  -----------------------------PEVAEEPVMGDVVSIKQERLRGDFSK-QRLKCS-------------SP-----SS-AIRGN Tv-2*  ------------------------------------------------------------------------------------------ Tc-2   ----------------------------TDDVAVAAEAGDAVSLKQEKLRSALRE-KKLQCE-------------SL-----T--VPQGS Lm-2   ------------------------ALGGVKQQVKKHRIGDVVSIKQESLYETLHQ-SSVLRPRSGE--------CSG-----RD-ADAGD Li-2   ------------------------ALGGVKQQVKKHRIGDVVSIKQESLYETLHH-SSVLQPRSGE--------RSG-----RG-ADAGD Lb-2   ------------------------SLGRMKQLAKKERVGDAVSIKQEFLYETVHQ-SSVLWSRAAE--------RSG-----HG-AGADD Lmx-2  ------------------------ALGGVKEQVKKHRVGDVVSIKQESLYETLHQ-SSVLRPRSGE--------RSG-----CG-ADAGD Bs-2   YGEA-------SE-KNV---KRETNHGGEHSSPHNGRTGDAATVKRETLMNDVNH-ERRLVFGASETTRIAHANHSTFGGG-GGAPHTSI 
Ng-1   MKTK-------EDELEF---LKLV-KNAKDVNG----KLEDI--------PNDDF-QS-------------------------------- Ng-2   MNTK-------KEELDM---LAIV-KKAEDARG----QEEKI--------NVDDE-VE-------------------------------- Trva-1 LDTQ-------EKREDW---LRQM-MDTDDSLG----LDADA--------TVPDE-DRS---FD--------------VPQGGGQR---- Trva-2 SD-E-------KSEEEW---LRKM-LKVEKIQS----EETEY--------ESYSS-D-E---YE-------ESQ-SDYIDTIGKSA---- Gl     TWKKVRIFYDDVRQAAIEQKLSE------------------------------------------------------------------- Ehis-1 PAKE-------GKDINY---VTEM-LKKKDEKG----VKEVV--------KKTKK-KT-------------------------------- Ehis-2 ---T-------NEQLNL---IKYI-LNESDKRYFNSKSKKES--------IID---F--------------------------------- Edis-1 PAKE-------GKDINY---VTEM-LKKKDEKG----VKEIV--------KKTKK-KTFLN----------------------------- Edis-2 ---I-------NEQLNL---IKYI-LNESDKRYFNSKSKKEI--------NIN---D-----F--------------------------- Dd     YSSK-------QDQLDL---LAQV-LGEGEDSG----KNEIL--------EE----DF----DDITRG---------------------- Ac**   FTRD-------SKQDNL---LAAI-RQEMEKNPEGRSEYSEL--------DDKPT-KRETKKKGTTRQRLNK----IVNKRTGGREARE- Pf     YKNK-------KIQENL---LKCI-LASTDDGN----MDEDD--------DLFED-----QSFKKDNTKVNKTN-SNIL----------L Toxg   YGDP-------QRQREI---LTDI-LASDDNDK----TLDDD--------EDDPS-RQVLSAVAGDRGRFFRVN-SNLGDGWGGSEECQL Eimt** YGDR-------DRQQAL---LRDI-LLSDDLDK----SLDED--------EDEGA-YLPQQQEQQ------------------------- Ta     YSKP-------SIQQEL---LQDI-ITSAEDVD----DEEE----------VNPT-----DLFTPTNE----SS-LQVS----------- Tett-1 WMSQ-------LDESDY---LYTL-LMNSEQNQQNGK----MSS------EEESSSGDSSGSDSEESEG--------------------- Tett-2 YDPD-------ILDQKI---IR-----ASDEIIKDVKKDAWFLI------QDQPDKKV-DEQDDD------------------------- Part-1 YIKQ-------MNEMDL---LEQI-MLSSNDLTNKVI----DQI------EEEVQ--VVTNTFSQEFGG--------------------- Part-2 LDKI-------VDEM-----------------QRKVL-------------ETCTQ----KGDDDREEDG--------------------- At-1   YHSQ-------EEQLSL---LGKV-MNAGDDLV----GLEQL--------EE----DT----DGMA------------------------ At-2   YHSQ-------EEQLSL---LGKV-LNAGDDMV----GLEQL--------EE----DT----DGKA------------------------ Orys-1 YYTL-------NDQLEL---LAQL-LSARDDMI----GIEHL--------EE----DS----DGKA------------------------ Orys-2 YYTL-------NDQLEL---LAQS-LSARDDMI----GIEHL--------EE----DS----DGKA------------------------ 
Hs     -------------SQA-SRRFGTM-SSMSGAD-DTVYMEYHSSRSKA--P---------------------------------------- Mm     -------------GQA-SRRCGTM-SSLSGAD-DTVYMEYHSSRSKA--S---------------------------------------- Drer   --------------QF-SRRAGTM-SSMSGAD-DALYMEYQMPRGSKASV---------------------------------------- Dm     ----------SGSGGA-VRRVGGL-SSMSGGD-DAIYYEHRKK------N---------------------------------------- Ce     -----------GTIRI-SRREATM-ASMSGGQ-GAQYHSK-------AKA---------------------------------------- Sc     --------HKRFKSKA-VRGEGSL-SGLAGGE-DMAYMEYSTNKNKELKE---------------------------------------- Sp     --------LSRAPAKA-KRSSGSL-STLAGAD-NMAYVEYNKSANKQLKK---------------------------------------- Ca     ----MRLEQERNGGGA-TYSSGSL-AGLAGGE-DMAYIEYGKNKNKELRE---------------------------------------- Nc     ----RG-GAKGRAAAV-RRMAGTL-GELSGGQ-DMAYIEQNKAANKGLKK---------------------------------------- 
Tb-1   TATVLR-----DTPRPPE--LKN--MGVEEKW-TVCFSDSCAPETFGTVQLV-----------------EG------------------- Tco-1  TSSVLG-----DTPRPEG--LRD--SGVEERW-TVRFSDSNAPETFGTVQVS-----------------EG------------------- Tv-1   DGSVLV-----GTPRPEG--LGG--SSLEDSW-TVRFSDSNAPETFGIVQFV-----------------KE------------------- Tc-1   DSTVLN-----DTPRTAE--LAV--SGLGEKW-IVRFSASNAPETFGTVQMA-----------------ED------------------- Lm-1   RGSELG----RGTPRPSSEELGRYPLLSFESW-KVTFSSVDAPQTFGTVLIG-----------------EG------------------- Li-1   RGGELG----RGTPRPSSEELGRYPLLSSESW-KVTFSSVDAPRTFGTVLIG-----------------EG------------------- Lb-1   RGSDLG----RDTPRPSSEELGRYPLLSTESW-KVTFSSADAPQTFGTVLIG-----------------EG------------------- Lmx-1  RGSELG----RGTPLPSSEELGRYPLLSSESW-KVTFSSVDAPQTFGTVLIG-----------------EG------------------- Bs-1   RVSHAL----PSSSQRGSAALTLR--PGQLTL-RVTFSSADAPITFGTVQCFS--------------VAEG------------------- 
Tb-R   ----------VNPRSL-DYQEKLL-CRVVASW-ELDYQN---ATSQQNEPGVANDTATG------------------------LID---- Tco-2  ----------INVRSA-QYQLDLL-ARVVSNW-EMDYHN---AVSTQKGSGKSEGLQRG------------------------DLK---- Tv-2*  ------------------------------------------------------------------------------------------ Tc-2   ----------VDARKI-EYQLDLL-SRVVSNW-ELEYHS---QGLKQASSGHDGFPPDD------------------------DANVSE- Lm-2   ----------CRAESL-SYQLKLL-SKVVSSW-EIEFQQ---ECRKRRRTAVRDADDNA------------------------ANETDS- Li-2   ----------CRTESL-SYQLELL-SKVVSSW-EIEFQQ---ECRKRRRTAVRDADDNA------------------------ANETES- Lb-2   ----------RRTESL-SYQLGLL-SKVVSSW-EMEFQQ---ECRKRRRTAAEDVAENA------------------------T---DD- Lmx-2  ----------CRTESL-SYQLELL-SKVVSSW-EIEFQQ---ECRKRRRTAVRDADDNA------------------------ADETGS- Bs-2   ----------VDVGRR-KWQLRLL-ASMVGRW-ELQYLQ---ATSRGAVSAKTNARRTNQKGNRRNNQDEGNESESSVSSSSGSSDADNG 
Ng-1   --------------GS-HSGDTSL-ALLSGGANEVYYHTFEASNSSKK----------------------------------------KK Ng-2   --------------KS----SSSL-ASI-SGGNEIYYHSYEASTTTSRRRGK------------------------------------AT Trva-1 -------NQFKAIVK--------------------------------------------------------------------------- Trva-2 -------PHFSLLN---------------------------------------------------------------------------- Gl     ------------------------------------------------------------------------------------------ Ehis-1 ------------------------------------------------------------------------------------------ Ehis-2 ------------------------------------------------------------------------------------------ Edis-1 ------------------------------------------------------------------------------------------ Edis-2 ------------------------------------------------------------------------------------------ Dd     ----AKKSKSSAPTVS-RTTGGST-RALSGGN-DMNYMEYQAPAIYK------------------------------------------- Ac**   ------------------------------------------------------------------------------------------ Pf     ------NKKEDSLKKI-DNTTGGL-LKLSSNM-DVTFADKKKIP---------------------------------------------T Toxg   ESFGESLRGFGDAPHV-QPLQGGL-GRLAGDG-GAAYGARPGGRGGGRSGRS------------------------------------GG Eimt** --QQQQQQQHEQQPNV-RVVQGGL-AGISGKP-STHSFASP------------------------------------------------- Ta     ---------------I-SQKKTGL-ASLSGSL-KNQLQYKHLLPPS-EKPAK------------------------------------KS Tett-1 --------HFNITTKA-ANPLQNL-ALYKETQ----LNKY-------------------------------------------------- Tett-2 ------------------------------------------------------------------------------------------ Part-1 --------VYKFQ----------------------------------------------------------------------------- Part-2 --------Y--------------------------------------------------------------------------------- At-1   ------------LQKA-RRSMGSM-SVMSGSK-GMVYMEYNSGRHKSGQQFK------------------------------------KP At-2   ------------LK-T-RRSMGSM-SAMSGAN-GRVYMEYNSGRQKSGNQSK------------------------------------KP Orys-1 ------------LMKA-RRSAGSM-SAFSGSG-GMVYMEYSTGKGKAGA-SK------------------------------------KP Orys-2 ------------LMKA-RRSAGSM-SAFSGSG-GMVYMEYSTGKGKAGA-SK------------------------------------KP 
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Hs     --SKHVHPLFKRFRK--------------------------------------------------------------------- Mm     --SKHVHPLFKRFRK--------------------------------------------------------------------- Drer   --GKNIHPLFKRFRK--------------------------------------------------------------------- Dm     --IGSVHPLFKKFRG--------------------------------------------------------------------- Ce     --IAERHPLFKRFRQ--------------------------------------------------------------------- Sc     -----HHPLIRKMYYKNLKK---------------------------------------------------------------- Sp     -DSKEHHALFRKHLYTKRR-----------------------------------------------------------------Ca     ----SHHPLIQKMYYKQNKAKK--------------------------------------------------------------Nc     -KGAAKA--EQSAFFKKLQREKERSRAL-----------ARQG-----------------------------------------
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Tb-R   ---------------KKMKRARDETAEDIKREWNSGAQTTQPRG-----------DFCRLPLQR------LVGANDDVVYHES- Tco-2  ---------------KEVKAGVSDSPEAIKREWAPRAAAQNQGA-----------ALYRTSLQD------LVGVSDDFIYHEL- Tv-2*  ------------------------------------------------------------------------------------ Tc-2   -------------GRDVMEIVPDSDLAAIKREWAGGTRMDQFQF-----------GHSCTSLQG------LVSVDENFVYHEL- Lm-2   -------------ADDVVEVRPIRTYAAIKSEWRGGADSAA----------------RVTALRD------LVGVDDGFVYHEL- Li-2   -------------ADDVVEARPIRTYAAIKSEWRSGADSAA----------------RVTALRD------LVGVDDGFVYHEL- Lb-2   -------------ADGVTEARSMRTYATIKNEWRVSGDHET----------------RATALHN------LVGVDDGFVYHEL- Lmx-2  -------------ADDVVEARPIRTYAAIKSEWRGGADSAN----------------RVTALRD------LVGVDDGFVYHEL- Bs-2   SDVEIVEPAISKKGNKAQQSTNHRSLIDIKKEYGVTAGVPARGMTVVTTTTLQQQQDASMMLAR------FTTSADGIVYHELR 
Ng-1   KVAKTVHPLFKKRN---------------------------------------------------------------------- Ng-2   KVPSTVHPLFKTRTQHKD------------------------------------------------------------------ Trva-1 ------------------------------------------------------------------------------------ Trva-2 ------------------------------------------------------------------------------------ Gl     ------------------------------------------------------------------------------------ Ehis-1 ------------------------------------------------------------------------------------ Ehis-2 ------------------------------------------------------------------------------------ Edis-1 ------------------------------------------------------------------------------------ Edis-2 ------------------------------------------------------------------------------------ Dd     -SIPTQHALFKQRAKNKQ------------------------------------------------------------------Ac**   ------------------------------------------------------------------------------------ Pf     KKFADKHILFRKFLSQNK------------------------------------------------------------------ Toxg   ADATSMHPLFRGLHGKK------------------------------------------------------------------- Eimt** ------------------------------------------------------------------------------------ Ta     KSSSEQHPYFKKLYSTK------------------------------------------------------------------- Tett-1 ------------------------------------------------------------------------------------ Tett-2 ------------------------------------------------------------------------------------ Part-1 ------------------------------------------------------------------------------------ Part-2 ------------------------------------------------------------------------------------ At-1   KDPTKRHNLFKKRYV--------------------------------------------------------------------- At-2   KDPTKRHNIFKKRYV--------------------------------------------------------------------- Orys-1 KDPSKRHYLFKKRYQ--------------------------------------------------------------------- Orys-2 KDPSKRHYLFKKRYQ--------------------------------------------------------------------- 
Fig. S1. Multiple sequence alignment of XPB amino acid sequences 
The encoded protein sequences of specified XPB genes were aligned using the Clustal Omega server of the 
European Bioinformatics Institute (http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalo) at default 
parameters (Sievers et al., 2011). 
The XPB domain, Walker motifs (WM I, WM Ia, WM II-VI), RED residue loop, thumb-like domain (Thm) and XPB 
signature motif were highlighted in the members of the Opisthokonta supergroup, comprising the eukaryotic model 
organisms for TFIIH research (top nine sequences). If a position within the Opisthokonta was more than 50% 
identical or similar, the residue was highlighted in black or gray, respectively, and the highlighting was then applied 
to the kinetoplastid sequences (blue lettering) to demonstrate the conservation of these domains in the latter. 
To detect putative DNA repair-specific sequence conservation in kinetoplastid XPB-R sequences, positions of XPB-
R-specific identity (one mismatch allowed) that was not present in any of the kinetoplastid XPB sequences was 
highlighted in purple. If this position was also conserved in the Opisthokonta model organisms (more than 50% 
similarity) the identities were highlighted in red. 
If a species contained two XPB sequences, the one with greater similarity to T. brucei XPB received the name affix 
1 and the other sequence the affix 2. 
Kinetoplastid accession numbers were derived from www.GeneDB.org. Ac, Acanthamoeba castellanii (XP_004356478); At-
1/At-2, Arabidopsis thaliana (Q38861 / NP_568591); Bs-1/Bs-2 Bodo saltans (BS16690.1:pep / BS91250.1:pep); Ca, Candida albicans 
(EEQ43396); Ce, Caenorhabditis elegans (NP_499487); Dd, Dictyostelium discoideum (XP_647819); Dm, Drosophila melanogaster 
(NP_001137931); Drer, Danio rerio (Q7ZVV1); Edis-1/Edis-2, Entamoeba dispar (EDI_083940 / EDI_292260); Ehis-1/Ehis-2, Entamoeba 
histolytica (XP_649651 / XP_654948); Eimt, Eimeria tenella (ETH_00032995); Gl, Giardia lamblia (GL50803_16512);  Hs, Homo sapiens 
(accession number P19447); Lb-1/Lb-2, Leishmania braziliensis (LbrM.29.0600 / LbrM.32.4160); Li-1/Li-2, Leishmania infantum (LinJ.29.0610 / 
LinJ.32.4070); Lm-1/Lm-2, Leishmania major (LmjF29.0590 / LmjF32.3920); Lmx-1/Lmx-2, Leishmania mexicana (LmxM.08_29.0590 / 
LmxM.31.3920); Mm, Mus musculus (NP_598419); Nc, Neurospora crassa (XP_957329); Ng-1/Ng-2, Naegleria gruberi (XP_002674455 / 
XP_002683056); Orys-1/Orys-2, Oryza sativa (EEE55219 / EEC71313.1); Part-1/Part-2, Paramecium tetraurelia (XP_001448651 / 
XP_001425941); Pf, Plasmodium falciparum (PF10_0369); Sc, Saccharomyces cerevisiae (CAY80363); Sp, Schizosaccharomyces pombe 
(NP_593474); Ta, Theileria annulata (XP_952567.1); Tb-1/Tb-R, Trypanosoma brucei XPB/XPB-R (Tb927.3.5100 / Tb927.11.16270); Tc-1/Tc-
2, Trypanosoma cruzi (TcCLB.510149.50 / TcCLB.511527.20); Tco-1/Tco-2, Trypanosoma congolense (TcIL3000_3_3090 / TcIL3000.11. 
16180); Tett-1/Tett-2, Tetrahymena thermophila (XP_001032673 / XP_001470758); Toxg, Toxoplasma gondii (XP_002365647); Trva-1/Trva-2, 
Trichomonas vaginalis (XP_001582312 / XP_001326086); Tv-1/Tv-2, Trypanosoma vivax (TvY486_0304470 / TvY486_1117180). 
* The T. vivax XPB-2 gene appears to be a partial gene, missing sequence for ~220 C-terminal amino acids
** The single E. tenella and A. castellanii XPB genes miss a large portion of the XPB N-terminus including the
XPB domain, suggesting that the reading frames of these genes are incomplete. 
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Fig. S2. XPB-R is not essential for trypanosome proliferation in culture.
Growth curve of a representative bloodstream form cell line in which doxycycline-induced XPB-R dsRNA
synthesis led to RNAi-mediated XPB-R silencing. The lower panel shows a semi-quantitative PCR
analysis of total RNA that was reverse transcribed with oligo-dT and prepared from non-induced cells (ni)
and cells that were induced with doxycycline for one or two days. The spliceosomal U2A/ coding
sequence was amplified as a control.
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Fig. S3. XPB-R knockout appears to affect completion of mitosis 
A. Diagram showing the number of wild-type procyclic (n=100) and XPB-R knockout cells (XPB-
R KO; n= 100) that are in the 1K1N (1 kinetoplast and 1 nucleus), 2K1N, and 2K2N stages of
the cell cycle. “Other” combines aberrant cells that have no nuclei (zoids) or more than two
nuclei.
B. Image of XPB-R KO cells stained with DAPI showing an accumulation of 2K2N cells (white 
arrows). 
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Fig. S4. PTP tagging and tandem affinity purification (TAP) of XPB-R
A. Schematic depiction (not to scale) of a XPB-R wild-type (WT) allele and of the XPB-R locus of procyclic TbXRee
cells that exclusively express XPB-R-PTP and no wild-type, untagged XPB-R. XPB-R, HYGR/NEOR coding regions
and PTP tag are indicated by open, striped and black boxes, respectively. Gene flanks for RNA processing signals
are drawn as smaller gray boxes.
B. Whole cell lysates and crude, cell-free extracts of two TbXRee cell lines were analyzed by immunoblotting with
the monoclonal anti-Protein C epitope antibody HPC4 that recognizes the PTP tag.
XPB-R-PTP is N-terminally degraded upon extract preparation.
C. Immunoblot monitoring of XPB-R-PTP tandem affinity purification. Aliquots of crude extract (Inp), the flowthrough
of the IgG affinity chromatography (Ft-IgG), the TEV protease elution (TEV), the flowthrough of the anti-ProtC
affinity chromatography (Ft-ProtC), and the final eluate (Elu) were probed with the HPC4 antibody. The x-values
indicate relative amounts analyzed. Note that during the TEV protease digest ~19 kDa of protein is removed from
XPB-R-PTP resulting in XPB-R-P. Asterisks indicate the XPB-R degradation product.
D. Aliquots of input material (Inp), the TEV protease eluate (TEV) and the final eluate (Elu) were separated on a 10-
20% SDS-polyacrylamide gradient gel and stained with sypro ruby. Percentages indicate relative amounts
analyzed. Band assignments on the right are guided by apparent protein size.
E. List of proteins that were unambiguously identified by liquid chromatography/tandem mass spectrometry in the
final TAP eluate.
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Fig. S5. XPB-R-PTP co-localizes with p52-HA outside putative SLRNA expression foci in the nucleus 
p52-HA (green) was co-localized with XPD-PTP (red; left panels) or with XPB-R-PTP (red, right 
panels). White bars represent 10 m. 
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Fig. S6. Divergent XPB paralogs are present in several protistan taxa.  
Multiple eukaryotic XPB amino acid sequences were aligned and phylogenetically analyzed using 
maximum likelihood. Bootstrap values were obtained by sampling a thousand replicates and are 
indicated as percentages. The scale bar indicates the number of amino acid substitutions per site. 
Open circles mark the splits of two divergent XPB paralogs within a taxon. If a species contained two 
XPB genes/sequences, the one with greater similarity to T. brucei XPB received the name affix 1 and 
the other sequence the affix 2. Accession numbers are specified in Fig. S1. Ac, Acanthamoeba 
castellanii; At-1/At-2, Arabidopsis thaliana; Bs-1/Bs-2, Bodo saltans; Ca, Candida albicans; Ce, 
Caenorhabditis elegans; Dd, Dictyostelium discoideum; Dm, Drosophila melanogaster; Drer, Danio 
rerio; Eimt, Eimeria tenella; Gl, Giardia lamblia; Hs, Homo sapiens; Lb-1/Lb-2, Leishmania 
braziliensis; Li-1/Li-2, Leishmania infantum; Lm-1/Lm-2, Leishmania major; Lmx-1/Lmx-2, Leishmania 
mexicana; Mm, Mus musculus; Nc, Neurospora crassa; Ng-1/Ng-2, Naegleria gruberi; Orys-1/Orys-2, 
Oryza sativa; Part-1/Part-2, Paramecium tetraurelia; Pf, Plasmodium falciparum; Sc, Saccharomyces 
cerevisiae; Sp, Schizosaccharomyces pombe; Ta, Theileria annulata; Tb-1/Tb-R, Trypanosoma 
brucei; Tc-1/Tc-2, Trypanosoma cruzi; Tco-1/Tco-2, Trypanosoma congolense; Tett-1/Tett-2, 
Tetrahymena thermophila; Toxg, Toxoplasma gondii; Trva-1/Trva-2, Trichomonas vaginalis; Tv-1/Tv-
2, Trypanosoma vivax. 
* The T. vivax XPB-2 gene appears to be a partial gene, missing sequence for ~220 C-terminal amino acids
** The single E. tenella and A. castellanii XPB genes miss a large portion of the XPB N-terminus including the
XPB domain, suggesting that the reading frames of these genes are incomplete.  
Method of Phylogenetic Analysis 
XPB amino acid sequences from 33 organisms representing the major eukaryotic supergroups (Dacks et 
al., 2008) were aligned using the multiple sequence alignment tool MUSCLE at the EMBL European 
Bioinformatics Institute (http://www.ebi.ac.uk/Tools/msa/muscle/). The alignment was uploaded onto the 
graphical user interface Seaview (Gouy et al., 2010); http://pbil.univ-lyon1.fr/software/seaview.html) to 
drive the GBlocks program using the less stringent option for the selection of conserved sequence blocks 
that are likely to be aligned correctly and for the removal of poorly aligned positions (Talavera and 
Castresana, 2007). The best-fit evolution model for phylogenetic analysis was determined by using the 
ProtTest Server 2.4 (Abascal et al., 2005); http://darwin.uvigo.es/software/prottest2_server.html). A 
maximum likelihood tree was generated employing the LG empirical matrix (Le and Gascuel, 2008) with 
estimated invariable sites, substitution rate categories of 4, estimated gamma distribution and model 
equilibrium frequencies. 
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Fig. S7. XPB-derived phylogenetic tree with the archaeon Sulfolobus solfataricus as an outgroup
The phylogenetic analysis corresponds to that shown in figure 7 except that the XPB sequence from
Sulfolobus solfataricus (Ss, accession number NP_342443) was included.
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Table S1. Oligonucleotide used in this study 
pGene Sequence Usage 
XPB-R 5′-GGAGTGGAACTGCGAGGCCAGTAGTG-3′ / 
5′-CCAAATCCACCTGAATACGGCGACG-3′ 
Sense/antisense oligonucleotides that 
hybridize in the 5/ and 3/ XPB-R gene flanks, 
respectively; used to analyze correct 
integration of transfected DNA constructs that 
replace the wild-type XPB-R alleles. 
5′-TAAGGGCCCAGCACACCGAACTGCATTCCTCG-3′/ 
5′-TAACGGCCGCGATGACGTTGTCTATCATGAGAG 
T-3′
Sense/antisense oligonucleotides that 
hybridize within the coding region of XPB-R; 
used for RT-PCR of XPB-R mRNA. 
U2A 5′-TAGGGCCCTCCAAAAACGGCAGTGCCGATACTG 
C-3′ / 5′-TACGGCCGTGATGTGCGAGTCTTCTTTGTC
CCTTTAGAAGC-3′
Sense/antisense oligonucleotides that 
hybridize within the coding region of U2A/; 
used for RT-PCR of U2A/ mRNA. 
SL RNA 5′-CTACCGACACATTTCTGGC-3′ / 5′-GGTATGAGAA 
GCTCCCAGTAGCAGC-3′ 
Sense/antisense oligonucleotides that 
hybridize in the SLRNA promoter region; used 
for PCR / qPCR amplifications in ChIP 
experiments. 
5′-ATGGCTTATACGTGCTCGTTTCTCC-3′ / 5′-CACAT 
ATAGGCGCTTTAAAGTCTGCT-3′ 
Sense/antisense oligonucleotides that 
hybridize in the SLRNA intergenic region; used 
for PCR / qPCR amplifications in ChIP 
experiments.  
α-Tubulin 
p52 
5′-GTGCATTGAACGTGGATCTG-3′ / 5′-GCCTACCAC 
GAGCAACTCTC-3′ 
5′-TAGGGCCCGCAGCCCCTTCAACAACAGTGG-3′ / 
5′- TACGGCCGATCCGGAGTAATGAAATTGGAC-3′ 
Sense/antisense oligonucleotides that 
hybridize within the coding region of α-tubulin; 
used for PCR / qPCR amplifications in ChIP 
experiments. 
Sense/antisense oligonucleotides that 
hybridize within the coding region of p52; used 
for RT-PCR of p52 mRNA. 
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Table S1 Accession numbers of relevant T. brucei genes 
Gene Accession number 1 
RPB1 Tb927.4.5020, Tb927.8.7400
CRK1 Tb927.10.1070
CRK3 Tb927.10.4990 
CRK7 Tb927.7.1900 
CRK9 Tb927.2.4510
MTR1 Tb927.10.7940
MTR2 Tb927.11.4890 (previously Tb11.02.2500) 
MTR3 Tb927.9.12040 (previously Tb09.211.3130) 
SNIP Tb927.8.3710 
1 Accession numbers are from the GeneDB (www.genedb.org)/TritrypDB (www.tritrypdb.org) genome 
data bases. 
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FIG S1 CRK1 and CRK3 expression silencing. For each knockdown, representative growth curves from one of
three independently derived clonal cell lines were obtained in the absence and presence of the dsRNA synthesis-
inducing reagent doxycycline (-/+ dox). CRK mRNA levels were determined by semi-quantitative RT-PCR of total
RNA in non-induced (ni) cells and in cells that were silenced for 1 to 3 days (boxed panels). In the same RNA
preparations, the relative abundances of  tubulin ( TUB) and of GPEET procyclin mature and pre-mRNAs were
determined by semi-quantitative RT-PCR, those of the large ribosomal RNAs by ethidium bromide staining, and
those of the SL RNA, the U2 snRNA, and the SL intron by primer extension assays.
CRK1 and CRK3 silencing did not lead to a clear disturbance in gene expression patterns. In case of CRK1
silencing, however, we did notice a reproducible, minor reduction in rRNA and compensatory increases in other
RNAs suggesting a minor function of this kinase in the control of ribosome biogenesis.
232
1.0E+05
1.0E+06
1.0E+07
1.0E+08
1.0E+09
1.0E+10
0 1 2 3 4 5 6 7
1 No- Induced
1 Induced
1.E+04
1.E+05
1.E+06
1.E+07
1.E+08
1.E+09
1.E+10
CRK7
0
5
0
6
0
7
0
8
0
9
0
10
0
4
c
e
lls
/m
l
- dox
+ dox
ni 1 2 3
CRK7
 TUB
RRNA
GPEET
days
1.0E+02
1.0E+03
1.0E+04
1.0E+05
1.0E+06
1.0E+07
1.0E+08
1.0E+09
1.0E+10
1.0E+11
0 1 2 3 4 5
Not- Induced
Induced
BF: CRK9
- dox
+ dox
1.E+04
1.E+05
1.E+06
1.E+07
1.E+08
1.E+09
1.E+10
10
3
10
4
10
5
0
6
10
7
10
8
10
9
10
10
10
11
10
2
c
e
lls
/m
l
days
ni 1 2 3
CRK9
 TUB
pre- TUB
U2A
/
RRNA
FIG S2 CRK9 silencing in bloodstream trypanosomes. A representative growth curve in the absence and presence
of the dsRNA synthesis-inducing reagent doxycycline (-/+ dox) of one of two independently derived clonal cell
lines. Mature mRNAs of CRK9, the spliceosomal protein U2A
/
and  tubulin ( TUB) as well as pre-mRNA of 
tubulin (pre- TUB) were analyzed by semi-quantitative reverse transcription (RT)-PCR in non-induced (ni) cells
and cells that were silenced for 1, 2 or 3 days. The relative RNA abundances show the same trend as in procyclics:
mRNA abundances decrease whereas the pre-mRNA level increases in CRK9-silenced bloodstream trypanosomes.
FIG S3 CRK7 silencing in procyclic trypanosomes. A representative growth curve of one of three independently
derived clonal cell lines obtained in the absence and presence of doxycycline (-/+ dox). Abundances of CRK7, 
tubulin ( TUB) and of GPEET procyclin mRNAwere analyzed in total RNA prepared from non-induced (ni) cells
and from cells that were silenced for 1, 2 or 3 days by semi-quantitative RT-PCR. The large ribosomal RNAs were
detected by ethidiumbromide staining.
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FIG S4 Anti-CRK9-PTP chromatin immunoprecipitation (ChIP). ChIP experiments were carried out with two cell
lines expressing either the RNA pol II subunit RPB9 or CRK9 with a functional fusion of the composite PTP tag.
Chromatin was precipitated with a ChIP-grade rabbit polyclonal anti-ProtA antibody (-PTP IP). In negative
control immunoprecipitations (ctrl IP) a comparable, rabbit-derived non-specific antibody was used. Precipitated
DNA was analyzed by amplification of the SLRNA promoter region and, as a negative control, of the 18S rRNA
coding region. For comparison, DNA of total chromatin (INP) was analyzed. The percent precipitation values
specified under each lane were determined by qPCR.
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FIG S5 CRK9 silencing does not affect SL RNA pseudouridylation. Total RNA, prepared from non-induced cells
(ni), from cells in which CRK9 was silenced for 2 days and from cells which were incubated with the general
methyltransferase inhibitor sinefungin (sin) for six hours, was analyzed by primer extension with 5
/
radiolabeled
oligonucleotide SLf. RNA was either mock incubated or treated with N-cyclohexyl-N
/
--(4-
methylmorpholinium)ethyl-carbodiimide p-tosylate (-/+ CMC) according to a published protocol (Bakin and
Ofengand, 1993, Biochemistry 32, 9754-9762) to create an extension stop before the pseudoruridylated residue at
position 28 (Ψ 28). To account for the SL RNA increase in CRK9-silenced and sinefungin-treated cells the amount
of RNA in these samples was reduced by one half.
sin sin
 28
SL RNA
hypomethylated
fully methylated
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Table S2 List of oligonucleotides 
Gene Name Usage Sequence (5/ – 3/) 
CRK1 CRK1 ApaI RT-PCR of CRK1 mRNA TAGGGCCCGTTACGAGCGGCTTCAGAAGATTG 
CRK1 NotI RT-PCR of CRK1 mRNA TACGGCCGGAACTCGACAGAAAAGTATGGGTG 
CRK3 CRK3 ApaI RT-PCR of CRK3 mRNA TAGGGCCCCGGAATCTGGAAAGCGCGAGC 
CRK3 NotI RT-PCR of CRK3 mRNA GATCGCGGCCGCTACAATGCTTGGGGCGTTAACC 
CRK7 CRK7 ApaI RT-PCR of CRK7 mRNA TAGGGCCCGACCGATTTGTCGGCGGTGCTCTG 
CRK7 EagI RT-PCR of CRK7 mRNA TACGGCCGGTACTCGTTGAAATATGTATGAC 
CRK9 CRK9 RNAi-S RT-PCR of CRK9 mRNA GTTGTTAAGAAAGAAAATTGAGG 
CRK9 3/ RT RT-(q)PCR of CRK9 mRNA CGCCGCCGCTGCCAACCCCACTC 
CRK9 qPCR 5/ RT-qPCR of CRK9 mRNA GAGGAAGTGCAACAGCAGCG 
CRK9 UTR RNAi 5/ RT-PCR of CRK9 mRNA GATAAGCTTACGCGTAGGATGGAAGGGGTTGTGAC 
CRK9 UTR RNAi 3/ RT-PCR of CRK9 mRNA GATCTAGACTCGAGGCACTCGATACTTCAAAGAGC 
CRK9 Apa1 RT-PCR of CRK9 mRNA TAGGGCCCGCTCTGTGAATGAATATGTTCCCG 
HA antisense RT-PCR of CRK9 mRNA TTAAGCGTAGTCAGGTACGTCGTAAGGGTA 
 tubulin -Tub Fw q1 RT-(q)PCR of  tub. pre-mRNA ACAGTTTCTGTACTATATTG
-Tub Rv q1 RT-(q)PCR of  tub. pre-mRNA GTGGATGCAGATAGCC
-Tub Fw q3 RT-(q)PCR of  tub. mRNA GTGCATTGAACGTGGATCTG
-Tub Rv q3 RT-(q)PCR of  tub. mRNA GAGAGTTGCTCGTGGTAGGC
GPEET Pre-GPEET 5/ RT-(q)PCR of GPEET pre-mRNA CATGTTCTCGTGATCGCTGC
Pre-GPEET 3/ RT-(q)PCR of GPEET pre-mRNA GCAGATAAAGGGAACGAGGTGC
GPEET 5/ RT-(q)PCR of GPEET mRNA ATGGCACCTCGTTCCCTTTATCTGC
GPEET 3/ RT-PCR of GPEET mRNA TTAGAATGCGGCAACGAGAGCAGC
GPEET qPCR 3/ RT-qPCR of GPEET mRNA CCTTTGCCTCCCTTCACGATAAC
18S rRNA 18SrRNAcoding5/ RT-(q)PCR of 18s rRNA TCATCAAACTGTGCCGATTAC
18SrRNAcoding3/ RT-(q)PCR of 18s rRNA CTATTGAAGCAATATCGG 
SLRNA SL_PE Primer extension of SL RNA &
RT-(q)PCR of SL RNA CGACCCCACCTTCCAGATTC
SL sense RT-(q)PCR of SL RNA ACAGTTTCTGTACTATATT
U1 snRNA U1_PE Primer extension of U1 snRNA CACTCAAAGTTTACTGCA 
U2 snRNA U2_PE Primer extension of U2 snRNA &
RT-(q)PCR of U2 snRNA ACAGGCAACAGTTTTGATCC 
U2 5/ RT-(q)PCR of U2 snRNA ATATCTTCTCGGCTATTTAGC 
U5 snRNA U5_PE Primer extension of U5 snRNA CCGCTCGAGGACACCCCAAAGTTT 
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S1 Table. CRK9-PTP co-purified proteins
Score Expectation Accession # MW (Da) % Coverage emPAI Annotation Comment
13418 0 Tb927.2.4510 / Tb427.02.4510 * 85,465 73.90 10.28 CRK9
9956 0 Tb927.10.9160 / Tb427.10.9160 * 71,208 43.30 8.09 CYC12
2551 0 Tb927.1.2340 / Tb427.01.2340 * 49,756 60.10 3.46 alpha tubulin
2419 0 Tb927.1.2330  / Tb11.v5.0469 * 49,672 60.20 3.12 beta tubulin
1897 0 Tb927.11.11330 / Tb427tmp.01.3110 * 76,002 52.70 3.12 HSP70
1797 0 Tb927.7.3880 * 87,018 49.70 2.13 protein kinase Domain  PKc_DYRK_like (E=8.77e-135)
1358 0 Tb11.v5.1046 * 49,075 41.50 1.99 elongation factor 1-alpha
1179 2.50E-114 Tb927.3.5050 / Tb427.03.5050 * 41,830 57.10 2.97 60S ribosomal protein L4 
1080 1.90E-104 Tb927.10.3930  / Tb11.v5.0501 * 29,404 52.70 4.35 40S ribosomal protein S3A, putative
1014 8.90E-98 Tb927.10.14600 / Tb427.10.14600 * 28,624 77.20 4.6 40S ribosomal protein S2, putative
1010 2.30E-97 Tb927.11.3590  / Tb427tmp.02.1085 * 30,611 63.60 6.49 40S ribosomal protein S4, putative
1006 4.60E-97 Tb927.11.2050 * 34,606 39.10 1.92 60S acidic ribosomal subunit protein, putative
991 1.80E-95 Tb927.11.3590  / Tb11.v5.1059 * 30,625 59.60 6.49 40S ribosomal protein S4, putative
965 6.40E-93 Tb927.9.6070 / Tb427tmp.160.4450 * 30,361 44.60 4.07 40S ribosomal protein S3, putative
936 5.00E-90 Tb927.9.5690 / Tb427tmp.160.4200 * 11,083 99.20 11.73 60S acidic ribosomal protein, putative
878 2.90E-84 Tb927.8.6150 / Tb427.08.6150 25,004 35.20 2.72 40S ribosomal protein S8, putative
874 8.40E-84 Tb927.7.1730 / Tb427.07.1730 * 27,696 54.00 4.1 60S ribosomal protein L7, putative 
817 4.40E-78 Tb927.11.11820 / Tb427tmp.01.3675 16,212 61.70 8.6 40S ribosomal protein S17, putative 
805 7.20E-77 Tb927.9.13970 / Tb427tmp.211.4520 * 36,766 47.30 2.84 hypothetical conserved Trypanosoma-specific, no human homolog
800 1.90E-76 Tb927.9.15110 / Tb427tmp.244.2730 * 34,615 52.80 4.28 60S ribosomal protein L5, putative
796 5.50E-76 Tb11.v5.0243 17,499 48.40 7.11 40S ribosomal protein S18, putative
795 6.30E-76 Tb927.10.350 / Tb11.v5.0564 * 58,564 35.50 1.5 protein kinase, putative  Domain PKc_DYRK_like (E=1.77e-129)
742 1.30E-70 Tb927.11.9710 / Tb427tmp.01.1470 24,601 60.80 4.28 60S ribosomal protein L10a, putative
724 7.60E-69 Tb927.9.10770 / Tb427tmp.211.2150 62,195 37.80 1.71 Polyadenylate-binding protein 2
692 1.20E-65 Tb927.11.6300 / Tb427tmp.02.4170 * 21,372 44.80 2.15 40S ribosomal protein S5, putative
689 2.30E-65 Tb927.11.10790 / Tb427tmp.01.2560 27,592 61.80 2.81 40S ribosomal protein SA, putative 
683 1.10E-64 Tb927.9.3920 / Tb427tmp.160.2490 * 23,826 48.90 5.62 ribosomal protein S7, putative 
661 1.80E-62 Tb927.3.1610 / Tb427.03.1610 74,199 34.10 0.95 protein kinase, putative Domain  PKc_CLK (E=5.90e-57)
648 3.40E-61 Tb927.9.8070 / Tb427tmp.211.0110 24,720 46.30 4.24 60S ribosomal protein L10, putative 
647 4.00E-61 Tb927.9.15360 / Tb427tmp.244.2630 * 28,405 36.40 3.91 40S ribosomal protein S6, putative
641 1.50E-60 Tb927.7.5180 / Tb427.07.5180 24,667 49.50 2.21 60S ribosomal protein L23a, putative
634 7.40E-60 Tb927.10.190 / Tb427.10.190 * 28,433 39.10 3.91 40S ribosomal protein S6, putative 
632 1.40E-59 Tb927.10.11390 / Tb427.10.11390 21,172 68.60 5.89 60S ribosomal protein L6, putative
605 5.90E-57 Tb927.4.1100 / Tb427.04.1100 18,013 73.90 6.71 ribosomal protein L21E (60S), putative
588 3.20E-55 Tb927.7.2370 / Tb427.07.2370 19,952 45.80 3.19 40S ribosomal protein S15, putative
588 3.40E-55 Tb927.10.3370 / Tb427.10.3370 11,528 63.00 7.16 60S acidic ribosomal protein P2, putative
568 3.30E-53 Tb927.3.4170 / Tb427.03.4170 * 13,001 37.20 5.5 CRK9AP
567 4.30E-53 Tb927.10.15290 / Tb427.10.15290 178,152 21.50 0.29 hypothetical conserved domain TBCC (E=1.13e-09) Tubulin binding cofactor C
555 6.70E-52 Tb927.10.1100 / Tb427.10.1100 21,938 52.10 3.44 60S ribosomal protein L9, putative 
541 1.80E-50 Tb927.4.1790 / Tb427.04.1790 * 54,402 45.10 1.49 ribosomal protein L3, putative
539 2.30E-50 Tb927.10.560 Tb427.10.560 20,075 38.90 3.16 40S ribosomal proteins S11, putative
535 6.10E-50 Tb927.10.10970 / Tb427.10.10970 * 80,780 31.60 0.76 heat shock protein, putative
532 1.20E-49 Tb927.10.6400 / Tb427.10.6400 59,466 37.40 1 chaperonin HSP60, mitochondrial precursor
529 2.50E-49 Tb927.9.11470 / Tb427tmp.211.2650 16,284 51.30 2.48 60S ribosomal protein L27a
527 3.80E-49 Tb927.4.3550 / Tb427.04.3550 39,091 26.70 0.88 60S ribosomal protein L13a, putative
525 6.80E-49 Tb927.3.3740 69,133 34.40 0.82 hypothetical conserved Zn finger (RING) protein, potential dsRNA-binding
501 1.60E-46 Tb927.1.3180 / Tb427.01.3180 20,047 39.00 3.16 40S ribosomal protein S11, putative
493 9.30E-46 Tb927.7.1040 / Tb427.07.1040 16,987 57.00 5.82 40S ribosomal protein S16, putative
475 6.30E-44 Tb927.9.11380 / Tb427tmp.211.2630 14,953 45.60 2.88 60S ribosomal protein L23, putative 
474 7.80E-44 Tb927.1.4680 / Tb427.01.4680 37,288 36.30 1.17 hypothetical conserved Trypanosoma-specific, no human homolog
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469 2.40E-43 Tb927.8.1110 / Tb427.08.1110 22,124 55.70 4.3 40S ribosomal protein S9, putative
465 6.20E-43 Tb927.10.5360 Tb427.10.5360 19,274 56.50 3.4 40S ribosomal protein S10, putative
464 8.00E-43 Tb927.10.7330 / Tb427.10.7330 15,674 29.50 1.83 40S ribosomal protein S24E, putative
454 8.50E-42 Tb927.9.12200 / Tb427tmp.211.3270 21,651 40.10 2.11 60S ribosomal subunit protein L31, putative
418 3.40E-38 Tb11.0290 15,503 58.20 1.85 40S ribosomal protein S14, putative
413 9.90E-38 Tb927.9.7590 / Tb427tmp.160.5580 22,355 48.70 2.61 60S ribosomal protein L11, putative
406 5.30E-37 Tb927.7.710 / Tb427.07.710 * 70,168 17.10 0.42 HSP70, putative
406 5.70E-37 Tb927.11.16280 / Tb427tmp.01.7960 28,320 35.00 1.76 60S ribosomal protein L2, putative
382 1.10E-34 Tb927.10.11600 / Tb427.10.11600 66,008 21.70 0.65 hypothetical conserved RS domain, Trypanosoma-specific, no human homolog
378 3.30E-34 Tb927.11.3510 / Tb427tmp.02.1000 * 91,873 8.10 0.14 hypothetical conserved no human homolog
367 4.30E-33 Tb927.11.2990 / Tb427tmp.02.0490 46,419 20.60 0.09 RNA-editing complex protein KREPB4
353 1.10E-31 Tb927.11.6320 / Tb427tmp.02.4190 53,247 29.30 0.59 MRB1-associated protein
335 6.00E-30 Tb927.11.14130 / Tb427tmp.01.5720 20,965 50.40 2.22 ribosomal protein L18, putative
335 6.70E-30 Tb927.6.2640 / Tb427.06.2640 57,920 28.30 0.9 importin alpha subunit, putative (TbKap60)
334 7.70E-30 Tb927.6.5120 / Tb427.06.5120 10,438 52.70 5.89 60S acidic ribosomal protein P2, putative
333 9.40E-30 Tb927.10.5460 / Tb427.10.5460 14,586 40.00 3.04 60S ribosomal protein L24, putative 
316 4.70E-28 Tb927.9.5750 / Tb427tmp.160.4250 22,410 46.10 3.31 tryparedoxin peroxidase
313 1.10E-27 Tb927.10.15360 / Tb427.10.15360 192,223 11.00 0.16 hypothetical conserved DEAD-like helicase
299 2.80E-26 Tb927.11.14000  / Tb427tmp.01.5570 28,774 37.80 1.72 RNA-binding protein NRBD1
296 5.70E-26 Tb927.10.1590 / Tb427.10.1590 12,367 47.10 8.96 ribosomal protein L36, putative 
295 6.00E-26 Tb927.10.270 / Tb427.10.270 15,386 25.70 3.87 60S ribosomal protein L32, putative
295 6.60E-26 Tb927.5.1820 / Tb427.05.1820 10,126 57.60 1.22 60S acidic ribosomal protein, putative 
285 5.80E-25 Tb927.7.3080 / Tb427.07.3080 47,288 31.90 1.01 hypothetical conserved Trypanosoma-specific, no human homolog
285 6.90E-25 Tb927.11.11360 / Tb427tmp.01.3170 34,668 18.70 1.04 receptor for activated C kinase 1 (RACK1)
282 1.20E-24 Tb927.11.6140 / Tb427tmp.02.4000 14,636 48.10 3 40S ribosomal protein S15A, putative
278 3.10E-24 Tb927.2.820 * 60,490 25.50 0.51 retrotransposon hot spot protein, putative
275 6.60E-24 Tb927.4.3150 / Tb427.04.3150 38,135 27.70 0.72 hypothetical conserved Trypanosoma-specific, no human homolog
273 9.70E-24 Tb927.10.9880 / Tb427.10.9880 21,858 27.20 1.11 60S ribosomal protein L18, putative
273 9.90E-24 Tb927.11.11230 / Tb427tmp.01.3020 21,514 46.00 1.59 40S ribosomal protein L14, putative
270 2 20E 23 Tb927 11 15880 / Tb427tmp 01 7535 15 572 37 40 5 25 60S ribosomal protein L27 putative. - . .    . . , . .    , 
268 3.50E-23 Tb927.11.6180 16,850 49.60 2.35 60S ribosomal protein L28, putative
262 1.30E-22 Tb927.7.230 Tb427.07.230 11,163 59.10 1.94 40S ribosomal protein S33, putative
262 1.40E-22 Tb927.6.4280 / Tb427.06.4280 * 39,023 26.20 1.33 glyceraldehyde 3-phosphate dehydrogenase
257 3.80E-22 Tb927.9.11840 24,059 32.50 1.34 hypothetical conserved homolog of human pre-rRNA-processing protein PNO1 (E=9e-65)
254 8.70E-22 Tb927.10.8430 / Tb427.10.8430 16,051 52.10 1.75 40S ribosomal protein S12, putative
252 1.40E-21 Tb927.11.6790 / Tb427tmp.02.4620 88,968 27.00 0.45 predicted WD40 protein BOP1
251 1.60E-21 Tb927.3.3310 / Tb427.03.3310 25,412 37.70 1.24 60S ribosomal protein L13, putative
249 2.70E-21 Tb927.10.14580 / Tb427.10.14580 19,048 37.00 1.92 60S ribosomal protein L17, putative 
245 6.70E-21 Tb927.7.700 74,204 19.60 0.25 hypothetical conserved domain COG2319 (E=5.35e-08; WD40 repeat)
230 1.80E-19 Tb927.4.1860 / Tb427.04.1860 18,834 47.90 1.95 ribosomal protein S19, putative 
229 2.80E-19 Tb927.9.9950 / Tb427tmp.211.1480 55,884 18.50 0.34 hypothetical conserved no human homolog
226 4.90E-19 Tb927.5.4170 / Tb427.05.4170 11,135 47.40 3.28 histone H4, putative
226 5.00E-19 Tb927.8.900 / Tb427.08.900 37,395 22.10 0.55 splicing factor TSR1
224 7.30E-19 Tb927.10.2890 / Tb11.v5.0650 46,563 26.50 0.43 enolase
223 1.10E-18 Tb927.9.13820 / Tb427tmp.211.4511 11,069 54.70 3.28 kinetoplastid membrane protein KMP-11 
219 2.50E-18 Tb927.4.2180 17,010 44.00 1.61 60S ribosomal protein L35a, putative 
204 9.00E-17 Tb927.11.9720 / Tb427tmp.01.1475 9,622 80.00 2.48 40S ribosomal protein S27, putative
199 2.70E-16 Tb927.3.1370 / Tb427.03.1370 12,552 58.70 2.64 40S ribosomal protein S25, putative
198 3.30E-16 Tb927.6.3740 / Tb427.06.3740 71,430 24.80 0.5 HSP70, mitochondrial precursor, putative
197 4.50E-16 Tb927.11.3340 / Tb427tmp.02.0840 26,640 21.90 0.59 RNA-binding protein RBP34, putative
197 4.20E-16 Tb927.8.6180 / Tb427.08.6180 16,444 40.80 1.7 60S ribosomal protein L26, putative
196 5.10E-16 Tb927.8.1330 / Tb427.08.1330 * 30,860 25.00 0.95 60S ribosomal protein L7a, putative
194 8.10E-16 Tb927.11.10160 / Tb427tmp.01.1920 15,257 57.00 1.23 60S ribosomal protein L22, putative
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189 2.50E-15 Tb927.2.5910 / Tb427.02.5910 17,308 48.90 2.25 40S ribosomal protein S13, putative
188 3.10E-15 Tb927.8.760 / Tb427.08.760 35,022 15.10 0.26 nucleolar RNA-binding protein Nopp44/46
185 6.10E-15 Tb927.10.1080 / Tb427.10.1080 15,919 33.90 1.16 40S ribosomal protein S23, putative
178 3.20E-14 Tb927.9.8200 / Tb427tmp.211.0180 76,367 20.20 0.18 hypothetical conserved NOP7
171 1.60E-13 Tb927.2.5130 43,530 31.10 0.33 hypothetical conserved Trypanosomatid-specific, no human homolog
170 2.20E-13 Tb927.10.2240 / Tb427.10.2240 66,436 21.40 0.21 hypothetical conserved Domain NTF2 (E=6.74e-15)
169 2.50E-13 Tb927.10.220 / Tb427.10.220 10,464 43.10 1.16 60S ribosomal protein L37a, putative
169 2.30E-13 Tb927.10.4740 / Tb427.10.4740 7,401 40.10 3.97 nucleolar RNA-binding protein, putative
161 1.50E-12 Tb927.11.10960 71,727 12.90 0.12 hypothetical conserved similar to human alpha-ketoglutarate-dependent dioxygenase (E=2e-24)
154 7.80E-12 Tb927.11.4190 / Tb427tmp.02.1670 59,183 21.60 0.23 hypothetical conserved domain Proliferation-associated_protein_2G4 (E=4.66e-58)
152 1.20E-11 Tb927.9.5150 / Tb427tmp.160.3670 * 13,563 21.90 0.35 ribosomal protein S6, putative
150 2.20E-11 Tb927.11.8200 / Tb427tmp.01.0355 12,798 44.70 0.89 ribosomal protein S26, putative
149 2.60E-11 Tb927.2.6090 / Tb427.02.6090 12,446 42.40 2.68 60S ribosomal protein L44
148 3.40E-11 Tb927.10.10460 / Tb427.10.10460 12,562 34.20 1.63 histone H2B, putative 
144 8.60E-11 Tb927.08.6030 / Tb427.08.6030 17,566 14.40 0.26 60S ribosomal protein L12, putative
137 4.20E-10 Tb927.9.1810 / Tb427tmp.160.0700 15,090 42.30 2.85 60S ribosomal protein L35, putative
133 9.20E-10 Tb927.9.8740 / Tb427tmp.211.0560 36,961 13.70 0.4 RNA-binding protein DRBD3
131 1.40E-09 Tb927.4.4060 / Tb427.04.4060 104,023 13.30 0.17 hypothetical conserved putative chromosome segregation protein
126 4.70E-09 Tb927.7.2820 / Tb427.07.2820 14,245 26.30 1.36 histone H2A, putative 
125 6.20E-09 Tb927.10.14700 37,678 14.90 0.39 hypothetical conserved no human homolog
117 4.20E-08 Tb927.11.15180 / Tb427tmp.01.6835 12,938 39.10 0.87 hypothetical conserved no human homolog
115 6.00E-08 Tb927.9.5320 55,412 16.70 0.35 nucleolar RNA binding protein, putative
113 1.10E-07 Tb927.10.3500 / Tb427.10.3500 96,597 5.00 0.09 RNA-binding protein RBSR4, putative
110 1.90E-07 Tb927.11.11330 / Tb427tmp.02.5450 71,403 10.80 0.19 HSP70
110 2.20E-07 Tb927.9.11270 / Tb427tmp.211.2570 61,414 19.00 0.14 T-complex protein 1, eta subunit, putative
108 3.30E-07 Tb927.10.2370 / Tb427.10.2370 37,648 22.20 0.24 La protein
107 4.50E-07 Tb927.8.1720 68,077 6.60 0.06 phosphatidylglycerophosphate synthase, putative
106 4.90E-07 Tb927.1.180 / Tb427.01.180 94,247 6.70 0.09 retrotransposon hot spot protein 1, putative 
105 7.00E-07 Tb927.8.3530 / Tb427.08.3530 37,810 34.00 0.39 glycerol-3-phosphate dehydrogenase
105 7 00E 07 Tb927 3 1920 / Tb427 03 1920 66 646 16 00 0 06 NOT5 protein. - . .   . . , . .  
103 0.0000011 Tb927.1.2430 / Tb427.01.2430 14,741 45.50 0.73 histone H3, putative 
97 0.0000037 Tb927.11.9550 / Tb427tmp.01.1310 37563 5 0.12 replication factor C, subunit 4, putative 
97 0.0000039 Tb927.10.4110 / Tb427.10.4110 11545 45.7 1.01 60S ribosomal protein L30
96 0.0000057 Tb927.7.3680 / Tb427.07.3680 16972 31.8 0.62 ubiquitin/ribosomal protein S27a, putative 
95 0.0000061 Tb927.3.3950 62209 9.7 0.07 hypothetical conserved no unambiguous human homolog
95 0.0000067 Tb927.11.8050 / Tb427tmp.01.0490 59922 12.5 0.15 hypothetical conserved putative SAS10 homolog (U3 processome complex, E=1.67e-17)
93 0.0000093 Tb927.7.1780 / Tb427.07.1780 25956 16.5 0.17 Adenine phosphoribosyltransferase, putative
92 0.000014 H25N7.12 97751 18.7 0.09 retrotransposon hot spot protein, RHS4
91 0.000018 Tb927.8.4660 / Tb427.08.4660 117829 7.9 0.07 hypothetical conserved putative homolog of human exportin-7 (E=3e-23)
90 0.000022 Tb927.9.5730 / Tb427tmp.160.4240 47586 10.6 0.19 nucleosome assembly protein-like protein
89 0.000023 Tb927.11.10030 / Tb427tmp.01.1790 8217 62.9 3.3 60S ribosomal protein L29, putative
89 0.000024 Tb927.8.3750 / Tb427.08.3750 54281 13.4 0.16 nucleolar protein, putative
89 0.000028 Tb927.10.4560 / Tb427.10.4560 94274 11.3 0.09 elongation factor 2 
87 0.000039 Tb927.2.1140 / Tb427.02.1140 52161 20.7 0.17 retrotransposon hot spot protein, putative 
86 0.000051 Tb927.10.10360 / Tb427.10.10360 * 367419 3.5 0.01 microtubule-associated protein, putative 
84 0.000083 Tb927.3.3130 / Tb427.03.3130 177874 10.1 0.02 hypothetical protein, conserved no human homolog
84 0.00009 Tb927.11.16890 / Tb427tmp.01.8650 228855 11.4 0.02 hypothetical protein, conserved Tetratricopeptide repeat protein (TPR), putative 
83 0.000092 Tb927.11.740 / Tb427tmp.03.0410 17809 8 0.26 eukaryotic translation initiation factor 5a, putative
83 0.00011 Tb927.10.13720 Tb427.10.13720 40636 6.5 0.11 RNA-binding protein, putative (RBP29)
83 0.00011 Tb09.v4.0126 55005 17.8 0.08 variant surface glycoprotein, pseudogene
82 0.00013 Tb927.2.560 / Tb427.02.560 95966 27.9 0.09 retrotransposon hot spot protein, putative
81 0.00016 Tb927.8.7530 / Tb427.08.7530 39779 8.8 0.11 3,2-trans-enoyl-CoA isomerase, putative
81 0.00016 Tb927.10.15870 / Tb427.10.15870 26965 8.2 0.16 RNA binding protein, putative
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80 0.00022 Tb927.1.1350 96521 9 0.04 kinesin heavy chain, putative
79 0.00027 Tb927.1.2100 / Tb427.01.2100 126075 5.6 0.03 calpain-like cysteine peptidase, putative
78 0.0003 Tb927.10.170 / Tb427.10.170 48363 8.6 0.09 pseudouridine synthase, Cbf5p 
76 0.00047 Tb927.7.2980 / Tb427.07.2980 21229 12.4 0.47 hypothetical protein, conserved Nitroreductase 4
76 0.00057 Tb927.10.14750 31653 30.9 0.3 fibrillarin, putative 
75 0.0006 Tb927.6.5040 / Tb427.06.5040 24494 26 0.65 ribosomal protein L15, putative
75 0.00065 Tb11.v5.0537 70086 5.3 0.13 polyubiquitin, putative 
73 0.00094 Tb927.2.2390 / Tb427.02.2390 16769 33.5 0.28 hypothetical protein, conserved no human homolog
73 0.0011 Tb927.7.5000 / Tb427.07.5000 29405 26.9 0.15 60S ribosomal protein L19, putative
72 0.0012 Tb927.4.2040 / Tb427.04.2040 20796 39.7 0.48 ALBA3
71 0.0015 Tb927.9.13650 / Tb427tmp.211.4460 20639 13.9 0.22 ADP-ribosylation factor, putative
71 0.0015 Tb927.2.100 94873 5.3 0.09 retrotransposon hot spot protein 1, putative
70 0.0019 Tb927.11.3120 / Tb427tmp.02.0620 74731 15.7 0.12 nucleolar GTP-binding protein 1 
70 0.0021 Tb927.4.3060 / Tb427.04.3060 17694 15.5 0.59 hypothetical protein, conserved no human homolog
70 0.0022 Tb927.6.2790 / Tb427.06.2790 36934 18.5 0.25 L-threonine 3-dehydrogenase, putative
69 0.0027 Tb927.8.4450 / Tb427.08.4450 47151 12.4 0.09 RNA-binding protein, putative (RBP11) 
67 0.0039 Tb927.11.10280 / Tb427tmp.01.2050 131127 3.4 0.03 zinc carboxypeptidase, putative 
66 0.0054 Tb927.10.9400 / Tb427.10.9400 31611 13.6 0.14 SF1 (branch point binding protein)
65 0.0059 Tb927.1.1700 / Tb427.01.1700 55121 11.8 0.16 AATF protein, putative
65 0.0068 Tb927.11.9590 / Tb427tmp.01.1350 48456 10.4 0.09 S-adenosylhomocysteine hydrolase, putative
64 0.0089 Tb927.10.8170 / Tb427.10.8170 144316 8 0.03 nuclear pore complex protein (NUP155), putative
63 0.0093 Tb927.10.15180 / Tb427.10.15180 * 41221 5.6 0.11 nucleosome assembly protein, putative 
63 0.0094 Tb11.v5.0366 120510 8.4 0.03 hypothetical protein, conserved putative chromosome segregation ATPase
List of proteins that were identified in two CRK9-PTP tandem affinity purifications by LC/MS/MS. The list shows the protein IDs of the second, more comprehensive mass 
spectrometric analysis. All protein identifications with an Expect value smaller than 0.001 are listed and ranked according to their Mascot Scores. Proteins that were also identified in 
the first analysis are marked with an asterisk after their accession numbers. Peptides were identified in both the T. brucei brucei 927 and 427 genome databases at 
www.TriTrypDB.org. Annotations are according to the 927 database. Top-scoring and “hypothetical, conserved” proteins were analyzed by standard BLASTP searches of the Human 
Genome database. CRK9 complex subunits are highlighted in yellow, ribosomal proteins in green, non-ribosomal proteins in orange, and standard PTP purification contaminants in 
gray. 
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   Tb427   ----------MSSNNPSDIRIRTELLQEMQLLHAQQEGMKNIRQSEASHSDENDKKERGT  50 Tb927   ----------MSSNNPSDIRIRTELLQEMQLLHAQQEGMKNIRQSEASHSDENDKKERGT  50 Tv      ----------MPAVDPLQV--QTELLERMKTLHVQHMQSLGRRTVNKGS--GASNGVKGT  46 Tc-el   MDLPPSERPAMPESGPLAFRARTVLLEQLRDLHRQEQQQKKRRGQLRPSNNGPQTGT---  57 Tc-nel  MDLPPSENPALSESGPLAFRARTALLEQLRDLHRQEQQQQKRRGQLRLSNNGPQTGT---  57 Tgr     ----------MSENVSSKFCARTALLQQLLETC--EEQQKQQRAVQRWSRPEAVSGERTE  48 Cfa     ----MSSDPNNGTSAGGALRLRTSLLEAVERYNTAQLASAAASDK-----N---------  42 Lbr     ---MQSRKDTPTRHTGGTLRIRTALLESVCHYNEAYLSTLTAAAA-----MEEPLET---  49 Lta     ---MPGGKDTTTTGRGGRLQIRTALLESVRRYNEDCLNTSTATAV-----VEEPLGT---  49 Lmx     ---MQGTKGAPTTNSGGKLQIRTALLESVRRYNEECLNMSTATTA-----AEEPLAT---  49 Lm      ---MQGAKDTPTANSGGKLQIRTTLLEAVRRYNEDCLNTSTAAAA-----AEEPLAT---  49 Li      ---MRGTNDTPTANSGGKLQIRTALLESVRRYNEDCLNTSTAA-A-----AEEPLAT---  48 Ld      ---MRGTNDTPTANSGGKLQIRTALLESVRRYNEDCLNTSTAA-A-----AEEPLAT---  48 Bs      ------------------------MMQELRQQQQQQQQSVGSTSSSRLT-----------  25   Tb427   RSGSTTGTCSEFDVCAVYDDDDVPLAAQFVRSCPPLTDPSWAMEELLRINSHVAVWT-GS 109 Tb927   RSGSTTGTCSEFDVCAVYDDDDVPLAAQFVRSCPPLTDPSWAMEELLRINSHVAVWT-GS 109 Tv      VAHGSD-GGKDMVNCEGIREDDLPLAVQFVRSCPPLTNPTWAMEELLRINPNVAVWT-GS 104 Tc-el   ESN-------NDDDSDDESDNSAPMAVRFVRGCPPLTDPSWAMEELLRIDPNVALWT-GT 109 Tc-nel  ESN-------NDDDSDDESDNSAPMAVRFVRGCPPLTDPSWAMEELLRIDPNVALWT-GT 109 Tgr     AVH---TAKSDSEDDGEESDNNVSTAVWLMRNCAPLTNPSWAMEELQRIHRGTPVWAAGT 105 Cfa     ---------------DGEFS---SLVKVLVQRAPNVTNPSWAMEECGRLCPSAELWS-GS  83 Lbr     ----------SKQSVDRFPD---VLPRMIAQLNPSLTNPSWAMEECMRLCPSAEVWC-GT  95 Lta     ----------PTQRVDKFPD---ALPRMIAQLYPSLTNPSWAMEECVRLCPSAEVWC-GT  95 Lmx     ----------QTQRIDRFPD---ALPRMIAQLYPSLTNPSWAMEECVRLCPAAEVWC-GT  95 Lm      ----------PTQRVDRFPD---ALPRMIAQLYPSLTNPSWAMEECVRLCPAAEVWC-GT  95 Li      ----------PTQRGDRFPD---ALPRMIAQLYPSLTNPSWAMEECVRLCPAAEVWC-GT  94 Ld      ----------PTQRGDRFPD---ALPRMIAQLYPSLTNPSWAMEECVRLCPAAEVWC-GT  94 Bs      -------------------S---SEITDAIRQDEEMSHPNWTHEEMARTNKACPSGG-DS  62   Tb427   ALPNSVWALPGS---------GHCPFGSTDADFARIR     137 Tb927   ALPNSVWALPGS---------GHCPFGSTDADFARIR     137 Tv      TLSSTVWAPPAS---------GHCPFGTTSGDFVRHR     132 Tc-el   GLSTAVWAPPGS---------GHCPFGTTQADFIRHR     137 Tc-nel  GLSTAVWAPPGS---------GHCPFGTTQADFIRHR     137 Tgr     QLSSAVWAPPGT---------ANCPFGTKPTDFLRHS     133 Cfa     ALPLDVWAPPGT---------PDCPFGTTPADFRVHH     111 Lbr     ALPKDVWAPPGT---------AECPFGTEPMDFNAHR     123 Lta     ALSKDVWAPPGT---------AECPFGTEPMDFNAHR     123 Lmx     ALPKDVWAPPGT---------AECPFGTEPMDFNAHR     123 Lm      ALPKDVWAPPGT---------AECPFGTEPMDFNAHR     123 Li      ALPKDVWAPPGT---------AECPFGTEPMDFNAHR     122 Ld      ALPKDVWAPPGT---------AECPFGTEPMDFNAHR     122 Bs      RLMSTVWTPPRRQPPAAHLPSFPCPFNLQYQDVISVQHRSH 103 
S2 Figure. CRK9AP is conserved among kinetoplastid organisms. Kinetoplastid CRK9AP 
sequences were aligned using the Clustal Omega server of the European Bioinformatics Institute 
(http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalo) at default para-meters [1]. Positions 
with more than 50% identity or similarity are highlighted in black or gray, respectively. Dashes indicate 
that a corresponding residue is missing. Sequences were obtained from www.TriTrypDB.org or 
www.GeneDB.org and comprise those of T. brucei brucei strains 427 (Tb427, accession number 
Tb427.03.4170) and 927 (Tb927, Tb927.3.4170), Trypanosoma vivax (Tv, TvY486_0303410), 
Trypanosoma cruzi CL Brener Esmeraldo-like (Tc-el; TcCLB.509669.80) and Non-Esmeraldo-like (Tc-
nel; TcCLB.506175.30), Trypanosoma grayi (Tgr, Tgr.163.1040), Crithidia fasciculata (Cfa, 
CfaC1_25_1880), Leishmania braziliensis (Lbr, LbrM.29.1690), Leishmania tarentolae (Lta, 
LtaP29.1740), Leishmania mexicana (Lmx, LmxM.08_29.1585), Leishmania major (Lm, LmjF.29.1585), 
Leishmania infantum (Li, LinJ.29.1710), Leishmania donovani (Ld, LdBPK_291710.1), and the bodonid 
Bodo saltans (Bs, BS14910.1..pep). 
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S3 Figure. Generation of a highly specific rat anti-CRK9AP immune serum. CRK9AP was
expressed in Escherichia coli as a C-terminal fusion to glutathione S-transferase and purified
from bacterial extract by glutathione affinity chromatography. By injecting the purified protein
into the rat bloodstream, [pre-]immune serum was obtained according to a published protocol
[1]. Pre-immune (pre-IS) and -CRK9AP immune sera (IS) were used to probe whole cell
lysates (wcl) and crude extract (extr) of procyclic Trypanosoma brucei brucei strain 427. As a
loading control, transcription factor TFIIB was detected on the same blots. Marker sizes in kDa
are indicated on the left.
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Tb_CYC12   9 WLCDARRAFCAYGVDLIRTGSILVRTTPSVTYRASVLFQRFQAAAE[74]EDHDDIVYLAAACILVAAKVEDPST Tc_        7 WIDDARRGYSSYGVDLIRTGCLLLRTTPSVTYRAAVLFQRFQAVAE[64]REHDDITYLTAACVLIATKMEDHSM Lm_        2 TDAAARDAYTAYGVDLIRTTGLLLRTTPSTIYRASILFQRFEASVE[93]SDHEDIMYLVAACLLIATKMEDPST Bs        22 SAARADQIFNTYTADLLRTLCCLMGVGPTVVFRAQALFQRLTTIVK[50]FTDDSMLYFVAAVVLITCKLECPQA 
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Tb_CYC12 154 RIRSIVSVFMRLNQRRRNEPVI--------E--LLQPPPERYENFKTRVREAEEIVLQTLGFQTFVECPFKYAII Tc_      142 RVRLIVGVFMRLNQRRRGEPVI--------E--QLQPPPERYDDFKSCILEAEEVVLQALGFQTFVESPFKYAIL Lm_      166 RIRAVVNVCMRLSLRRSGIPVT--------E--QSKPSLPRYEDFKACVIEAEEVVLHQLGFQTFVESPYKYVLL Bs       143 KIRLVVHAVHRLNYRRKQRTPVSGSLAAAAT--LPPISPEVYDALKRQVVQAEWIVLVQLGFQVTVECPHKFVFP 
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S4 Figure. Multiple sequence alignment of the CCL1 domain of eukaryotic cyclin L and 
kinetoplastid CYC12 proteins. Cyclin L and CYC12 sequences were aligned using the Clustal Omega 
server at default parameters. Shown are the sequences of the CCL1 domain (COG5333) as defined in 
human cyclin L1 according to the Conserved Domain Database [3]. Dashes indicate that a corresponding 
residue is missing. Numbers in parentheses specify number of residues without significant sequence 
similarity. Positions with more than 50% identity or similarity are highlighted in black or gray, respectively. 
Identical positions in model organisms without similarity in kinetoplastids were highlighted in blue and 
insertions or unique identical positions in kinetoplastids were highlighted in red. Stars and colons denote 
positions that are identical or similar in all sequences analyzed. Yellow highlighting indicates cyclin folds 
1 and 2 within the CCL1 domain and question marks indicate positions of the human cyclin L1 sequence 
that were not recognized as part of the CCL1 domain. Cyclin L sequences are from Homo sapiens (Hs; 
L1, accession number NP_064703; L2A, NP_112199), Mus musculus (Mm, NP_064321), Danio rerio 
(Dr, NP_956034), Caenorhabditis elegans (Ce, NP_506007), Arabidopsis thaliana (At, NP_565622) and 
Schizosaccharomyces pombe (Sp, NP_593045). Kinetoplastid CYC12 sequences, obtained from 
www.TriTrypDB.org or www.GeneDB.org, were from T. brucei (Tb, accession number Tb927.10.9160), 
Trypanosoma cruzi (Tc, TcCLB.503525.20), Leishmania major (Lm, LmjF.36.5640), and the bodonid 
Bodo saltans (Bs, BS70770.1). 
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S5 Figure. CYC12 clusters phylogenetically with cyclin L of model organisms. Amino acid 
sequences of cyclins from Homo sapiens (Hs), Mus musculus (Mm), Drosophila melanogaster 
(Dm), Caenorhabditis elegans (Ce), Arabidopsis thaliana (At), Saccharomyces cerevisiae (Sc), 
and Schizosaccharomyces pombe (Sp) as well as kinetoplastid CYC12 from Trypanosoma 
brucei brucei strains 427 (Tb427) and 927 (Tb927), Trypanosoma congolense (Tco), 
Trypanosoma vivax (Tv) Trypanosoma cruzi (Tc), Leishmania major (Lm), Leishmania infantum 
(Li), Leishmania donovani (Ldon), Leishmania mexicana (Lmex), Leishmania tarentolae (Ltar), 
Leishmania braziliensis (Lbr), and the bodonid Bodo saltans (Bs) were aligned using the Clustal 
Omega server at http://www.ebi.ac.uk [4]. The multiple sequence alignment was imported into 
the ClustalX software package [5] and phylogenetically analyzed using the neighborhood joining 
method. Bootstrap values were obtained by sampling a thousand replicates and are indicated 
as percentages. The node for the cyclin L/CYC12 cluster is drawn in red. Cyclin clusters of cell 
cycle-regulating and transcriptional CDKs, according to Ma et al. [6], are indicated. The cyclin 
sequences were obtained from the following accession numbers: Hs_A (CAA35986.1), Hs_B1 
(CAO99273.1), Hs_B2 (AAI05087.1), Hs_B3 (CAC94915.1), Hs_C (AAH41123.1), Hs_D1 
(AAH23620.1), Hs_D2 (CAA48493.1), Hs_D3 (AAA52137.1), Hs_E1 (AAH35498.1), Hs_E2 
(AAC78145.1), Hs_F (AAB60342.1), Hs_G1 (AAC78145.1), Hs_G2 (AAC41978.1), Hs_H 
(AAA57006.1), Hs_I (AAF43786.1), Hs_J (AAH43175.1), Hs_K (AAH43175.1), Hs_L1 
(AAH43175.1), Hs_L2A (Q96S94.1), Hs_O (NP_066970.3), Hs_T1 (AAC39664.1), Hs_T2 
(AAW56073.1), Hs_Y (AAH94815.1), Mm_A (CAA81331.1), Mm_B1 (AAH85238.1), Mm_B2 
(AAH08247.1), Mm_B3 (AAI38356.1), Mm_C (AAH03344.2), Mm_D1 (AAO13813.1), Mm_D2 
(AAH49086.1), Mm_D3 (AAC53363.1), Mm_E1 (AAI38663.1), Mm_E1 (AAC80527.1) Mm_F 
(AAA63152.1), Mm_G1 (AAC42082.1), Mm_G2 (AAC32372.1), Mm_H (AAH38861.1), Mm_I 
(AAF43391.1), Mm_J (AAI20923.1), Mm_K (AAH27297.1), Mm_L1 (AAH94383.1), Mm_L2 
(AAI32296.1), Mm_O (AAI47760.1), Mm_T1 (AAD13656.1), Mm_T2 (AAH54122.1), Mm_Y 
(NP_080760.2), Dm_A (NP_524030.2), Dm_B (AAF46904.1), Dm_C (CAA44720.1) Dm_D 
(NP_523355.2), Dm_E (AAF53477.1), Dm_H (NP_524207.1), Dm_K (AAN11146.1), Dm_L 
(putative, Dm_T (AAS64974.1), Dm_Y (AAF53122.1), Ce_A (AAA84393.1), Ce_B1 (Q10653.1), 
Ce_B3 (AAA84395.1), Ce_C (Q9TYP2.2), Ce_D (AAC35273.1), Ce_E (AAM78547.1), Ce_H 
(NP_494564.2), Ce_L (AAS64750.1), Ce_T1.1 (P34425.1), Ce_T1.2 (P34424.2), Ce_Y1 
(NP_498857.2), Ce_Y2 (NP_498858.2), At_A1 (Q9C6Y3.1), At_A2 (AED93433.1), At_A3 
(NP_199122.1), At_B1 (P30183.2), At_B2 (Q39068.2), At_B3 (NP_173083.3), At_D1 
(P42751.3), At_D2 (P42752.3), At_D3 (P42753.3), At_H (BAB72144.1), At_L (Q8RWV3.2), 
At_T1 (NP_174775.1), Sc_CLB1 (CAA97112.1), Sc_CLB2 (CAA44195.1), Sc_CLB3 
(CAA49201.1), Sc_CLB4 (CAA49202.1), Sc_CLB5 (AAA34503.1), Sc_6 (NP_011623.3), 
Sc_CLN1 (NP_013926.1), Sc_CLN2 (CAA97982.1) Sc_CLN3 (NP_009360.1), Sp_C 
(NP_595953.1), Sp_H (NP_595776.1), Sp_L (NP_593045.1), Sp_T (NP_596149.1) Sp_Puc1 
(NP_596539.1), Sp_Btype1 (NP_588110.2), Sp_Btype2 (NP_595171.1), Sp_Btype3  
(NP_593889.1), Tb927_CYC12 (Tb927.10.9160), Tb427_CYC12 (Tb427.10.9160), Tc_CYC12 
(TcCLB.503525.20), Tv_CYC12 (TvY486_1009010), Tco_CYC12 (TcIL3000_10_7930), 
Lm_CYC12 (LmjF.36.5640), Ltar_CYC12 (LtaP36.5790), Lmex_CYC12 (LmxM.36.5640), 
Ldon_CYC12 (LdBPK_365890.1), Li_CYC12 (LinJ.36.5890), Lbr_CYC12 (LbrM.35.5920) and 
Bs_CYC12 (BS70770.1). 
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S6 Figure. CYC12 and CRKAP silencing in BFs. (A) Growth curves of uninduced (- dox) BF
cultures or cultures in which CYC12 or CRK9AP was conditionally silenced by the addition of
doxycyline to the medium (+ dox). Note that a second cell line for each gene knockdown was
analyzed in parallel, producing nearly congruent growth curves (data not shown). The cross
indicates that subsequent to day 3 of induction no intact cells were detected in cultures. (B)
RNA analyses. Total RNA was prepared from [un-]induced cells and the relative amounts of
mature CYC12/CRK9AP and  tubulin mRNA was determined by reverse transcription using an
oligo-dT primer and semi-quantitative PCR, performed in the linear range of the amplification
reaction. Unspliced,  tubulin pre-mRNA was analyzed by reverse transcription using random
hexamers and PCR with an oligonucleotide that hybridized upstream of the  tubulin SL addition
site. rRNA served as a loading control and was detected after RNA separation on agarose gel
by ethidium bromide staining. (C) Both gene knockdowns led to dephosphorylation of the RNA
pol II subunit RPB1. Immunoblot analysis of whole cell lysates of [un-]induced cells detecting
RPB1 with an immune serum directed against the CTD. As a loading control, the similar sized
protein RPA1, the largest subunit of RNA pol I, was detected on the same blot.
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S7 Figure. Depletion of CRK9, CYC12 or CRK9AP leads to round-up of cells. Microscopic
images of un-induced procyclic cells that look normal (top row) and of rounded cells from the
same cell lines (bottom row) when CRK9, CYC12 or CRK9AP was depleted for three days.
White scale bars correspond to 10 m.
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Table S1. List of oligonucleotides 
Purpose  Description Sequence 
RT-PCR SPF27 mRNA 5/-AAGCTTACGCGTCCCATGGTGCTTCCTTAC-3/
5/-TCTAGACCCGAACGTTTCTCAGCC-3/ 
RT-PCR 7SL RNA 5/-TTGCTCTGTAACCTTC-3/ 
5/-TCTACAGTGGCGACCTCAAC-3/ 
RT-PCR ORC1 mRNA 5/-AAGCTTACGCGTCGAAGGAGGGACAGTAAC-3/
5/-TCTAGAAAAACGCATACGGTAGAC-3/ 
RT-[q]PCR  tubulin 
pre-mRNA 
5/-GTAAGTGGTGGTGGCGTAAG-3/ 
5/-CAATGTGGATGCAGATAGCC-3/ 
RT-[q]PCR  tubulin mRNA 5/-ACAGTTTCTGATCTATATTGATCTT-3/
5/-GAGAGTTGCTCGTGGTAGGC-3/ 
Competitive 
RT-PCR 
PAP [pre-]mRNA 5/-GTGCAGCGGCACTCCCAAAAC-3/ 
5/-CGTTAAAACAGATGGACAAATC-3/ 
RT-qPCR SL RNA 5/-ACAGTTTCTGTACTATATTG-3/ 
5/-CGACCCCACCTTCCAGATTC-3/ 
RT-qPCR RPB7 pre-mRNA 5/-CCACTCGAAGGAGTAGTTTTC-3/ 
5/-TTATGTGCACTTGCTGGTG-3/ 
RT-qPCR RPB7 mRNA 5/-CATGGGCCCGAGAGGAATATAAAAGTGGAGCCT
...C-3/ 
5/-ATTCTGATTTGTGCGGGC-3/ 
RT-qPCR PAP pre-mRNA 
(exon 1-intron) 
5/-GTGCAGCGGCACTCCCAAAAC-3/ 
5/-GGGATTAAGGAAAGAACTCAC-3/ 
RT-qPCR 18S rRNA 5/-TCATCAAACTGTGCCGATTAC-3/ 
5/-CTATTGAAGCAATATCGG-3/ 
Primer extension SL_PE (SL RNA) 
SL40 (SL RNA) 
7SL_PE (7SL RNA) 
U1_PE (U1 snRNA) 
U2f (U2 snRNA) 
U4_PE (U4 snRNA) 
U5_PE (U5 snRNA) 
U6_PE (U6 snRNA) 
5/-CGACCCCACCTTCCAGATTC-3/ 
5/-CTACTGGGAGCTTCTCATAC-3/ 
5/-GAACCCCCGCTTGTC-3/ 
5/-AGCACGGCGCTTTCGTGATG-3/ 
5/-ACAGGCAACAGTTTTGATCC-3/ 
5/-TACCGGATATAGTATTGCAC-3/ 
5/-GGGAGAGTGCTAATCTTCTC-3/ 
5/-GAACCCCCGCTTGTC-3/ 
The gene-specific sequence is underlined when oligonucleotides carry additional nucleotides. 
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Hs        -----------MAAIPPDSWQPPNVYLETSMGIIVLELYWKHAPKTCKNFAELARRGYYN  49 Dr        -----------MAGIPPDSWQPPTVSLDTTMGTIVLELYWNHAPKTCKNFAELGRRGYYN  49 Dm        MLS--LSDPNNAGGIPDKAWQPHFVTLETSMGEITVELYWKHAPNTCRNFAELSRRGYYN  58 Ce        -------------MPAPINDQAPYVILDTTMGKIALELYWNHAPRTCQNFSQLAKRNYYN  47 Sp        ---------------------MANVELQTSLGKILIELYTEHAPKTCQNFYTLAKEGYYD  39 Nc        --------------------MATDVAVETTMGTFTLELYTNHAPKTCKNFATLADRGYYD  40 At        -----------MSAR--PEGSPPEVTLETSMGPFTVEMYYKHSPRTCRNFLELSRRGYYD  47 
Lbr       -----------------MEKAARVVQLQSTAGALSFELYSNFC---ADSFWQLASSGQLR  40 Lm        -----------------MGQVARVVQVQSSAGALSIELYNNFC---ADSFWQLARSDQLR  40 Ld        -----------------MERVARVVQLQSTAGALSIELYNNFC---ADSFWQLARSGQLR  40 Tv        ----------MPNTTPYSCSYSRVVELYTNCGVISVELYDDESHCVAESFYRLAASGQLD  50 Tb        -------------MKVVVNEMSQVVEIITNEGVISVELYDTFAPRAAESFRRFAESGQLD  47 Tcon      -------------MKL-IDNGVSVVELYTNEGVVSIELYELEAPCAAKSFLQLAESGQLN  46 Bs        MAAPSSGTSSTTATTRSSSLSCRVVTFHTTAGAFSIELYDTYAPRLTHHMYELAKSNAYN  60  Hs        GTKFHRIIKDFMIQGGDPTGTGRG[.0]GASIYGKQFEDELHPDLKFTGAGILAMANAGP 105 Dr        STKFHRIIKDFMVQGGDPTGTGRG[.0]GASIYGKQFEDEFHPELKFTGAGILAMANAGP 105 Dm        NVVFHRIIRDFMIQGGDPTGTGRG[.0]GASIYGSEFADELHGDLRHTGAGILSMANSGP 114 Ce        GTIFHRIIADFMIQGGDPTGTGRG[.0]GASIYGDKFSDEIDERLKHTGAGILSMANAGP 103 Sp        GVIFHRVIPDFVIQGGDPTGTGRG[.0]GTSIYGDKFDDEIHSDLHHTGAGILSMANAGP  95 Nc        STVFHRIIKDFMIQGGDPTGTGRG[.0]GSSIYGEKFEDEIHPGLKHTGAGVLSMANAGP  96 At        NVLFHRIVKDFIVQGGDPTGTGRG[.0]GESIYGSKFEDEINKELKHTGAGILSMANAGP 103 
Lbr       RLVFRQLLCGFALLGEVEAVQGHS[.5]----VDAAAESPDGLSLLHVGAGLLTCSPTVG  97 Lm        RLTFRKLLGGFALLGEVEAVQGHS[.5]----VDAAAQSPDDVPLLHVGAGLLSCRPTVG  97 Ld        RLTFRQLLGGFALLGEVETVQGHS[.5]----VDAAARSPDGVPLLHVGAGLLSCRPTIG  97 Tv        GVVVSRLIPSFVIEFSV-------[.0]GHPVFGEWMDVDVCNSLHHTGAGIVSCPR--R  98 Tb        GAVFDRMVPTFLLECRL-------[.0]EFSVYGELVGREENNHLHHTGAGILTCFG--T  95 Tcon      GARFERMVPGFLLECRV-------[.0]GDMAYGELTEAEEGKTLRHTGAGIVSCYG--S  94 Bs        NTLFHKLVPGQYLQGGAATLSPSS[13]KQHLLSVFQDDEIHSSLRFTGAGIVGFASAGP 129  Hs        DTNGSQFFVTLAPTQWLDGKHTIFGRVCQGIGMVNRVGMVET--NSQDRPVDDVKIIKAY 163/166 Dr        DTNGSQFFLSLAPTQWLDGKHTIFGRVCQGIGVLNRIGMVET--NSQDRPVDDIKILRVN 163/166 Dm        DTNGSQFFITLAPTQWLDGKHTIFGRVYTGMEVVKRIGMVET--DKNDRPVDPLRIIKAK 172/176 Ce        NTNGSQFFITLAPTQHLDGKHTIFGRVAAGMKVIANMGRVDT--DNHDRPKIEIRILKAY 161/169 Sp        NTNSSQFFITLAPTPWLDGKHTIFGRVVSGLSVCKRMGLIRT--DSSDRPIEPLKIIKAV 153/155 Nc        NTNGSQFFITLAPTPWLDGKHTIFGRVKKGMGVIRRMGMVPT--DKEDRPATEVKIVKAR 154/163 At        NTNGSQFFITLAPQPSLDGKHTIFGRVCRGMEVIKRLGSVQT--DNTDRPIHEVKILRTK 161/164 
Lbr       AVTASRFLITLSPQPQLDKTHVIFGRVYSGIQTLERMSHMQV--DADFVLYSPVTVIKWS 155/192 Lm        AVTASRLLITLSPQPQLDKTHVVFGRVYSGIHTLEQISHMQV--DADFVLYSPVTVMKCS 155/192 Ld        AVTASRLLITLSPQPQLDKTHVVFGRVYSGIHTLEQISRMQV--GADFVLYSPVTVVKCS 155/192 Tv        GLEAGSFFITLGPQPFLDEACIIFGRVYSGMRVVQNISQLSV-SAETFHLFSPVVIERCN 157/196 Tb        VLESGAFFITLGPQPELDNVCTIFGRVRSGMRVVEKISRSRV-AEKTFRLYTPVVVERCL 154/194 Tcon      VVEKGRFFITLAPQPKLDGVCTIFGRVYSGMSIVRKISQSRV-MEENFRLYTPVVIQRCT 153/192 Bs        DLNSSQFFITLAPQPKFDGVFSVIGRVSSGMKVLQTLSTQYQVDPSTSAPYNPIRISHCS 189/243 
Fig. S1.   Multiple sequence alignment of PPIL1 orthologues. 
Clustal Omega (McWilliam et al., 2013) was used at default parameters to align PPIL1 amino acid 
sequences from Homo sapiens (Hs, accession number NP_057143), Danio rerio (Dr, NP_001029350), 
Drosophila melanogaster (Dm, NP_523874), Caenorhabditis elegans (Ce, NP_501118), 
Schizosaccharomyces pombe (Sp, NP_593308), Neurospora crassa (Nc, XP_964739), Arabidopsis 
thaliana (At, NP_181157), and from the kinetoplastid species Leishmania braziliensis (Lbr, 
LbrM.23.0140), Leishmania major (Lm, LmjF.23.0125), Leishmania donovani (Ld, LdBPK_230140.1), 
Trypanosoma vivax (Tv, TvY486_0801580), Trypanosoma brucei (Tb, Tb927.8.2090), Trypanosoma 
congolense (Tc, TcIL3000_8_2090), and Bodo saltans (Bs, BS78785.1..pep). Positions with more than 
50% similarity or identity are shaded in gray and black, respectively. Identical positions in model 
organisms without conservation in kinetoplastids are shaded blue and identical position is kinetoplastids 
without conservation in model organisms are shaded in red. A hyphen indicates lack of an amino acid at 
this position. Numbers in parentheses specify lengths of non-conserved insertions. Saccharomyces 
cerevisiae and Trypanosoma cruzi appear to lack a PPIL1 homolog. 
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Fig. S2. PTP tagging and tandem affinity purification of CDC5 isolated the complete PRP19 complex
A. Schematic (not to scale) of the CDC5 locus after integration of pCDC5-PTP-NEO, fusing the PTP
coding sequence (black box) to an endogenous allele.
B. Immunoblot monitoring of the CDC5-PTP tandem affinity purification CDC5-PTP and CDC5-P (after
removal of the ProtA domains) were detected with the anti-ProtC HPC4 antibody in crude extract (Inp),
flowthrough of the IgG column (FT-IgG), TEV protease eluate (TEV), flowthrough of the anti-ProtC
column (FT-ProtC) and the final eluate (Elu). x-Values indicate relative amounts loaded. Apparently,
during extract preparation and purification, part of CDC5 was converted into a truncated form in which an
N-terminal domain was cleaved off (trCDC5).
C. The final eluate of a CDC5-PTP tandem affinity purification was sedimented through a linear sucrose
gradient, fractionated, and visualized by Sypro Ruby staining of an SDS-PAGE gel, the same as with
PRP19 shown in figure 1D. Protein bands were excised and protein identities confirmed by LC/MS/MS.
Asterisks indicate the sedimentation peak.
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Fig. S3. ORC1 silencing
Procyclic trypanosome culture growth in the absence and presence of doxycycline which
induced ORC1 silencing.
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Fig. S4. Only a minor amount of spliceosomal U snRNAs are bound to the PRP19 complex in extract
Primer extension analysis of total RNA prepared from the SmD1-PTP and SPF27-PTP pull-downs
documented in figure 6A. The analysis shows the snRNA profiles of crude extracts (Inp), supernatants
(Sn) and precipitates (P) in reaction A which detects SL RNA, U2/U4/U6 snRNAs and the Y structure
intermediate, and reaction B which detects U5/U1 snRNAs. x-Values indicate relative amounts loaded.
Note that the high volume of the P sample for the SPF27 analysis (right panel) led to a slight upward shift
of signals. Also note that the SmD1 and SPF27 reactions were separated on 6% and 8% polyacrylamide
gels, respectively, leading to different spacing of primer extension products. Nevertheless, the results
clearly show that SmD1 precipitation depleted U2, U4, U5, and U1 snRNAs and, to a lesser extent, SL
RNA and U6 snRNA, whereas SPF27 precipitation did not lead to a detectable reduction of snRNAs.
This indicates that, in extract, only a minor amount of snRNAs are stably associated with SPF27 in a
spliceosomal complex.
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Fig. S5. Spliceosomal U snRNAs remain stable upon TbSPF27 silencing
Total RNA was prepared from non-induced cells (n.i.) and from cells in which either SPF27 or, as a
control, ORC1 was silenced (KD for knockdown) for 3 days. RNA abundances were determined by two
primer extension assays. In assay A, 32P-5/-endlabeled oligonucleotides were combined that specifically
hybridize to SL RNA and U2, U4 and U6 snRNAs. In assay B, U1- and U5-specific oligonucleotides were
used. Primer extension products were separated on 8% polyacrylamide-50% urea gels and visualized by
autoradiography. M, marker MspI-digested pBR322. On the right, SL RNA and U snRNA products are
specified. Y denotes a product of the SL RNA-specific oligonucleotide that is generated by the Y
structure intermediate after the first step of splicing. The arrows point to increased and decreased signals
of SL RNA and Y structure intermediate in RNA of SPF27-silenced cells, respectively. Other signal
strengths remained comparable confirming that the trypanosome PRP19 complex is a non-snRNP
component of the spliceosome.
255
Supplemental Reference 
McWilliam,H., Li,W., Uludag,M., Squizzato,S., Park,Y.M., Buso,N. et al. (2013) Analysis Tool Web 
Services from the EMBL-EBI. Nucleic Acids Res 41: W597-W600. 
256
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Trypanosoma brucei is a vector borne, lethal protistan parasite of humans and livestock in sub-Saharan Africa. An-
tigenic variation of its cell surface coat enables the parasite to evade adaptive immune responses and to live freely
in the blood of its mammalian hosts. The coat consists of tenmillion copies of variant surface glycoprotein (VSG)
that is expressed from a single VSG gene, drawn from a large repertoire and located near the telomere at one of
fifteen so-called bloodstreamexpression sites (BESs). Thus, antigenic variation is achievedby switching to the ex-
pression of a different VSG gene. A BES is a tandem array of expression site-associated genes and a terminal VSG
gene. It is polycistronically transcribed by a multifunctional RNA polymerase I (RNAPI) from a short promoter
that is located 45–60 kb upstream of the VSG gene. The mechanism(s) restricting VSG expression to a single
BES are notwell understood. There is convincing evidence that epigenetic silencing and transcription attenuation
play important roles. Furthermore, recent data indicated that there is regulation at the level of transcription ini-
tiation and that, surprisingly, the VSGmRNA appears to have a role in restricting VSG expression to a single gene.
Here, we review BES expression regulation and propose a model in which telomere-directed, epigenetic BES si-
lencing is opposed by BES promoter-directed, activated RNAPI transcription.
© 2014 Elsevier B.V. All rights reserved.
1. Introduction
The tsetse borne, unicellular parasite Trypanosoma brucei, which be-
longs to the phylogenetic order Kinetoplastida, is the only known or-
ganism that has evolved a multifunctional RNA polymerase I (RNAPI)
system. This system is used to transcribe ribosomal gene units (RRNA)
in the nucleolus, as in all eukaryotes, yet also to transcribe gene units
that encode the parasite's major cell surface antigens (Günzl et al.,
2003; Kooter and Borst, 1984). Trypanosomes have a unique mode of
protein coding gene expression that allows them to utilize other RNA
polymerases than RNAPII for the production of functional mRNA. In
their genome, protein coding genes are arranged in long tandem arrays
which are polycistronically transcribed. The precursor RNA is processed
by spliced leader (SL) trans splicing and polyadenylation, resulting in
mature, monocistronic mRNAs (Günzl, 2010; Michaeli, 2011; Preußer
et al., 2012). Since in trans splicing the same capped leader sequence,
derived from the SL RNA, is spliced onto the 5′ end of each mRNA, this
process represents a post-transcriptional mode of capping that is
decoupled from RNAPII transcription. Consequently, trypanosomes, in
contrast to mammals (Grummt and Skinner, 1985), are able to use
RNAPI to effectively and specifically express endogenous gene units
that encode their major cell surface antigens (Rudenko et al., 1991;
Zomerdijk et al., 1991a). This antigen, in mammalian-infective
metacyclic and bloodstream form (BF) trypanosomes, is known as the
variant surface glycoprotein (VSG), while themajor cell surface antigen
in insect-stage procyclic trypanosomes is procyclin.
T. brucei causes Human and Animal African Trypanosomiasis (also
known as Sleeping Sickness and Nagana, respectively) throughout
sub-Saharan Africa (Fevre et al., 2006). The parasite lives freely in the
bloodstream of its mammalian host, evading the immune systemby an-
tigenic variation of its cell surface coat. The coat consists of ten million
copies of the same VSG, shielding invariant membrane proteins from
immune recognition (Schwede et al., 2011). T. brucei possesses roughly
2500 different VSG genes and pseudogenes (Cross et al., 2014), and pe-
riodic switching to the expression of an alternative VSG gene leads to
antigenic variation. VSG genes are located in subtelomeric regions of
11 megabase, 5 intermediate-sized and ~100 minichromosomes cover-
ing, in total, ~30% of the genome (Ersfeld, 2011; Horn, 2014). However,
the active VSG gene is invariably located next to the telomere within an
expression site, with the coding region ending ~200–1800 bp upstream
of the telomeric repeats. Metacyclic trypanosomes express a single VSG
Gene 556 (2015) 68–73
Abbreviations:BES, bloodstreamexpression site;BF, bloodstreamform[trypanosome];
CITFA, class I transcription factor A; DOT1B, disruptor of telomeric silencing; ESAG,
expression-site associated gene; ESB, expression site body; FACT, “facilitates chromatin
transcription” factor; NEO, neomycin phospho-transferase; NLP, nucleoplasmin-like pro-
tein;ORC1,originrecognitioncomplexsubunit1;RNAP,RNApolymerase;RRNA, ribosomal
RNAgene unit; SL, spliced leader; VSG, variant surface glycoprotein.
⁎ Corresponding author at: Department of Genetics and Developmental Biology,
University of Connecticut School of Medicine, 400 Farmington Avenue, Farmington, CT
06030-6403, USA.
E-mail address: gunzl@uchc.edu (A. Günzl).
http://dx.doi.org/10.1016/j.gene.2014.09.047
0378-1119/© 2014 Elsevier B.V. All rights reserved.
Contents lists available at ScienceDirect
Gene
j ourna l homepage: www.e lsev ie r .com/ locate /gene
257
monocistronically from one of five metacyclic expression sites in which
the RNAPI promoter is located ~1–4 kb upstream of the coding region
(Cross et al., 2014; Ginger et al., 2002; Kolev et al., 2012). Conversely,
BFs express the active VSG from one of fifteen polycistronic “blood-
stream expression sites” (BESs) which comprise a tandem array of typ-
ically 8–9 expression-site associated genes (ESAGs) and a terminal VSG
gene (Fig. 1) (Hertz-Fowler et al., 2008). ESAGs appear to be important
for the successful infection of the mammalian host since they encode a
variant heterodimeric transferrin receptor (ESAG6 and ESAG7), whose
varying affinity for transferrins of different host species is thought to ex-
pand the parasite's host range (Bitter et al., 1998). These also encode
adenylate cyclases (ESAG4) that inhibit the innate immune system
upon trypanosome lysis (Salmon et al., 2012).
The BES promoter resides 45–60 kb upstream of the telomere
(Zomerdijk et al., 1990). It extends only 67 bp upstreamof the transcrip-
tion initiation site and comprises two short sequence elements (Pham
et al., 1996; Vanhamme et al., 1995). Both elements are required for ef-
ficient binding of themulti-subunit class I transcription factor A (CITFA),
which is essential for RNAPI transcription in the trypanosome
(Brandenburg et al., 2007). The active BES is transcribed outside the nu-
cleolus (Chaves et al., 1998), apparently in a small compartment termed
the expression site body (ESB) (Navarro and Gull, 2001). In BFs the
switch to the expression of another VSG occurs by two principal ways:
either the active BES is silencedwhile one of the silent BESs is activated,
or a DNA recombination event replaces the VSG gene in the active BES
with a VSG gene from the repertoire.
Antigenic variation andmono-allelic VSG expression in T. bruceihave
been a research focus for decades. Several factors involved in BES silenc-
ing have been identified (see below) and BES silencing has been linked
to DNA replication/ORC1 (Benmerzouga et al., 2013; Tiengwe et al.,
2012), chromosome maintenance (Kim et al., 2013), and association of
BESs with the nuclear lamina (DuBois et al., 2012). In addition, cohesin
plays a critical role in maintaining the activated state of the BES during
the cell cycle (Landeira et al., 2009). Recently, excellent and detailed re-
views have addressed antigenic variation in trypanosomes and the biol-
ogy of BES silencing (Alsford et al., 2012; Glover et al., 2013; Horn, 2014;
Horn andMcCulloch, 2010; Rudenko, 2010). Here we focus on themost
recent findings of factors that appear to be directly involved in BES reg-
ulation, and propose a model in which BES-specific telomeric silencing
is opposed by a mechanism that activates transcription initiation at
the promoter of the active BES.
2. Telomeric silencing
The active VSG gene, independent ofwhether it resides inmetacyclic
or bloodstream expression sites, is invariably located near the telomere,
indicating that the telomere has an essential function in regulating VSG
expression. Accordingly, repression of RNAPI-mediated transcription by
the telomere was directly demonstrated by integrating a plasmid with
seeds for de novo telomere formation either at BESs or, internally, at
RRNA loci (Glover and Horn, 2006). At the latter, tight repression ex-
tended only 2 kb upstream of telomeric repeats whereas, at inactive
BESs, repression reached at least 5 kb in these experiments. The more
extended repression of silent BESs was consistent with previous find-
ings in which integration of RNAPI promoter-driven reporter cassettes
at different positions of a silent BES were repressed, even when placed
14 kb upstream of the telomere (Horn and Cross, 1997). Several lines
of evidence suggest that the pronounced silencing of BESs is dependent
on the telomere. Depletion of the telomeric protein RAP1 led to de-
repression of silent BESs, co-expression of multiple BES-encoded VSG
genes, and the formation of additional extranucleolar RNAPI foci
(Yang et al., 2009). Furthermore, depletion of the disruptor of telomeric
silencing B (DOT1B), which methylates lysine 76 of trypanosome his-
tone H3 (Janzen et al., 2006), similarly led to de-repression of silent
BESs (Figueiredo et al., 2008). Direct evidence for repression of a BES
from the telomere stems from a recent study in which induced expres-
sion of a VSG transgene, inserted into one of the RRNA loci, surprisingly
led to a short-term, reversible attenuation of the active BES, indicating
that VSG mRNA plays a direct role in the regulation of mono-allelic
VSG expression (Batramet al., 2014). Interestingly, a time course exper-
iment showed that this silencing of the active BES spread from the telo-
mere towards the BES promoter in a DOT1B-dependent manner
(Batramet al., 2014). Together, these data strongly indicated that BES si-
lencing is directed by the telomere. Furthermore, it is likely that the VSG
gene on silent BESs is protected from RNAPI transcription bymore than
onemechanism becauseDOT1B knockout cells could still shut down the
active VSG gene upon ectopic VSG expression but were unable to atten-
uate expression of the remainder of the active BES (Batram et al., 2014).
3. BES transcription attenuation
Inactive BESs are completely silent only in regard to their telomere-
proximal regions, including the terminal VSG gene. VSGmRNA from in-
active BESs is 104 to 105-fold less abundant than that from the active BES
(Figueiredo et al., 2008; Yang et al., 2009). Despite this strongdifference,
several observations have shown that transcription does initiate at si-
lent BESs at a clearly detectable level. The first evidence came from a
study in which insertion of a selectable marker gene 1 kb downstream
of a “silent” BES promoter led to resistant parasites (Navarro and
Cross, 1996). BES sequences are highly similar, especially at the promot-
er and in the proximal downstream region, differing from each other
only by a few single nucleotide polymorphisms. However, the first
genes within BESs are ESAG7 and ESAG6which encode the heteromeric
transferrin receptor and harbor short hypervariable regions that distin-
guish them from each other (Zomerdijk et al., 1991b). Analysis of ESAG6
cDNA sequences,which on BESs are located ~5 kb downstream from the
Fig. 1. Schematic outline of BES5 and interacting proteins. Depiction of BES5 (to scale) as a representative BES according to the published sequence (Hertz-Fowler et al., 2008). The diagram
includes ESAGs (labeled 1, 2, 4–8 and 12), a VSG pseudogene (Ψ), 70 bp repeats preceding the terminal VSG gene, and the telomeric repeats (T). Note that some BESs have an additional
promoter and an ESAG10 gene ~14 kb upstream of the depicted promoter (not shown). The green arrow and red X represent the promoter when the BES is in the active state and silent
state, respectively. Activating factors that are predominantly associatedwith the active BES are indicated above the diagram in greenwhereas factorswhich are implied in BES silencing are
listed below the diagram in red. Filled and empty arrowheads indicate positive and negative ChIP results, respectively. Histone H1 and SPT16 associate predominately with silent sites
whereas TbISWI and NLP were shown to interact equally with expression sites in both states.
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promoter, revealed that 20% of the ESAG6 mRNA in BFs was derived
from various silent BESs whereas 80% stemmed from the active BES,
demonstrating that, even in the absence of selective pressure, produc-
tive transcription did occur in the promoter-proximal domain of inac-
tive BESs (Ansorge et al., 1999). Subsequently, a vast cDNA clone
analysis along whole BESs showed that silent BESs contributed much
more to the promoter-proximal cDNA pool than to pools of promoter-
distant cDNAs, revealing that transcription that initiated at silent BESs
was attenuated along the BES (Vanhamme et al., 2000). Recently, this
approach was repeated with single cells, confirming that silent BESs
are transcribed in their promoter-proximal region and that transcrip-
tion was attenuated further downstream within a single trypanosome
(Kassem et al., 2014). Finally, the demonstration that BES silencing
spreads gradually from telomere to promoter and BES reactivation oc-
curs gradually in the opposite direction (Batram et al., 2014) strongly
supports the notion that transcription is attenuated at silent BESs.
4. Regulation of BES transcription initiation
Although the promoters of inactive BESs are not “silent”, there is
now convincing evidence that there is substantial regulation at BES pro-
moters. Consistently, promoter-proximal RNA levels were found to be
much higher from the active versus silent BESs. Thus, when the neomy-
cin phosphotransferase gene (NEO) was inserted 1 kb downstream of
the promoter of an inactive BES, it conferred parasite resistance to a
low concentration of the drug G418 (1 μg/ml) while the same gene,
when inserted at the identical position of an active BES, boosted resis-
tance at least 100-fold (Navarro and Cross, 1996). The finding that in
BFs 80% of ESAG6 mRNA stemmed from the active BES suggested that
there is at least a 50-fold stronger ESAG6 expression from the active
BES than from the average silent BES. When Yang et al. (2009) intro-
duced a luciferase gene immediately downstream of the active or a si-
lent BES promoter, the active BES produced 1500–4000-fold more
light units than the silent BES.
More direct evidence for BES regulation at the level of transcription
initiation came from the analysis of CITFA. CITFA consists of seven sub-
units, CITFA1-7, which are conserved only among kinetoplastid organ-
isms, and the dynein light chain DYNLL1 (also known as LC8).
Silencing of CITFA1, CITFA2 and CITFA7was lethal to BFs grown in culture
and strongly and specifically reduced the abundance of rRNA and VSG
mRNA (Brandenburg et al., 2007; Nguyen et al., 2012; Park et al.,
2014). Accordingly, depletion of CITFA2 from extract virtually abolished
RNAPI transcription in vitro, as assayed by ~100 bp-long primer exten-
sion products, and the purified CITFA complex produced a specific gel
shift with the BES promoter (Brandenburg et al., 2007). Moreover, a
ChIP-seq analysis indicated thatwithin a BES, CITFA7 occupancywas re-
stricted to the promoter region (Nguyen et al., 2014). Together, these
findings identified CITFA as a basal and general transcription initiation
factor for RNAPI transcription in trypanosomes.
Interestingly,marking the active BES and a silent BES ~500 bp down-
stream of the transcription initiation site (Figueiredo et al., 2008) re-
vealed that CITFA2 and CITFA7 predominantly occupied the promoter
of the active BES relative to that of the marked silent BES, a phenotype
that was maintained after consecutive in situ switches between the
two marked sites (Nguyen et al., 2014). In accordance with CITFA's
role as an RNAPI transcription initiation factor, higher CITFA occupancy
at the active versus the silent BES promoter correlated with a ~70-fold
higher abundance of promoter-proximal, unspliced RNA and a ~17-
fold higher occupancy of the RNAPI-specific subunit RPB6z at themark-
er gene (Nguyen et al., 2014). Finally, CITFA7 silencing led to a strong re-
duction of RNAPI occupancy and of promoter-proximal RNA levels,
which directly demonstrated that CITFA binding to the promoter is re-
quired for high transcription rates in vivo (Nguyen et al., 2014). These
data unequivocally showed that mono-allelic BES expression entails a
mechanism that functions at the BES promoter, apparently limiting
access of CITFA to silent BES promoters and/or ensuring maximal pro-
moter occupancy of CITFA at the active BES.
It should be noted that this mechanism is not an “all or nothing”-
mechanism because, in these experiments, the marked silent BES pro-
moter was consistently occupied by CITFA above the level of negative
control experiments. This finding is in accordance with promoter-
proximal transcription occurring at silent BESs (see above) and it likely
explainswhyhypersensitive DNase I sites in the promoter region, indic-
ative of a bound transcription factor, were not restricted to the active
BES but were also detected at a silent BES (Navarro and Cross, 1998).
It appears that trypanosomes cannot completely shut down transcrip-
tion initiation from silent BESs. Alternatively, low level transcription of
the promoter-proximal part of silent BESsmight serve a biological func-
tion. For instance, co-expression of different forms of the heteromeric
transferrin receptor, e.g. ESAG6 and ESAG7, could ensure initial survival
in different mammalian hosts.
5. Factors involved in BES transcription regulation
There is strong evidence that inactive BESs are silenced epigenetical-
ly. Thus, while silent BESs have a nucleosomal structure, the active BES
is largely depleted of nucleosomes (Figueiredo and Cross, 2010; Stanne
and Rudenko, 2010). Direct evidence that nucleosomes are important
for BES promoter silencing stems fromdepleting histoneH3, which rap-
idly led to a ~11-fold de-repression of a GFP gene introduced down-
stream of the promoter of a silent BES (Alsford and Horn, 2012). In
addition, CAF-1b, a replication-dependent histone chaperone, and the
replication-independent chaperone ASF1A, were shown to be impor-
tant for the inheritance and maintenance of the silenced state of BESs
(Alsford and Horn, 2012). Interestingly, silencing the gene of either
chaperone led to apparent nucleosome depletion and a de-repression
of the promoter-proximal BES region. However, it did not affect expres-
sion of the corresponding VSG gene suggesting that nucleosomal struc-
ture is particularly important for the regulation of BES promoter activity.
Several chromatin remodeling and modifying proteins have been
implicated in BES repression so far. The first epigenetic factor found to
play a role in BES regulation was the chromatin remodeler TbISWI
(Hughes et al., 2007). Depletion of this factor increased themRNAabun-
dance of a reporter gene inserted promoter-proximally into a silent BES
up to 60-fold, whereas only a fivefold increase of the corresponding si-
lent VSGmRNA was observed. TbISWI was found to occupy the entire
length of both silent and active BESs, but was not enriched at BES pro-
moters (Stanne et al., 2011). Although the specific function of TbISWI
remains to be determined, these results suggest that TbISWI controls
RNAPI transcription elongation rather than initiation.
Similar de-repression of a promoter-proximal reporter genewas ob-
servedwhen the histonedeacetylase DAC3 (Wang et al., 2010), the link-
er histone H1 (Pena et al., 2014; Povelones et al., 2012), or the
nucleoplasmin-like protein NLP (Narayanan et al., 2011) was depleted.
The function of DAC3 appears to be promoter-specific since expression
of theVSG gene in themarked BESwasunaffected at both themRNAand
the protein level (Wang et al., 2010). However, direct association of
DAC3 with BESs has not been demonstrated yet and it remains a possi-
bility that DAC3's control of BES silencing is indirect.
The role of histone H1 in BES promoter repression has been more
deeply investigated. Histone H1 is important for chromatin architecture
and generally functions in chromatin condensation and transcription
repression (Happel and Doenecke, 2009). Accordingly, co-silencing of
the T. brucei H1 multigene family opened up chromatin globally with
the strongest effect on silent BES promoters (Pena et al., 2014). Meta-
bolic labeling of nascent RNA then showed that histoneH1depletion re-
sulted in an approximately six-fold higher promoter-proximal
transcription rate at a silent BES, indicating that relaxation of the nucle-
osome structure in the promoter region led to an increase of the tran-
scription initiation rate at the silent BES (Pena et al., 2014).
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NLP is a ubiquitous nuclear protein and, accordingly,was found to be
associatedwith all genomic loci analyzed, including the active and silent
BESs (Narayanan et al., 2011). Despite this apparent general association
with genomic DNA, NLP seems to be particularly important for BES pro-
moter regulation. Depletion of NLP de-repressed a silent BES 45–65-
fold, as measured by fluorescence derived from a promoter-proximal
GFP gene. Moreover, NLP silencing also reduced promoter-proximal
gene expression from the active BES about threefold (Narayanan et al.,
2011). While it was speculated that NLP may have a dual function in
BES silencing and in promoting processive transcription at the active
BES (Narayanan et al., 2011), it is equally possible that loss of NLP en-
abled competition between silent and the active BES for the RNAPI tran-
scription machinery. However, the specific function of NLP in BES
regulation remains to be determined.
SPT16 is a subunit of the trypanosome FACT (“facilitates chromatin
transcription”) complex (Patrick et al., 2008) and appears to have a di-
rect role in BES promoter silencing because itwas foundhighly enriched
at a silent BES promoter (Denninger et al., 2010). Accordingly, SPT16 si-
lencing increased promoter-proximal GFP expression from a silent BES
up to 25-fold, yet de-repression did not extend to theVSG genes of silent
BESs. However, the de-repression effect was strongly correlatedwith an
arrest in the G2/early M cell cycle phase, raising the possibility that
SPT16 does not generally facilitate BES repression in the bloodstream
trypanosome. Moreover, SPT16 depletion strongly reduced VSG expres-
sion from the active BES, suggesting a separate BES-related function of
SPT16 in facilitating processive RNAPI transcription. Overall, the specific
function of FACT in the multifunctional RNAPI system remains unclear.
While SPT16 has been co-purified with RNAPII of the related organism
Leishmania major (Martinez-Calvillo et al., 2007), its association with
T. brucei RNAPI remains to be shown.
The epigenetic factors discussed so far, including RAP1 and DOT1B
(see Section 2, Telomeric silencing, above), function in BES silencing.
The only such factor found to be important for efficient transcription
of the active BES is the highmobility group protein TDP1,which belongs
to a family of architectural chromatin proteins (Narayanan and
Rudenko, 2013). Interestingly, TDP1 exhibited an inverse occupancy
pattern to the core histone H3 at RNAPI-transcribed loci and was up to
fivefold more abundant at the active BES promoter relative to a silent
BES promoter. Accordingly, TDP1 depletion decreased the abundance
of pre-rRNA and VSGmRNA from the active BES. In addition, TDP1, a nu-
clear protein, exhibited predominant localization to the nucleolus and
the ESB, and its DNA association was found throughout the active BES
and RRNA gene units. Thus, it appears that TDP1 facilitates high rates
of processive RNAPI transcription required for trypanosome survival
(Narayanan and Rudenko, 2013).
6. A model of BES regulation
It is difficult to integrate the data from BES de-repression studies be-
cause, for most factors, specific functions in BES silencing have not been
determined yet. Nevertheless, recent data strongly indicated that BES
regulation occurs at both ends of expression sites. RAP1 and DOT1B de-
pletion studies have clearly shown that BESs are silenced by a telomere-
directed mechanism. Moreover, the demonstration that BES silencing
spreads from the telomere towards the promoter (Batram et al., 2014)
strongly supports a telomere-directed BES silencing mechanism. How-
ever, it is unlikely that this is the only mechanism regulating mono-
allelic BES expression. If this was the case one would expect full activa-
tion of promoter-proximal transcription once telomeric silencing re-
treats beyond the promoter region, which should result in a leveling
of the transcription rate between active and silent BESs (given the ex-
tremely high expression level of the active BES, it is unlikely that a try-
panosome can support full activation of all fifteen BESs). However, in
all cases reported, de-repression of silent BESs is, at best, moderate
with the promoter-proximal expression level remaining manifold
below that of the active BES. Furthermore, RAP1 silencing did not
strongly affect promoter-proximal transcription of de-repressed BESs
andhad only aminor influence on the high expression level of the active
BES (Yang et al., 2009). Similarly, DOT1B silencing did not affect expres-
sion of the active BES at all (Figueiredo et al., 2008). These results
strongly argue for the presence of a separate mechanism involved in
BES regulation.
Transcription attenuation has been proposed to be that mechanism
and, as discussed, there is clear evidence that it does occur on silent
BESs (Kassem et al., 2014; Vanhamme et al., 2000). Moreover, some
data suggested that transcription attenuation is caused by inefficient
transcript processing (Vanhammeet al., 2000) rather than by repressive
chromatin. However, recent data do not support this scenario. The find-
ing that RAP1 silencing caused gradual BES de-repression with the
greatest effect on telomere-proximal genes, strongly indicated that
transcription elongation on silent BESs is “antagonized” by telomere-
directed spreading of repressive chromatin (Yang et al., 2009). Further-
more, upon removal of the apparent transcription elongation barrier,
e.g. pronounced telomeric silencing, by RAP1 (Yang et al., 2009) or
DOT1B (Figueiredo et al., 2008) depletion, promoter-proximal expres-
sion remained magnitudes below that of the active site, making it un-
likely that transcription attenuation accounts for the strong difference
in promoter-proximal transcription observed between active and silent
BESs. Hence, transcription attenuation appears to be a consequence of
epigenetic silencing rather than a regulatory mechanism, and seems to
be in place to prevent the low level of transcription that does initiate
at silent BESs from reaching the distally located VSG gene.
Based on the RAP1 silencing results on BES de-repression, Yang et al.
(2009) suggested that there has to be a mechanism functioning on the
BES promoter that could explain the striking difference in promoter-
proximal expression levels between the active and de-repressed/silent
BESs. The strongest support for this idea stems from the demonstration
that CITFA, which is absolutely required for RNAPI transcription, is pre-
dominantly associatedwith the active BES promoter, versus a silent site,
strongly indicating that there is a mechanism in place that allows CITFA
to preferentially interact with the active BES. In addition, the fact that
depletion of several epigenetic factors increased promoter-proximal
transcription with no or very little effect on the downstream VSG gene
further supports the notion of a promoter-dependent regulatory
mechanism.
Taking these data into account, we propose a model in which BESs
are regulated by two opposing forces, namely telomere-directed epige-
netic silencing acting on silent BESs and activated transcription initia-
tion at the active BES (Fig. 2). In this model, the active BES promoter
has unrestricted access to CITFA and RNAPI, allowing it to achieve the
high transcription rate necessary for productive VSG expression. In addi-
tion, processive RNAPI transcription at the active BES is ensured by the
presence of TDP1. At the same time, telomeric silencing at the active
BES is impaired or pushed back so far that RNAPI transcription can
extend productively past the VSG gene. In contrast, in this model, silent
BES promoters are unable to recruit CITFA and RNAPI in sufficient
amounts to allow for high transcription rates. In addition, a telomere-
directed repressive epigenetic gradient spreading from the telomere
into the BES causes transcription attenuation to prevent the low level
of transcription, initiating at inactive BESs, from reaching the VSG gene.
How are BES promoters differentially regulated? An obvious barrier
that could prevent CITFA from interacting with silent BES promoters
and from recruiting RNAPI is a repressive chromatin structure at the
promoter. The epigenetic factors whose depletion led to promoter-
proximal BES de-repression, e.g. DAC3, histone H1 and NLP, may be
important to build up a repressive chromatin structure at the promoter.
If this is correct, depletion of these factors should lead to higher CITFA
and RNAPI occupancies at de-repressed promoters. An alternative idea
for the low promoter activity at “silent BESs” has been put forward in
studies of CITFA. CITFA was found to be concentrated in both the
nucleolus and the ESB (Nguyen et al., 2014), and it retained this locali-
zation even when its promoter-binding capability was impaired by
71A. Günzl et al. / Gene 556 (2015) 68–73
260
depletion of the essential subunit CITFA1 (Park et al., 2014). It was
therefore suggested that sequestration of CITFA into the nucleolus and
the ESB could restrict maximal RNAPI transcription to these compart-
ments. This idea is in line with a previous study in which BFs were
forced to co-express two BESs simultaneously by antibiotic selection.
The two marked BESs were consistently detected in close spatial prox-
imity (Chaves et al., 1999), as if theywere competing for an essential ex-
pression factor. Furthermore, it may explain why de-repressed BES
promoters remain much less active than the promoter from the active
BES.
Finally, this model of two opposing forces is supported by the mon-
itoring of the shut-down/reactivation of the active BES upon ectopic ex-
pression of VSGmRNA (Batram et al., 2014). In these experiments the
active BES was gradually inactivated from the telomere towards the
promoter, most likely by an active, telomere-directed process of repres-
sive chromatin spreading, whereas the reactivation of the same BES oc-
curred in the reverse direction, possibly by removal of nucleosomes by
the transcription machinery. An important question emanating from
this study is how does the ectopically expressed VSGmRNA cross-talk
to the active BES? Although this question is beyond the scope of this ar-
ticle, it is tempting to speculate that the VSGmRNA sequestered an im-
portant factor for RNAPI transcription, allowing repressive chromatin to
spread onto, and silence, the active BES.
7. Conclusion
Mono-allelic VSG expression in T. brucei differs from other allelic ex-
clusion systems, such as var gene expression in Plasmodium falciparum
(Guizetti and Scherf, 2013; Kirkman and Deitsch, 2012) or olfactory re-
ceptor expression in mammals (Magklara and Lomvardas, 2013) by the
fact that the active VSG gene must be transcribed at an extremely high
rate to enable rapidly proliferating trypanosomes to completely cover
themselves with VSG. The careful measurement of RNA abundances
and half lives indicated that the active VSG gene is transcribed at a 50-
fold higher rate than a β tubulin gene (Ehlers et al., 1987). At the
same time, T. bruceimust ensure that VSG genes on other BESs are not
expressed. The parasite achieves this balancing act apparently by
restricting full RNAPI transcription initiation to the active BES and by
shielding VSG genes on silent BESs by a telomere-dependent silencing
mechanism that causes attenuation of RNAPI transcription.
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